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Summary	
Driver	genes,	mutational	signatures	and	the	timing	of	mutations	in	
oesophageal	adenocarcinoma	
James	Michael	John	Weaver	The	development	of	oesophageal	adenocarcinoma	(OAC)	from	Barrett’s	oesophagus	provides	an	excellent	model	of	the	step-wise	progression	of	malignancy.	This	process	is	strongly	associated	with	the	reflux	of	stomach	contents	into	the	oesophagus.	However	the	exact	mechanism	by	which	low	pH	and	bile	acids	contribute	to	the	development	of	OAC	remains	unclear.	The	disease	mostly	presents	late	and	treatment	options	are	limited	resulting	in	poor	outcomes.	A	paucity	of	information	regarding	the	mutations	and	mutational	processes	that	drive	OAC	is	likely	contributing	to	this.	However	to	understand	the	development	of	a	cancer	it	is	not	enough	to	simply	identify	commonly	mutated	genes,	rather	it	is	also	crucial	to	identify	the	timings	at	which	these	mutations	occur	in	the	development	of	disease.	My	aims	in	this	thesis	were	to	develop	pipelines	for	the	identification	of	somatic	mutations	using	next-generation	sequencing	and	to	utilize	these	to	provide	an	initial	insight	into	the	mutational	signatures	and	genes	that	drive	OAC.	Using	the	unique	opportunity	presented	by	having	material	from	multiple	stages	of	disease	development	I	aimed	to	understand	better	the	timing	of	mutations	in	the	development	of	cancer.	By	studying	single	nucleotide	variants	from	43	tumours	I	was	able	to	identify	the	signatures	of	7	mutational	processes	acting	on	the	OAC	genome.	These	include	ageing,	enzymatic	DNA	damage	(by	the	APOBEC	enzymes)	and	homologous	recombination	deficiency.	Two	novel	signatures	dominated	the	genomes	and	were	seen	only	very	rarely	in	tumours	from	other	sites.	These	signatures	may	represent	the	action	of	mutagens	in	the	novel	environment	found	around	the	oesophagus	and	stomach	with	bile	acids	and	low	pH	being	potential	culprits.		Previous	work	has	suggested	that	OAC	may	harbour	large	numbers	of	complex	rearrangements	and	that	reflux	may	contribute	to	this.	I	have	developed	and	validated	a	pipeline	for	the	sensitive	and	specific	detection	of	structural	variants	in	cancer.	As	part	of	this	I	have	explored	the	factors	contributing	to	false	positive	structural	variant	calls	in	‘next-generation’	sequencing	and	developed	filters	to	remove	these.		I	have	shown	that	mismappings	and	germline	variants	are	the	greatest	source	of	error	and	therefore	that	choice	of	a	highly	accurate	aligner	is	essential.		Most	importantly	I	have	shown	that	a	simple	filter	using	mismapped	reads	seen	in	a	large	panel	of	normals	is	capable	of	filtering	the	vast	majority	of	false	positive	variants.	I	also	provide	here	a	detailed	sensitivity	estimate	for	our	pipeline.	Using	this	pipeline	I	was	able	to	identify	a	further	5	structural	variant	mutational	processes	molding	the	OAC	genome.	Finally	I	have	identified	new	potential	OAC	driver	genes	including	members	of	the	SWI/SNF	complex	and	the	toll-like	receptor	signaling	pathway.			
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To	understand	the	role	these	mutations	play	in	the	development	of	OAC	I	screened	for	these	mutations	in	samples	representing	multiple	stages	in	the	progression	from	Barrett’s	oesophagus	to	cancer.	Intriguingly	almost	all	putative	driver	genes	were	found	mutated	at	the	earliest	stages	of	disease	development	at	the	same	frequency	as	seen	in	cancer.	Importantly	this	questions	the	role	of	these	mutations	in	the	development	of	the	malignant	phenotype.	This	first	pass	analysis	of	the	OAC	genome	has	highlighted	novel	mutational	signatures	that	point	to	the	central	role	of	the	unique	mutagenic	exposures	seen	in	OAC.	Most	importantly	I	have	shown	that	the	majority	of	OAC	drivers	are	mutated	early	in	the	development	of	disease	and	do	not	predict	risk	of	progression	to	invasive	cancer.	 	
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1.1 Cancer	
In	2012	cancer	was	responsible	for	8.2	million	deaths	worldwide.		With	improvements	in	public	health	across	the	globe	leading	to	a	progressive	improvement	in	life	expectancy	the	incidence	is	continuing	to	increase.		Survival	for	many	cancers	has	increased	through	a	combination	of	earlier	detection,	improved	systemic	therapy	and	improved	surgical	techniques	[1].	This	has	lead	to	the	headline	figure	of	over	50%	of	patients	diagnosed	with	cancer	now	surviving.	For	several	cancer	types,	though,	there	has	been	little	improvement	in	survival.	This	includes	lung	cancer,	pancreatic	cancer,	oesophageal	cancer,	gastric	cancer	and	glioblastoma.	With	the	exception	of	glioblastoma	these	tumours	have	several	common	clinical	features.	They	often	present	at	much	later	stages,	when	metastatic	disease	is	present,	preventing	cure	by	surgical	resection	alone.	They	have	high	levels	of	resistance	to	systemic	chemotherapy,	with	low	response	rates	seen	in	clinical	trials	of	multiple	different	agents.	They	are	often	rapidly	proliferating	with	recurrences	occurring	early	after	the	potential	curative	treatment	of	the	disease.	The	advent	of	Next	Generation	Sequencing,	allowing	the	screening	of	the	entire	cancer	genome,	offers	the	possibility	of	insight	into	each	of	these	factors.	Each	individual’s	tumour	–	and	clones	within	this	–	provides	a	unique	view	of	the	mechanisms	by	which	cells	proliferate	and	interact	with	their	surrounding	environment.		Thus	by	studying	cancer	and	its	associated	genetic	lesions	we	can	learn	not	only	about	malignancy	but	also	about	the	normal	progression	of	a	cell’s	lifecycle.		
1.2 Cancer	as	a	disease	of	somatic	mutation	
Cancer	is	fundamentally	a	disease	driven	by	the	accumulation	of	somatic	genomic	alterations.	The	first	suggestion	of	a	link	between	somatic	mutation	and	cancer	came	a	century	ago	when	Boveri	recorded	his	hypothesis	that	cancer	was	driven	by	alteration	in	the	number	of	chromosomes	–	aneuploidy	-	and	that	this	
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aneuploidy	was	itself	driven	by	unequal	segregation	of	chromosomes	during	mitosis.	This	hypothesis	developed	from	earlier	observations	by	Hanseman	of	frequent	aberrant	mitoses	in	cancer	and	Boveri’s	own	work	on	multipolar	mitoses,	their	effect	on	sea	urchin	embryogenesis	and	Boveri	and	Sutton’s	work	showing	the	chromosome	to	be	the	unit	of	heritability	in	cells	[2].	Several	lines	of	evidence	support	the	so-called	somatic	mutation	hypothesis	of	malignancy.	In	the	19th	century	Robert	Koch	formulated	a	set	of	requirements	for	demonstrating	causation	of	a	disease	by	a	specific	pathogen;	these	are	known	as	Koch’s	postulates.	They	can	be	used	as	a	framework	for	reviewing	the	evidence	of	the	need	for	somatic	mutation	in	malignancy.		The	first	requirement	is	that	the	putative	disease	causing	entity	–	bacteria	in	Koch’s	original	formulation	and	somatic	mutation	in	our	discussion	here	-	is	isolatable	from	all	instances	of	the	disease.	Mutated	genes	have	been	identified	in	all	malignancies.	This	was	initially	shown	by	targeted	approaches	looking	at	genes	that	were	thought	to	play	a	role	in	malignancy	from	previous	functional	studies	[3-5].		Recent	large-scale	genome	sequencing	studies	have	confirmed	the	presence	of	mutations	in	all	tumours,	with	the	identification	of	recurrent,	strong	drivers	mutated	in	a	large	number	of	cancers.	In	addition	several	hereditary	cancer	syndromes	occur	in	individuals	with	altered	DNA	repair	pathways	allowing	them	to	accrue	additional	somatic	mutations	[6,7].	Furthermore,	several	cancer	predisposition	syndromes	arise	from	mutations	in	genes	not	thought	to	play	a	role	in	DNA	repair.		In	all	cases	further	somatic	mutations	are	required	for	the	development	of	the	disease,	including	the	loss	of	the	remaining	allele.	Harbouring	one	mutated	copy	increases	the	frequency	of	malignant	transformation	as	it	clearly	increases	the	chance	of	a	cell	losing	both	copies	[8].	One	of	the	clearest	demonstrations	of	the	roles	of	mutations	in	the	development	of	cancer	is	in	the	tracking	of	mutations	through	differing	stages	of	disease	biology.	The	archetypal	example	of	this	is	the	adenoma-dysplasia-malignancy	sequence	seen	in	colorectal	cancer,	the	mutational	sequence	of	which	has	been	well	documented	[9,10].	By	sequencing	these	lesions	at	different	stages	of	disease	and	identifying	somatic	mutations	it	can	be	shown	that	accumulation	of	key	drivers	is	required	for	phenotypic	change	[11].	
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The	second	criterion	is	that	the	pathogen	must	be	isolatable	in	a	pure	form,	such	that	it	is	not	contaminated	by	anything	else	that	may	be	the	cause	of	the	disease.	Several	molecular	biology	techniques	allow	the	isolation	and	expansion	of	mutated	DNA	including	polymerase	chain	reaction	and	molecular	cloning	thereby	allowing	for	further	analysis.	The	third	criterion	is	that	the	pathogen	isolated	purely	must	be	able	to	cause	the	disease	when	reintroduced	to	the	host.	Countless	experiments	have	demonstrated	the	ability	of	somatic	mutations	to	induce	malignancy	in	cancers.	These	include	the	transfection	of	mutated	DNA	into	cells	in	culture.	Indeed	the	first	experiments	involving	cell	transfection	lead	to	the	identification	of	the	KRAS	oncogene	[12].		This	has	been	utilized	to	demonstrate	that	mutated	DNA	can	generate	several	of	the	hallmarks	of	cancer	in	both	in	vitro	and	in	vivo	setting.	Transgenic	mice	provide	some	of	the	best	evidence	available	for	the	malignant	potential	of	somatic	mutations	[13].	In	particular	the	use	of	conditional	alleles	that	can	be	induced	specifically	in	certain	tissues	at	differing	stages	of	development	have	produced	convincing	evidence	of	the	role	of	mutations	in	cancer	development.	The	fourth	and	final	criterion	is	that	the	pathogen	must	be	re-isolated	from	the	lesion	it	has	induced	demonstrating	that	its	presence	is	necessary	for	disease	development.	Clearly	demonstrating	the	continued	presence	of	the	putative	transforming	sequence	is	a	key	part	of	all	molecular	biology	experiments	involving	cell	transformation.	However	fulfillment	of	this	criterion	can	also	be	seen	in	vivo.	Of	note,	the	regression	of	malignancy	demonstrated	by	drugs	targeted	at	the	mutated	gene,	for	example	Vemurafenib	targeting	mutated	BRAF,	provides	a	neat	demonstration	of	the	ongoing	importance	of	certain	mutations	[14].	In	addition	when	the	drug	is	removed	and	the	patient	is	subsequently	re-challenged,	responses	are	seen	demonstrating	the	ongoing	presence	and	addiction	to	this	mutation.	This	is	also	seen	in	mouse	transgenic	models	where	mutations	are	added	then	removed	at	a	later	stage	leading	to	marked	disease	shrinking	supporting	the	crucial	role	of	those	mutations	in	inducing	and	maintaining	the	malignant	phenotype	[15,16].		
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In	summary,	there	is	ample	evidence	that	somatic	mutation	is	the	crucial	driver	of	malignancy.		A	comprehensive	assessment	of	the	somatic	variants	within	an	individual	tumour	would	therefore	seem	to	be	the	most	feasible	approach	for	better	understanding	the	processes	that	drive	them.	
1.3 How	do	somatic	mutations	contribute	to	the	malignant	phenotype?		
A	seminal	paper	collating	many	decades	of	research	separated	the	complex	phenotype	of	malignancy	into	6	core	hallmarks.	Though	this	list	of	hallmarks	has	proved	controversial	in	some	aspects	and	is	still	under	development	it	provides	a	useful	scaffold	for	the	consideration	of	the	role	of	genomic	alterations	in	the	development	of	cancer[17,18].	Mutations	can	therefore	be	assigned	to	the	hallmark	of	cancer	that	they	cause	[19].		In	brief	the	key	hallmarks	include;	evasion	of	apoptosis,	limitless	replicative	potential,	evasion	of	growth	inhibitory	signals,	angiogenesis,	metastasis,	metabolic	reprogramming,	evasion	of	the	immune	system	and	escape	from	senescence.		This	relatively	simple	system	does	not	directly	translate	into	a	consecutive	accrual	of	mutations	each	providing	a	single	hallmark	[20].	Mutations	may	contribute	to	one	or	more	hallmarks	or	may	need	to	work	in	conjunction	with	other	genetic	lesions	to	provide	an	effect	[21,22].	An	additional	and	controversial	hallmark	is	genetic	instability.	Genetic	instability	has	been	classified	as	an	enabling	hallmark,	allowing	the	more	rapid	accumulation	of	the	other	hallmarks	by	generating	enhanced	rates	of	somatic	mutation.	Ideally,	genome	sequencing,	as	undertaken	in	this	thesis,	provides	an	unbiased	view	of	mutations	within	the	genome.	Thus	it	allows	insight	into	the	types	of	genetic	instability	at	play	during	the	evolution	of	a	tumour.		Though	the	genomes	of	cancer	cells	appear	significantly	altered	it	is	not	clear	whether	this	results	from	a	normal	rate	of	mutation	acting	over	an	increased	number	of	cell	divisions,	or	an	increased	mutation	rate.		Arguments	based	around	the	need	for	a	mutator	phenotype	to	accumulate	the	required	number	of	transforming	mutations	over	the	lifetime	of	an	individual	have	been	put	forward	[23-25].	However	they	are	generally	thought	to	be	flawed	[26,27].	In	particular	they	
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overlook	the	effect	of	clonal	expansion,	a	process	now	demonstrated	to	be	the	norm	for	a	variety	of	epithelial	tissues	even	without	mutations	[28-30].	Notwithstanding	doubts	about	the	absolute	need	for	genetic	instability,	there	is	substantial	evidence	that	many	human	cancers	do	show	genetic	instability,	perhaps	reflecting	a	greater	probability	of	achieving	malignancy	through	genetic	instability,	and	most	authors	now	assume	that	genetic	instability	is	the	norm	if	not	universal	[18,31].	Crucially	this	instability	does	not	appear	to	be	present	in	normal	cells	and	therefore	represents	an	excellent	potential	target	for	cancer	specific	drugs.	
1.4 Types	of	Somatic	variation	in	the	cancer	genome	
Somatic	variants	can	be	simply	classified	based	on	the	proportion	of	the	genome	they	affect.		At	the	larger	end	of	the	spectrum	lies	gain	or	loss	of	whole	chromosomes	whilst	at	the	smallest	end	are	variants	targeting	only	a	single	base	pair.	Focus	in	cancer	genomics	has	shifted	between	the	variants	on	this	spectrum	dependent	on	the	availability	of	technologies	to	assay	for	each	subtype.	With	the	advent	of	next	generation	sequencing	technology	we	now	have	a	unifying	approach	allowing	all	forms	of	somatic	genomic	variation	to	be	assayed	in	a	single	experiment.	
1.5 Small	scale	variation	
Small-scale	variation	in	the	cancer	genome	can	be	divided	into	insertions	and	deletions	INDELs)	and	substitutions	(single	nucleotide	variants	–	SNVs).	
1.5.1 INDELs	
An	INDEL	is	a	short	insertion	or	deletion	of	sequence.	The	exact	length	of	a	variant	classified	as	an	INDEL	is	a	matter	of	debate	and	is	in	reality	an	arbitrary	cutoff	defined	by	the	ability	of	various	techniques	to	detect	these	variants	and	the	mechanisms	that	produce	them.	Throughout	this	thesis	I	will	refer	to	an	INDEL	as	any	variant	<	100bp	in	size.	I	have	selected	this	definition	criterion	
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based	on	pipelines	used	to	detect	these	variants	and	in	particular	the	methods	used	in	this	study.		Short	INDELs	contribute	a	large	proportion	of	variation	to	the	normal	human	genome	[32].	In	the	first	studies	to	assess	whole	genome	rates	of	INDELs	a	total	of	135	262	to	823	396	were	identified	ranging	in	size	from	1	to	82	711	bp.		[33-35].	The	vast	majority	of	these	were	below	100bp	in	size.	In	the	most	comprehensive	collection	of	human	genomes	published	to	date	–	the	1000	genomes	project	-	between	546	000	to	625	000	INDELs	was	identified	per	genome	with	the	maximal	variation	seen	within	African	populations	[36].	Given	the	difficulty	in	detecting	these	variants	with	current	alignment	techniques	it	is	likely	that	this	represents	a	significant	underestimate.	This	was	studied	in	detail	by	Jiang	et	al,	who	by	comparing	INDEL	detection	rates	in	a	single	Yoruban	genome	using	two	orthogonal	technologies	–	sanger	sequencing	and	Illumina	high-throughput	sequencing	estimated	the	total	number	of	short	INDELs	to	be	955	839	[37].		They	also	play	an	extensive	role	in	cancer	progression.	As	in	germline	genomes,	INDELs	are	less	prevalent	than	substitutions	in	all	cancer	types.		In	a	large	scale	study	of	exomes	from	3	281	cancers	598	675	substitution	mutations	were	detected	compared	to	only	18	679	INDEL	mutations	[38].	Whole	genome	cancer-sequencing	studies	have	confirmed	that	this	phenomenon	is	not	limited	to	the	coding	region	[39-42].	There	are	several	reasons	why	INDELS	may	be	less	abundant	than	base	pair	substitutions.	It	may	be	partly	explained	by	difficulties	in	detection	cause	by	altered	mapping	and	difficulties	in	mapping	split-reads	with	current	short	read	aligners,	discussed	in	more	detail	in	the	INDEL	pipeline	section.		Additionally	INDELs	cause	significant	disruption	to	protein	structure	if	they	occur	in	the	coding	region.	They	may	therefore	be	subject	to	more	stringent	purifying	selection	–	where	deleterious	mutations	are	lost	due	to	their	fitness	disadvantage.	Evidence	against	this	is	that	the	number	of	nonsense	mutations,	expected	to	be	as	deleterious	as	INDELs,	was	double	that	of	INDELs	in	Kandorth	
et	al’s	exome	study	[38].	Alternatively	the	rates	at	which	INDELs	are	generated	
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may	be	substantially	lower	than	that	seen	for	SNVs	or	they	may	be	more	efficiently	repaired.	
1.5.1.1 Mechanisms	of	INDEL	formation	Mechanisms	of	small	INDEL	formation	may	be	distinguished	by	the	size	of	the	INDEL	generated.	INDELS	at	the	shorter	end	of	the	spectrum	are	often	generated	by	the	expansion	or	contraction	of	short	repetitive	sequences.	Commonly	effected	sequences	are	homopolymers	–	1bp	-	and	microsatellites-	2	to	5bp	[43].	During	DNA	replication	the	DNA	polymerase	enzyme	may	slip,	leading	to	an	insertion-deletion	loop	in	the	daughter	strand.		This	process	involves	pausing	of	the	polymerase	leading	to	dissociation	from	the	nascent	DNA	strand.	The	newly	synthesized	DNA	may	then	pair	with	adjacent	complementary	sequences	creating	a	loop	and	priming	for	reassociation	of	the	polymerase	and	further	extension.	If	the	aberrant	pairing	occurs	with	more	3’	sequence	on	the	parent	strand	then	an	insertion	of	the	intervening	sequence	will	occur,	whilst	pairing	with	more	5’	sequence	will	lead	to	deletion	of	the	intervening	genomic	material.	Polymerase	pausing	may	be	mediated	by	secondary	structureswithin	the	repeat	sequence,	by	the	presence	of	modified	bases	(for	example	modified	by	oxidation)	or	by	the	collision	of	replication	forks	and	transcription	machinery	[44].	Notably,	oxidative	DNA	damage	has	been	shown	to	lead	to	increased	rates	of	expansion	of	repeat	sequences	[45].		Insertion/deletion	loops	are	recognized	and	repaired	by	the	MMR	system.		If	missed,	and	the	altered	daughter	strand	is	replicated,	then	an	insertion	or	deletion	of	sequence	is	generated	[6].	Though	simple	repeats	increase	the	likelihood	of	this	occurring,	it	may	happen	at	any	point	in	the	genome	particularly	when	bulky	adducts	or	mispaired	bases	are	present.			Short	INDELS	may	also	be	the	result	of	the	repair	of	larger	DNA	lesions	such	as	double	strand	breaks	(DSBs).	Non-Homologous	end	joining	(NHEJ)	frequently	leads	to	loss	of	1	-	50	bp	and	short	insertions	around	the	site	of	repair	as	broken	ends	are	resected	to	allow	rejoining	[46-49].	Canonical	NHEJ,	Ku	mediated,	leads	to	short	deletions,	as	ends	are	processed	to	allow	ligation,	removing	modified	
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bases.	An	alternative	version	of	NHEJ	(alt-EJ),	also	known	as	microhomology	mediated	end	joining	is	thought	to	be	used	in	cells	where	canonical	NHEJ	is	non-functional.	It	utilizes	microhomology	near	to	the	DSB	and	may	generate	more	complex	INDELS	with	both	insertion	and	deletion	components	[46,50].	Of	interest,	there	is	evidence	that	alt–EJ	may	occur	even	when	c-NHEJ	is	still	active—levels	of	Ku	may	play	a	role	in	this	along	with	the	complexity	of	damage	at	the	DSB	junctions	and	degree	of	resection	at	the	DSB.	Tumours	with	homologous	recombination	deficits	caused	by	loss	of	BRCA	gene	function	have	been	shown	to	have	numerous	such	INDELs,	demonstrating	their	reliance	on	NHEJ	or	alt–EJ	mediated	processes	[40].		In	addition,	DSBs	may	be	repaired	by	the	incorporation	of	short	sequences	from	highly	expressed	RNAs.	Though	these	are	usually	longer	insertions,	short	INDELs	may	also	be	generated	by	truncated	insertions	[51,52].		
1.5.1.2 Effects	of	INDELs	INDELs	have	several	effects	on	gene	expression	and	function,	depending	on	their	length	and	location	within	the	target	genes.		INDELs	within	the	coding	region	of	genes	maintain	the	reading	frame	if	they	are	a	multiple	of	3	bp	long.	Non-3n	INDELs	disrupt	the	reading	frame,	usually	leading	to	a	truncation	of	the	protein	with	introduction	of	an	early	stop	codon.		This	may	lead	to	the	loss	of	domains	crucial	for	function,	decreased	expression	of	the	protein	via	nonsense	mediated	decay	of	mRNA	or	misfolding	and	protease-mediated	degradation	[53,54].	Truncating	INDELs	play	a	significant	role	in	many	genetic	diseases	e.g.	familial	Parkinsons’	disease	and	several	syndromes	of	familial	cancer	predisposition,	including	Cowden’s,	BRCA1	and	2	and	Familial	Adenomatous	Polyposis	coli	[55-58].	Within	the	majority	of	cancer	tumour	suppressor	genes	an	excess	of	truncating	somatic	INDELs	is	observed	relative	to	that	expected	if	substitutions	and	INDELs	were	evenly	distributed	[59].	Genes	commonly	targeted	by	truncating	INDELs	in	cancer	include	TP53,	APC,	PTEN	and	VHL	which	harbour	substitution	to	INDEL	ratios	of	3.41,	0.49,	1.12	and	0.64	respectively	when	the	germline	average	is	11	.29	[59,60].	Given	the	relative	difficulty	of	detecting	
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INDELs	even	this	is	likely	to	be	an	underestimation	of	their	true	functional	importance.	Several	genes,	both	tumour	suppressor	genes	and	oncogenes,	harbour	regular	non-frameshifting	INDELS.			As	with	frameshift	INDELS	this	may	lead	to	protein	misfolding	and	degradation,	as	in	the	classical	DeltaF508	mutation	in	cystic	fibrosis,	which	when	homozygous	leads	to	absence	of	expression	on	the	cell	surface.		Alternatively	these	mutations	may	have	direct	effects	on	protein	function.	Examples	of	this	include	mutations	in	the	tyrosine	kinases	KIT	and	EGFR.	Short	inframe	INDELs	of	both	these	genes,	both	complex	and	simple,	remove	the	flexible	loop	that	forms	part	of	the	ATP	binding	domain	[61,62].	These	INDELs	correlate	strongly	with	response	to	targeted	tyrosine	kinase	inhibitors	[61].	INDELs	within	non-coding	regions	of	the	genome	may	also	have	an	effect	on	gene	expression.	INDELs	are	capable	of	making	significant	modifications	to	a	transcription	factor-binding	motif.		Within	plants	it	has	been	shown	that	promoter	INDELS	contribute	the	majority	of	variation	in	gene	expression.	INDEL	polymorphisms	in	human	gene	promoters	have	also	been	shown	to	regulate	gene	expression		
1.5.2 SNVs	
A	single	nucleotide	variant	or	substitution	refers	to	the	change	of	one	Watson-Crick	base	pair	to	another.	These	represent	the	most	abundant	form	of	variation	in	both	the	germline	genome	and	the	[36]	somatic	cancer	genome.		
1.5.2.1 Mechanism:	Base	damaging	processes	SNVs	occur	via	a	multitude	of	differing	routes.	Twelve	mutation	types	are	possible	with	any	one	of	the	four	standard	bases	–	thymine,	cytosine,	guanine,	and	adenine	–	being	converted	to	any	one	of	the	other	three.		The	propensity	for	a	given	mutagenic	process	to	target	a	specific	base	is	not	only	determined	by	the	target	base	but	also	by	its	local	base	context,	in	particular	the	bases	5’	and	3’	of	
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the	target	site.	As	there	are	four	bases	and	2	sites	each	mutation	can	occur	in	24	=	16	dinucleotide	contexts	giving	192	(12	x	16)	possible	mutation	types.		Broadly	speaking,	the	processes	that	generate	SNVs	can	be	split	into	two	camps;	processes	that	increase	the	generation	of	mutations	and	processes	that	decrease	the	rate	of	repair	of	mutations.	This	is	obviously	simplistic	and	the	complex	interaction	of	these	two	subtypes	leads	to	numerous	subtleties	in	the	patterns	of	mutations	generated	[63].		Perhaps	the	most	well	known	form	of	endogenous	mutation	is	the	conversion	of	C:G	Watson	Crick	base	pair	to	a	T:A	base	pair	occurring	at	CpG	dinucleotides.	This	is	thought	to	be	due	to	the	process	of	spontaneous	deamination.	In	the	human	genome	in	somatic	cells	the	majority	of	CpG	sites	are	methylated,	i.e.	a	methyl	group	is	attached	to	the	5’	cytosine.	Spontaneous	deamination	of	unmethylated	cytosine	results	in	the	production	of	uracil,	which	is	recognized	and	repaired	by	the	base	excision	repair	(BER)	apparatus	or	mismatch	repair	(MMR)	system.	In	contrast	spontaneous	deamination	of	a	methyl-cytosine	residue	leads	to	the	production	of	a	thymidine:	guanine	mispair.	Though	BER	recognizes	and	repairs	T/G	mismatches	it	does	so	far	less	efficiently	than	for	U/G	pairings.		In	addition	the	methylated	cytosine	has	an	increased	likelihood	of	undergoing	spontaneous	deamination.	There	is	therefore	a	significant	excess	of	C:G	>	T:A	mutations	at	CpG	dinucleotides	versus	other	cytosine	dinucleotides.	This	process	underlies	the	majority	of	variation	between	human	genomes	[36]	and	somatic	variation	between	cells	within	an	individual.	A	recent	study	of	malignancies	arising	from	multiple	different	tissue	types	has	shown	that	in	the	majority	of	cells	types	the	number	of	mutations	generated	by	this	process	correlates	with	the	age	of	the	individual	from	which	the	cell	was	taken	[64].	Furthermore	the	signature	is	seen	at	much	greater	levels	in	cancers	derived	from	tissues	with	high	proliferation	rates	suggesting	it	may	be	driven	by	cell	division.	The	authors	therefore	suggest	that	the	signature	may	act	as	a	‘molecular	clock’,	identifying	the	age	of	the	founding	cancer	cell.		Notably	deamination	of	adenine	to	hypoxanthine	also	occurs,	though	at	a	much	lower	rate.	Hypoxanthine	can	be	mispaired	with	cytosine	leading	to	T:A	>	C:G	mutations	[65].	Several	cancer	types	harbour	increased	rates	of	mutations	of	this	type,	and	as	part	of	signature	
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5	it	is	seen	to	correlate	with	ageing	in	certain	cell	types	[64],	though	there	remains	no	direct	evidence	that	spontaneous	deamination	is	the	cause	of	this	signature.	As	well	as	spontaneous	deamination,	enzymatic	processes	may	also	generate	cytosine	to	thymine	mutations.	The	AID	(Activation	induced	cytidine	deaminase)	/	APOBEC	(Apolipoprotein	B	MRNA	editing	enzyme,	catalytic	polypeptide	like)	family	of	proteins	are	capable	of	deaminating	cytidine	residues	to	uracil.	As	with	spontaneous	deamination,	if	not	promptly	repaired,	replication	can	lead	to	inappropriate	pairing	of	U	and	A	and	therefore	a	C:G	>	T:A	mutation	occurs	on	one	daughter	strand.	Alternatively	an	abasic	site	may	be	generated	by	the	removal	of	uracil	by	Uracil-DNA	glycosylase.	The	recruitment	of	error	prone	DNA	polymerases	to	bypass	this	abasic	site,	for	example	polymerase	theta,	can	lead	to	the	insertion	of	a	thymine	or	more	commonly	a	guanine	generating	C:G	>	G:C	mutations	[66].	In	addition	the	use	of	MMR	to	repair	U	or	T/G	mismatches	leads	to	the	recruitment	of	error	prone	polymerase	for	patch	repair	[67-69].	Use	of	this	form	of	repair	may	lead	to	localised	mutations	at	A:T	base	pairs	as	well	as	C:G	sites	and	is	thought	to	be	particularly	prevalent	during	somatic	hypermutation.	There	are	11	members	of	the	AID/APOBEC	family	though	only	AID	and	the	ABOPBEC3	proteins	(comprising	7	members	in	total)	have	been	shown	to	have	a	role	in	modifying	DNA.		AID	is	expressed	primarily	in	germinal	centre	B-cells	undergoing	somatic	hypermutation	and	is	responsible	for	this	process.	AID	targets	cytosine	found	at	a	specific	motif	–	WRCY	(where	C	represents	a	Watson	Crick	base	pair	of	C:G,	W	represents	A/T,	Y	represents	T/C	and	R	represents	A/G)-	and	is	targeted	to	specific	areas	of	DNA	by	the	presence	of	super	enhancers,	interconnectivity	of	regulatory	elements	and	high	levels	of	transcription	[70,71].	As	well	as	point	mutations	AID	also	contributes	to	the	generation	of	translocations	in	DNA,	a	process	crucial	for	VDJ	recombination	and	class	switching	of	antibodies,	but	also	capable	of	generating	oncogenic	events	in	B-cell	derived	malignancies[72-74].	Deamination	of	a	methylated	cytosine	base	leads	to	the	relatively	difficult	to	
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repair	T:G	pairing	with	the	mismatch	leading	to	looping	out	of	DNA[75].	This	looped	DNA	is	recognized	by	RAG	recombinase	enzymes	that	cleave	the	DNA	and	generate	translocations.	Hence	in	B-Cells	the	majority	of	translocation	junctions	are	found	at	CpG	sites	[76]	despite	their	relative	paucity	in	the	genome.	Most	B-cell	malignancies	demonstrate	significant	signs	of	AID	mediated	mutagenesis	[71,77].	Recently	the	combined	action	of	AID	and	RAG	has	been	implicated	as	the	major	driver	of	B	cell	Acute	lymphoblastic	leukaemia	initiation	and	clonal	heterogeneity	[73,78].	AID	expression	has	also	been	observed	in	numerous	other	somatic	cell	types	including	gastrointestinal	and	liver	cells	[79-81],	but	more	recent	large	scale	studies	have	not	identified	an	enrichment	of	AID	mutation	patterns	in	cancers	arising	from	these	organs	[77,82].		APOBEC3	family	proteins	are	responsible	for	the	control	of	viral	insertion	sequences	and	thus	represent	part	of	the	innate	immune	system.	Of	relevance	to	structural	variation	they	have	also	been	shown	to	suppress	the	ability	of	LINE	and	SINE	sequences	to	migrate	throughout	the	genome.	The	activated	enzymes	target	single	stranded	DNA	for	deamination,	allowing	uracil-DNA	glycosylase	to	cleave	the	strands,	inactivating	the	virus.	Each	APOBEC3	family	member	demonstrates	an	affinity	for	cytosines	in	different	sequence	contexts	with	particular	selectivity	for	the	2	bases	immediately	5’.	APOBEC3C	targets	cytosine	in	a	5’	-	TYC	context	(where	Y	represents	T/C)	whilst	APOBEC3G	targets	cytosine	precede	by	2	additional	cytosines	[83].	APOBEC3A,	3B	and	3H	favour	cytosine	with	a	thymine	at	the	-1	position	(that	is	1	bp	5’	to	the	target	cytosine).	Unlike	other	APOBEC3	family	members	they	show	little	selectivity	for	the	-2	site	[83],	though	deamination	by	these	enzymes	does	occur	more	commonly	when	the	3’	base	is	A/T	[84,85].	These	3	proteins	have	been	linked	with	the	presence	of	an	APOBEC3	signature	in	multiple	cancer	types.	The	strongest	evidence	supports	the	role	of	APOBEC3B	in	breast,	lung,	cervical,	bladder	and	head	and	neck	squamous	carcinoma[77,85-88].		Importantly,	this	signature	acts	as	more	than	just	a	passenger,	causing	the	majority	of	mutations	in	the	oncogene	PIK3CA	in	cervical	carcinomas	in	which	it	is	active	[89].	APOBEC3A	has	been	suggested	to	be	active	in	a	single	breast	tumour	based	on	
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mutation	patterns,	but	expression	at	the	protein	level	has	not	been	observed	in	cancer	cells	[83,90].	In	breast	tumours	from	patients	with	inactive	APOBEC3B	due	to	a	common	deletion	polymorphism	it	has	been	suggested	that	APOBEC3H	may	be	the	source	of	the	majority	of	mutations	[90,91].	In	tumours	associated	with	HPV	it	is	thought	that	APOBEC3	upregulation	is	driven	by	the	presence	of	viral	sequence	triggering	Type	1	IFN	release	[92].		It	is	less	clear	why	APOBEC3	proteins	are	upregulated	in	non-viral	associated	cancers	such	as	breast	cancer.	Interestingly	it	has	been	shown	that	APOBEC3	expression	in	mammary	epithelial	cells	is	important	for	the	prevention	of	neonatal	transmission	of	retroviruses	in	lactating	mice	[93].	Here	APOBEC3G	is	packaged	within	the	virion	leading	to	a	reduced	infectivity	[93,94].	APOBEC3	expression	may	also	be	upregulated	as	a	protective	factor	against	LINE	and	SINE	element	insertions,	a	process	common	in	cancer	genomes	[95,96].	Intriguingly	though	this	ability	appears	to	be	independent	of	their	cytidine	deaminase	activity	[97].	APOBEC	enzyme	action	is	also	thought	to	underlie	the	mutational	clustering	process	known	as	kataegis	[40,77,83].	This	describes	the	apparent	clustering	of	sets	of	mutations,	in	a	focal	region	of	the	genome	and	on	a	single	strand	of	DNA,	first	observed	in	breast	cancer	[40].	This	process	appears	to	be	due	to	APOBEC3	targeting	processed	single	stranded	DNA	at	break	points.	Notably	APOBEC3	induced	mutations	at	these	sites	show	an	increased	rate	of	C:G>G:C	mutations	instead	of	C:G:>T:A	transitions	suggesting	the	majority	of	these	kataegic	mutations	are	repaired	by	replication	of	polymerases	over	abasic	sites	following	UNG	action.	Though	spontaneous	deamination	of	CpG	dinucleotides	appears	to	be	the	most	common	endogenous	form	of	base	damage,	cells	produce	several	mutagens.	One	of	the	major	sources	of	endogenous	DNA	damage	is	thought	to	be	the	production	of	reactive	oxygen	species	(ROS).	ROS	production	has	been	shown	to	be	elevated	in	cancer	cells	from	many	different	sites	including	breast,	gastric,	colorectal,	leukaemia	and	prostate	[98].	There	are	several	mechanisms	for	this	including	increased	metabolic	activity,	alterations	in	metabolism	related	to	oncogene	activation	and	growth	factor	signalling,	mitochondrial	dysfunction	and	immune	cell	infiltration	[99-102].	ROS	appear	to	be	the	key	signaling	molecules	and	have	
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been	shown	to	promote	tumourigenesis,	including	promoting	metastasis,	increasing	proliferation	and	promoting	angiogenesis.	[101-104].	However	ROS	are	also	capable	of	causing	significant	damage	to	multiple	cellular	components	including	DNA,	proteins	and	lipid	membranes.	Cancers	therefore	appear	to	strike	a	careful	balance	in	ROS	levels	upregulating	antioxidant	proteins	allowing	them	to	survive	raised	ROS	levels	whilst	also	taking	advantage	of	their	signaling	properties	[105-107].		ROS	are	capable	of	damaging	both	incorporated	bases	and	also	those	within	the	nucleotide	pool[108-111].		A	huge	number	of	oxidized	base	products	can	be	formed	(reviewed	in	[112].	The	best	studied	of	these	is	7,8-Dihydro-8-oxoguanine	(from	here	on	referred	to	as	8-oxoguanine).	Its	incorporation	favours	the	generation	of	C:G	>	A:T	mutations	as	during	replication	it	is	preferentially	paired	with	adenine.	Interestingly,	if	the	7,8-Dihydro-8-oxoguanine	originates	in	the	nucleotide	pool	and	is	incorporated	opposite	adenine	it	will	lead	to	the	opposite	mutation,	a	T:A	>	G:C	transversion	[110,113].	This	mutation	pattern	is	markedly	enhanced	in	the	absences	of	the	nucleoside	triphosphatase	MutT	in	E.	Coli	which	acts	to	preferentially	degrade	7,8-Dihydro-8-oxoguanine	nucleotides,	sanitizing	the	nucleotide	pool	[108,113].	Repair	of	these	oxidative	damage	lesions	is	mostly	via	the	BER	pathway	though	NER	and	MMR	are	also	thought	to	play	roles	[114].	One	of	two	glycosylases	are	used,	either	oxoguanine	glycosylase	(OGG1	gene),	which	removes	the	damaged	base	or	MutY	DNA	glycosylase	that	removes	an	adenine	mispaired	with	8-oxoguanine	[113,115].	There	is	some	evidence	that	the	oxidative	damage	may	preferentially	target	certain	guanine	residues.	It	has	been	suggested	that	oxidative	damage	of	telomeres	may	underlie	increased	ageing	of	tissues	seen	in	situations	of	oxidative	stress.	In	these	studies	it	was	noticed	that	the	5’	guanine	in	the	hexameric	telomere	sequence	(5’-TTAGGG)	was	the	particular	target	[116].	In	addition	to	endogenous	sources	of	DNA	damage	there	are	many	exogenous	mutagens	that	are	known	to	play	a	role	in	cancer	SNVs.	These	include	UV	light,	Aristolochic	acid,	cigarette	smoke	and	other	pollutants	and	DNA	damaging	drugs.		
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UV	light-mediated	DNA	damage	plays	a	potent	role	in	the	genesis	of	skin	cancers,	in	particular	cutaneous	squamous	cell	carcinomas	and	melanomas.	Both	demonstrate	huge	numbers	of	mutations	with	the	hallmarks	of	UV	light	induced	damage	[117-120].	UV	light	mostly	targets	dipyrimidine	sites	(CC,	CT,	TT,	TC)	forming	2	main	photoproducts	cyclobutadipyrimidines	and	pyrimidine	(6-4)	pyrimidone	photoproducts		with	the	former	most	prevalent	in	mammalian	cells[121].	The	most	frequent	mutation	type	resulting	from	this	UV	induced	base	damage	is	C:G	>	T:A	and	commonly	both	members	of	the	dipyrimidine	are	mutated	giving	CC	>	TT	[122].	This	is	driven	by	the	deamination	of	the	cytosine	involved	in	the	dimer	and	subsequent	replication	passed	the	CPD	by	trans	lesion	polymerases	[123,124].	Of	note	UV	light	appears	to	play	a	direct	role	in	generating	malignancy	by	forming	TP53	mutations	in	squamous	cell	carcinomas	and	is	implicated	in	certain	BRAF	mutations	found	in	melanoma	[125].	Notably	melanomas	and	squamous	carcinomas	from	non-sun-exposed	sites	do	not	harbour	this	C:G	>	T:A	at	pyridine	dimers	signature,	supporting	the	role	of	UV	light	in	this	process	[87,126,127].	Cigarette	smoking	has	long	been	implicated	in	the	development	of	malignancy,	in	particular	that	of	the	bronchus	[128].	Evidence	from	sequencing	studies	has	confirmed	this.	In	the	first	instance	it	was	observed	that	TP53	mutation	patterns	differed	between	non	-	smokers	and	smokers	and	that	mutations	in	TP53	in	smokers	occur	most	commonly	at	sites	where	polyaromatic	hydrocarbon	adducts	form	(a	known	smoking	induced	lesion)	[129-131].	This	has	been	emphatically	confirmed	by	the	presence	of	large	numbers	of	smoking-related	mutations	in	whole	genome	and	exome	sequencing	of	lung	and	head	and	neck	cancers.	Particularly	convincing	is	the	evidence	of	a	dose	response	relationship	between	the	signature	of	smoking	damage	and	the	lifetime	level	of	smoking	[19,87,88,132,133].	Numerous	potentially	carcinogenic	products	are	produced	and	inhaled,	but	the	main	source	of	DNA	damage	is	thought	to	be	polyaromatic	hydrocarbons	(PAH)	[134,135].	These	compounds	form	bulky	adducts	on	DNA	which	lead	to	C:G	>	A:T	due	to	trans	lesion	synthesis	when	targeted	by	transcription	coupled	repair	[136].	Methylated	CpG	sites	have	been	observed	to	be	a	more	potent	source	of	mutation	if	incorporated	into	a	pyrimidine	dimer,	
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likely	due	to	deamination	leading	to	the	more	difficult	to	repair	C:G>T:A	transition	[134].	Direct	smoking	is	not	the	only	mechanism	by	which	polyaromatic	hydrocarbons	can	enter	the	lungs.	Second	hand	smoke	and	pollution	are	also	potent	sources	of	these	compounds,	and	exposure	to	both	leads	to	increased	cancer	risk	[137,138].	Indeed,	as	increased	numbers	of	smoking	related	cancers	are	being	sequenced,	it	has	already	become	apparent	that	patients	with	no	smoking	history	may	also	have	significant	enrichment	for	PAH	mediated	damage	(Sanger	mutational	sig	smoking	paper	2016	science).	Dietary	toxins	may	also	play	a	role	in	mutagenesis.	One	of	the	most	potent	mutagens	so	far	identified	is	Aristolochic	acid	(AA).	Epidemiology	has	strongly	linked	this	compound	to	urothelial	cancer	and	Balkan	hereditary	endemic	nephropathy	[139].	The	compound	is	found	in	grain-based	products	contaminated	with	the	seed	of	Aristolochia	Clematis	and	in	some	traditional	Chinese	herbal	medicines.	Cancers	driven	by	contact	with	this	mutagen	harbour	high	levels	of	A:T	>	T:A	mutations	at	a	RpApGp(where	R	=	pyrimidine	base)	[140,141]	.	Another	dietary	toxin,	aflatoxin	B1,	is	strongly	associated	with	the	development	of	hepatocellular	carcinoma	(HCC)	[142,143].	This	toxin	is	produced	by	
Aspergillus	Flavus	and	is	often	found	contaminating	food	supplies	in	developing	countries	where	storage	methods	may	be	poor.	Tumours	in	patients	exposed	to	aflatoxin	show	a	distinctive	pattern	of	mutations	with	C:G	>	A:T	mutations,	which	is	replicated	in	experimental	systems	[144,145].	The	majority	of	chemotherapeutic	agents	are	thought	to	exert	their	anti-tumour	action	through	mutagenesis	of	DNA.	The	signatures	associated	with	these	have	been	extensively	studied	recently	in	several	innovative	in	vitro	models	[146-148].	It	is	interesting	to	note	that	exposure	to	a	chemotherapeutic	may	not	immediately	lead	to	enhancement	of	a	signature.	For	mutations	of	chemotherapy	to	be	detected,	cells	would	have	to	be	exposed	to	the	drug	then	allowed	to	clonally	expand	such	that	the	novel	mutations	were	in	a	detectable	fraction	of	DNA.	Given	that	few	chemotherapies	regularly	lead	to	a	complete	response	(that	is,	no	tumour	detectable	by	CT	scan	or	on	microscopic	examination	of	resected	
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tissue)	it	is	unlikely	that	single	cells	exposed	to	the	drug	would	then	adequately	clonally	expand	in	the	majority	of	cases.			One	possibility	to	allow	detection	of	chemotherapy	induced	mutations	in	samples	would	be	to	sequence	metastases	that	occur	after	chemotherapy	or	locally	recurrent	disease	post	resection	as	the	lesions	in	these	cases	would	more	likely	represent	clonal	outgrowths	[149,150].			Another	factor	limiting	the	detection	of	chemotherapy	mutational	signatures	in	recurrent	cancers	is	that	the	surviving	cells	are	likely	to	be	those	that	have	suffered	least	genomic	damage,	whether	because	they	were	quiescent	at	the	time	of	drug	exposure	or	because	they	have	mechanisms	for	limiting	the	effect	of	the	chemotherapy,	e.g.	drug	efflux	pumps	or	enhanced	repair	[7,151,152].		Despite	these	caveats	mutational	signatures	of	chemotherapeutic	agents	have	been	observed	in	some	cancers.	The	most	prevalent	of	these	is	a	signature	of	Temozolomide-induced	DNA	alkylation	seen	in	melanomas	and	astrocytomas	exposed	to	this	agent	[150].	This	signature	is	a	unique	pattern	of	C:G	>T:A	mutations	at	XpCpC	trinucleotides	[77].	The	most	common	resistance	mechanism	is	thought	to	be	re-expression	of	previously	suppressed	MGMT	leading	to	increased	repair	of	O6-methyl	guanine	to	guanine,	a	common	alkyl	adduct	[153,154].	Alternatively	cells	may	develop	resistance	to	temozolomide	by	ignoring	the	damage	it	causes	via	mutations	of	MSH6	or	alteration	of	other	components	of	the	MMR	pathway	involved	in	lesion	recognition	and	DNA	damage	signaling	[155,156].	The	recurrent	resistant	tumours	display	huge	numbers	of	mutations	in	keeping	with	their	ability	to	ignore	the	damage.	Cyclophosphamide,	another	alkylating	agent,	also	increases	mutation	burden	in	treated	cells	but	generates	a	different	mutational	spectrum	with	an	increase	rate	of	T:A	>A:T	mutations	seen	at	RpTpT	trinucleotides	[147].	In	studies	of	oesophageal	and	urothelial	tumours	pre-	and	post-exposure	to	chemotherapy	an	increase	in	C:G>A:T	mutations	has	been	observed	[157,158].	Cisplatin	has	been	shown	to	cause	C:G>A:T	mutations	in	particular	at	CpC	dinucleotides	the	most	common	site	of	intrastrand	crosslinks	and	to	generate	large	numbers	of	single	base	INDELs.	[146,147].		In	addition,	and	uniquely,	
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Cisplatin	generates	dinucleotide	mutations	at	CpT	sites	with	conversion	of	these	to	ApC	dinucleotides	[146].	There	is,	however,	no	clear	evidence	in	either	of	these	studies	of	an	enrichment	of	cisplatin-specific	mutations.	The	minor	increase	in	C:G>A:T	mutation	may	instead	represent	the	increased	identification	of	previously	subclonal	mutations	generated	before	the	exposure	to	chemotherapy.	Further	studies	of	post-chemotherapy	tumours	are	therefore	obviously	warranted	to	determine	if	surviving	cells	do	indeed	accumulate	cisplatin-induced	damage.	This	would	provide	valuable	insight	into	resistance	mechanisms,	separating	out	those	tumours	that	survive	with	damage	from	those	surviving	without	damage.	Of	note,	Etoposide,	the	topoisomerase	inhibitor,	has	been	shown	to	cause	low	levels	of	damage	at	all	nucleotides	with	no	trinucleotide	specificity	[147].	As	discussed	previously	exposure	to	microorganisms	have	been	suggested	to	alter	the	mutation	signature	seen	in	cancers.	There	are	two	main	plausible	mechanisms	behind	this;	inflammation	driven	by	the	presence	of	the	organism	-	leading	to	cell	death,	oxidative	DNA	damage	and	increased	replication	-	and	stimulation	of	DNA	damaging	enzymes	meant	to	destroy	the	DNA	of	the	pathogen,	i.e.	HPV	and	the	APOBEC3B	signature	[92,159].	In	gastric	cancer	it	has	been	proposed	that	the	presence	of	Helicobacter	Pylori	induced	inflammation	stimulates	the	expression	of	AID	in	gastric	epithelial	cells	leading	to	characteristic	DNA	damage	[81].	However	there	is	not	sufficient	evidence	from	this	paper	to	differentiate	the	AID	signature	from	that	of	simple	age	induced	mutagenesis	at	XpCpGp	sites	and	a	signature	of	AID-induced	mutagenesis	has	not	been	observed	in	gastric	cancer	in	additional	studies	[160].	Liver	fluke-associated	cholangiocarcinomas	did	not	demonstrate	any	enrichment	for	novel	signatures	though	there	was	an	increase	in	the	overall	number	of	mutations	observed	[161,162].	Larger	studies	of	comprehensively	clinically	annotated	samples	using	whole	genome	sequencing	may	be	required	to	identify	more	subtle	signatures	of	microorganism	induced	DNA	damage.	
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1.5.2.2 Mechanism:	Replication	and	repair	As	well	as	direct	enzymatic	attack,	endogenous	damage	can	also	come	from	the	action	of	DNA	replication.		One	source	of	massive	numbers	of	mutations	is	the	mutation	of	the	two	catalytic	subunits	of	the	two	main	polymerases	involved	in	DNA	replication	in	mammalian	cells,	POLD	(polymerase	δ)	or	POLE	(polymerase	ε),	lagging	and	leading	strand	polymerases	respectively.	Mutations	in	both	genes	have	been	identified	that	remove	the	3’-5’	exonuclease	function	eliminating	the	proofreading	ability	of	these	enzymes	[163-165].	These	mutations	were	first	identified	in	the	germline	of	patients	presenting	with	multiple	colorectal	adenomas	and	carcinomas	[163].	Tumours	with	somatic	POLE	or	POLD	mutations	also	harbour	exceptionally	large	numbers	of	C:G	>	A:T	or	C:G	>	T:A	mutations	across	their	genome	arising	in	a	TpCpG	context.	[77].	Interestingly	somatic	mutations	of	these	DNA	polymerase	enzymes	show	a	similar	tissue	distribution	to	loss	of	function	of	the	mismatch	repair	pathway,	i.e.	high	rates	in	colorectal	and	endometrial	carcinomas	and	lower	prevalence	in	gastric	and	glioblastoma	amongst	others	[166,167].	Given	MMRs	major	role	in	repairing	defects	of	replication	this	is	perhaps	not	surprising.	However	it	is	not	clear	why	defects	in	replication	fidelity	would	specifically	lead	to	tumours	of	the	colon	or	endometrium.	One	possibility	is	that	they	represent	two	of	the	most	proliferative	tissues	in	the	body	that	are	not	exposed	commonly	to	any	major	known	mutagens,	reflected	in	the	absence	of	any	signature	of	mutagen	exposure	in	either,	though	this	is	purely	speculative.	Several	other	explanations	have	been	proposed	including	the	potential	exposure	to	high	levels	of	alkylating	agents,	a	lesion	repaired	by	MMR,	and	the	tissue	specificity	of	mutations	generated	by	MMR	[168].	These	seem	less	likely	given	the	similar	tissue	specificity	of	POLE	and	POLD	mutations.	The	most	prevalent	tumour	deficiency	in	repair	systems	is	loss	of	the	mismatch	repair	apparatus	leading	to	high	levels	of	mutation	in	microsatellites	[43,169].	This	is	most	commonly	associated	with	germline	inheritance	of	a	mutation	in	one	of	the	key	proteins	involved	in	this	process,	known	as	Lynch	syndrome	or	Hereditary	nonpolyposis	colorectal	cancer	(HNPCC)	[170-172].	This	results	in	an	increased	preponderance	of	tumours	in	multiple	organs	in	particular	the	colon	
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and	the	endometrium,	with	several	variants	of	the	disease	showing	differing	tumour	types	in	addition	to	the	ubiquitous	colorectal	cancer	[173].	Within	tumours	from	patients	with	HNPCC	the	second	allele	is	commonly	lost	resulting	in	abrogation	of	MMR	function.	This	is	seen	in	the	very	earliest	stages	of	disease	before	cellular	phenotypic	changes	[174].	The	MMR	system	plays	a	key	role	in	the	repair	of	replication-induced	errors	including	base-base	mismatches	and	small	INDELS	caused	by	replication	slippage.	The	key	and	unique	components	of	the	MMR	system	in	E.	Coli	include	MutS,	MutL	and	MutH	which	together	recognize	the	mismatch	base	or	insertion	deletion	loop	(MutS)	and	then	recruit	the	required	enzymatic	repair	apparatus	(MutL	and	H).	Briefly,	an	endonuclease	is	recruited	that	cleaves	3’	or	5’	of	the	defect.	This	is	followed	by	recruitment	of	an	exonuclease	and	helicase	that	together	remove	a	section	of	the	newly	synthesized	strand	incorporating	from	the	nick	up	to	and	just	past	the	mismatch.	A	DNA	polymerase	and	ligase	are	then	recruited	to	repair	the	defect	a	re-join	the	two	ends	[6].	Further	sequencing	studies	have	shown	that	as	well	as	multiple	short	INDEL	type	mutations	at	homopolymers	and	microsatellites	these	tumours	also	harbour	numerous	point	mutations.	In	particular	it	appears	that	C:G	>	T:A	transitions	are	the	most	prevalent	form	of	mutation	in	MMR	deficient	cells	occurring	preferentially	at	NpCpG	sites,	with	a	high	prevalence	of	C:G	>	A:T	mutations	at	CpCpC	sites	also	observed	[77].	This	combination	of	SNVs	and	short	INDELs	combined	with	very	high	mutation	rates	acts	as	a	signature	of	MMR	deficiency	[175].	Recently	tumours	from	patients	with	biallelic	germline	loss	of	MMR	(mutations	in	MSH6)	have	been	sequenced.	The	normal	tissue	in	these	patients	did	not	show	an	increased	mutation	rate	and	it	required	somatic	mutations	in	POLD	or	POLE	to	cooperate	in	induction	of	the	huge	mutational	burden	[176].	MMR	has	also	been	implicated	in	the	fluctuating	distribution	of	mutations	across	the	tumour	and	germline	genome.	Poorly	transcribed	genes	and	areas	that	are	replicated	late	in	S	phase	are	known	to	harbour	increased	levels	of	mutation	[177,178].	In	tumours	with	a	deficiency	in	MMR	this	skewed	distribution	of	
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mutations	is	not	observed,	suggesting	that	it	is	driven	by	altered	repair	[179].	Interestingly	a	similar	pattern	is	seen	for	NER	deficient	cells	with	loss	of	mutation	distribution	bias.	In	both	cases	the	mechanism	is	thought	to	be	linked	to	chromatin	configuration,	with	more	closed	chromatin	conformations	or	binding	of	transcription	factors	preventing	appropriate	access	of	repair	machinery	[63,180,181]	Nucleotide	excision	repair	(NER)	recognizes	and	removes	bulky	helix	distorting	lesions	caused,	for	example,	by	UV	light	and	smoking	[182].	In	brief,	NER	proteins	recognize	the	presence	of	ssDNA	opposite	a	bulky	adduct;	helicases	are	then	recruited	which	confirm	the	presence	of	the	adduct.	This	then	triggers	the	excision	of	a	short	(~20bp)	section	of	DNA	by	5’	and	3’	endonuclease	action.	The	gap	is	then	repaired	by	a	variety	of	polymerases	and	ligases	depending	on	the	proliferative	state	of	the	cell	[182].	As	well	as	recognizing	distorted	DNA	helices	NER	is	also	transcription	coupled	and	therefore	recognizes	lesions	that	stall	transcription	complexes	[183].	Aberration	in	either	of	these	pathways	leads	to	marked	phenotypes	with	defects	in	transcription	coupled	repair	causing	severe	neurodegenerative	disease	without	increased	cancer	risk	(Cockayne	Syndrome)	[184],	and	defects	in	global	NER	causing	increased	UV	sensitivity	and	cancer	predisposition	(Xeroderma	Pigmentosa)[185,186].	Of	note,	a	more	mild	phenotype	of	just	skin	UV	sensitivity	is	seen	with	some	defects	of	TCR	[187]	though	the	reasons	for	the	difference	between	this	and	Cockayne	syndrome	are	unclear.	NER	like	MMR	has	also	been	shown	to	play	a	role	in	the	global	distribution	of	mutations.	A	pattern	of	increased	mutations	in	promoters	-	where	TFs	block	access	-	and	decreased	mutation	in	open	chromatin,	is	seen	in	cells	with	functional	NER	[63,188].	As	a	signature	of	the	activity	of	NER,	several	mutational	patterns	thought	to	be	caused	by	bulky	DNA	adducts	show	transcriptional	bias	with	increased	mutation	rates	on	the	non-transcribed	strand	[77,118,132].	Recently	a	mutational	signature	of	NER	deficiency	has	been	observed	within	a	subset	of	bladder	tumours	with	mutations	in	ERCC2,	a	helicase	involved	in	unwinding	DNA	around	damaged	sites.	This	signature	leads	to	increases	in	rates	of	all	types	of	SNV	and	is	enhanced	in	smokers	[189].	
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Base	excision	repair	removes	damaged	bases	generated	as	a	result	of	endogenous	processes	such	as	deamination,	oxidation,	aldehyde	adducts	and	depurination.	The	first	step	is	recognition	and	removal	of	the	altered	base	leaving	an	abasic	site.	This	is	performed	by	a	variety	of	glycosylase	enzymes	each	capable	of	recognizing	unique	forms	of	base	damage	with	some	redundancy.	Substrates	include	uracil:	guanine	mismatches	(UNG1,	SMUG1),	thymine:	guanine	mismatches	(TDG	and	MBD4),	8-oxoguanine	(MUTYH	and	OGG1)	and	oxidized	pyrimidines	(NTH1,	NEIL1-3).	Cleavage	and	removal	of	the	altered	base	is	followed	by	endonuclease	(APEX1)	action	leading	to	nicking	and	the	entry	of	polymerase	β and	DNA	ligase	III	with	the	scaffold	protein	XRCC1	to	repair	the	damage	[190,191].		In	cancer	samples,	several	patterns	of	mutations	have	been	associated	with	lesions	usually	repaired	by	BER	[77].	Alteration	of	DNA	glycosylase	function	in	mice	leads	to	accumulation	of	mutations,	in	particular	deletion	of	OGG1	lead	to	the	accumulation	of	C:G	>	A:T	mutations	[192].	MUTYH	germline	mutations	are	associated	with	reduced	ability	to	clear	oxidative	DNA	lesions	and	a	form	of	familial	adenomatous	polyposis	coli	[193].	However,	somatic	mutations	in	BER	apparatus	have	yet	been	found	to	increase	tumour	mutation	rates.		
1.5.2.3 Effects	of	SNVs	Single	nucleotide	variants	are	amongst	the	most	well	characterized	defects	thought	to	drive	malignancy.	They	can	be	broadly	classified	into	those	affecting	protein	structure	and	those	altering	expression	levels	by	altering	non-coding	regions	of	the	genome.	The	most	well-described	of	these	are	mutations	altering	protein	function.	These	include	nonsynonymous	mutations,	that	alter	a	single	amino-acid,	nonsense	mutations,	that	introduce	a	premature	stop	codon	truncating	the	protein	or	leading	to	nonsense	mediated	decay,	splice	site	mutations,	that	remove	a	splice	site	altering	the	protein	structure,	synonymous	mutations	and	mutations	of	functionally	relevant	non-coding	sites.	Nonsynonymous	mutations	result	in	a	change	in	a	single	amino	acid	altering	the	structure	of	the	target	protein.	They	can	act	to	enhance	function	of	an	oncogene	
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or	may	disrupt	the	function	of	a	tumour	suppressor	gene.		These	mutations	commonly	disrupt	catalytic	sites	of	pro-growth	proteins	leading	to	hyperactivation	of	growth	pathways	in	particular	the	Ras/Raf/RTK	pathway.	This	pathway	harbours	recurrent	mutations	in	many	members.	An	excellent	example	is	mutation	of	the	BRAF	gene	at	codon	600	leading	to	conversion	of	a	valine	residue	(V)	to	a	glutamate	(E).	This	mutation	was	identified	originally	during	screening	of	key	genes	in	pathways	thought	to	be	involved	in	human	malignancy	[194].	It	targets	a	domain	known	to	stabilize	the	inactive	form	of	BRAF.	Thus	the	mutation	constitutively	activates	the	kinase	leading	to	hyperactivation	of	downstream	ERK	and	pro-growth	signaling	[195]	.	Drugs	designed	to	specifically	target	the	mutant	form	of	the	kinase	have	lead	to	significant	improvement	in	overall	survival	of	melanoma	patients	[14].	Nonsense	mutations	are	found	commonly	in	tumour	suppressor	genes.	They	have	significant	effects	on	the	gene	they	target,	either	truncating	the	protein	or	decreasing	its	expression	levels	via	nonsense	mediated	decay	[53].	Genes	commonly	targeted	by	this	form	of	mutation	include	TP53,	APC	and	ARID1A.	In	the	case	of	TP53	and	ARID1A	nonsense	mutations	are	thought	to	abrogate	protein	expression	via	NMD	[196,197].	However	in	APC	their	role	is	more	complex	generating	a	truncated	protein	that	still	retains	some	activity	and	is	thought	to	play	a	role	in	sensitizing	cells	to	WNT	pathway	ligands	[198].	It	has	recently	been	demonstrated	that	synonymous	mutations—those	that	do	not	alter	the	protein	coding	sequence	of	a	gene—may	also	play	a	role	in	cancer	[199].	Between	6-8%	of	synonymous	mutations	in	oncogenes	such	as	EGFR	and	
ITK	demonstrate	signs	of	positive	selection.	These	mutations	were	enriched	in	conserved	exonic	sequences	that	play	a	role	in	splicing	known	as	exon	splice	silencer	(ESS)[200].	By	analyzing	RNAseq	data	it	was	possible	to	show	that	these	mutations	promoted	the	retention	of	exons	potentially	resulting	in	increased	expression	levels	by	increasing	expression	of	the	full	length	transcript[199,201].	Of	note,	mutations	that	directly	target	splice	sites	either	disrupting	them	or	creating	novel	splice	donors	or	acceptors	are	also	well	recognized	to	play	a	role	in	disrupting	gene	function	[202].	
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There	are	many	other	putative	mechanisms	by	which	synonymous	mutations	may	alter	protein	function,	for	example	by	decreasing	miRNA	mediated	degradation	of	the	gene’s	mRNA	via	disruption	of	the	miRNA	binding	site	[203].	The	alteration	of	codon	usage	can	speed	up	or	slow	down	the	rate	of	transcription.	This	in	turn	can	lead	to	alterations	in	protein	structure	as	protein	folding	has	been	shown	to	be	dependent	on	speed	of	transcription,	however	this	has	not	yet	been	shown	to	have	a	role	in	tumour	biology	[204].	Somatic	SNVs	arising	in	the	non-coding	regions	of	the	genome	have	also	been	shown	to	play	a	significant	role	in	tumour	biology.	Most	striking	of	these	is	the	recurrent	mutations	of	the	TERT	promoter	–	encoding	the	catalytic	subunit	of	the	telomerase	enzyme	-		in	melanoma	and	other	malignancies	[144,205-208].	This	mutation	alters	the	binding	of	ETS	family	transcription	factors	to	the	TERT	promoter	[205,206].	In	differentiated	cells	these	mutations	have	been	shown	to	bypass	the	repression	of	the	TERT	enzyme	and	thereby	permit	continued	telomere	lengthening	and	immortalization	[209].	Additional	functional	regulatory	mutations	have	been	proposed	though	their	relevance	remains	uncertain	[210-213]	These	poorly	characterized	non-standard	forms	of	single	nucleotide	variation	have	been	referred	to	as	the	dark	matter	of	the	cancer	genome.	[214].	In	several	common	tumours	the	absence	or	small	number	of	driver	gene	mutations	in	a	subset	is	often	lamented		[211,215]).	Whilst	there	are	likely	many	possible	explanations	for	this	it	is	probable	that	novel	mechanisms	of	TSG	and	oncogene	disruption	once	properly	understood	will	help	bring	many	of	these	tumours	back	in	to	the	fold.	
1.5.3 Large	scale	variation	in	the	cancer	genome	
1.5.3.1 Numerical	instability	or	Aneuploidy	Numerical	instability	of	cancer	cells	chromosome	number—aneuploidy—is	common.	This	may	range	from	the	loss	or	gain	of	individual	chromosomes	to	the	complete	reduplication	of	the	entire	genome.		
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The	role	of	aneuploidy	in	cancer	has	been	controversial.	That	the	majority	of	cancers	–	both	of	solid	and	liquid	organs	-	harbour	an	aneuploid	genotype	is	indisputable,	having	been	shown	by	multiple	methods	[216-218].	However	it	is	also	clear	that	a	significant	minority	of	cancers	harbour	a	near	diploid	genome	but	are	nonetheless	as	malignant	as	their	aneuploid	counterparts	[219].	Certain	large	scale	abnormalities	occur	more	commonly	than	others	providing	support	for	the	activity	of	a	selective	process	[217,220-223].	Discussion	has	focused	around	whether	the	presence	of	an	aneuploid	genotype	was	the	cause	of	the	malignant	phenotype	or	simply	a	consequence	of	the	aberrant	replication.	Recently	it	has	been	shown	that	mice	with	a	defect	in	the	centromere-linked	motor	protein	CENP-E	demonstrate	both	enhanced	spontaneous	tumourigenesis	and	suppressed	mutagen	induced	tumourigenesis	[218,224].		There	are	two	main	mechanisms	through	which	aneuploidy	may	facilitate	cancer.	Firstly	it	may	facilitate	an	increase	in	the	rate	of	mutation	(genetic	instability);	secondly	it	may	lead	to	changes	in	the	genome	that	provide	selective	advantage	to	the	tumour	cell.	Does	aneuploidy	require	or	cause	genetic	instability?	As	discussed	previously	in	the	section	on	genetic	instability,	though	the	genomes	of	cancer	cells	appear	significantly	altered,	it	is	not	clear	whether	this	results	from	a	normal	rate	of	mutation	acting	over	an	increased	number	of	cell	divisions,	or	an	increased	mutation	rate.	Nevertheless	there	is	evidence	that	cancers	display	increased	rates	of	numerical	instability.	Assessment	of	the	DNA	content	of	single	cells	either	via	flow	sorting	to	assess	total	quantity	or	more	recent	single	cell	sequencing	studies	has	shown	that	within	tumours	that	appear	homogenous	at	the	whole	biopsy	level	there	are	multiple	ongoing	changes	in	chromosome	number	[216,225-227].	In	putatively	normal	cells,	episodes	of	numeric	instability	are	seen	with	loss	and	gain	of	chromosome	arms	and	whole	chromosomes[228].	Though	this	does	occur	it	is	not	to	the	extent	seen	in	cancers,	supporting	the	role	of	an	instability	phenotype	[229-231].	This	has	been	backed	up	by	studies	demonstrating	increased	rates	of	chromosome	segregation	abnormalities	in	aneuploid	cancer	cell	lines	versus	chromosomally	stable	cancer	cell	lines	[232,233].	
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The	mechanism	of	numeric	instability	remains	unclear	[218].	Proposals	have	included	mutations	in	the	spindle	assembly	checkpoint	(SAC)	allowing	aberrant	chromosomal	segregation	to	proceed	unchecked.	Mutations	of	the	SAC	protein	are	the	cause	of	mosaic-variegated	aneuploidy	in	certain	patients.	However	mutations	of	the	SAC	do	not	exist	commonly	in	human	cancers	and	have	not	been	shown	to	be	causal	of	aneuploidy.	Mutations	of	cohesion	complex	genes	e.g.	
STAG2	have	also	been	proposed,	but,	although	defects	are	seen	in	some	cancers,	the	correlation	with	aneuploidy	has	proved	controversial	[234,235].		One	intriguing	possibility	is	that	aneuploidy	itself	may	itself	cause	numeric	and	structural	instability	via	enhanced	merotelic	attachment	and	aberrant	segregation.	A	recent	study	has	provided	strong	evidence	that	the	gain	of	even	a	single	additional	chromosome	can	lead	to	marked	instability	[236,237].	In	addition	merotelic	attachments	have	been	shown	to	lead	to	micronucleus	formation	and	chromothripsis	(discussed	below)	providing	a	potential	mechanism	for	this	link.	Does	aneuploidy	represent	the	accumulation	of	potentially	driving	mutations?	Much	work	has	focused	on	the	identification	of	TSGs	in	areas	of	recurrent	aneuploidy.	The	most	striking	example	of	this	is	the	high	prevalence	of	recurrent	deletions	of	chromosome	17p	in	many	different	cancers.	This	is	strongly	associated	with	mutation	of	the	TP53	gene	on	the	remaining	allele	suggesting	that	loss	of	17p	occurs	to	remove	the	remaining	normal	allele	[217,223].	The	same	is	true	of	loss	of	9p	and	chromosome	10	in	glioblastoma;	common	lesions	that	are	thought	to	occur	to	remove	the	remaining	copy	of	tumour	suppressor	genes	(CDKN2A/p16INK4A	/P14ARF		plus	PTPRD	and	PTEN	plus	ANXA7	respectively)	[238,239].	However	the	gain	or	loss	of	a	whole	chromosome	or	chromosomal	arm	represents	a	relatively	crude	mechanism	for	obtaining	proliferative	advantage.	Many	1000s	of	genes	with	both	pro–proliferative,	anti	proliferative	and	essential	housekeeping	function	exist	on	each	chromosome	arm.	An	recent	study	provides	an	explanation	for	the	idea	that	even	loss	or	gain	of	a	whole	chromosome	or	chromosome	arm	may	promote	the	development	of	cancer.	In	this	
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comprehensive	study	19	011	genes	were	knocked	out	in	immortalized	mammary	epithelial	cells	using	shRNA.	Enrichment	or	loss	of	shRNAs	was	assessed	in	culture	after	knockdown.	If	an	shRNA	targeted	an	anti	proliferative	gene	it	would	be	expected	to	lead	to	increased	cell	proliferation	and	thus	be	present	in	a	larger	portion	of	residual	cells.	Using	this	process,	genes	were	classified	as	STOP	genes	(i.e.	anti-proliferative).	Pro-proliferative	or	GO	genes	were	identified	as	those	whose	knockout	lead	to	>	1.5	fold	decrease	in	proliferation	when	knocked	out	in	several	cell	lines	from	normal	tissues.	The	authors	demonstrated	that	chromosomal	arms	commonly	lost	in	cancer	harbour	an	increased	number	of	STOP	genes	and	a	depletion	of	GO	genes,	overall	providing	a	selective	advantage	[240].	In	an	extension	of	this	work	the	same	authors	identified	STOP	and	GO	genes	by	looking	at	their	mutational	patterns	in	8	813	cancer	genomes.	A	training	set	of	mutations	in	known	TSGs	and	oncogenes	was	used	to	identify	novel	cancer	genes.	Again	an	enrichment	of	TSGs	genes	was	seen	in	areas	of	hemizygous	deletion	independent	of	whether	the	tumour	harboured	a	mutation	in	that	gene.	In	addition,	areas	of	low	level	copy	number	gain	were	found	to	be	enriched	for	oncogenes	[241].	Overall	then	it	seems	that	complex	aneuploidy	may	in	fact	represent	a	series	of	individual	mutations	each	offering	small	proliferative	gains	to	the	tumour	cell.		In	summary,	although	it	seems	a	relatively	blunt	process,	numerical	instability	within	cancers	may	contribute	directly	as	a	cancer	driving	mutation.	In	addition,	it	may	actively	promote	malignancy	by	enhancing	instability	within	the	genome	allowing	the	accumulation	of	mutations	at	a	faster	rate.		However,	whilst	aneuploidy	may	provide	some	advantage	to	cancer	cells	it	has	also	been	demonstrated	to	be	deleterious,	putting	cells	under	considerable	proteomic	stress	[242].	The	mechanisms	by	which	it	is	tolerated	in	tumour	cells	are	poorly	understood	but	may	represent	potential	therapeutic	targets.	
1.5.3.2 Structural	variation	As	well	as	gains	and	losses	of	whole	chromosomes,	smaller	scale	structural	variants	are	also	seen	in	cancers.	These	include	intrachromosomal	changes	such	as	deletions,	insertions,	tandem	duplications,	inversions	and	interchromosomal	
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changes	known	as	translocations.	These	structural	variants	are	often	presumed	to	be	initiated	by	a	double	strand	break	(DSB),	generated	by	either	an	exogenous	or	endogenous	source,	but	may	also	arise	from	misrepair	of	stalled	replication	forks	[243,244].	DSBs	are	highly	toxic	to	cells	and	several	complex	repair	mechanisms	exist	to	rapidly	resolve	the	break.	These	repair	mechanisms	differ	in	their	success	rates	with	aberrant	repair	a	significant	source	of	damage	in	the	cancer	and	germline	genome.	Error	free	repair	is	achieved	if	the	two	ends	of	the	DSB	are	rejoined	without	loss	of	genetic	material	at	the	junction.	If	there	is	a	change	in	orientation	or	genomic	location	of	either	of	the	break	points	a	structural	variant	is	generated.	Homologous	recombination	(HR)	is	able	to	perform	error	free	repair	of	DSBs	and	resolve	stalled	replication	forks	[245].	It	utilizes	a	series	of	proteins	to	identify	DSBs	and	resect	the	ends	to	generate	single	stranded	DNA.	This	single	stranded	DNA	then	invades	into	local	homologous	sequences	–	ideally	on	an	identical	newly	replicated	stretch	of	DNA	(the	sister	chromatid	available	in	S	and	G2)	–	and	uses	this	as	a	template	for	replication	past	the	breakpoint.	Final	rejoining	and	full	repair	can	then	occur	via	resolution	of	Holliday	junctions	or	single	strand	dependent	annealing.		HR	is	active	only	in	G2/M	and	during	DNA	replication	when	a	sister	chromatid	is	available	to	act	as	template	for	repair.	However	repair	by	HR	is	not	guaranteed	to	be	error	free.	The	homologous	sequence	targeted	is	not	always	that	which	is	on	the	sister	chromatid.	Invasion	into	a	homologous	repeat	sequence	can	lead	to	structural	variation	known	as	non-allelic	homologous	recombination	(NAHR).	NAHR	is	known	to	generate	expansion	and	contraction	of	repeats	in	the	germline	via	misalignment	and	non-equal	meiotic	crossover	[47,246].	Alternatively,	invasion	into	the	other	parental	copy	of	the	chromosome	at	the	correct	genomic	location	can	lead	to	cross	over	of	genetic	material	and	loss	of	heterozygosity	(LOH)		An	additional	process	of	HR	known	as	break	induced	replication	(BIR)	may	generate	reciprocal	translocations	and	large	segmental	duplications.	In	BIR	a	single	ended	DSB		-	generated	at	a	replication	fork	meeting	a	single	strand	break	
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-	triggers	HR.	Strand	invasion	occurs	and	replication	continues	until	the	end	of	the	invaded	chromosome	is	reached.	This	has	been	shown	to	generate	translocations	in	yeast	and	segmental	duplications	[243,247].		In	cancer,	defects	of	HR	are	known	to	predispose	to	malignancy.	This	is	thought	to	be	driven	by	the	use	of	the	more	error	prone	non-homologous	end	joining	(NHEJ).	However	as	discussed	above	HR	itself	can	be	error	prone	e.g.	NAHR	and	it	remains	unclear	as	to	the	exact	mechanism	by	which	its	loss	drives	tumourigenesis	[47].	Identifying	rearrangements	driven	by	HR	in	cancer	has	proven	challenging.	The	largest	cancer	SV-focused	study	to	date	using	NGS	data	identified	no	examples	of	mutagenic	NAHR	in	64	tumours	from	a	variety	of	tissues	(defined	as	breakpoints	with	homology	>	100bp).	However,	sequencing	of	junctions	identified	by	BAC	(bacterial	artificial	chromosomes)	paired	end	sequencing	in	the	breast	cancer	cell	line	MCF-7	identified	4	NAHR	mediated	junctions	of	a	total	of	86	sequenced	to	breakpoint	resolution.	This	sequencing	strategy	used	longer	read	lengths	and	longer	fragment	sizes	than	available	in	next	generation	sequencing	experiments.	The	precise	length	of	homologous	sequence	required	by	HR	is	unclear,	however	this	need	for	repetitive	sequence	makes	identification	of	abnormal	junctions	by	current	next	generation	sequencing	technologies	difficult	due	to	the	use	of	short	fragment	and	read	lengths.	In	brief,	increased	fragment	lengths	allow	the	bypassing	of	repeat	sequence	if	both	ends	of	the	fragment	fall	in	unique	sequence.	Increased	read	length	increases	the	chances	of	a	unique	match	for	the	read,	however	many	repeat	segments	are	longer	even	than	the	average	read	length	available	from	Sanger	sequencing.	Unfortunately	for	the	study	of	MCF-7	no	matched	germline	DNA	exists	for	this	cell	line	and	it	is	possible	that	these	4	rearrangements	represent	host-unique	SVs.	A	panel	of	90	normal	samples	was	used	as	a	control.	However,	individuals	carry	numerous	unique	SVs	and	a	panel	of	90	is	unlikely	to	have	captured	all	diversity.	Other	forms	of	somatic	variation	may	be	due	to	HR.	It	may	be	that	long	stretches	of	copy	number	neutral	LOH	that	are	observed	frequently	in	tumours	may	represent	the	action	of	NAHR,	a	process	known	as	gene	conversion.	These	can	
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also	be	generated	by	the	loss	or	gain	of	whole	chromosomes	following	translocations.		By	contrast,	the	majority	of	rearrangements	in	cancer	have	been	assigned	to	the	NHEJ	or	MMBIR	(microhomology	mediated	break	induced	replication)	processes,	harbouring	short	or	no	microhomology	at	the	rearrangement	junctions.	Non	homologous	end	joining	is	active	at	all	stages	of	the	cell	cycle	and	directly	ligates	together	exposed	DSBs.	Its	activity	is	important	for	maintaining	genomic	stability	as	it	favours	local	joining	of	DSBs	[46].	Recently	an	additional	pathway	has	been	identified	known	as	alternative	non-homologous	end	joining	or	alt-NHEJ[248].	This	is	thought	to	be	slower	and	to	utilize	greater	stretches	of	micro-homology	though	the	binary	separation	of	canonical	and	alternative-NHEJ	is	controversial	[249,250].	MMBIR	is	a	more	complex	repair	process.	Here,	at	a	stalled	replication	fork,	it	is	proposed	that	a	growing	DNA	strand	switches	to	another,	illegitimate,	template,	leading	to	joining	of	sequences	and	the	formation	of	complex	genomic	rearrangements	[244,251].	
1.5.3.3 Complex	structural	variation	Several	complex	forms	of	rearrangement	have	been	proposed	to	occur	with	multiple	SVs	occurring	simultaneously	in	a	tightly	clustered	pattern.	The	process	known	as	chromothripsis	has	recently	been	identified.	Here	a	single	chromosome	or	chromosome	arm	is	shattered	and	stitched	back	together	in	a	single	event.	This	can	lead	to	100’s	of	localized	rearrangements	with	alteration	in	copy	number	between	2	states	supporting	the	occurrence	of	all	breaks	at	one	timepoint	with	loss	of	intervening	material	[252,253].	Further	amplification	of	genomic	segments	may	occur	if	double	minute	chromosomes	are	formed.	These	are	extrachromososmal	circles	of	DNA	that	segregate	randomly	between	daughter	cells	and	can	proliferate	by	rolling	circle	amplification	[254-256].	The	mechanism	of	chromothripsis	is	unclear	and	shattering	mechanisms	involving	replication	and	physical	processes	have	been	proposed	[257,258].	
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On	a	smaller	scale	a	process	known	as	chromoplexy	has	been	described	[259].	This	shows	a	characteristic	pattern	of	rearrangement	where	the	ends	of	multiple	DSBs	appear	to	be	joined	together	at	random.	It	has	been	proposed	that	this	may	be	due	to	the	formation	of	multiple	DSBs	in	a	spatially	confined	area	of	the	nucleus	such	as	a	transcription	factory.		The	most	well	known	complex	from	of	amplification	in	malignancy	is	the	break	fusion	bridge	cycle	[260,261].	In	this	a	break	at	the	end	of	a	chromosome	leads	to	loss	of	telomere.	Replication	then	leads	to	sister	chromatids	with	identical	uncapped	sequences.	To	shelter	these	DSBs,	end-to-end	fusion	occurs	between	sister	chromatids.	Separation	of	the	two	connected	centromeres	during	anaphase	leads	to	formation	of	an	anaphase	bridge	and	a	further	double	strand	break.	Subsequent	replication	and	end-to-end	fusion	in	the	daughter	cell	then	occurs,	repeating	the	process.	This	leads	to	a	classic	pattern	of	multiple	fold-back	inversions	and	a	stepped	amplicon	with	the	initial	and	most	amplified	junction	being	teleomeric	of	the	target	region	and	all	subseqeucnt	breaks	being	centromeric	preserving	the	selected	sequence	[261,262].	
1.5.3.4 Effects	of	structural	variation	Structural	variation	can	generate	a	huge	variety	of	genomic	disruption.	Most	common	and	well	studied	are	changes	in	copy	number.		Deletion	of	tumour	suppressor	genes	is	a	well-recognized	phenomenon.	Homozygous	deletion	of	tumour	suppressor	genes	such	as	CDKN2A	and	PTEN	is	well	documented	[223].	Additionally	hemizygous	deletion	leading	to	some	down	regulation	of	gene	expression	is	also	thought	to	play	a	significant	role	in	tumour	progression	[263].	Amplification	of	oncogenes	is	also	common	in	CIN	cancers.	Common	targets	include	receptor	tyrosine	kinases	such	as	EGFR	and	HER2/ERBB2.	The	amplification	leads	to	excessive	gene	expression	and	upregulation	of	downstream	signaling.	Identification	of	these	amplifications	predicts	response	to	novel	targeted	therapeutic	agents	[264,265].	Amplicons	may	contain	multiple	genes	and	the	target	of	the	amplicon	may	not	be	immediately	apparent.	By	
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increasing	the	number	of	samples	studied	the	chance	of	identifying	a	minimally	common	amplified	region	containing	only	one	gene	is	increased,	the	so-called	minimal	common	amplicon	approach	[266].		Statistical	approaches	have	also	been	developed[267].	Alternatively,	combining	analysis	of	mRNA	levels	and	amplicon	analysis	can	be	used	to	identify	the	target	by	identifying	the	gene	with	the	most	significant	change	in	expression	levels.	Intriguingly,	this	has	shown	that	in	some	cases	more	than	one	gene	may	be	driving	selection	of	an	amplicon	[266,268].	In	addition	to	simple	gain	or	loss	of	gene	copy	number	the	structure	of	the	gene	may	be	changed.	This	can	take	the	form	of	translocations	fusing	two	protein	coding	sequences	together	generating	a	novel	oncogenic	protein	[220,269].		These	genes	were	first	identified	in	the	more	karyotypically	simple	hametological	malignancies,	the	classic	example	of	this	being	the	BCR-ABL	fusion	gene	pathognomic	of	chronic	myeloid	leukaemia	[270].	It	is	now	accepted	that	fusion	genes	also	play	a	signifcant	role	in	solid	tumours	with	numerous	fusion	genes	identified	in	many	individual	cancers	[271,272].	Furthermore	ALK	fusion	genes	in	lung	adenocarcinoma	have	been	identified	as	candidates	for	targeted	therapies	demonstrating	the	importance	of	identifying	these	changes	[273].	Alternatively,	translocations	may	disrupt	non-coding	regulatory	sequence	of	a	gene	altering	its	expression.	The	classic	example	of	this	is	the	fusion	of	the	Immunoglobulin	heavy	chain	promotor	with	the	oncogene	MYC	in	Burkitt’s	lymphoma	[274-276].	This	leads	to	massive	and	unregulated	overproduction	of	MYC	in	early	B-cells	driving	proliferation.	Recently,	several	translocations	in	medulloblastoma	have	been	shown	to	alter	the	enhancer	landscape	around	oncogenes	leading	to	their	overexpression	[277].	Additionally,	several	complex	fusions	of	non-coding	RNAs	and	alternative	transcripts	have	been	identified	[53]	on	deep	analysis	of	transcriptomic	data.		
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1.6 Next	generation	sequencing	for	somatic	variant	detection	
Next	generation	or	Massively	Parallel	sequencing	refers	to	a	cluster	of	technologies	that	utilize	a	variety	of	approaches	to	perform	many	millions	of	sequencing	reactions	simultaneously	[33,278-281].	These	technologies	rely	on	the	solutions	to	two	key	problems	in	the	parallelisation	of	sequence	analysis;	first,	how	to	clonally	amplify	large	numbers	of	diverse	target	sequences	whilst	keeping	the	clonal	products	spatially	segregated,	and	second,	how	to	simultaneously	sequence	these	clonally	amplified	fragments.	In	classical	Sanger	sequencing	clonal	amplification	is	achieved	by	restricting	individual	PCR	and	flourophore	addition	reactions	to	single	reaction	wells	or	individual	bacterial	colonies,	thus	increased	throughput	is	achieved	by	increasing	the	number	of	wells	or	number	of	colonies.	As	sequencing	is	dependant	on	gel	electrophoresis,	parallelization	of	this	process	is	via	an	increasing	number	of	gel	filled	capillaries.	Two	key	systems	–	the	Illumina	Solexa	platform	and	the	454	platform	are	worth	considering	in	greater	detail,	the	former	as	it	is	by	some	distance	the	most	commonly	utilized	platform	and	the	latter	as	it	provides	a	more	rapid	and	clinically	applicable	turn	around	time.	For	both	platforms	sequencing	libraries	must	first	be	prepared.	These	libraries	consist	of	target	DNA	fragmented	to	a	size	that	is	easily	and	robustly	amplifiable	(roughly	between	100	and	800	bp)	with	universal	adaptor	sequences	ligated	to	the	ends	of	each	fragment.	These	universal	adaptors	allow	clonal	amplification	and	sequencing	to	take	place	using	a	single	primer	sequence	for	each	unique	DNA	fragment.	In	the	454	system	individual	library	fragments	are	then	captured	onto	beads	that	are	partitioned	into	individual	droplets	of	oil.	This	emulsion	is	then	subject	to	PCR	cycles	to	amplify	the	individual	molecules	of	DNA	attached	to	the	surface	of	the	beads.	The	individual	beads	are	then	captured	in	wells	of	a	chip	and	utilized	for	sequencing	[282].	In	the	Illumina	system,	amplification	takes	place	in	the	solid	state	on	the	surface	of	a	glass	slide	by	a	process	known	as	‘bridge	amplification’.	Individual	DNA	molecules	are	captured	on	to	the	surface	of	the	
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slide,	known	as	a	flow	cell,	which	is	coated	with	covalently	bound	short	oligonucleotides	complementary	to	the	ligated	adaptor	sequences.	A	single	cycle	of	polymerase	amplification	is	performed	followed	by	a	denaturation	step,	removing	the	parental	fragment,	leaving	a	daughter	strand	now	bound	to	the	surface	of	the	slide.	The	unbound	3’	end	of	this	fragment	is	free	to	interact	with	one	of	the	complementary	lawn	of	covalently	bound	oligonucleotides	–	forming	a	‘bridge’	structure	-	and	a	second	round	of	polymerase	amplification	is	performed	resulting	in	two	fragments	of	DNA	bound	to	the	slide.	This	process	is	repeated	resulting	in	a	localised	cluster	of	PCR	product	derived	from	the	individual	DNA	fragment.	The	methodology	of	sequencing	is	substantially	different	in	each	approach.	On	the	454	platform,	pyrosequencing	is	performed.	In	pyrosequencing	a	series	of	enzymatic	reactions	converts	the	pyrophosphate	released	when	a	nucleotide	is	added	to	an	extending	DNA	strand	to	an	emission	of	light.[283,284].	The	release	of	light	is	then	detected	and	quantified	allowing	prediction	of	the	number	of	nucleotides	incorporated.	Each	of	the	four	nucleotides	is	released	into	the	sequencing	reaction	independently	and	each	is	fully	removed	before	the	addition	of	the	next	by	the	laminar	flow	of	reagents	over	the	surface	of	the	wells.	It	is	therefore	possible	to	determine	the	sequence	of	the	strands	present	in	a	well	by	identifying	which	nucleotide	was	present	in	the	reaction	when	light	was	released.	Pyrosequencing	relies	on	an	optimized	system	of	enzymes	for	the	detection	of	nucleotide	incorporation.	An	elegant	extension	of	this	process	that	allows	the	removal	of	this	enzymatic	cascade	has	recently	been	developed,	known	as	the	IonTorrent	platform.	The	IonTorrent	platform	works	by	directly	detecting	the	hydrogen	ion	released	when	a	nucleotide	is	incorporated	into	the	extending	DNA	strand.	To	do	this	it	utilizes	an	array	of	semiconductors	that	detect	the	drop	in	pH	associated	with	an	increase	in	hydrogen	ion	concentration	within	individual	wells	when	a	nucleotide	is	incorporated	[281].	Sequencing	on	the	Illumina-Solexa	system	is	performed	by	the	detection	of	fluorophores	conjugated	to	incorporated	nucleotides.	To	ensure	only	one	base	is	
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incorporated	in	each	cycle,	reversible	terminator	bases	are	utilized,	modified	at	the	3’	position	(3’-O-azidomethyl)	to	prevent	further	extension.	The	unique	fluorophore	attached	to	the	base	is	detected	by	excitation	with	a	laser	and	imaging.	The	fluorophore	is	then	removed	along	with	the	addition	of	a	hydroxyl	group	to	the	3’	position	to	allow	further	extension	cycles	[278,285].	
1.7 Somatic	variant	detection	in	NGS	data	
If	sequencing	were	100%	accurate	it	would	be	a	simple	matter	to	identify	mutations	within	the	cancer	genome,	if	coverage		(i.e.	the	number	of		sequencing	reads	covering	the	target	site)	was	sufficient.	Difficulty	arises	for	all	forms	of	variation	as	errors	are	common	in	the	sequencing	process	and	mutations	are	relatively	rare	compared	to	the	overall	genomic	size	[77,286].	These	errors	may	be	generated	by	damage	to	the	DNA	from	storage	processes	[287],	sequencing	library	preparation	artifacts	,	sequencing	process	artifacts	[288]	and	data	analysis	difficulties,	the	most	predominant	of	which	is	alignment	of	the	sequencing	reads	[289-291].	In	addition,	cancer	harbours	numerous	copy	number	changes,	sub-clonality	and	is	an	admixture	of	tumour	and	normal	cells.	This	means	that	clinically	relevant	tumour	variants	may	be	found	at	almost	any	allele	frequency	[177,292].	The	role	of	variant	calling	pipelines	is	to	identify	the	signal,	true	mutations,	from	the	noise,	sequencing	errors	and	germline	variants.	This	broadly	takes	two	forms,	comparison	to	the	matched	normal	with	statistical	tests	–	identifying	stochastic	errors,	systematic	errors	and	germline	variation,	or	application	of	heuristic	filters	derived	from	previous	experience	of	artifacts	–	identifying	systematic	errors	or	germline	variation.	Recent	surveys	of	multiple	pipelines	utilized	by	the	ICGC	group	suggests	we	are	a	long	way	from	accurate	and	comprehensive	assessment	of	somatic	variants,	particularly	those	within	repeat	regions	of	the	genome	[293].	
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1.7.1 SNV	calling	pipelines	
There	are	numerous	SNV	calling	pipelines	available	for	the	analysis	of	NGS	data.	All	work	in	similar	ways	with	the	main	differences	being	statistical	tests	used	to	differentiate	between	tumour	and	normal	mutant	allele	numbers	and	the	filters	applied	to	the	data	to	remove	false	positive	calls.		The	first	step	in	the	process	following	alignment	of	the	reference	genome	is	to	identify	mismatched	positions	and	count	the	number	of	reads	containing	mismatches	to	the	reference	and	the	number	matching	the	reference,	in	both	the	tumour	and	the	normal.	A	statistical	test	for	significant	difference	is	then	applied	to	the	data	with	the	aim	of	identifying	if	there	is	a	significant	excess	of	mutant	reads	in	the	tumour	sample.	Statistical	tests	include	the	use	of	Fisher’e	exact	test	[294]	or	more	complex	Bayesian	approaches	altering	the	prior	probability	based	on	machine	error	rates	and	expected	tumour	mutation	rates	[295,296].	A	series	of	heuristic	filters	are	then	applied	to	the	data	to	correct	for	sources	of	error.	Several	factors	are	commonly	included	in	these	filters	including;	depth	of	sequencing	in	both	the	tumour	and	normal,	read	direction	in	which	the	mutant	reads	occur	–	accounting	for	strand	bias	of	sequencing	errors,	location	of	mutant	reads	in	the	read	i.e.	clustering	at	the	3’	end	(most	sequencing	technologies	become	more	error	prone	as	read	length	progresses),	and	absolute	number	of	mutant	reads	identified	within	the	normal	sample.		Several	comparisons	of	SNV	calling	pipelines	have	been	performed	[293,295,297,298].	The	choice	of	comparison	genome	is	particularly	important.	It	is	difficult	to	identify	a	gold	standard,	i.e.	a	genome	with	a	fully	verified	list	of	variants.	Several	papers	have	used	simulated	genomes	with	simulated	errors	and	mutations	however	this	is	hopelessly	biased	as	the	errors	introduced	in	these	pipelines	are	invariably	the	errors	that	the	specific	SNV	caller	being	tested	by	the	authors	is	designed	to	recognize.	The	current	gold-standard	verification	was	performed	by	the	ICGC	groups.		A	high	cellularity	medulloblastoma	genome	was	sequenced	to	300x	coverage	to	generate	a	high	quality	set	of	mutations.	A	down	sampled	read	set	was	then	analysed	by	multiple	competing	groups.	Only	about	
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80%	of	the	high	quality	variants	were	found	to	be	‘easily	detectable’	(present	in	the	majority	of	pipelines),	with	the	highest	sensitivity	being	76%	at	the	expense	of	a	specificity	of	13%.	The	most	interesting	outcome	from	this	study	was	that	a	combination	of	SNV	calling	pipelines	likely	yields	the	best	results	and	that	optimal	level	of	coverage	is	100x	in	both	tumour	and	normal	samples.	Of	note	this	coverage	level	is	far	above	the	current	ICGC	and	TCGA	aims	for	WGS	studies.	Despite	these	analyses	it	is	current	normal	practice	to	verify	a	subset	of	mutations	using	orthogonal	technologies	or	higher	depth	NGS	of	the	tumour	and	normal	reads.	An	alternative	approach	has	been	to	review	manually	the	potential	variants	using	a	read	displaying	genome	browser	such	as	the	Integrative	genomics	viewer	[215].		Popular	current	pipelines	include;	Varscan2,	SomaticSniper,	MuTect	and	CaVEMan	[215,294-296].	The	2	latter	pipelines	are	notable	as	they	address	the	current	major	difficulty	in	sequencing	pipelines,	poor	signal	to	noise	ratios	for	low	variant	allele	frequency	mutations	(sub-clonal	or	in	areas	of	high	copy	number).	Of	particular	note	Caveman	utilizes	copy	number	information	to	alter	the	detection	threshold	within	areas	of	differing	copy	number	states	[211,215],	again	seeking	to	leverage	statistical	methods	to	identify	low	allele	fraction	mutations.	Of	note,	mutants	within	certain	recurrently	mutated	genes	e.g.	TP53	have	an	increased	chance	of	being	true	positives.	These	mutations	are	of	high	importance,	as	they	are	known	to	be	functional,	allow	sub-grouping	of	tumours	and	have	potential	therapeutic	relevance.	A	possible	optimised	pipeline	would	therefore	include	an	initial	step	of	identifying	mutations	and	assigning	them	to	high	and	low	probability	groups.	Low	probability	mutations	could	then	be	annotated	by	genomic	position	and	higher	probability	assigned	to	those	that	are	likely	to	be	driver	mutations	based	on	prior	knowledge	of	relevant	cancer	genes.	
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1.7.2 INDEL	calling	pipelines	
INDEL	variant	calling	represents	arguably	the	greatest	challenge	in	NGS	data	analysis.	The	difficulty	stems	primarily	from	the	difficulty	in	aligning	reads	containing	INDELs	accurately.		Thus	sequencing	coverage	is	lower	across	INDELs.	This	stems	from	two	main	issues,	first	INDELs	tend	to	occur	around	repeat	rich	regions	which	are	more	difficult	to	match	as	the	majority	of	alignment	pipelines	require	the	removal	of	reads	with	a	non-unique	mapping.	Secondly,	the	presence	of	a	small	INDEL	within	a	read	increases	the	difficulty	of	alignment	with	current	seed-and-extend	based	strategies	(BWA,	SOAP).	Aligners	often	tend	to	align	reads	with	INDELS	by	ignoring	the	INDEL	and	labeling	subseqeucnt	bases	as	mismatches	due	to	the	frameshift	relative	to	the	reference.		INDEL	identification	pipelines	therefore	typically	utilize	an	additional	local	realignment	or	local	de-novo	assembly	phase	with	a	more	accurate	but	typically	slower	aligner	aiming	to	minimize	the	number	of	mismatched	bases	in	a	read	[299,300]	favouring	gapped	alignments	instead.	Somatic	status	is	then	assigned	by	a	comparison	of	the	results	of	this	new	alignment	between	the	tumour	and	the	normal	[301].		Popular	INDEL	calling	pipelines	include,	Indelocator,	GATK,	and	PINDEL2	[165,298,301].	Again	benchmarking	of	these	has	shown	poor	sensitivity	and	specificity	and	so	much	further	work	is	required	[293].	
1.7.3 SV	calling	pipelines	
SV	calling	remains	the	most	developmental	of	all	somatic	variant	detection.	Four	primary	strategies	exist;	discordant	read	pair	mapping,	split	read	assembly,	local	reconstruction	and	read	depth	analysis.		Read	depth	analysis	allows	the	identification	of	changes	in	the	number	of	copies	of	a	given	position	in	the	genome	relative	to	all	others.	If	all	areas	of	the	genome	are	homogenously	targeted	by	copy	number	alteration,	for	example	
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endoreduplication	leading	to	tetraploidy,	then	read	depth	analysis	would	not	be	able	to	identify	this.	Using	sequencing	data	can	provide	highly	accurate	localization	of	copy	number	steps	due	to	the	relatively	small	fragment	sizes.	The	process	relies	on	the	fact	that	next	generation	sequencing	should	not	favour	any	area	of	the	genome,	thus	the	number	of	reads	that	occur	from	a	region	is	proportional	to	the	representation	of	that	region	within	the	sample.	In	a	100%	cellularity,	diploid	tumour	sample	and	area	of	hemizygous	deletion	would	expect	to	have	half	the	number	of	reads	in	a	fixed	length	of	gemone	than	is	seen	in	diploid	areas	of	the	genome.		Unfortunately	next	generation	sequencing	approaches	do	not	provide	homogenous	distribution	of	sequencing	reads.	Several	factors	bias	the	distribution	of	reads	including	the	GC	content	of	the	genome	and	the	mappability	of	an	area	(i.e.	repeat	regions	have	poor	mappability).	This	can	be	corrected	for	either	by	comparison	to	the	read	depth	at	a	given	region	in	a	known	diploid	sample,	or	by	correction	for	known	biasing	factors	such	as	GC	content	[302,303].	Whilst	read	depth	analysis	can	provide	accurate	copy	number	plots	for	tumours	it	does	not	allow	for	the	identification	of	exact	junctional	sequence	and	therefore	cannot	provide	detailed	information	on	the	structure	of	junctions.	In	addition	it	is	not	capable	of	detecting	rearrangements	in	which	no	genetic	information	is	gained	or	lost,	so-called	balanced	translocations.	Discordant	read	pair	mapping	has	become	the	workhorse	of	SV	detection	in	particular	from	Illumina	next	generation	sequencing	data	[304-309].	It	utilizes	the	fact	that	both	ends	of	a	DNA	fragment	are	sequenced	as	part	of	a	standard	Illumina	pipeline	for	whole	genome	sequencing	When	aligned	to	the	target	genome	these	reads	should	map	closely	to	each	other	within	a	fragment	length.	Additionally,	one	read	should	map	to	the	positive	strand	and	the	other	to	the	negative	strand	and	should	be	orientated	such	that	the	read	which	maps	to	the	positive	strand	is	upstream	of	the	read	that	maps	to	the	negative	strand.	Any	deviation	from	this	normal	mapping	suggests	that	a	rearrangement	of	genomic	sequence	has	occurred.		
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Though	this	approach	can	be	sensitive,	several	problems	occur.	As	with	INDELs	and	SNVs	one	of	the	major	difficulties	comes	from	removal	of	errors	generated	by	the	sequencing	process.	These	include	the	generation	of	novel	chimeric	reads	during	library	preparation	and	frequently	small	inversions	as	fragments	are	joined	end-to-end	and	refragmented	[310].	Alignment	issues	can	also	generate	novel	SVs,	in	particular	errors	of	the	sequencing	process	can	lead	to	alignment	of	reads	to	a	nearly	homologous	area	of	the	genome.	Correction	for	these	errors	can	be	either	by	masking	particularly	error	prone	genomic	regions;	comparison	to	a	matched	normal	sample	with	or	without	multiple	additional	non-matched	normal	samples;	or	by	requiring	greater	levels	of	evidence	e.g.	identification	of	a	read	spanning	the	junction	or	requiring	multiple	discordant	read	pairs	to	span	a	junction.	Split	read	analysis	utilizes	individual	reads	that	span	SV	junctions.		These	reads	will	have	sequences	from	at	least	two	areas	of	the	genome	depending	on	the	junctional	complexity	and	will	therefore	not	be	mappable	to	the	reference	genome.		Local	genome	alignment	utilizes	reads	from	around	the	astructural	variant	to	derive	the	exact	junctional	sequence.	It	is	not	usually	utilized	for	the	identification	of	the	presence	of	a	rearrangement,	instead	it	is	used	to	confirm	the	presence	of	the	variant	suggested	by	alternative	approaches	and	provide	exact	sequence	level	information.		Unlike	split	read	approaches,	de	novo	alignment	utilizes	all	reads	from	an	area	around	possible	SV	and	thus	should	generate	two	sequences,	a	normal	haplotype	and	mutant	haplotype	containing	the	SV.	Several	algorithms	have	been	developed	using	this	de	novo	assembly	approach	[42,308].	Typically	the	sensitivity	is	lower	than	is	seen	for	discordant	read	pair	analysis	however	the	specificity	is	greater	[42].		Verification	of	SVs	is	usually	via	PCR	and	identification	of	a	product	on	gel	electrophoresis,	though	this	represents	a	gold	standard	PCR	is	known	to	fail	in	highly	repetitive	regions.	A	more	accurate	pipeline	for	verification	should	therefore	include	orthogonal	techniques	such	as	comparison	to	read	depth	
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analysis,	karyotyping	techniques	such	as	Floursesnce	in	situ	hybridization	and	resequencing	of	the	junctions.	
1.8 Oesophageal	adenocarcinoma	
The	following	review	is	taken	from	an	article	written	by	myself,	Dr		Caryn	Ross-Innes	and	Professor	Rebecca	Fitzgerald	[311].	It	provides	a		summary	of	what	was	known	regarding	somatic	variation	before	this	project	came	to	fruition.		
1.8.1 Epidemiology	and	clinical	pattern	
Oesophageal	adenocarcinoma	(OAC)	has	increased	sevenfold	to	become	the	predominant	form	of	oesophageal	cancer	in	the	western	world	over	the	past	30	years[312].	An	intense	research	effort	to	better	understand	this	disease	is	underway	as	a	result	of	the	dramatic	epidemiological	shift	in	incidence	and	the	abysmal	patient	outcomes:	the	overall	5-year	survival	is	<20%.	Even	for	those	patients	(<50%)	deemed	fit	for	curative	interventions	with	aggressive	neoadjuvant	therapy	followed	by	surgery,	the	outcomes	are	still	poor	with	a	5-year	survival	of	<45%	[313].	Current	treatment	regimes	depend	on	radiological	and	histopathological	assessments	of	disease	location	and	stage	with	little,	if	any,	consideration	of	the	molecular	pathogenesis;	by	contrast,	for	other	epithelial	cancers	(such	as	colon	cancer),	stratification	already	takes	into	account	molecular	information.		The	natural	history	of	OAC	is	poorly	understood;	however,	it	is	known	that	the	majority	of	cases	arise	on	a	background	of	Barrett	oesophagus	[314,315].	Barrett	oesophagus	occurs	when	the	normal	oesophageal	cells	are	replaced	by	glandular	cells	and	this	change,	with	time,	can	progress	to	low-grade	dysplasia,	high-grade	dysplasia	and	then	finally	to	adenocarcinoma.	OAC	generally	occurs	in	the	distal	oesophagus	and	at	the	gastro-oesophageal	junction.	OACs	are	considered	as	gastro-oesophageal	tumours	if	they	lie	within	5	cm	of	the	junction	and	are	further	subclassified	depending	on	where	the	bulk	of	the	tumour	lies:	type	I	tumours	lie	predominantly	within	the	oesophagus,	occur	more	often	in	men	and	are	more	strongly	associated	with	the	presence	of	Barrett	oesophagus	as	a	
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consequence	of	gastro-oesophageal	reflux;	type	III	tumours,	by	contrast,	lie	predominantly	within	the	proximal	stomach	and	are	associated	with	atrophic	gastritis	and	intestinal	metaplasia	of	the	cardia	with	less	of	a	male	predominance;[316,317]	and	type	II	tumours	have	an	intermediate	profile[318].	The	position	of	the	tumour	determines	the	surgical	approach,	although	it	is	not	yet	clear	the	extent	to	which	the	molecular	evolution	of	these	disease	subtypes	is	distinct.	A	better	understanding	of	the	molecular	pathogenesis	and	classification	might	have	major	implications	for	targeted	therapies.		Over	the	past	few	years	genome-wide	technologies,	so	called	–omics,	have	revolutionized	the	research	environment,	enabling	large-scale	projects	that	could	not	have	been	conceived	of	15	years	ago.	The	–omics	era	started	with	the	sequencing	of	the	human	genome	in	1990	and,	since	then,	the	speed	and	scale	of	genome	analysis	has	increased	exponentially,	driven	by	the	development	of	microarrays	and	high-throughput	sequencing	technologies.	In	addition	to	analysis	of	the	DNA	sequence	(genomics),	the	–omics	revolution	has	incorporated	the	analysis	of	transcribed	RNA	(transcriptomics)	and	the	regulatory	mechanisms	underlying	control	of	transcription	including	the	microRNA	(miRNA)	profile	of	a	cell	(so-called	miRNAomics),	the	methylated	cytosines	within	the	genome	(epigenomics)	and	the	regulatory	regions	within	the	genome	to	which	the	transcription	factors	bind	(cistromics).	All	proteins	present	in	a	sample	can	also	be	determined	(proteomics)	and	the	microorganisms	present	in	different	tissues	can	also	be	deduced	(microbiomics).	Each	of	these	technologies	alone	is	powerful	and	enables	an	unbiased	view	of	the	features	making	up	a	cancer	cell;	when	combined	together,	they	are	even	more	effective,	enabling	an	overall	picture	of	the	perturbed	systems	occurring	in	that	cell.	The	challenge,	however,	still	remains	as	to	how	to	fully	integrate	these	data	and	how	to	delineate	and	understand	the	pathways	that	are	interacting	within	and	between	cells	that	are	disrupted	in	cancer,	thus	permitting	the	manipulation	of	these	pathways	and	identification	of	new	diagnostic	approaches	and	drug	targets.		Although	early	detection	of	OAC	is	the	ideal	scenario,	the	vast	majority	of	patients	with	OAC	present	late	with	unresectable	disease.	For	most	patients,	
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treatment	options	are	limited	and	prognosis	is	exceptionally	poor.	A	greater	understanding	of	the	biology	of	OAC	is	required	to	further	stratify	patients	and	provide	new	therapeutic	directions.		
1.9 The	role	of	NGS	in	advancing	understanding	of	OAC	
1.9.1 Somatic	variation	in	the	OAC	genome	
Prior	to	2012,	relatively	little	was	known	about	the	genomic	changes	that	drive	OAC.	Several	small	studies	had	utilized	transcriptomic	analyses	[319-326]	and	large-scale	copy	number	variants,[327-331]	but	no	systematic	unbiased	screen	for	point	mutations	or	small	insertions	and	deletions	had	been	undertaken.	Recent	years	have	seen	an	explosion	of	studies	using	genome-wide	analyses	to	catalogue	the	genomic	events	that	define	OAC		[332-335].	Although	much	work	remains,	these	first	insights	have	already	begun	to	transform	our	understanding	of	this	tumour,	identifying	26	genes	that	are	recurrently	affected	by	single	nucleotide	variants,	19	regions	targeted	by	recurrent	deletions	and	24	regions	affected	by	recurrent	focal	amplifications.	The	observations	from	these	studies	have	also	confirmed	the	results	of	earlier	work	on	smaller	cohorts	that	had	identified	the	known	tumour	suppressors	TP53	and	CDKN2A	as	recurrently	targeted	genes	in	OAC	development	[336,337].		Novel	findings	from	these	latest	genomic	studies	included	the	observation	that	almost	one	quarter	of	OACs	harbour	at	least	one	mutation	in	a	chromatin-remodelling	gene	[333,335]with	ARID1A	and	SMARCA4,	members	of	the	SWI/SNF	(Switch/sucrose	nonfermentable)	complex	being	the	most	frequently	targeted.	Notably,	there	seems	to	be	mutual	exclusivity	between	mutations	in	members	of	this	functional	network,	supporting	the	hypothesis	that	each	mutation	could	be	contributing	to	a	common	phenotype.	OAC	therefore	now	joins	the	long	list	of	tumours	in	which	disruption	of	chromatin	regulation	seems	to	be	a	crucial	step	in	tumourigenesis	[338-341].	In	addition,	recurrent	mutations	were	identified	in	ELMO1	and	DOCK2,	genes	feeding	into	the	RAC1	GTPase	pathway[333].	Many	roles	have	been	suggested	for	RAC	GTPase	signalling	in	cancer,	including	increased	invasion,	decreased	apoptosis	and	
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increased	cell	survival	[342].	The	researchers	were	able	to	demonstrate	that	the	majority	of	the	observed	mutations	contributed	to	increased	invasive	capacity,	but	no	role	in	proliferation	was	investigated.		Despite	these	notable	new	discoveries,	perhaps	the	most	striking	finding	from	these	data	is	the	marked	heterogeneity	seen	between	OACs.	Only	the	tumour	suppressor	gene,	TP53,	is	mutated	in	greater	than	half	of	OACs.	In	one	of	the	first	genome-wide	screens	for	point	mutations	and	INDELs	in	cancer,	Wood	et	al.	observed	that	only	very	few	genes	are	mutated	in	a	large	proportion	of	cases	for	a	given	cancer	type,	so-called	‘mountain’	genes;	the	majority	of	recurrent	mutations	are	found	only	in	a	small	percentage	of	tumours,	‘hill’	genes.		
1.9.2 Classification	of	junctional	tumours		
It	has	been	suggested	that	OAC	and	intestinal-type	gastric	adenocarcinoma	should	be	considered	together	in	future	trials	owing	to	similar	responses	in	a	previous	randomized	control	trial	[343].	Intriguingly	though,	findings	from	recent	genomic	studies	suggested	that	there	are	major	genetic	differences	between	tumours	of	gastric	origin	and	those	that	arise	from	the	oesophagus.	A	single	study	comparing	the	copy	number	profiles	of	189	OAC	tumour	samples	with	129	gastric	carcinomas	was	able	to	identify	several	genes	that	seemed	to	be	targets	of	amplification	and	deletion	in	only	one	disease	site	[334].	These	genes	include,	among	others,	FGFR2,	CDK6	and	MET,	whose	amplification	was	unique	to	OAC,	and	EPHB3,	whose	amplification	was	unique	to	gastric	adenocarcinoma.	Although	it	remains	undetermined	why	such	tissue-specific	differences	are	observed,	these	data	provide	evidence	that	these	tumours	should	be	separated	on	more	than	anatomical	grounds	and	further	work	is	needed	in	this	area.	As	yet,	relatively	few	distal	gastric	carcinomas	have	been	subject	to	exome	or	whole-genome	sequencing	and	it	is	not	yet	clear	what	differences	might	exist	at	this	level[340,344,345].	The	observation	that	a	unique	mutational	signature	is	enriched	in	OACs	arising	more	proximally	suggests	that	the	mutational	patterns	within	a	junctional	tumour	might	be	used	to	discriminate	its	aetiology	and	this	aspect	should	be	further	explored	[333].	
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Transcriptomic	data	could	also	be	used	to	differentiate	junctional	tumours.	The	use	of	transcriptomic	profiles	to	differentiate	between	different	tumour	types	has	been	most	elegantly	demonstrated	in	the	profiling	of	metastatic	cancers	of	unknown	primary	site	(CUP)	[346].	In	this	study,	the	authors	were	able	to	predict	the	primary	site	of	origin	in	98%	of	assayable	patients	utilizing	a	92-gene	signature.	Chemotherapy	regimens	were	chosen	based	on	this	prediction	and	an	improved	overall	survival	was	demonstrated	relative	to	previous	trials.	With	future	clinical	trials	and	further	–omics	analyses	it	might	be	possible	to	design	a	panel	of	somatic	variants	and	transcriptomic	profiles	that	combined	could	more	accurately	classify	junctional	tumours	into	different	molecular	subtypes.		
1.9.3 Novel	therapeutic	strategies	for	OAC		
For	OAC,	the	response	rate	to	conventional	chemotherapeutic	regimens	is	dismal	[313].	Novel	targeted	approaches	have	demonstrated	striking	efficacy	in	several	cancer	types	with	the	majority	of	drugs	targeting	the	receptor	tyrosine	kinase	signalling	pathway.	Several	studies	published	in	the	past	few	years	have	comprehensively	demonstrated	amplification	and	overexpression	of	receptor	tyrosine	kinase	in	OAC	[334,347,348]	When	single	nucleotide	mutations	are	also	considered,	nearly	half	of	OACs	harbour	a	somatic	variant	potentially	targetable	by	drugs	currently	in	clinical	trials	[333]	Disappointingly,	trials	using	single	targeted	agents	such	as	gefitinib,	have	so	far	shown	little	efficacy	in	OAC	[349,350].	These	studies	have	largely	been	in	unselected	populations	with	analysis	of	pathway	activation	performed	after	therapy	has	been	delivered.	Trials	with	more	specific	molecular	inclusion	criteria	are	therefore	warranted.	The	efficacy	of	this	targeted	approach	was	demonstrated	by	the	ToGA	trial	[264].	In	this	trial,	patients	with	junctional	OAC,	or	gastric	adenocarcinoma,	with	overexpression	or	amplification	of	HER2,	were	randomly	assigned	to	chemotherapy	with	or	without	the	addition	of	trastuzumab,	a	monoclonal	antibody	against	HER2.	Improved	overall	survival	was	observed	in	the	trastuzumab	plus	chemotherapy	arm.	Given	the	high	rates	of	TP53	mutation	in	OAC,	the	results	from	this	trial	will	be	of	particular	interest.	In	the	interim,	comprehensive	–omic	profiling	of	the	samples	from	these	trials	has	the	potential	
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to	return	huge	benefits	in	the	form	of	novel	markers	of	sensitivity	and	resistance	to	specific	therapies.	The	advent	of	the	–omics	revolution	has	generated	a	plethora	of	new	findings	driving	forward	our	understanding	of	OAC	biology.	Some	of	the	findings	have	confirmed	previous	discoveries	from	candidate-driven	studies;	however,	several	new	discoveries	have	been	made	as	a	result	of	genome-wide	unbiased	screens.	These	new	findings	include	the	identification	of	alterations	in	the	chromatin-remodelling	system	and	the	identification	of	global	hypomethylation	during	the	progression	from	Barrett’s	oesophagus	to	cancer.		The	ability	to	accurately	risk	stratify	patients	entering	into	the	curative	surgical	pathway	has	the	potential	to	dramatically	improve	the	selection	of	patients,	limiting	futile	surgery	along	with	its	associated	mortality	and	morbidity.	However,	limited	possibilities	remain	for	treating	those	patients	deemed	in	need	of	palliative	care	and	their	prognosis	is	dismal.	For	this	reason,	much	effort	in	cancer	–omics	studies	has	centred	on	developing	targeted	medications	in	the	hope	of	finding	Ehrlich’s	fabled	‘magic	bullet’.	The	finding	that	nearly	half	of	OACs	harbour	at	least	one	of	a	list	of	genomic	aberrations	that	might	be	the	target	of	a	drug	in	current	clinical	development	is	promising.	However,	it	now	seems	that	the	heterogeneity	inherent	in	all	tumours	may	preclude	such	a	strategy	from	ever	providing	a	complete	cure	[292,351,352].	Early	detection,	therefore,	remains	the	most	promising	approach	for	limiting	cancer	mortality.	A	unique	feature	of	OAC	is	the	development	from	a	readily	detectable	pre-malignant	lesion,	Barrett	oesophagus,	making	it	a	prime	candidate	for	the	exploration	of	novel	approaches	to	early	diagnosis	[353].	A	combination	of	genomics,	transcriptomics	and	microbiomics,	among	others,	might	well	provide	a	detailed,	personalized	risk-stratification	profile	for	each	patient,	enabling	time	for	early	intervention	and	the	possibility	of	a	prevention	strategy	for	OAC.		Although	it	is	now	possible	to	generate	genome-wide	data	in	a	clinically	relevant	time	frame,	applicability	is,	as	yet,	limited	by	sample	input	requirements,	cost,	computational	time	required	and,	perhaps	most	importantly,	the	ability	to	usefully	interpret	the	output.		Well-designed,	adequately	powered	and	
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well-managed	clinical	studies	with	properly	curated	clinical	information	(such	as	provided	by	the	ICGC	and	TCGA	efforts)	are	required.		
1.10 Aims	of	this	PhD	
1. Identify	number	and	patterns	of	single	nucleotide	variants	in	
oesophageal	adenocarcinoma	OAC	is	subject	to	a	unique	exposure;	acid	and	bile	acid	refluxing	from	the	stomach	[314].	Degree	of	reflux	is	associated	with	risk	of	malignancy	and	risk	of	developing	the	precursor	of	malignancy,Barrett’s	oesophagus.	Multiple	mechanisms	have	been	proposed	for	the	link	between	reflux	oesophagitis	and	OAC,	including	direct	DNA	damage,	inflammation	mediated	DNA	damage	and	alteration	of	microenvironment.	Cancers	such	as	melanoma	and	non-small	cell	lung	cancer	with	strong	epidemiological	links	to	powerful	mutagens	harbour	large	numbers	of	mutations	with	unique	signatures.				In	this	thesis	I	will	use	whole	genome	sequencing	data	from	oesophageal	cancer	and	matched	normal	to	identify	the	number	of	somatic	mutations	in	the	average	oesophageal	adenocarcinoma.	Using	the	methodology	developed	in	Alexandrov	et	al	I	will	characterize	novel	mutational	signatures	in	OAC.		
2. Develop	and	validate	a	pipeline	for	identifying	structural	variants	in	
oesophageal	adenocarcinoma	Early	studies	of	OAC	have	shown	substantial	rearrangement	of	its	genome	in	almost	all	cases.		Next	generation	sequencing	provides	important	information	over	and	above	that	available	from	array	based	methods.	These	including	details	as	to	the	structure	of	the	junctions	and	the	exact	connections	between	rearranged	fragments	of	DNA.	However	pipelines	for	SV	calling	remain	rudimentary	and	have	little	validation	of	their	sensitivity	and	specificity.		In	this	PhD	I	will	aim	to	develop	and	validate	a	pipeline	for	calling	structural	variants.		In	
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particular	I	will	focus	on	assessment	of	the	sensitivity	of	the	pipeline	by	comparison	to	copy	number	profiles	and	specificity	by	developing	a	pipeline	for	the	high	throughput	PCR	and	sequencing	verification	of	identified	variants.	
3. Characterize	the	timing	of	these	mutations	in	the	development	of	
oesophageal	adenocarcinoma	The	presence	of	Barrett’s	oesophagus	close	to	OAC	provides	a	unique	model	of	malignant	progression.	This	thesis	will	utilize	this	material	to	identify	the	timing	of	muations	in	OAC	relative	to	the	phenotypic	progression	described	by	the	Barrett-dysplasia-carcinoma	progression.	This	will	provide	insight	into	the	role	of	these	mutations	in	the	development	of	the	hallmarks	of	malignancy.													
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Chapter	2 	
	
	
	
Methods		 	
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2.1 Molecular	biology	
2.1.1 Verification	of	somatic	SNVs	and	INDELs	by	PCR	and	Sanger	sequencing	
The	sequence	200bp	upstream	and	downstream	of	the	variant	was	manually	extracted	using	the	UCSC	genome	browser.	Primers	were	designed	using	the	BatchPrimer	3	website	[354]	with	a	Tm	of	60°C.	PCR	was	carried	out	on	the	tumour	and	normal	samples	using	HotMaster	Taq	Polymerase	(VWR)	with	the	following	reaction	mix:	1X	HotMaster	Buffer,	0.4mM	dNTP	mixture,	0.4μM	each	of	forward	and	reverse	primers,	1U	Taq	DNA	Polymerase	and	20ng	DNA	in	a	total	25μl	reaction.	Cycling	conditions	were;	an	initial	denaturation	step	of	95°C	for	5	minutes,	followed	by	35	cycles	of	95°C	for	30	seconds,	then	primer	annealing	temperature	(calculated	Tm)	for	30	seconds,	72°C	for	20s	and	finally	72°C	for	10	minutes.		
Amplification	was	confirmed	by	gel	electrophoresis	in	1.5%	Agarose	gel	made	by	dissolving	agarose	in	1x	TBE	buffer.	Ethidium	bromide	was	added	to	a	concentration	of	0.5	μg	ml-1	to	allow	visualization	by	UV	light	and	products	were	visualized	using	the	G:BOX	gel	doc	system	(Syngene).	Size	was	compared	to	a	commercially	available	DNA	fragment	ladder	(Hyperladder	I).	If	amplification	was	confirmed	in	both	tumour	and	normal	samples	the	resulting	products	were	purified.	Successful	PCR	reactions	were	purified	using	the	QIAquick	PCR	Purification	Kit	(Qiagen)	according	to	manufacturer’s	instructions		and	sequenced	by	Sanger	sequencing.	This	was	performed	by	Eurofins	GATC	Biotech	(European	Genome	and	Diagnostics	Centre,	Jakob-Stadler-Platz,	778467,	Constance,	Germany)	using	standard	conditions	and	equipment.	All	traces	were	visualized	using	Chromas	lite	2.01	and	were	manually	reviewed	for	presence	of	the	variant.	An	indel	or	SNV	was	considered	somatic	if	it	was	present	only	in	the	tumour	trace.		
2.1.2 Verification	of	single	nucleotide	variants	by	targeted	re-sequencing		
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As	part	of	a	larger	benchmarking	exercise	of	our	SNV	calling	pipeline	we	selected	2007	SNVs	to	be	verified.	These	SNVs	included	those	that	had	failed	filters	and	those	that	had	been	predicted	using	the	Illumina	pipeline,	ELAND	alignment	plus	STRELKA.	The	complete	analysis	of	these	data	is	ongoing	with	the	overall	aim	of	optimizing	the	sensitivity	of	our	SNV	calling	pipeline.	Following	a	preliminary	analysis	and	comparison	to	the	ICGC	benchmarking	exercise	we	chose	to	increase	the	stringency	of	our	filters	for	this	pilot	dataset	(detailed	above).	The	verification	data	in	this	manuscript	are	for	only	those	SNVs	passing	these	additional	filters.	Putative	non-synonymous	SNVs	(1330	in	total)	underwent	ultra-high-depth	targeted	sequencing.	For	eight	samples	all	non-synonymous	variants	were	sent	for	verification.	In	the	remaining	14	cases,	the	selected	SNVs	were	restricted	to	non-	synonymous	variants	in	genes	mutated	in	more	than	one	sample.	Amplicons	were	generated,	indexed	and	pooled,	and	libraries	constructed	as	per	Shah	et	al[355].	Samples	were	pooled	separately	and	a	single	lane	of	HiSeq-2000	data	was	generated	for	each,	leading	to	a	typical	depth	of	coverage	of	13,855	(IQR:3,408	to	39,059	for	the	amplicons).	For	1086	of	these	≥50-fold	coverage	was	generated	for	both	tumour	and	normal.	An	SNV	was	confirmed	as	somatic	if	the	variant	allele	frequency	was	≤	1%	in	the	matched	normal	and	≥	2%	in	the	tumour.	
2.1.3 PCR	and	sequencing	for	somatic	SV	verification	
Details	of	the	primer	design	process	are	given	in	Chapter	3	under	the	heading	‘Development	of	a	pipeline	for	the	high	throughput	verification	of	SVs’	and	below	in	the	bioinformatics	methods	section.	All	first	round	primers	were	tagged	with	the	Fluidigm	universal	sequences	CS1	and	CS2	allow	addition	of	the	Illumina	adaptor	sequence	in	the	second	round	of	PCR.	As	repeat	sequence	was	left	unmasked	(described	in	Chapter	3)	the	more	sensitive	and	specific	touch	down	PCR	procedure	was	used	[356].	Cycling	conditions	were	an	initial	denaturation	step	of	95°C	for	5	minutes,	followed	by	a	single	cycle	of	95°C	for	30	seconds,	then	primer	annealing	temperature	+10°C	for	30	seconds	then	72°C	for	90s;	this	is	repeated	for	10	cycles	decreasing	by	1°C	for	every	cycle	until	the	Tm	of	the	primers	is	reached.	
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Following	this	a	further	25	cycles	are	performed	as	above	but	with	the	annealing	step	performed	at	the	primer	annealing	temperature.	A	final	elongation	stage	of	10	minutes	is	then	performed.	Visualisation	of	products	was	undertaken	as	per	the	SNV	verification	protocol.		PCR	products	from	tumour	samples	were	quantified	using	a	Nanodrop	instrument,	diluted	to	equal	concentrations	and	pooled.	Primers	from	the	initial	reaction	were	then	digested.	Two	microlitres	of	IllustraExostar	1-step	(GE	Healthcare	UK	Ltd)	were	added	to	the	5	ul	of	pooled	PCR	products	and	the	Exostar	reaction	was	performed	(15	minutes	at	37°C	followed	by	15	minutes	at	80°C).	One	microlitre	of	the	pooled	Exostar-treated	products	was	then	added	to	the	second	round	PCR.	In	this	reaction,	Illumina	adaptors	were	added	to	the	PCR	product	using	the	Fluidigm.	Barcode	primers	were	used	as	they	contain	a	sequence	that	binds	to	the	CS1	and	CS2	sequences.	The	barcode	PCR	mix	consisted	of	1	×	Q5	master	mix,	5%	DMSO,	final	concentration	of	400	nM	of	each	barcode	primer	pair	and	1	ul	of	undiluted	Exostar-treated	DNA.	The	cycling	conditions	for	the	PCR	were:	initial	denaturation	at	98°C	for	30	seconds	followed	by	6	cycles	of	98°C	for	10	seconds,	60°C	for	10	seconds	and	72°C	for	2	minutes.	A	final	extension	at	72°C	for	10	minutes	was	also	included	to	ensure	elongation	of	all	PCR	products.		The	library	was	quantified	using	the	Agilent	BioAnalyzer	and	subjected	to	Illumina	cluster	generation	at	the	Cancer	research	UK	Cambridge	institute.	Two-hundred	and	fifty	base	pair	paired-end	sequencing	was	performed	on	a	MiSeq	using	custom	sequencing	primers	targeted	to	the	CS1	and	CS2	tags	for	both	read1	and	read	2	according	to	manufacturer’s	recommendations.		
2.1.4 Oesophageal	adenocarcinoma	sample	collection	and	pathology	review	
The	study	was	approved	by	the	Institutional	Ethics	Committees	(REC	Ns	07/H0305/52	and	10/H0305/1)	and	all	patients	gave	individual	informed	consent.	For	the	cohort,	of	43	patients	who	underwent	WGS,	esophageal	adenocarcinoma	(OAC)	patients	were	recruited	prospectively	and	samples	were	obtained	either	from	surgical	resection	or	endoscopic	ultrasound	(EUS).	Blood	or	
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normal	squamous	esophageal	samples,	distant	at	least	5cm	from	the	tumour,	were	used	as	germline	reference.	All	tissue	samples	were	snap-frozen	in	liquid	nitrogen	immediately	after	collection	and	stored	at	−80°C.		Prior	to	DNA	extraction,	one	section	was	cut	from	each	tissue	sample	and	H&E	staining	was	performed.	Cancer	samples	were	deemed	suitable	for	DNA	extraction	only	after	consensus	review	by	two	expert	pathologists	had	confirmed	tumour	cellularity	≥70%.		Where	blood	was	not	available	the	same	review	process	was	applied	to	the	normal	esophageal	samples	to	ensure	that	only	squamous	epithelium	was	present.	For	the	Discovery	cohort	127	cases	were	screened	from	two	centres	(Cambridge	and	Southampton).	63	cases	had	70%	cellularity	required	to	meet	ICGC	criteria	and	of	these	43	tumour:normal	pairs	had	sufficient	quality	and	quantity	of	DNA	extracted	(total	yield	≥	5μg),	and	were	submitted	for	whole	genome	sequencing.	Data	from	twenty-two	of	these	cases	(Batch	0	or	pilot	cohort)	were	used	in	Chapter	5	for	the	identification	of	driver	genes.	Data	from	all	43	cases	were	used	for	Chapters	3	and	4,	developing	pipelines	of	SNV	and	SV	calling	and	identifying	mutational	signatures	For	the	pre-	invasive	disease	cohort	we	screened	our	entire	10	year	prospective	Barrett’s	cohort	of	>500	patients	and	selected	cases	in	which	there	was	frozen	material	available	and	for	which	review	of	the	frozen	section	revealed	a	homogeneous	grade	of	dysplasia	or	BE	following	expert	histopathological	review	(Dr	Maria	O’Donovan,	Consultant	Histopathologist,	University	of	Cambridge	NHS	Foundation	trust)	.	
2.1.5 Sample	preparation	and	DNA	extraction	
DNA	extraction	was	performed	using	the	Qiagen	DNeasy	blood	and	tissue	system	following	the	manufacturer’s	instructions.	Tissues	samples	were	marodissected	and	10mg	pieces	were	used	for	extraction.	For	blood	extraction	100μl	of	whole	blood	was	added	to	20μl		of	proteinase	K	and	100μl	of	PBS.	All	solid	tissue	samples	were	lysed	using	the	Precellys	24	system	(Bertin	Technologies	SAS,	Parc	
	 67	
d’activités	du	Pas	du	Lac,	10	bis	avenue	Ampère,	78	180,	Montigny-le-Bretonneux,	FRANCE)	in	2ml	tubes	containing	1.4mm	ceramic	beads	for	mechanical	lysis.	Samples	were	placed	in	bead-	containing	tubes	with	180	μl	of	Qiagen	Buffer	ATL	and	20μl	of	proteinase	k	and	lysed	for	1	minute.	Both	tissue	and	blood	samples	were	then	incubated	at	56	°C	for	90	minutes.		Buffer	AL	(200	μl)	and	ethanol	(200	μl)	were	added	following	lysis/	digestion	and	each	sample	was	vortexed	for	10s	before	being	transferred	to	a	DNeasy	mini	spin	column.	Samples	were	passed	through	the	DNeasy	column	by	centrifuging	at	6000	g	for	1	minute	then	washed	with	Qiagen	Buffer	AW1	(500	μl)	and	Qiagen	Buffer	AW2	(500	μl)	to	remove	contaminants.	The	column	was	then	dried	by	centrifuging	at	20	000	g	for	3	minutes	to	remove	residual	ethanol.	To	elute	maximum	quantities	of	concentrated	DNA	we	modified	the	manufacturers	protocol.	Qiagen	Elution	Buffer	AE	was	warmed	to	45	°C	and	50	μl	was	added	directly	to	the	DNeasy	membrane	and	allowed	to	incubate	at	45	°C	for	10	minutes.	Columns	were	then	centrifuged	at	6000	g	for	30	s.	The	elutate	was	reapplied	directly	to	the	membrane,	and	incubated	for	a	further	3	minutes	before	being	centrifuged	at	6000	g	for	30s.	Eluted	DNA	was	stored	at	-20°C.		
2.1.6 Whole	genome	sequencing	
All	sequencing	and	library	preparation	was	performed	under	contract	by	Illumina.	A	single	library	was	created	for	each	tumour	sample	and	a	matched	normal,	and	100bp	paired-end	sequencing	was	performed	at	a	typical	depth	of	at	least	50x,	with	94%	of	the	known	genome	being	sequenced	to	at	least	8x	coverage	while	achieving	a	PHRED	quality	of	at	least	30	for	at	least	80%	of	mapping	bases.	Typically,	5	lanes	of	a	HiSeq-2000	(Illumina,	5200	Illumina	Way,	San	Diego,	CA	92122,	USA)	flow	cell	achieved	this,	but	samples	were	not	multiplexed,	so	some	exceeded	these	minimum	standards	by	a	large	margin.	Filtered	read	sequences	were	mapped	to	the	human	reference	genome	(GRCh37)	using	Burrows-Wheeler	Alignment	(BWA),	and	duplicates	marked	using	Picard	(http://picard.sourceforge.net).	The	FastQCpackage	was	used	to	assess	the	quality	score	distribution	of	the	sequencing	reads,	and	enabled	the	identification	of	three	lanes	of	sequencing	that	required	trimming	due	to	a	drop	in	quality	in	
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the	later	cycles	of	sequencing			
2.1.7 Selection	of	recurrently	mutated	target	genes		
Using	SNV	calls	generated	by	STRELKA	as	part	of	the	Illumina	whole	genome	sequencing	pipeline	[357]	genes	were	ordered	by	an	estimated	probability	of	frequency	of	mutation	above	a	baseline,	non-silent	calling	rate.	Frequently	mutated	genes	with	a	p-	value	<	4	x	10-5	(n=26	genes)	were	selected.	We	applied	stringent	filtering	criteria	to	this	cohort,	removing	those	genes	for	which	a	mutation	fell	in	a	poorly	mapping	region	(n=7)	and	those	classified	as	uncharacterized	(n=1),	to	enrich	for	functionally	relevant	mutation	targets.	We	also	removed	a	further	two	genes	as	members	of	large	families	we	suspected	were	more	likely	to	be	passengers	(OR10R2,	C10orf71).	A	further	two	genes	were	removed	as	no	mutations	were	identified	in	either	in	the	discovery	cohort	under	the	adapted	SNV	calling	pipeline	in	section	2.2.1	(PCDHGA11,	HMX2).		Additional	genes	were	selected	for	validation	based	on	a	known	association	with	carcinogenesis	(ABCB1,	SMARCA4,	UNC13C,	CNTNAP5,	MYO18B,	MMP16)	and	for	their	relevance	to	the	NFκB-pathway,	known	to	be	associated	with	the	development	of	OAC	(TLR1,	TLR4,	TLR7,	TLR9,	MYD88,	TRAF3,	TRAF6).	In	total	27	genes	were	taken	forward	to	the	primer	design	stage.		
2.1.8 Immunohistochemsitry	for	ARID1A		
Immunohistochemistry	was	performed	on	tissue	microarrays	containing	tissue	cores	from	298	OACs.	The	ARID1A	antibody	-	sigma,	HPA005456	-	was	used	at	a	dilution	of	1:200.	Staining	was	performed	using	a	BONDMax	autostainer	(Leica,	Milton	Keynes,	UK).	Cores	were	scored	as	0	(loss	of	staining),	1	(weak	intensity	staining),	2	(moderate	intensity	staining)	or	3	(strong	intensity	staining).		
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2.1.9 Mutation	validation	in	independent	samples		
Mutation	validation	was	performed	in	a	cohort	of	90	additional	OACs	and	109	Barrett’s	esophagus	biopsies,	including	43	Barrett’s	esophagus	biopsies	with	histopathologically	confirmed	HGD	and	66	with	no	dysplasia.	The	Access	Array	microfluidics	PCR	platform	(Fluidigm)	together	with	high-throughput	sequencing	(Illumina)	was	used	for	the	targeted	re-sequencing.		Amplicons	with	a	median	size	of	180bp	(range	100-200bp)	were	designed	using	Fluidigm	in-house	software.	After	two	iterations	of	primer	design,	one	gene	remained	uncovered	by	suitable	amplicons	(DIRC3)	and	this	was	removed	from	further	analysis.	Hence,	in	total	26	genes	were	selected	(Supplementary	Table	13	and	14).	All	primers	were	synthesised	with	universal	sequences	(termed	CS1	and	CS2)	appended	at	the	5′-end.		Target	amplification	and	sample	barcoding	were	performed	using	the	manufacturer’s	standard	multiplex	protocol	(Fluidigm,	Access	Array	User	Guide).	Primers	were	combined	into	multiplex	pools	ranging	from	1	to	12	primer	pairs.	The	Access	Array	system	was	used	to	combine	PCR	reagents	(FastStart	High	Fidelity	PCR	System,	Roche)	with	47	DNA	samples	(50ng)	plus	a	single	negative	control	and	48	sets	of	multiplexed	primers	into	2,304	unique	35nL	PCR	reactions.	Thermal	cycling	was	then	applied	to	amplify	all	selected	targets	by	PCR.	Post-PCR,	a	harvesting	reagent	was	used	to	collect	the	amplified	products	of	the	48-multiplex	reactions,	per	sample,	through	the	sample	inlets,	for	subsequent	sequencing.	Illumina	sequencing	adaptors	and	a	10bp	sample	specific	barcode	were	attached	through	an	additional	15	cycles	of	PCR.	After	the	PCR	products	were	barcoded,	the	PCR	products	from	a	small	number	of	samples,	as	well	as	the	water	controls,	were	analyzed	using	the	Agilent	2100	BioAnalyzer	(Agilent,	5301	Stevens	Creek	Blvd.	Santa	Clara,	CA	95051,	USA)	to	ensure	the	expected	amplicon	size	was	obtained	and	that	there	was	no	contamination	across	the	PCR	reactions.	They	were	then	pooled	together	and	purified	using	AMPure	XP	beads	using	a	bead	to	amplicon	ratio	of	1.8:1.0.	The	library	was	quantified	using	the	Agilent	BioAnalyzer	and	subjected	to	Illumina	cluster	generation.	One-hundred	to	150bp	paired-end	sequencing	was	performed	on	a	
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HiSeq	2000	or	MiSeq	with	a	10-base	indexing	(barcode)	read,	using	custom	sequencing	primers	targeted	to	the	CS1	and	CS2	tags	for	both	read1,	read	2	(index	read)	and	read	3,	according	to	manufacturer’s	recommendations.		Methods	used	for	analysis	of	targeted	sequencing	data	generated	using	TAm-Seq	have	been	reported	previously	[358].	Reads	were	de-multiplexed	using	a	known	list	of	barcodes	allowing	zero	mismatches.	Each	set	of	reads	was	aligned	independently	to	the	hg19	reference	genome	using	BWA	in	the	paired-end	mode[359].	Using	expected	genomic	positions,	each	set	of	aligned	reads	was	separated	further	into	its	constituent	amplicons.	A	pileup	was	generated	for	each	amplicon	using	SAMtools	v1.1737.	Using	a	base	quality	and	a	mapping	quality	cut-	off	of	30,	observed	frequencies	of	non-reference	alleles	for	every	sequenced	locus	across	all	amplicons	and	barcodes	were	calculated.	For	each	locus	and	base,	the	distribution	of	non-	reference	background	allele	frequencies/reads	was	modeled	and	the	probability	of	obtaining	the	observed	frequency/number	of	reads	(or	greater)	was	calculated.	Putative	substitutions	were	identified	based	on	a	probability	cut-off	(confidence	margin)	of	0.9995.	Known	SNPs	obtained	from	the	1000	Genomes	project,	dbSNP	version	135	and	regions	covering	amplification	primers	were	discarded.	Any	substitutions	observed	at	>5%	allele	frequency	in	more	than	half	of	the	sequenced	samples	were	discarded.	Small	insertions	and	deletions	of	sequence	were	predicted	using	GATK.	All	remaining	putative	mutations	were	annotated	with	sequence	ontology	terms	to	describe	consequence	and	position	relative	to	Ensembl	gene	annotations.	In	the	final	list,	all	nonsense	or	missense	exonic	mutations	and	splicing	mutations	with	an	allele	frequency	of	10%	or	greater	at	loci	covered	at	least	100-fold	were	retained.	Three	genes	were	removed	at	this	stage	due	to	poor	sequence	coverage	in	all	samples,	TLR1,	TLR7	and	TLR9,	leaving	a	total	of	23	genes	for	further	analysis	(Supplementary	Table	14).		In	order	to	verify	the	called	mutations,	all	nonsynonymous	mutations	identified	from	the	Fluidigm	Access	Array	sequencing	were	re-amplified	using	the	CS1-/CS2-tagged	primer	pair	targeting	the	region	and	DNA	from	the	original	sample.	Where	available,	DNA	from	a	matched	normal	sample	(blood,	duodenum	or	normal	squamous	epithelium)	was	also	amplified	using	the	identical,	tagged	
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primer	pair.	Amplification	was	performed	in	5	μl	reactions	(0.1	Phusion®	High-Fidelity	DNA	Polymerase	(New	England	BioLabs),	1x	Phusion	Buffer,	4.5	mM	MgCl2,	5%	DMSO,	0.2	mM	dNTPs,	1	μM	forward	and	reverse	primer,	25	ng	genomic	DNA.	The	PCR	cycling	conditions	were	as	follows;	50°C	for	2	minutes,	70°C	for	20	minutes,	95°C	for	10	minutes	followed	by	10	cycles	of	95°C	for	15	seconds,	60°C	for	30	seconds	and	72°C	for	1	minute,	followed	by	2	cycles	of	95°C	for	15	seconds,	80°C	for	30	seconds,	60°C	for	30	seconds	and	72°C	for	1	minute,	followed	by	8	cycles	of	95°C	for	15	seconds,	60°C	for	30	seconds	and	72°C	for	1	minute	followed	by	2	cycles	of	95°C	for	15	seconds,	80°C	for	30	seconds,	60°C	for	30	seconds	and	72°C	for	1	minute,	and	8	cycles	of	95°C	for	15	seconds,	60°C	for	30	seconds	and	72°C	for	1	minute	followed	by	5	cycles	of	95°C	for	15	seconds,	80°C	for	30	seconds,	60°C	for	30	seconds	and	72°C	1	minute.	Following	amplification,	2μl	of	each	PCR	reaction	were	collected	and	pooled	in	batches	of	12	reactions	such	that	only	unique	amplicons	were	contained	within	each	pool.	Thereafter,	5μl	of	the	pooled	reaction	mix	was	added	to	2μl	of	ExoSAP-IT®	(Affymetrix).	The	samples	were	incubated	at	37°C	for	15	minutes	followed	by	80°C	for	15	minute.	The	resulting	product	was	diluted	1:100	in	sterile	water	and	Illumina	sequencing	adaptors	and	a	10bp	barcode	was	attached	to	each	pool	using	an	additional	15	cycles	of	PCR	(0.1	unit	Phusion®	High-Fidelity	DNA	Polymerase	(New	England	BioLabs),	1x	Phusion	Buffer,	4.5mM	MgCl2,	5%	DMSO,	0.2mMdNTPs,	1	μM	forward	and	reverse	barcoding	primers,	1μl	ExoSAP-IT®-treated	PCR	product	(1:100	dilution).	Cycling	conditions	were	as	follows:	heat	activation	at	95°C	for	2	minutes,	followed	by	15	cycles	of	95°C	for	15	seconds,	60°C	for	30	seconds	and	72°C	for	1	minute,	followed	by	a	final	elongation	step	of	72°C	for	3	minutes.		As	previously,	PCR	products	following	barcoding	were	first	analyzed	using	an	Agilent	2100	BioAnalyzer	to	ensure	the	expected	amplicon	size	was	obtained.	They	were	then	pooled	together	and	purified	using	AMPure	XP	beads	using	a	bead	to	amplicon	ratio	of	1.8	to	1.0.	The	library	was	quantified	using	the	KAPA-Library	Quantification	Kit	(KAPA	Biosystems)	on	a	Lightcycler®	480	(Roche),	diluted	to	2nM	and	subjected	to	Illumina	cluster	generation	and	sequencing	on	the	Illumina	MiSeq	(150bp	paired-end).	Reads	were	de-multiplexed	using	a	
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known	list	of	barcodes	allowing	zero	mismatches.	Each	set	of	reads	was	aligned	independently	to	the	hg19	reference	genome	using	BWA	in	the	paired-end	mode	[359].Samtoolsmpileupv1.17		[360]	was	used	to	generate	counts	for	each	nucleotide	at	the	position	of	the	putative	somatic	mutation.	Samples	with	a	mutant	allele	frequency	≥3%	and	a	depth	of	coverage	≥	50	were	considered	as	verified	mutations.	In	addition,	mutant	allele	frequency	in	the	matched	normal	was	required	to	be	<1%.	We	additionally	removed	all	mutations	from	those	samples	without	a	matched	normal	that	were	confirmed	as	germline	in	the	cohort	of	samples	with	sequenced	matched	normal.	
2.2 Bioinformatics	
The	tools	SomaticSniper	[295],	BWA,	Samtools,	PINDEL	and	SVfromSAM	were	run	on	the	local	cluster	at	the	Cancer	research	UK	Cambridge	Institute	by	Dr	Mark	Dunning,	Dr	Matthew	Eldridge	or	Dr	Nicholas	Shannon.	Dr	Nicholas	Shannon	implemented	the	significance	testing	that	produced	the	initial	list	of	driver	genes	that	was	then	filtered	by	myself	as	detailed	in	section	2.1.7.	
2.2.1 SNV	pipeline	
Somatic	single	nucleotide	variants	(SNVs)	were	predicted	using	SomaticSniper	V1.0.2	run	[295]with	the	following	command:	>		somaticsniper	-q	1	-Q	15	-F	vcf	-J	-r	0.001000	-T	0.850000	-N	2	-s	0.01	-f		The	output	from	SomaticSniper	was	then	filtered	using	the	following	criteria	derived	from	comparison	of	heuristic	filters	applied	to	SomaticSniper	[295]and	VarScan	2	[294]	and	implemented	using	scripts	provided	in	Koboldt	et	al	and	custom	scripts	(homopolymer	filter).	The	filtering	criteria	were;	1)	germline	and	tumour	sample	coverage	≥10,	2)	average	variant	position	in	read	between	positions	10	and	90,	3)	percentage	of	supporting	reads	from	each	strand	≥1%	and	≤99%,	4)	total	number	of	supporting	reads	≥4,	5)	average	distance	of	variant	base	from	effective	3′	end	of	supporting	reads	≥20	bp,	6)	average	mapping	quality	difference	between	reference	and	variant	supporting	reads	<30,	7)	
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average	difference	in	length	of	trimmed	sequences	between	reference	and	variant	reads	<25bp,	8)	mismatch	quality	sum	difference	<100	between	reference	and	variant	reads,	9)	adjacent	homopolymer	<5bp	away,	and	10)	nearest	INDEL	≥	40bp	away.	In	addition,	all	variants	were	compared	to	dbSNP129	and	removed	if	overlapping	with	predicted	germline	SNPs.	A	median	of	99.7%	of	the	mappable	genome	was	covered	to	at	least	10-fold	coverage	in	the	tumour	and	matched	germline	sample	and	so	was	defined	as	callable	
2.2.2 INDEL	pipeline	
Candidate	somatic	INDELs	were	taken	as	the	consensus	between	SAMtools	[360]	and	Pindel	[301],	filtered	to	exclude	those	INDELs	present	in	the	matched	normal	genome	of	any	of	the	22	samples	(including	non-consensus	INDEL	calls).	INDELs	falling	within	coding	regions	and	splice	sites	were	manually	inspected	to	generate	a	final	list	of	calls.	Variants	were	annotated	with	sequence	ontology	terms	to	describe	consequence	and	position	relative	to	Ensembl	gene	annotations.	SNVs	and	INDELs	were	also	annotated	with	matching	or	nearest	features	in	UniSNP.	
2.2.3 Structural	variant	pipeline	
This	pipeline	was	initially	developed	by	Kevin	Howe	(CRUK	Cambridge	Institute).	Subsequent	modifications	were	made	by	Dr	Matthew	Eldridge	(CRUK	Cambridge	institute).	Reads	generated	from	the	Illumina	sequencing	pipeline	were	first	aligned	to	the	reference	genome	(GRCh37/hg19)	with	BWA	[359].	Non-normal	read	pairs	were	the	realigned	using	Novoalign	(Novocraft	Technologies,	Selangor,	Malaysia),	a	more	sensitive	aligner.	Read	pairs	with	a	quality	score	<	30	following	novoalign	were	discarded.	Discordant	read	pairs,	those	that	align	with	aberrant	orientation	or	insert	size,	were	retained.	A	custom	Perl	script	was	used	to	cluster	discordant	reads	together	that	supported	the	same	rearrangement	junction.	Filters	were	then	applied	as	detailed	in	Chapter	4.	
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2.2.4 Structural	variant	verification	
As	detailed	in	Chapter	4	two	alternative	approaches	were	taken	to	high	throughput	verification	of	SVs.	Firstly	a	custom	R-script	is	used	to	generate	CN	plots	for	tumour	and	normal	samples	at	both	Node	1	and	node	2	of	an	SV.	This	script	is	available	in	Appendix	1.	This	facilitates	manual	review	of	SV:CN	step	overlap.		An	SV	was	considered	verified	a	somatic	if	it	overlapped	with	a	CN	change	in	the	tumour	but	not	the	normal.	Secondly,	for	high	throughput	verification	I	have	written	a	Perl	script	to	extract	sequence	for	primer	design.	This	script	was	developed	from	an	idea	and	original	Perl	script	written	by	Dr	Scot	Newman.	The	script	is	available	in	Appendix	1	and	is	modified	in	the	following	ways	from	Dr	Scot	Newman’s	original.		1. Sequence	is	now	extracted	directly	from	a	local	copy	of	the	human	genome	rather	than	by	accessing	the	ucsc	genome	browser,	facilitating	offline	use.		2. Sequence	is	not	repeat	masked	3. Sequence	is	only	extracted	from	within	the	areas	covered	by	read	pairs	that	support	the	SV	(nodes)		
2.2.5 Pipeline	for	the	extraction	of	mutational	signatures	
As	bases	are	paired	across	strands	-	A:T	and	G:C	-	the	12	possible	mutation	classes	(A>T,	A>C,	A>G,	T>C,	T>G,	T>A,	G>A,	G>T,	G>C,	C>A,	C>T,	C>G)	can	be	collapsed	to	6	classes	where	the	mutated	base	is	always	considered	as	the	pyrimidine	i.e.	A>C	is	equivalent	to	T>G.	The	bases	immediately	5’	and	3’	of	the	mutated	base	are	known	to	alter	the	rate	at	which	differing	mutational	classes	may	occur	at	the	base	[40].	Each	mutation	class	can	therefore	occur	at	one	of	12	trinucleotide	contexts,	giving	a	total	of	96	possible	class-context	combinations.		For	each	sample	in	the	discovery	cohort	we	extracted	the	trinucleotide	context	in	which	all	somatic	mutations	occurred	using	the	hg19/	GRCh37	reference	genome	(https://www.genome.ucsc.edu/)	and	a	custom	perl	script.	The	number	of	occurrences	of	each	possible	mutation-class-context	combination	was	
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assessed.	The	prevalence	of	a	specific	mutation	class	at	a	given	trinucleotide	is	determined	both	by	the	mutational	processes	active	in	a	tumour	and	by	the	prevalence	of	the	trinucleotide	in	the	reference	genome.	To	determine	the	fold	enrichment	due	specifically	to	mutational	processes	affecting	the	tumour,	we	corrected	for	the	relative	prevalence	of	each	trinucleotide	within	the	mappable	hg19	reference	genome.	To	assess	for	novel	mutational	signatures,	heat	maps	were	created	and	visually	inspected	following	the	protocol	established	in	Nik-Zainal	et	al,	2012.	To	extract	signatures,	non-negative	matrix	factorization	was	used	following	the	protocol	in	Alexandrov	et	al	[361].	NMF	allows	the	extraction	of	the	constituent	‘parts’	/	features	of	a	dataset	that	can	be	represented	as	an	N	x	M	matrix	(V)	where	N	represents	number	of	samples	and	M	represents	number	of	variables.	The	output	of	this	algorithm	is	two	matrices;	N	x	k	(W)	and	k	x	N,		(H)	where	k	represents	the	number	of	‘parts’.	The	N	x	k	matrix	therefore	provides	the	contribution	of	each	‘part’	to	each	sample	and	the	k	x	M	matrix	represents	the	contribution	of	each	variable	to	each	‘part’.	In	the	case	of	mutations,	in	a	cancer	the	total	burden	in	an	individual	sample	can	be	seen	as	being	derived	from	exposure	to	a	set	of	mutagens.	It	is	therefore	dependent	on	the	type	of	mutagen	and	the	extent	of	the	exposure.	In	the	case	of	a	matrix	for	application	of	NMF,	N	would	represent	a	list	of	samples	for	which	information	on	mutation	number	and	types	were	available.	M	would	represent	the	mutations,	where	each	type	of	mutation	is	considered	in	its	trinucleotide	context	(as	discussed	in	the	Introduction)	giving	a	total	of	96	variables.	Therefore	the	two	output	matrices	would	represent;	1.)	the	types	of	mutation	that	contribute	to	an	individual	mutagen	(N	x	k)	aka	signatures	and	2.)	contribution	of	each	mutagen	to	the	overall	mutagenic	burden	in	a	given	tumour	(k	x	M)	aka	exposures.	As	MATLAB	requires	a	license	and	is	thus	prohibitive	to	use	I	rewrote	the	pipeline	using	the	packages	in	the	open	source	R	statistical	language.	The	multiplicative	update	algorithm	used	was	that	developed	by	Brunet	et	al	[362]	and	implemented	in	the	R	NMF	package	[363].	The	initial	values	for	matrices	W	and	H	were	generated	stochastically	using	the	random	seeding	method	implemented	in	the	R	NMF	Package	[363].	As	the	starting	point	can	affect	the	
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final	selected	factorization	1000	runs	were	performed,	using	the	in	built	nruns	function,	with	selection	of	the	final	factorization	that	achieved	the	lowest	approximation	error.	To	account	for	the	variance	in	the	NMF	convergence	100	iterations	of	this	process	were	performed	and	exposure	and	signature	matrices	were	collected	for	each.	Clustering	of	the	signature	matrix	was	performed	using	a	partition-clustering	algorithm	(implemented	using	the	pam	package	in	R)	with	the	number	of	clusters	set	to	the	expected	number	of	signatures	that	had	been	used	for	that	round	of	NMF.	The	final	signature	was	calculated	as	the	average	values	of	all	signatures	within	a	cluster.	Standard	deviations	for	each	mutation	type	were	calculated	similarly	from	all	signatures	within	a	cluster.	This	process	was	performed	for	multiple	possible	factorization	ranks	(signature	numbers)	and	the	optimal	rank	was	assessed	using	multiple	previously	published	methods	as	discussed	further	in	Chapter	4.	Verification	of	this	pipeline	is	provided	in	Chapter	4,	demonstrating	that	it	extracts	identical	signatures	to	the	original	MATLAB	version	in	the	breast	cancer	dataset	used	in	[40].	
2.2.6 Clonal	analysis	of	15	recurrently	mutated	genes	in	EAC		
The	analysis	below	was	developed	and	conducted	by	Dr	Andy	Lynch	(Cancer	Research	UK,	Cambridge	Institute).	Text	is	quoted	directly	from	the	paper	we	co-authored	[364]	and	this	section	was	written	by	Dr	Andy	Lynch.	1)	Germline	heterozygous	sites	in	non-coding	regions	were	identified	in	the	following	manner.	A	GATK	walker	identified	all	sites	with	Q30	base-quality	coverage	of	the	normal	sample	between	30	and	150,	at	least	12	reads	supporting	a	variant	and	a	B-allele	frequency	of	at	least	0.35.		2)	For	each	chromosomal	arm,	FREEC	counts	for	10000	base	windows	were	iteratively	segmented	(using	fastseg)	and	GC	corrected.		3)	Those	segments	were	then	themselves	segmented	by	the	B-allele	frequency	of	sites	identified	as	germline-heterozygous.		
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4)	All	segments	of	length	>1000	SNPs	are	plotted	on	a	depth	vs	BAF	plot	and	regions	sought	that	will	positively	identify	the	coverage/copy	number	relationship.		5)	For	the	segment	containing	a	gene	of	interest,	all	models	consisting	of	a	single	copy-number	state	mixed	with	normal	diploid	(AB)	tissue	are	considered.	The	distribution	of	depth	in	the	segment,	distribution	of	B-allele	frequencies	for	germline	heterozygous	SNPs	for	the	segment,	and	distribution	of	allele	frequency	for	somatic	variants	are	all	considered	to	determine	if	the	copy-number	state	is	feasible,	and	if	so	what	proportion	of	cells	carry	the	copy	number	mutation	(cellularity).	If	no	model	provides	a	good	fit,	the	tumour	is	presumed	to	be	a	mixture	of	subclonal	copy-number	mutations.	This	step	identifies	whether	LOH	has	taken	place	at	the	location	of	the	gene.		6)	All	major	clusters	of	regions	in	the	depth	v	BAF	plot	are	considered	in	this	manner	to	determine	the	maximum	cellularity	of	any	region	in	the	sample,	presumed	to	be	the	proportion	of	cells	that	are	malignant.	The	cellularity	of	the	copy	number	change	of	the	gene	of	interest	is	then	compared	to	judge	whether	it	might	be	present	in	all	tumour	cells.	Where	this	is	not	clear	(as	is	often	the	case	with	lower	cellularity	tumours,	older	copy	number	changes,	or	changes	with	no	allelic	imbalance),	the	‘benefit	of	the	doubt’	is	given	to	the	mutation	and	it	is	called	‘clonal’.		7)	Finally,	the	mutation	is	considered	relative	to	the	copy	number	state	and	assessed	as	being	clonal	(or	not).			 	
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Chapter	3 	
Structural	variant	detection	in	oesophageal	
adenocarcinoma	
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3.1 Introduction	
Structural	variation—defined	here	as	those	events	affecting	a	region	of	the	genome	greater	than	1Kb	in	length—provides	a	considerable	portion	of	the	somatic	events	in	epithelial	cancers.	Whereas	the	functional	role	of	a	single	nonsynonymous	mutation	within	a	protein-coding	gene	may	be	questionable	the	disruptive	impact	of	a	deletion	or	translocation	on	that	copy	of	the	gene	is	more	difficult	to	dispute.	Oesophageal	adenocarcinoma	is	no	exception	to	this	with	several	reports	detailing	extensive	rearrangement	patterns.	Previous	reports	have	utilized	array	technology	(aCGH	and	SNP	arrays)	to	analyse	copy	number	variants	with	considerable	success	in	the	identification	of	novel	OAC	gene	targets.	At	the	commencement	of	this	PhD	no	report	of	the	use	of	NGS	to	study	OAC	rearrangements	had	been	published.	Dulak	et	al	in	2013	analysed	15	whole	genomes	as	part	of	a	larger	exome	study,	but	a	detailed	analysis	of	structural	variants	was	not	performed	on	these	cases.	Thus,	as	yet,	no	comprehensive	analysis	of	patterns	of	OAC	structural	variation	has	been	presented.		As	discussed	in	the	Introduction,	several	pipelines	exist	for	the	prediction	of	structural	variants	in	cancer	genomes.	Despite	this	no	clear	“market	leader”	has	emerged.	Several	factors	likely	contribute	to	this	including:	incomplete	documentation,	unreleased	software	and	the	limited	availability	of	up	to	date	versions	of	pipelines.		Therefore	there	is	still	the	necessity	for	the	development	of	in-house	SV	calling	pipelines	with	high	specificity	and	sensitivity.	In	addition,	the	implementation	of	an	in-house	pipeline	has	two	major	advantages;	firstly,	the	mechanisms	and	logic	of	the	pipeline	are	easily	accessible	facilitating	accurate	downstream	interpretation	of	the	data,	and	secondly,	modifications	can	more	easily	be	integrated,	facilitating	more	rapid	improvement	of	the	pipeline.	The	aims	of	this	chapter	therefore	are:	1.) Develop	and	verify	a	pipeline	for	prediction	of	SVs	in	cancer	genomes	2.) Perform	a	preliminary	analysis	of	the	patterns	of	structural	variation	across	the	OAC	genome	
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3.2 Previous	work	
Dr	K.	Howe	(Now	at	the	Wellcome	Trust	Sanger	Institute	and	formerly	of	the	Cancer	Research	UK	Cambridge	Institute)	developed	the	first	generation	of	the	pipeline	discussed	in	this	chapter.	This	pipeline,	termed	structural	variation	from	SAM	(SVFS),	used	discordant	read	pair	clustering	to	identify	possible	structural	variants.	Reads	were	first	aligned	using	BWA	and	duplicates	were	flagged	using	PICARD	and	removed	from	further	processing.	Three	categories	of	aberrant	read	pairs	are	then	identified	for	further	analysis:	1.) Discordant	read	pairs	i.e.	those	mapping	to	two	different	chromosomes,	in	the	wrong	orientation	or	too	great	a	distance	apart	2.) Single	end	mapping	reads	i.e.	those	where	one	read	of	the	pair	has	a	normal	mapping	whilst	the	other	is	unable	to	be	mapped	uniquely	to	the	reference	genome	3.) Unmapped	read	pairs	i.e.	those	read	pairs	in	which	neither	read	of	the	pair	is	able	to	be	uniquely	mapped	to	the	reference	genome	Read	pairs	that	meet	any	of	the	above	criteria	are	passed	to	Novoalign,	for	a	second	round	of	alignment	with	flags	set	as	in	Methods.	Novoalign	is	a	more	precise	short	read	mapper	utilising	the	Needleman-Wunsch	algorithm	for	alignment	for	all	reads	whilst	in	BWA	a	more	complex	alignment	(Smith-Waterman	in	this	case)	is	reserved	for	the	unmapped	partner	of	a	mapped	read,	where	the	search	space	can	be	restricted	to	sequence	local	to	the	mapped	partner	read.	Discordant	read	pairs	are	identified	from	the	resulting	Novoalign	output	and	passed	to	a	Perl	script	for	clustering.	In	the	clustering,	steps	reads	are	identified	that	lie	within	the	maximum	insert	size	of	each	other	and	are	in	the	same	orientation.	The	genomic	position	of	partner	reads	of	each	read	within	the	cluster	is	determined	and	an	SV	is	identified	if	at	least	3	reads	within	the	cluster	also	show	clustering	of	their	partner	reads.	If	a	matched	normal	sample	has	been	
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sequenced	the	aberrant	reads	from	this	are	clustered	with	the	aberrant	reads	from	the	tumour	to	identify	germline	structural	variants.	To	avoid	false	positive	calls	due	to	ligation	events	generated	during	library	preparation	and	sequencing,	structural	variants	were	accepted	only	if	at	least	3	independent	read	pairs	predicted	the	same	event.		Four	aspects	of	this	pipeline	are	important	for	further	consideration	in	light	of	the	developments	presented	in	this	chapter:	1.) Coverage	of	the	cancer	genome,	corrected	for	both	ploidy	and	cellularity	2.) Number	of	discordant	read	pairs	required	to	confirm	an	SV	with	good	specificity	3.) Remapping	of	discordant	read	pairs	with	Novoalign	4.) Selection	and	filtering	of	black-listed	regions	Dr	S.	Newman,	Dr	S.	Cooke	and	Dr	C.	Ng	performed	two	independent	rounds	of	verification	of	the	original	pipeline.		An	SV	was	considered	verified	if	PCR	primers	designed	to	span	the	junction	gave	a	product	in	the	tumour	but	not	in	the	matched	normal	or—where	a	matched	normal	was	not	available—in	a	pool	of	genomic	DNA	from	10	normal	female	subjects.	In	addition	SVs	were	considered	verified	if	they	were	associated	with	a	copy-number	variant	identified	from	sequencing	or	SNP6	data	[365].	The	specificity	was	determined	to	be	between	29%-66%	(testing	was	performed	on	SVS	from	4	separate	tumours)	with	a	sensitivity	of	14%	(analysis	of	SVs	that	would	account	for	observed	copy	number	variants	was	performed	on	a	single	tumour)	[366]	There	was	therefore	some	scope	for	improvement	of	this	pipeline.	
3.3 Development	and	improvement	of	the	SVFS	pipeline		
3.3.1 Filtering	against	multiple	normal	samples	
False	positive	SV	calls	may	arise	from	three	sources.	First,	artefacts	introduced	during	library	preparation	may	cause	them.	In	the	standard	preparation	protocol	
	 82	
for	Illumina	sequencing	a	ligation	step	is	performed.	This	may	create	novel	chimeric	DNA	fragments	with	the	appearance	of	having	arisen	somatically.	In	addition	ligation	may	occur	between	both	ends	of	a	fragment	followed	by	subsequent	breakage	of	this	circularized	DNA	during	sonication,	creating	artefacts	with	the	appearance	of	a	somatic	inversion.				Secondly,	artefacts	may	arise	due	to	the	incorrect	mapping	of	sequences	to	the	reference	genome,	so-called	mismapping	artefacts.	The	human	genome	contains	many	highly	repetitive	sequences	of	varying	lengths,	many	segmental	duplications	and	many	deletions	of	sequence	relative	to	the	reference	genome.	Errors	inserted	into	sequencing	reads	may	therefore	lead	to	one	read	of	a	pair	mapping	to	an	homologous	but	aberrant	position.	In	addition	when	a	sequence	is	deleted,	reads	may	be	aligned	to	the	next	closest	match,	generating	an	aberrantly	mapping	read	pair.	Third,	false	positive	calls	may	be	made	due	to	inadequate	coverage	of	the	matched	normal	sample,	resulting	in	germline	SVs	being	missed	in	this	sample.	In	this	case	true	germline	SVs	would	be	misclassified	as	somatic	SVs.	To	address	the	latter	two	sources	of	artefact,	we	performed	discordant	read	pair	clustering	with	increasing	numbers	of	normal	samples.	We	reasoned	that	mismapping	artefacts	would	accumulate	in	the	collection	of	discordant	reads	from	our	normal	samples	as	we	increased	the	effective	coverage	of	the	human	genome.	In	contrast,	genuine	somatic	SV	junctions	would	be	unaffected	as	the	probability	of	generating	a	chimeric	read	identical	to	a	true	somatic	variant	is	extremely	remote.	Given	the	previous	estimates	for	the	specificity	of	this	pipeline	it	would	be	sub-optimal	to	immediately	begin	large-scale	verification.	To	assess	the	specificity	of	our	modified	pipeline	we	therefore	counted	the	number	of	SVs	identified	as	unique	to	the	matched	normal,	rather	than	the	tumour	sample,	for	each	patient.	The	most	mutated	tumours	still	have	a	genome	that	is,	in	the	main,	constructed	from	normal	DNA.	In	addition	most	samples	are	contaminated	with	normal	cells	limiting	the	effect	of	large	stretches	of	loss	of	heterozygosity,	which	may	occur	in	tumours	causing	the	loss	of	germline	SVs.		We	can	expect	that	if	our	pipeline	
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were	100%	sensitive	and	100%	specific	we	should	not	identify	any	SVs	unique	to	the	normal	sample.		Therefore	the	number	of	SVs	identified	in	the	normal	sample	provides	an	approximation	of	the	number	of	false	positives	in	the	list	of	tumour	specific	SVs.	A	caveat	to	this	approach	is	that	somatic	structural	variants	may	exist	uniquely	only	in	clones	of	cells	present	in	the	matched	normal	[229,230].	This	would	lead	to	an	underestimation	of	the	true	specificity	of	the	pipeline,	as,in	this	case,	we	would	be	classifying	a	true	positive	SV	(i.e.	genuinely	somatic	and	restricted	to	one	sample—in	this	case	the	normal)	as	a	false	positive	by	assuming	all	variants	in	the	normal	represent	false	calls.	However	such	clonally	expanded	somatic	mosaicism	is	rare	with	an	estimated	1.5	fully	clonal	variants	(SVs	>50kb)	detectable	per	person.	In	addition	<1%	of	subjects	harbour	subclonal	variants	[229,230]	Five	samples	(3303,	3305,	3314,	3317,	3323:	matched	normal,	3301,	3304,	3313,	3316,	3322	respectively)	were	selected	from	the	pilot	data	set	and	discordant	read	pair	clustering	was	performed	for	each	tumour-normal	pair	in	the	presence	or	absence	of	varying	numbers	of	unmatched	normal	samples.			We	chose	three	categories	to	analyse	with	increasing	numbers	of	unmatched	normals	used	in	clustering;	n	=	1	i.e.	only	the	tumour	and	matched	normal	were	included	in	clustering,	n=	5	i.e.	a	tumour,	it’s	matched	normal	and	4	unrelated	normals	were	included	in	each	clustering,	n=	10	i.e.	a	tumour,	it’s	unmatched	normal	and	9	unrelated	normals	were	included	in	each	clustering.		A	decrease	in	the	number	of	SVs	unique	to	the	matched	normals	was	observed	when	increasing	numbers	of	unmatched	normal	samples	were	included	in	clustering	(Fig	3.1	and	Table	3.1).	The	mean	numbers	of	SVs	unique	to	the	matched	normal	was:	n=	1,	235.4	(range	175-382,	for	all	5	tumour-normal	comparisons),	n	=	5,	53.4	(range	25-114,	for	all	5	tumour-normal	comparisons),	n	=	10,	37.6	(range	20-	84,	for	all	5	tumour-normal	comparisons)).	The	number	of	SVs	unique	to	the	tumour	decreased	in	a	similar	fashion	from	a	mean	of	506	sample-unique	SVs	(range	309	–	831),	to	a	mean	of	322.2	(range	176-434)	with	5	normal	samples	and	a	mean	of	296.8	(range	164	–	381)	with	10	normal	samples.	
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We	next	proceeded	to	analyse	the	entire	pilot	cohort	using	discordant	read	pairs	from	all	22	normal	samples	clustered	with	each	tumour.	This	resulted	in	an	average	of	13.6	unique	SVs	per	normal	sample	(Table	3.2)	(range	1	–	39).	The	mean	number	of	normal	unique	SVs	can	be	used	as	a	rough	false	positive	rate	for	each	of	the	tumour	samples.	Using	this	value	to	calculate	the	specificity	of	SV	calling	for	each	sample	gives	a	mean	specificity	of	93%	(range	82-97%	SD,	4%).		Importantly	coverage	was	greater	in	the	normal	samples	than	in	the	tumour	samples	(mean	fold	coverage,	61.8	versus	73.4,	p	<	0.05,	two-tailed	T-test).	We	would	therefore	expect	more	false	positives	in	our	normal	samples	than	in	our	tumour	samples.	This	is	comparable	to	several	recent	analyses	of	alternative	pipelines,	though	the	gold	standard	for	verification	remains	PCR	and	sequencing	of	junctions	or	comparison	to	copy	number	data	[308,310].			Of	note,	it	is	possible	that	increasing	the	number	of	normal	samples	used	to	filter	against	may	act	to	remove	further	false	positive	SVs.	This	needs	to	be	balanced	against	the	risk	of	a	chimeric	read	being	generated	within	a	normal	library	leading	to	the	loss	of	a	true	positive	SV.	Our	data	shows	that	increasing	the	number	of	normal	samples	used	for	filtering	from	1	–	5	provides	a	proportionally	greater	benefit	than	when	increasing	from	5	–	10,	suggesting	that	increasing	much	beyond	this	may	have	a	suboptimal	cost-benefit	(loss	of	true	SVs	versus	removal	of	false	SVs)	ratio	(Figure	3.1).	Alternative,	more	targeted,	filters	are	therefore	also	required.	
3.3.2 Black	listing	high	contributor	regions	
It	was	apparent	from	manual	review	of	the	data	that	certain	regions	of	the	genome	were	contributing	large	numbers	of	aberrant	SVs.	To	allow	more	accurate	visualisation	of	these	regions	we	constructed	rainfall	plots	of	inter	SV	distance	i.e.	the	distance	from	Node	1	of	an	SV	to	Node	1	of	the	next	nearest	SV.	A	list	of	SVs	resulting	from	the	clustering	of	discordant	reads	found	in	libraries	from	22	normal	samples	was	used	for	this	analysis	(Figure	3.2,	Figure	3.25)	[40].	No	tumour	discordant	read	pairs	were	included	as	there	are	rare	reports	of	
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oncogenic	breakpoints	occurring	in	exceptionally	close	genomic	proximity	in	tumour	samples	from	multiple	individuals	[367].		Comparison	with	features	from	UCSC	revealed	that	these	areas	overlapped	those	identified	as	regions	of	exceptionally	high	read	depth	(Figure	3.2)	and	occurred	frequently	at	the	boundaries	of	gaps	in	the	reference	genome	[368].		These	regions	are	highly	repetitive	simple	DNA	sequences	(satellites)	or	L1	sequences	with	large	stretches	of	homology	and	represent	poorly	assembled	areas	of	the	genome	[369].	As	is	apparent	in	Figure	3.3—a	rainfall	plot	of	chromosome	4	SVs	identified	in	43	normal	samples—these	areas	contribute	a	mixture	of	SV	types	including	DEL,	INS	and	INV	type	SVs	representing	mismapping	of	reads	within	the	same	repeat	sequence	as	well	as	DIF	type	SVs	with	mismapping	between	similar	repeat	sequences	(in	this	case	satellite	sequence)	on	different	chromosomes.	The	rate	of	mismapping	occurring	at	these	positions	is	such	that	filtering	against	multiple	normal	samples	did	not	fully	remove	all	false	positive	SVs	falling	at	these	regions.	Each	region	of	high	depth	is	classified	by	its	read	count	as	either	being	in	the	top	0.1,	top	0.5,	top	1	or	top	5	percent	of	all	regions	of	the	genome.	We	therefore	compared	the	percentage	of	regions	within	each	of	these	categories	that	contained	clusters	of	SVs.	As	expected	the	percentage	of	regions	containing	multiple	SVs	increases	across	these	categories,	with	3.6%	of	regions	in	the	top	5%	of	read	depth	containing	multiple	SVs	whilst	15.7%	of	regions	in	the	top	0.1%	category	contained	multiple	SVs	(Table	3.3).	We	therefore	filtered	SVs	falling	within	regions	that	had	a	read	depth	in	the	top	1	percent	or	higher	of	the	whole	genome.	The	regions	of	high	depth	(top	0.1	percent,	top	0.5	percent,	top	1	percent)	were	downloaded	from	UCSC	in	BED	file	format	and	SVs	were	annotated	using	a	custom	Perl	script.	This	removed	28/294	(9.52%)	of	SVs	unique	to	the	normal	cases	and	178/5190	(3.43%)	of	SVs	unique	to	tumour	cases.		To	identify	regions	of	recurrent	mismapping	not	captured	by	the	high	depth	and	gap	tracks,	we	annotated	10Kb	non-overlapping	windows	across	the	genome	with	first	the	inter-SV	distances	of	SVs	falling	within	them,	second	the	overlap	with	regions	of	high	depth	and	third	overlap	with	gaps.	This	identified	184	10Kb	
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windows	containing	4	or	more	clustered	SVs	that	were	not	flagged	as	gaps	or	regions	of	high	read	depth.	These	novel	regions	were	filtered	to	exclude	overlap	with	potential	mobile	element	sites,	a	potential	source	of	multiple	consecutive	true	positive	SVs.	This	removed	two	windows;	chr12:66450001-66460001	and	chr15:77910001-77920001.	Annotating	with	the	remaining	list	lead	to	the	removal	of	a	further	5/266	(1.88%)	of	SVs	unique	to	normal	samples	and	11/5012	(0.22%)	of	SVs	unique	to	tumour	samples.	
3.3.3 Filtering	against	the	database	of	genomic	variants		
An	additional	source	of	false	positive	SVs	is	the	miscalling	of	germline	variants	as	somatic.	This	may	occur	if	coverage	of	an	area	of	the	matched	normal	were	insufficient	to	identify	a	single	read	supporting	the	germline	SV.	The	SV	would	therefore	only	be	detected	in	the	tumour	and	would	be	classified	as	somatic.	The	target	coverage	for	matched	normal	samples	for	the	ICGC	project	is	30x	sequence	coverage.	An	SV	can	only	be	identified	by	discordant	read	mapping	if	the	junction	falls	in	the	window	between	the	two	reads	of	a	fragment.	Fragment	size	is	therefore	a	key	determinant	of	effective	coverage	for	SVs	also	known	as	physical	coverage	(Fig.	3.10)	In	addition	there	is	substantial	variation	in	coverage	across	the	genome—driven	by	differences	in	GC-content	and	mappability—with	many	regions	falling	below	this	average.	Furthermore	many	germline	SVs	fall	within	repetitive	sequences	or	harbour	insertions	of	sequence	at	the	junction	leading	to	difficulties	mapping	read	pairs	across	them.	Comparison	to	multiple	other	normal	samples	as	discussed	above	may	identify	these	missed	germline	SVs;	however	many	events	have	a	low	prevalence	within	the	population	and	may	therefore	be	missed	by	this	approach.	To	remove	misclassified	germline	SVs	we	developed	an	annotation	pipeline	to	allow	comparison	of	SVs	from	our	dataset	with	SVs	present	in	the	database	of	genomic	variants	(DGV)[370].		The	DGV	contains	a	curated	list	of	germline	structural	variants	from	multiple	different	individuals	from	a	wide	variety	of	populations.	SVs	in	this	list	were	identified	using	multiple	methods	including	
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next	generation	sequencing,	array	comparative	genomic	hybridization	(aCGH)	and	single	nucleotide	polymorphism	arrays.		A	list	of	variants	was	downloaded	in	BED	format	from	the	UCSC	database.	This	list	was	curated	to	remove	duplicate	variants	and	converted	into	an	identical	format	to	that	outputted	from	the	SV	pipeline.	The	final	list	contained	359	179	germline	SVs.	Of	note	most	variants	in	the	DGV	have	not	been	identified	to	base	pair	resolution.	We	therefore	allowed	for	imperfect	matching	of	SVs	with	DGV	variants	by	extending	the	window	for	overlap	by	500bp	either	side	of	the	listed	positions	of	start	and	end	coordinates	in	the	DGV.	A	custom	Perl	script	was	written	to	allow	rapid	comparison	of	two	files	of	SVs	(SV_annotator.pl;	Appendix	1)	taking	as	input	two	lists	of	SVs—file	1	and	file	2—and	outputting	a	file	with	each	SV	in	file	1	annotated	with	any	overlapping	SV	in	file	2.	To	account	for	differences	in	reference	genome	choice,	deletion	and	insertion	SVs	were	classified	as	germline	if	they	overlapped	either	a	deletion	or	an	insertion	within	the	DGV	list.	Inversions,	inverted	tandem	repeats	and	translocations	between	chromosomes	were	only	flagged	as	germline	if	they	overlapped	with	a	variant	in	the	DGV	of	the	same	structure	(i.e.	inversions	had	to	overlap	with	an	inversion	etc.).	Annotating	against	the	DGV	identified	13/5001		(0.26%)	SVs	unique	to	tumour	samples	and	9/261		(3.45%)	SVs	unique	to	normal	samples	as	misclassified	germline	variants.	
3.3.4 Misalignment	as	a	source	of	false	positive	SVs	
The	second	aligner	in	the	pipeline,	Novoalign	(Novocraft	Technologies,	Selangor,	Malaysia),	has	been	demonstrated	to	be	a	more	accurate	though	slower	aligner	than	BWA	and	BWA-MEM	[289,371].	Given	that	a	predicted	source	of	false	positive	SV	calls	is	misalignment	of	one	or	both	reads	in	a	pair,	more	accurate	alignment	was	predicted	to	decrease	the	error	rate	of	the	pipeline.	In	addition,	the	increased	accuracy	of	alignment	may	serve	to	identify	true	discordant	read	pairs	left	as	unmapped	read	pairs	or	as	single-end	mapped	read	pairs	by	the	first	pass	alignment	with	BWA.	Though	several	studies	have	compared	the	use	of	
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different	aligners	for	calling	INDELS	and	SNPs,	no	study	has	yet	addressed	the	effect	on	SV	prediction.		To	assess	this	in	our	dataset	we	looked	at	the	final	SV	output	from	a	single	pilot	case	included	in	the	verification	exercise	3119.	SV	clustering	was	performed	with	discordant	reads	identified	using	Novoalign,	with	a	mapping	quality	cut	off	of	30	(Novo-30),	BWA	with	mapping	quality	cut-off	of	30		(BWA-30)	or	BWA	with	a	mapping	quality	cut	off	of	10	(BWA-10).	All	identified	SVs	were	assessed	for	reliability	by	comparison	with	copy	number	steps.	The	results	are	summarised	in	Figure	3.8.	BWA-10	identified	the	greatest	number	of	SVs	(205	versus	134	versus	134,	BWA-10	versus	BWA	30	versus	Novo-30).	However,	SVs	identified	from	Novoalign-30	alignments	had	the	greatest	reliability,	more	frequently	overlapping	with	observed	copy	number	steps	(55.6%	(114/205)	versus		77.6%	(104/134)	versus	82.1%,	(110/134)	BWA-10	versus	BWA	30	versus	Novo-30).		In	summary,	though	BWA-10	identified	the	greatest	number	of	true	positive	SVs,	its	high	false	positive	rate	makes	it	sub-optimal	for	downstream	analysis.	Novo-30	is	therefore	the	most	optimal	strategy	removing	many	of	the	false	positives	seen	with	more	permissive	alignments	(BWA-10)	whilst	also	identifying	additional	real	SVs	as	assessed	by	copy	number	comparison.	Much	of	the	human	genome	is	repetitive	and	therefore	single	base	pair	errors	in	sequencing	may	lead	to	aberrant	mapping	of	a	read	to	a	nearly	homologous	section	of	genome	and	therefore	formation	of	a	discordant	read	pair.	When	aligning	whole-genome	sequencing	data	both	BWA	and	Novoalign	are	usually	configured	to	output	only	the	top	match	for	a	read.	This	facilitates	speed	and	interpretability	of	output.			The	majority	of	DNA	in	a	tumour	is	normal	relative	to	the	reference	and	thus	the	vast	majority	of	read	pairs	sequenced	from	a	tumour	would	be	expected	to	have	normal	mapping	relative	to	the	reference	genome.	We	would	expect	that	if	a	read	has	both	a	normal	mapping	relative	to	its	partnered	read	and	an	abnormal	mapping	the	normal	mapping	is	the	most	likely,	even	if	the	abnormal	mapping	appears	to	be	more	closely	related	to	the	sequenced	read.	We	therefore	
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realigned	all	reads	contributing	to	high	quality	SVs	in	3119	using	Exonerate	outputting	all	potential	mappings.	This	identified	2	SVs	in	which	all	read	pairs	contributing	to	the	SV	could	be	assigned	a	normal	mapping	with	alignment	of		>	90%	of	the	bases	for	the	pair.	These	SVs	were	therefore	classified	as	false	positives	and	excluded	from	further	analysis.	A	custom	Perl	script	was	written	(Paul	Edwards,	unpublished	work)	to	analyse	all	SVs	in	batch	0	for	potential	normal	mappings.	First,	the	sequence	is	extracted	from	either	side	of	the	SV	junction	using	the	coordinates	of	the	most	read	most	distant	from	the	junction	that	contributes	to	the	cluster	of	discordant	read-pairs	that	identified	the	SV.	This	sequence	is	then	compared	to	the	expected	position	if	the	read	had	a	normal	mapping	i.e.	an	extension	of	1	x	maximal	insert	size	downstream	of	the	partner	junction.	If	either	read	gives	a	potential	normal	mapping	of	>	90bp	the	SV	is	considered	a	mismapping	artifact	and	is	excluded	from	the	final	list.	This	script	was	run	on	the	fully	filtered	list	of	somatic	SVs	from	batch	0	and	the	fully	filtered	list	of	SVs	identified	in	batch	0	matched	normals,	leading	to	the	exclusion	of	23/4988	(0.46%)	and	10/252	(3.97%)	SVs	respectively.	
3.4 Verification	of	the	pipeline	
3.4.1 Development	of	pipelines	for	high-throughput	verification	of	SVs	
As	previously	discussed,	the	gold	standard	for	verification	of	structural	variants	remains	either	PCR	and	Sanger	sequencing	of	the	variant	or	comparison	to	matched	copy	number	plots	of	both	the	tumour	and	normal	(Figure	3.4).	Implementation	of	either	method	on	100’s	of	putative	SVs	remains	a	labour-intensive	and	expensive	task,	and	has	contributed	to	low	levels	of	verification	of	SVs	relative	to	those	seen	in	studies	of	SNVs.	We	therefore	sought	to	develop	two	novel	pipelines	for	high	throughput	verification	of	SVs	in	cancer	genome	studies.	To	facilitate	high	throughput	verification	of	SVs	by	PCR,	two	bottlenecks	must	be	traversed;	primer	design	and	interpretation	of	Sanger	sequencing	results.	For	high-throughput	primer	design,	a	custom	Perl	script	was	developed	to	allow	the	extraction	of	sequence	spanning	the	breakpoint	(Seq_extractor_SV.pl,	all	scripts	are	provided	in	Appendix	1).	This	script	is	a	development	of	one	written	
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previously	by	Dr	S	Newman	with	the	following	modifications	based	on	analysis	of	predicted	breakpoints	and	a	preliminary	round	of	verification:	
• Non-repeat-masked	reference	genome	sequence	is	used	to	allow	the	design	of	primers	for	SVs	falling	in	repetitive	regions	
• Sequence	is	extracted	only	from	within	nodes	i.e.	the	areas	confirmed	to	be	present	at	the	junctions	by	the	presence	of	read	pairs.	Previously	sequence	was	extracted	up	to	1000	bp	away	from	the	junction,	but	in	preliminary	analysis	this	lead	to	false	negative	results	when	these	areas	overlapped	with	adjacent	SVs		
• Sequence	designed	at	least	30	bp	away	from	the	maximal	extent	of	the	node	towards	the	breakpoint,	to	prevent	overlap	of	primer	with	SV	junction	leading	to	false	negatives	Sequences	were	used	to	design	primers	using	the	online	primer	design	system	BatchPrimer3	[354]	which	allows	the	simultaneous	design	of	500	primer	pairs.	The	output	was	converted	to	an	appropriate	format	and	in	silico	PCR	was	used	to	identify	and	remove	primers	capable	of	mispriming.	Primer	pairs	failing	design	or	capable	of	mispriming	were	flagged	for	redesign	with	more	permissive	criteria,	(max	difference	in	annealing	temperature	was	allowed	to	vary	by	up	to	5	
°C).	The	universal	adaptor	sequences	CS1	and	CS2	were	added	to	the	forward	and	reverse	primers	for	each	junction	[358].		This	allows	for	a	second	round	of	PCR	in	which	Illumina	sequencing	adaptors	are	added	by	targeting	adaptor-containing	primers	to	the	universal	adaptor	sequence.		After	quantifying	the	PCR	products	from	the	first	round,	equimolar	volumes	of	each	product	were	pooled	for	PCR,	followed	by	addition	of	Illumina	sequencing	adaptors	and	sequencing	on	the	MiSeq	platform.	For	those	SVs	assessed	by	Sanger	sequencing,	the	forward	primer	was	tagged	with	the	M13-F	universal	sequence	and	the	sequencing	reaction	performed	with	the	M13	sequencing	primer.	Fastq	files	generated	by	the	MiSeq	software	were	searched	for	reads	that	contained	the	primer	sequence	used	to	amplify	each	target	plus	a	6bp	extension	
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into	the	target	region.	The	6bp	extension	would	exclude	primer	dimer	in	the	majority	of	cases,	as	primer-dimer	only	incorporates	sequence	from	the	original	primers	plus	occasionally	random	inserted	base	pairs.	However	in	some	cases,	by	chance,	primer	dimer	contained	the	same	6bp	as	the	target	region	leading	to	primer	dimer	being	extracted	in	addition	to	true	PCR	products	from	the	SV.	In	those	cases	in	which	primer	dimer	was	still	present	(identified	by	manual	review)	the	fastq	files	were	searched	again	using	extensions	into	the	target	regions	incremented	by	6bp	until	primer	dimer	was	eliminated	from	the	identified	list	of	reads.	To	identify	the	junctional	sequence	to	base	pair	resolution	the	reads	were	aligned	to	the	reference	genome	using	BLAT	and	the	results	were	manually	curated.	To	allow	for	high	throughput	verification	by	comparison	to	copy	number	data	a	custom	R	script	was	written.	This	script	(CN_checker.R)	takes	as	input	a	list	of	SVs	from	a	tumour,	matched	copy	number	data	generated	from	that	tumour	and	copy	number	data	from	the	matched	normal.	A	figure	is	generated	for	each	SV	allowing	direct	comparison	of	the	local	copy	number—2Mb	window—at	both	the	start	and	end	of	the	SV	in	the	tumour	and	normal	samples.		In	addition	the	probability	of	a	change	in	copy	number	is	assessing	using	Bayesian	change	point	analysis	and	plotted	alongside	the	read	depth	data	to	facilitate	manual	review	(Figure	3.5)[372].	Results	from	both	pipelines	were	collated	to	generate	a	final	list	of	verified	SVs	(i.e.	those	SVs	that	are	somatic).	Due	to	known	issues	with	the	sporadic	failure	of	PCR,	presence	of	a	junctional	sequence	or	PCR	product	in	the	tumour	alone	was	not	considered	sufficient	to	verify	an	SV.		Thus	an	SV	was	considered	verified	(i.e.	somatic)	if	the	results	met	one	of	5	criteria	(Figure	3.6):	either	(i)	variant	was	verified	by	PCR,	sequencing	and	copy	number	change	(ii)	variant	was	verified	by	PCR	and	sequencing	but	not	copy	number	change	(iii),variant	was	verified	by	copy	number	change	but	no	PCR	product	was	identified	and	no	junctional	sequence	was	identified	(iv)	variant	was	verified	by	sequencing	and	copy	number	change	but	no	PCR	product	was	
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visible	on	gel	electrophoresis	(v)	variant	was	verified	by	PCR	and	copy	number	change	but	no	junctional	sequence	was	identified..		Recently	it	has	become	clear	that	mobile	elements	contribute	a	large	number	of	somatic	structural	variants	to	the	OAC	genome	[96].	This	was	not	clear	at	the	outset	of	this	verification	project.	These	variants	have	a	strong	prior	probability	of	being	true	positives.	For	completeness	I	have	therefore	shown	the	number	of	MEs	verified	in	this	study	(Figure	3.6)	
3.4.2 Pipeline	verification	results	
Seven	tumours	were	selected	for	the	verification	study.	Six	had	libraries	constructed	using	a	PCR-free	protocol	whilst	one	had	libraries	constructed	using	a	standard	PCR-based	library	preparation.	The	6	tumours	for	which	libraries	were	constructed	using	a	PCR	free	protocol	are	tumours	from	batch	1,	which	contained	a	total	of	21	tumour-normal	pairs	(as	discussed	in	chapter	4	on	SNVs).	The	same	filters	were	applied	to	this	batch	as	to	the	data	discussed	above,	giving	a	total	of	7733	SVS	in	21	tumours.	For	each	tumour,	SVs	for	verification	were	randomly	selected	using	the	random	number	generator	function	of	Microsoft	ExcelTM.		A	total	of	255	SVs	had	primers	successfully	designed.	Of	the	255	tested	SVs,	12	were	deemed	to	be	not	somatic	variants,	giving	a	verification	rate	of	95%	(Figure	3.6,	full	details	in	Appendix	Table	4	and	5).	Of	the	12	non-somatic	variants;	one	represented	a	novel	germline	variant	not	present	in	DGV	(confirmed	germline	by	copy	number,	PCR	and	sequencing),	three	were	putative	germline	variants	by	PCR	i.e.	present	in	the	tumour	and	normal	on	gel	electrophoresis	but	had	no	associated	junctional	sequence	and	no	associated	copy	number	change.	Five	appeared	to	be	genuine	false	positive	SVs	generating	no	visible	PCR	product,	no	change	in	copy	number	in	tumour	or	normal	and	no	sequencing	results.	The	remaining	three	variants	gave	a	PCR	product	in	the	tumour	alone	but	were	not	seen	as	a	copy	number	change	and	did	not	generate	sequencing	results.	They	were	therefore	classified	as	false	positives	to	exclude	the	possibility	that	PCR	in	the	normal	sample	had	failed.			
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The	false	positives	were	not	biased	towards	any	particular	tumour	or	batch,	but	the	mean	number	of	supporting	read	pairs	was	lower	than	was	seen	in	the	verified	SVs—as	would	be	expected—though	this	difference	was	not	statistically	significant	(number	of	supporting	reads,	4	versus	15,	p	=	0.059,	2-tailed	t-test).	To	ensure	the	verification	cohort	was	an	accurate	representation	of	the	true	distribution	of	SV	types	we	compared	the	proportion	of	each	SV	type	in	Batch	1,	Batch	0	and	the	panel	of	seven	used	for	verification.	We	noted	that	there	was	an	excess	of	INS	type	SVs	in	Batch	1	when	compared	to	the	proportion	in	the	verification	panel	(Figure	3.7).	This	was	due	to	an	excess	of	INS	type	SVs	within	6	tumours,	none	of	which	were	included	in	the	verification	panel.	Manual	review	of	the	copy	number	plots	for	these	tumours	revealed	association	of	these	SVs	with	copy	number	changes	verifying	them	as	true	positive	SVs	and	thus	their	under-representation	will	not	have	artificially	inflated	the	verification	rate	for	this	cohort.	PCR	verification	of	SVs	is	commonly	used	to	confirm	the	findings	of	NGS	studies	[252,366].	We	thus	sought	to	better	understand	those	PCR	assays	that	had	failed	in	our	analysis.	A	total	of	42	of	255	(16.5%)	PCR	primers	generated	no	product	in	either	the	tumour	or	normal.	This	is	comparable	to	a	recent	large	study	of	PCR	primer	design	criteria	that	identified	a	failure	rate	of	17%	using	comparable	primer	design	criteria	[373].	The	majority	of	these	42	predicted	SVs	were	true	positives	since	34	of	the	42(81.0%)	were	unambiguously	associated	with	somatic	copy	number	changes.		We	therefore	randomly	selected	12	variants	that	had	failed	PCR	in	the	first	round	of	verification	and	redesigned	the	primers	for	these.		Using	the	redesigned	primers,	10	of	12	variants	(83.3%)	were	confirmed	as	somatic	with	sequence	obtained	from	all	ten.	
3.4.3 Verification	biases	introduced	by	PCR	primer	design	
Repetitive	regions	of	the	genome	are	enriched	for	mapping	errors	and	therefore	false	positive	SVs.		These	regions	may	be	excluded	from	PCR	based	verification	
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studies,	as	high	quality	PCR	primers	are	difficult	to	design	in	highly	repetitive	regions	of	the	genome.	This	selection	bias	would	lead	to	an	enrichment	of	true	positive	SVs	in	the	verification	cohort	and	therefore	would	artificially	inflate	the	specificity	of	the	pipeline	as	false	positives	SVs	are	less	likely	to	be	tested	than	true	positive	SVs.	We	reasoned	that	if	this	were	the	case;	firstly,	the	rate	of	failure	of	primer	design	for	predicted	SVs	would	be	greater	than	expected	by	chance	and	secondly	those	SVs	that	failed	primer	design	would	be	less	likely	to	be	verified	by	an	alternative	technique	than	the	SVs	that	passed	primer	design.	To	address	the	first	prediction,	we	used	our	high-throughput	pipeline	to	design	primers	against	4623	predicted	SVs	from	the	original	22	tumours	and	4623	simulated	SVs.	Simulated	SVs	were	generated	by	joining	together	randomly	selected	regions	of	the	mappable	genome	[374].	Node	sizes	were	randomly	selected	without	repetition	from	the	node	sizes	of	the	4623	real	SVs.	This	ensured	that	the	total	genomic	area	compared	for	primer	design	was	comparable	between	the	real	and	simulated	SVs.	There	was	a	significantly	higher	rate	of	primer	design	failure	in	the	real	SV	group	versus	the	simulated	SV	group	(437/4186	(9.5%)	versus	295/4328	(6.4%),	p	=	1.93	x	10	-7,	Chi-squared	test).		To	determine	if	the	verification	rate	was	lower	within	the	population	of	SVs	for	which	primers	could	not	be	designed	we	performed	SV	verification	by	comparison	to	copy	number	changes,	in	the	tumour	and	normal.	Note	verification	by	PCR	is	not	possible	for	these	variants.	For	this	we	used	nine	randomly	selected	tumours	from	Batch	1.	This	included	all	SVs	for	which	primer	design	failed	in	these	nine	tumours	(n	=	204	SVs)	and	408	randomly	selected	SVs	for	which	primer	design	was	successful.	Of	204	SVs	for	which	primer	design	failed	59	(28.9%)	were	not	confirmed	by	copy	number	change	analysis.		Of	the	SVS	for	which	primer	design	was	successful	49	of	408	(12.0%)	were	not	confirmed	by	copy	number	change	analysis	(p	=	
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8.496	x	10	-5,	Chi-square	test).	It	therefore	appears	that	some	bias	may	be	introduced	by	the	primer	design	constraints	in	PCR	based	verification	of	SVs.		
3.4.4 Estimating	the	sensitivity	of	our	pipeline	
Understanding	the	sensitivity	of	any	genomic	variant	calling	pipeline	is	essential	for	downstream	interpretation	of	the	data.	Examples	include	the	interpretation	of	the	number	of	samples	containing	lesions	of	a	particular	gene	or	understanding	the	number	of	SVs.	Of	note,	both	of	these	are	also	susceptible	to	additional	sample-specific	variables	including	degree	of	subclonality	and	the	cellularity	of	the	sample.	Previous	studies	have	addressed	the	issue	of	pipeline	sensitivity	by	either	simulating	SV	data	or	comparison	with	other	alternative	pipelines.	Both	methods	may	be	subject	to	biases;	the	former	being	prone	to	over	fitting	i.e.	a	pipeline	is	developed	that	is	highly	sensitive	to	detect	SVs	with	the	characteristics	that	you	expect	an	SV	to	have	and	therefore	have	simulated.	The	latter	leads	to	pipelines	that	are	iteratively	better	than	those	that	precede	them	but	does	not	address	the	fundamental	issue	of	the	proportion	of	true	SVs	that	can	be	detected.	The	theoretical	sensitivity	of	the	pipeline	can	be	predicted	using	the	Poisson	distribution.	Figure	3.9a	and	3.9b	show	the	proportion	of	single	copy	SVs	expected	to	be	covered	by	at	least	3	reads	for	diploid	(a)	and	triploid	(b)	tumours	with	varying	levels	of	normal	contamination.		Of	note,	the	average	ploidy	of	OAC	cases	has	recently	been	demonstrated	to	be	2.7,	therefore	the	triploid	state	is	likely	to	be	most	representative	of	real	life	data[217].	As	previously	discussed,	the	target	coverage	for	the	ICGC	tumour	and	normal	samples	is	50x	and	30x	sequence	coverage	respectively	[375].		The	coverage	required	to	detect	50%	(DET_50)	and	95%	(DET_95)	of	SVs	in	a	sample	is	summarised	in	Table	3.4.	The	ICGC	target	coverage	would	detect	95%	of	variants	in	a	triploid	cell	up	to	a	cellularity	of	40%.	Below	this,	sensitivity	rapidly	declines.		In	addition	when	considering	the	coverage	of	SVs	detected	using	discordant	read	pair	analysis	the	physical	coverage	of	the	genome	must	be	considered,	not	the	
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more	usually	quoted	sequence	coverage.	Whilst	the	sequence	coverage	is	defined	as	the	average	number	of	sequencing	reads	covering	each	base	pair	in	the	genome,	the	physical	coverage	is	the	average	number	of	read	pairs	spanning	each	base	and	the	key	variable	therefore	is	the	length	of	sequence	between	the	ends	of	read	1	and	read	2	(Figure	3.10).	Therefore	shorter	fragment	size	and	longer	sequencing	read	lengths	lead	to	decreased	physical	coverage.	An	average	fragment	size	of	317bp	–	as	in	our	cohort	-	and	100	bp	paired	end	sequencing	translates	to	a	physical	coverage	of	117bp	and	sequence	coverage	of	200bp	per	fragment	and	therefore	a	total	physical	coverage	of	59.5%	of	the	target	sequence	coverage.	The	mean	physical	coverage	of	a	library	with	50x	sequence	coverage	would	therefore	be	29x.		In	a	triploid	tumour	with	40%	cancer	cellularity	the	expected	sensitivity	would	therefore	be	74%	rising	to	93%	and	98%	in	samples	with	60%	and	80%	cellularity	respectively.	Given	that	the	target	cellularity	for	an	ICGC	samples	is	70%,	the	predicted	sensitivity	for	a	typical	tumour	sequenced	using	standard	Illumina	protocols	and	to	ICGC	coverage	standards	is	96%.	In	practice	many	variables	in	addition	to	ploidy,	cellularity	and	physical	coverage	may	affect	the	sensitivity	of	the	SV	pipeline.	An	example	is	the	number	of	SVs	falling	in	high-copy	number	amplicons	compared	to	single	copy	SVs,	as	SVs	present	in	increased	copy	number	are	more	likely	to	be	detected	due	to	increased	coverage	of	these	regions.	In	addition,	the	type	and	mechanism	of	SV	may	also	alter	sensitivity,	for	example	SVs	falling	in	repetitive	regions	with	lower	coverage	are	more	difficult	to	detect,	similarly	complexity	at	the	SV	junction	may	lead	to	fewer	discordant	read	pairs	with	accurate	mappings	to	the	genome.	To	resolve	this,	in	a	panel	of	34	tumours	(22	from	Batch	0	and	12	from	Batch	1),	we	directly	assessed	the	proportion	of	copy	number	steps	associated	with	the	SVs	identified	by	our	pipeline.	Copy	number	profiles	generated	using	FREEC	were	manually	reviewed.	To	allow	for	the	limited	resolution	of	copy	number	prediction	a	change	in	copy	number	was	considered	to	have	been	identified	if	an	SV	fell	within	20kb.		Manual	review	was	chosen	over	computational	
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segmentation	results	due	to	the	known	poor	sensitivity	and	specificity	of	such	analyses	in	low	cellularity	and	samples	with	complex	variation	[376].	The	mean	physical	coverage	for	the	34	selected	tumours	was	80	fold.	The	mean	sensitivity	for	SV	detection	was	80.5%	(range	51.1%	to	97.8%).	There	was	a	positive	correlation	with	the	depth	of	physical	coverage	(0.39	Pearson’s	r,	p		<		0.05).		
3.4.5 Comparison	to	alternative	pipelines	
We	compared	the	specificity	results	from	our	pipeline	to	other	published	pipelines	used	in	cancer	genomic	studies	that	had	also	undergone	verification.	The	compared	pipelines	utilize	either	discordant	read	pair	clustering;	dRanger,	BreakDancer[305,377-379],	split	read	mapping;	CREST	[310]	or	a	combined	approach,	MEERKAT,	DELLY,	qSV	[308,309,380,381].	Since	no	other	study	applied	a	correction	for	bias	introduced	by	PCR	design	failure	rates	we	used	our	uncorrected	specificity	value	of	95.1%.		Only	two	other	pipelines	achieved	a	specificity	greater	than	90%,	MEERKAT	and	DELLY	(Table	3.5).	However	the	majority	of	studies	only	report	the	specificity	with	a	single	round	of	PCR	primers.	As	discussed	previously	this	leads	to	an	underestimation	of	the	true	pipeline	specificity	and	it	is	therefore	likely	that	other	pipelines	may	provide	similarly	high	levels	of	specificity	when	this	is	taken	into	account.			
3.5 Patterns	of	SVs	in	the	OAC	genome	
We	next	assessed	the	number	and	type	of	SVs	across	the	OAC	genome.	For	this	analysis	mobile	element	(ME)	type	SVs	were	classified	separately,	using	the	list	of	mobile	element	positions	from	Tubio	et	al	and	including	additional	examples	identified	in	our	lab	[95,96].	Of	note	these	may	represent	a	true	movement	of	the	fragment	of	DNA	or	a	mismapping	created	by	movement	of	repeat	sequence.	All	other	rearrangements	were	classified	as	previously	described	based	on	the	
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orientation	and	relative	location	of	the	break	point	positions,	giving	a	total	of	six	categories;	ME,	INS,	INV,	ITR,	DEL	and	DIF.		We	identified	a	total	of	11	006	SVs	across	the	43	tumours	(excluding	MEs).	The	number	of	SVs	varied	widely	with	a	mean	of	256,	Figure	3.11	(range	70	–	687).	Only	a	small	number	of	inverted	tandem	repeat	(ITR)	type	junctions	were	identified.	INS,	DIF,	DEL	and	INV	type	junctions	occurred	at	similar	rates	across	the	cohort	(total	number	of	SVs,	INS	versus	DIF	versus	DEL	versus	INV,	2474	versus	2617	versus	2890	versus	2863).	Plotting	the	number	and	type	of	SVs	within	each	sample	shows	that	each	tumour	demonstrates	marked	differences	between	the	numbers	of	different	SV	types.	To	better	identify	patterns	of	structural	variation	we	separated	tumours	based	on	the	most	prevalent	SV	type.		In	total	9	tumours	were	DIF	dominant,	15	tumours	were	DEL	dominant,	13	tumours	were	INV	dominant	and	6	tumours	were	INS	dominant.	INS	dominant	tumours	showed	notably	higher	rates	of	SVs	than	tumours	where	the	most	prevalent	SV	type	was	DEL,	DIF	or	INV	(median	SV	number,	429	versus	193	versus	204	versus	203).		Structural	variants	can	be	classified	by	several	metrics	including;	their	size,	the	location	in	the	genome	in	which	they	occur	e.g.	centromeric,	subtelomeric,	repeat	sequence,	the	amount	of	homology	at	the	novel	junction,	their	relationship	with	copy	number	variation	and	their	relationship	to	other	structural	variants.	In	this	preliminary	analysis	we	have	focused	on	size	of	SVs	only.		We	first	plotted	histograms	of	structural	variant	size	for	INS,	INV	and	DEL	type	SVs—note	log10	transformation	was	used	to	facilitate	ease	of	viewing	(Figure3.12).		All	SV	types	show	a	peak	of	SVs	within	the	1-10Mb	range.	INS	and	DEL	type	SVs	show	a	further	peak	between	100k	and	1Mb.	INV	type	SVs	show	a	unique	peak	at	approximately	1Kb	in	size	whilst	DEL	type	SVs	show	a	unique	peak	between	1k	and	10kb	in	size.	Note	as	previously	discussed	DEL	type	SVs	less	than	1000bp	in	size	have	been	excluded	due	to	difficulties	identifying	this	variant	type	with	our	current	pipeline.		
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As	detailed	above	all	SV	types	showed	a	peak	between	1Mb	and	10Mb	in	size.	There	was	a	strong	correlation	between	the	number	of	SVs	>1Mb	of	all	types	(Figure	3.13,	Figure	3.14,	Figure	3.15).	We	next	manually	reviewed	the	copy	number	and	SV	connectivity	plots	for	tumours	showing	high	levels	of	large	SVs.	The	vast	majority	of	these	large-scale	events	are	clustered	in	regions	that	meet	the	criteria	for	chromothripsis	.	This	process	has	previously	been	shown	to	generate	large	SVs	of	multiple	types.		Notably,	given	the	putative	mechanism	of	chromothripsis	with	random	joining	of	fractured	DNA	segments,	INV	type	SVs	should	be	present	in	roughly	twice	the	number	of	DEL	and	INS	type	SVs	as	they	can	be	either	head	to	head	or	tail	to	tail	joins.	In	all	tumours	with	an	excess	of	large	SVs,	large	INV	type	SVs	were	present	in	excess	of	large	INS	or	large	DELs,	supporting	chromothripsis	as	the	mechanism.	To	identify	further	co-occurrence	of	SV	types	we	focussed	on	the	INS-dominant	tumours	reasoning	that	any	pattern	in	INS	type	SVs	would	be	enriched	in	these	cases.	(n	=	6).	These	tumours	showed	a	marked	increase	in	10	–	100Kb	and	100Kb	to	1Mb	sized	INS	type	SVs,	when	compared	to	tumours	in	which	other	SVs	were	the	predominant	type	(Figure	3.13,	Figure	3.14,	Figure	3.15).	SVs	may	be	associated	with	other	forms	of	somatic	variation	[40,211].	In	particular,	SVs	have	been	linked	to	specific	mutational	signatures.	We	therefore	assessed	the	correlation	between	number	of	SNVs	generated	by	each	mutational	signature	(discussed	in	Chapter	5)	and	the	total	number	of	SVs	in	each	tumour.	There	was	only	a	weak	positive	correlation	between	the	total	number	of	SVs	seen	in	a	tumour	and	the	total	number	of	SNVs	(r	=	0.111,	Pearson’s	correlation).	Only	signature	2	and	signature	6	demonstrated	any	correlation	with	total	SV	number	showing	weak	and	moderate	positive	correlation	respectively	(r	=		0.253	and	r	=	0.503,	Pearson’s	correlation).		As	with	SNVs,	although	signatures	may	be	immediately	apparent	by	manual	review	of	the	data,	formal	mathematical	approaches	may	provide	a	more	quantitative	insight	into	the	patterns	of	SV	seen	in	OAC.	We	therefore	performed	a	preliminary	analysis	of	SV	signatures	using	non-negative	matrix	factorisation.	
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SVs	were	divided	by	size	as	above	with	the	obvious	exceptions	of	DIF	and	ITR	type	SVs.	To	identify	the	optimal	number	of	signatures	we	utilised	the	methodology	suggested	by	Hutchins	et	al	2008,	discussed	in	Chapter	4,	and	took	the	signature	number	at	the	inflection	point	of	the	Residual	sum	of	squares	(RSS)	between	the	original	data	matrix	and	the	NMF	generated	matrix	[382],	as	this	had	previously	been	comparable	to	other	methods	in	our	SNV	analysis.	Using	this	method	suggested	an	optimal	signature	number	of	5.	The	5	SV	signatures	can	be	seen	in	Figure	3.16	and	Figure	3.17.		These	signatures	correlate	well	with	those	previously	identified	in	breast	cancer	and	a	recent	pan-cancer	analysis	[383,384].		Two	signatures	showed	a	predominance	of	INS	type	SVs,	signature	A	and	Signature	D.	Signature	D	was	associated	with	INSs	from	10kb	to	100kb	and	from	100kb	to	1Mb.	Across	the	43	tumours	this	signature	caused	a	mean	of	42	SVs	(range,	0-363).	To	better	characterise	this	signature	we	chose	the	top	7	tumours	enriched	for	this	signature.	Below	this	point	there	was	a	sharp	drop	off	in	SV	numbers	generated	by	this	signature.		We	next	plotted	histograms	of	INS	type	SV	and	used	the	density	function	in	R	to	estimate	the	average	size	of	the	major	SV	population	(Figure	3.18,	Figure	3.19).	There	appeared	to	be	a	bimodal	distribution	of	INS	sizes	with	3	tumours	showing	the	peak	SV	size	to	be	~	110	Kb	(125893bp,	112202bp,	102023bp)	and	4	tumours	showing	a	main	peak	size	of	~260Kb	(263224bp,	238661bp,	281243bp,	281456bp).	We	reviewed	the	copy	number	plots	for	these	7	tumours.	It	was	apparent	that	these	large	INS	type	SVs	in	tumours	dominated	by	this	signature	were	genome	wide,	associated	with	copy-number	steps	and	were	not	linked	or	clustered	with	other	SV	types	(Figure	3.20).	These	features	are	in	keeping	with	the	large	tandem	duplicator	SV	patterns	that	have	been	previously	identified	in	ovarian	and	breast	tumours	[366,385,386].	A	recent	paper	has	reported	that	these	larger	tandem	duplications	are	associated	with	amplification/	over	expression	of	CCNE1	[386].	Consistent	with	these	reports,	6	of	the	7	tumours	harboured	SVs	or	copy	number	gains	targeting	this	gene.	
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In	signature	A,	smaller	tandem	duplications	were	associated	with	deletions	of	various	sizes	in	roughly	equal	proportions.	Manual	review	of	copy	number	plots	for	the	5	tumours	most	enriched	for	this	signature	demonstrated	extensive	rearrangement	of	fragile	sites,	with	multiple	deletions	often	affecting	the	same	gene.	To	better	quantify	this	we	chose	6	genes	at	putative	fragile	sites	previously	identified	in	OAC	and	other	cell	types;	FHIT,	WWOX,	DMD,	MACROD2,	PDE4D	and	
RUNX1[334,387,388].	We	quantified	the	number	of	SVs	targeting	these	genes	in	each	tumour.	The	average	total	number	of	rearrangements	per	tumour	within	these	6	genes	was	12	(range,	1	-30).	We	compared	the	10	tumours	with	the	lowest	number	of	SVs	caused	by	signature	A	with	the	top	10	tumours	affected	by	this	signature.	There	was	a	significant	difference	in	number	of	fragile	site	SVs,	between	these	groups	(17.6	rearrangements	versus	7.8	signature	p		=	0.00187,	two-tailed	t-test).	Notably	this	association	of	fragile	site	deletions	and	tandem	duplications	seen	in	signature	A	has	recently	been	reported	in	a	large	pan-cancer	analysis.		A	single	tumour	enriched	for	signature	A,	7442,	showed	a	smaller	TD	pattern	with	a	lower	peak	SV	density	of	14	454	bp.	As	well	as	extensive	rearrangement	of	it’s	fragile	site	loci	this	tumour	also	showed	a	pattern	of	recurrent	small	TD	scattered	throughout	the	genome,	this	closely	resembles	the	pattern	seen	with	BRCA1	mutated	tumours	[211,386,389].	Signature	A	may	therefore	represent	a	combination	of	BRCA1	deficiency	and	fragile	site	rearrangement	signatures.	As	previously	noted	in	our	manual	review	of	the	data,	large	SVs	(>1Mb)	of	all	types	co-occur	in	samples.	In	our	signature	analysis	this	is	represented	by	signature	C.	Manual	review	of	copy	number	plots	showed	that	this	signature	was	enriched	in	tumours	with	large	numbers	of	focal	rearrangements	oscillating	between	1	to	2	different	copy	number	states	in	keeping	with	the	phenomenon	of	chromothripsis.	Though	the	mechanisms	underlying	chromothripsis	remain	unclear	[253,257,258]	in	all	cases	random	joining	of	DNA	ends	is	thought	to	occur.	As	INV	type	SVs	can	be	both	head	to	head	and	tail	to	tail	they	would	be	expected	to	occur	at	twice	the	rate	of	INS	and	DEL	type	SVs.	This	is	the	case	for	this	signature,	further	supporting	chromothripsis	as	the	cause.	
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Signature	B	comprises	of	ITR	and	small	INV	type	SVs.	This	signature	would	be	in	keeping	with	the	process	of	gene	amplification	known	as	break-fusion-bridge	cycles	[260,262,390].		However	this	pattern	could	also	be	generated	by	artificial	ligation	of	DNA	fragments	during	library	preparation.	As	discussed	previously	two	of	our	tumours	showed	this	artefact	with	tens	of	thousands	of	unique	INVs	identified	during	sequencing.		Other	tumours	enriched	for	this	signature	did	harbour	areas	of	amplification	in	keeping	with	BFB	cycles	and	gene	amplification	(Figures	3.22,	3.23	and	3.24).	However	this	signature	was	also	markedly	more	prevalent	in	tumours	where	the	sequencing	library	had	been	prepared	using	PCR	as	opposed	to	PCR	free	strategies	(mean	rearrangement	number	=	13	versus	40,	n=	22	vs	21,	p	=	0.02,	two-tailed	t-test).	This	significance	persisted	even	when	the	two-outlier	samples	3302	and	3314	were	removed	(200	signature	B	rearrangements	and	184	respectively).		It	is	therefore	possible	that	this	signature	represents	a	combination	of	artefactual	and	true	SV	generating	processes.		To	test	this	hypothesis	we	extracted	the	signatures	using	only	tumours	whose	libraries	were	prepared	without	a	PCR	step	(thus	preventing	the	amplification	of	novel	ligated	fragments).		The	5-signature	model	was	again	the	most	optimal	solution	with	the	small	INV	signature	being	retained.	Samples	enriched	for	the	small	INV	signature	persisted	and	harboured	large-scale	rearrangements	characteristic	of	BFB	cycles.		The	final	signature,	signature	E	is	dominated	by	DIF	type	SVs.		Manual	review	of	tumours	containing	this	signature	revealed	two	patterns	of	DIF	distribution	with	DIFs	either	broadly	distribute	across	the	genome	or	clustered	tightly	together.	In	tumours	with	the	clustered	pattern	DIFs	bordering	CN	steps	linked	2	or	more	areas	of	the	genome.	This	is	supportive	of	a	mechanism	such	as	chromothripsis	occurring	following	translocation	between	the	two	chromosomes	or	with	breaks/	replication	involving	2	or	more	chromosomes	simultaneously	(Figure	3.22).	The	genome	wide	DIF	pattern	was	explained	by	a	combination	of	previously	unrecognised	and	therefore	unfiltered	ME	element	movements	–	in	particular	seen	in	tumour	7396	-	and	reciprocal	translocation	pattern	SVs	(though	from	the	SV	data	it	is	impossible	to	distinguish	a	reciprocal	translocation	from	a	small	insertion	of	DNA).	
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Finally	we	looked	for	correlation	between	SV	signatures	and	SNV	signatures.	Spearman’s	correlation	was	used	as	our	data	contained	several	outliers.	Signature	5	(APOBEC)	showed	significant	moderate	correlation	with	the	large	INS	signature	,	signature	A,	(r	=	0.38,	p	=	0.033)	and	signature	4		(T:A>G:C	and	T:A>C:G)	showed	moderate	positive	correlation	with	the	small	INS	and	DEL	signature,	signature	D	(r	=	0.38,	p	=	0.038).	However	neither	result	remained	significant	when	controlled	for	multiple	testing	using	the	Benjamini-Hochberg	procedure	with	FDR	set	to	0.05.	
3.6 Discussion	
3.6.1 Development	of	a	pipeline	for	identification	and	verification	of	SVs	
In	the	above	analysis	our	pipeline	has	demonstrated	both	sensitivity	and	specificity	that	compare	favorably	with	the	literature.		Verification	by	PCR,	with	or	without	sequencing,	and	copy	number	analysis	are	considered	the	gold	standard	approaches	for	confirming	the	somatic	status	of	predicted	SVs,	with	verification	by	PCR	the	most	commonly	used	[308,309,380].	However,	each	is	subject	to	errors.	Copy	number	analysis	is	incapable	of	identifying	balanced	rearrangements—those	in	which	there	is	neither	gain	nor	loss	of	genetic	material	and	struggles	with	identification	of	smaller	variants	[302,391]	.	PCR	failure	in	both	tumour	and	normal	samples	may	lead	to	the	erroneous	classification	of	a	variant	as	a	false	positive	call.		Alternatively	mispriming	may	lead	to	a	variant	falsely	being	classified	as	germline,	if	aberrant	product	is	generated	in	both	tumour	and	normal	samples.	Finally,	sequencing	of	the	junction	may	fail	to	deliver	interpretable	sequence	if	passing	through	areas	of	repeat	sequence	due	to	slippage	of	the	Polymerase.	PCR	verification	is	frequently	the	sole	method	used	for	verification	of	SV	pieplines	[308-310,377].	A	major	issue	with	this	approach	is	that	it	may	bias	in	favour	of	SVs	in	areas	that	are	easier	to	design	PCR	primers	to,	and	this	may	exclude	regions	of	repeats	and	low	sequence	complexity	that	may	harbour	increased	rates	of	false	positive	SVs.	This	would	inflate	apparent	specificity.	By	
	 104	
not	repeat-masking	the	sequence	used	for	primer	design	and	allowing	substantial	flexibility	in	the	size	of	product,	we	aimed	to	mitigate	this	potential	bias.		Despite	this	our	analysis	of	randomly	generated	SVs	suggested	that	there	was	a	higher	than	expected	rate	of	PCR	design	failure	within	our	real	SVs	when	compared	to	randomly	generated	SVs.	Furthermore	we	were	able	to	demonstrate	a	decreased	verification	rate	(necessarily	by	copy-number	change	analysis	alone)	in	those	SVs	for	which	we	could	not	successfully	design	primers.	This	supports	the	hypothesis	that	verification	by	PCR	alone	will	artificially	inflate	the	specificity	of	an	SV	pipeline.	Though	it	is	also	possible	that	SVs	targeting	repeat	regions	may	be	more	likely	to	be	small	events	or	balanced	events	precluding	verification	by	CN	analysis.	Overall	the	effect	on	the	verification	rate	of	this	bias	is	likely	to	be	limited.	Assuming	all	variants	that	could	not	be	confirmed	by	copy	number	in	the	failed	primer	design	cohort	are	true	false	positives—unlikely	as	at	least	a	proportion	will	be	balanced	rearrangements	or	too	small	to	detect—the	additional	increase	in	the	false	positive	rate	identified	from	verification	of	only	those	SVs	for	which	primers	could	be	designed	will	be	2.98%	(28.9%	of	failed	primer	design	variants	are	false	positives,	failed	primer	design	variants	represent	10.3%	of	all	predicted	variants).	This	would	make	the	true	verification	rate	of	the	pipeline	92.1%	if	applied	to	all	predicted	SVs.	Given	our	permissive	primer	design	criteria	it	is	likely	that	the	effect	is	reduced	in	our	cohort	and	may	play	a	greater	role	in	previous	verification	studies	for	other	pipelines	[42,307,308,310,377,378,380,392].		It	is	important	to	note	that	our	verification	rate	by	PCR	is	likely	an	under	representation	of	the	true	specificity	of	the	pipeline	due	to	false	negative	results	associated	with	PCR	failure.	Two	lines	of	evidence	support	this.	Firstly,	of	the	42	variants	for	which	PCR	failed	to	generate	any	sequence,	34	(81.0%)	were	clearly	associated	with	copy	number	steps	at	both	junctions	–	given	the	size	of	the	genome	and	the	accuracy	of	segmentation	this	is	highly	unlikely	to	have	occurred	by	chance.	Secondly,	redesign	and	repeat	PCR	for	12	primer	pairs	identified	10	as	true	somatic	variants.	A	further	extension	of	our	verification	pipeline	would	be	to	automate	the	redesign	of	primers	that	fail	the	initial	cycle	of	design	and	verification.	
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In	summary,	to	understand	properly	the	specificity	of	our	pipeline	we	have	aimed	-	in	part	-	to	address	and	quantify	the	biases	within	each	of	the	verification	methods.	We	conclude	that	the	combined	use	of	all	3	modalities	likely	provides	the	most	appropriate	solution	for	future	verification	of	SV	pipelines.	For	example,	if	an	aberrant	PCR	product	is	generated	in	both	tumour	and	normal,	as	a	result	of	mispriming	or	primer	dimer,	then	comparison	to	the	copy	number	profile	may	confirm	that	these	SVs	are	in	fact	somatic.	In	addition,	identifying	sequence	information	across	the	novel	junction	can	confirm	that	the	resulting	PCR	product	is	indeed	mispriming	and	not	a	putative	germline	junction	allowing	primers	to	be	appropriately	selected	for	redesign.			We	also	present	here	an	analysis	of	the	sensitivity	of	our	SV	pipeline	for	CN	generating	SVs.	Our	sensitivity	analysis,	performed	in	34	tumours,	showed	a	mean	sensitivity	for	SV	detection	of	80.5%	(range	51.1%	to	97.8%).		Comparison	with	other	pipelines	is	difficult,	as	few	have	performed	a	sensitivity	analysis	on	genuine	SVs	in	multiple	tumours	with	most	opting	for	a	sensitivity	based	on	the	detection	of	simulated	SVs,	which	frequently	do	not	accurately	match	the	patterns	seen	in	tumours.	Our	true	sensitivity	for	SVs	is	likely	to	be	lower	than	estimated	by	CN	comparison	as	small	SVs	undetectable	by	CN	steps	are	also	less	likely	to	be	detected	by	our	pipeline	due	to	our	exclusion	of	deletions	<1000bp.	Furthermore	our	sensitivity	analysis	cannot	be	generalized	to	balanced	rearrangements	or	other	small	rearrangements	that	are	not	visualisable.	Use	of	a	more	sensitive	CN	detection	tool	capable	of	identifying	smaller	CN	using	variable	bin	sizes	and	sliding	windows	[391,393]		may	help	to	address	this	deficit	and	supplement	manual	review.	No	SV-pipeline	standard	has	yet	been	universally	accepted	in	NGS	studies.	Given	the	rapid	advancement	and	utilization	of	novel	software	and	hardware	for	the	generation	and	analysis	of	cancer	genomes	it	is	unlikely	that	a	universal	standard	will	ever	be	developed.	Thus	verification	will	remain	an	important	step	in	the	identification	of	SVs.	The	tools	we	have	developed	in	this	study	provide	a	simple	solution	for	the	rapid	verification	of	large	numbers	of	SVs	required	to	verify	the	output	of	a	new	or	modified	SV	pipeline.	A	comparable	pipeline	for	high	throughput	verification	of	SVs	using	PCR	has	recently	been	published	[380]	.	
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However	this	study	did	not	also	investigate	the	role	of	CN	variants	and	uses	strict	primer	design	criteria	that	may	introduce	bias	as	discussed	above.	Reasonable	next	steps	to	improve	the	SV-verification	pipeline	would	be	to	use	an	aligner	capable	of	accurately	providing	split-alignment	of	reads	e.g.	BWA-	MEM	to	automate	the	process	of	identifying	junction	sequence	from	PCR	products	[289].	In	addition	automation	of	the	CN	comparison	step	could	be	performed	with	a	suitably	accurate	CN	segmentation	algorithm	for	example,	however	manual	review	will	likely	remain	an	integral	part	of	this	assessment,	particularly	in	low	cellularity	or	heterogeneous	samples	[394,395].	
3.6.2 Increasing	sensitivity	
Poor	sensitivity	for	variant	calls	will	clearly	lead	to	a	decreased	power	to	identify	novel	variants	that	occur	at	low	frequency	within	the	cancer	population	[396].		Perhaps	more	importantly	poor	sensitivity	may	lead	to	aberrant	classification	of	co-occurrence	of	mutations,	making	interpretation	of	their	interaction	and	understanding	of	the	underlying	biology	more	difficult.	We	have	explored	the	theoretical	and	genuine	sensitivity	of	our	pipeline.	A	striking	finding	is	the	poor	sensitivity	seen	in	some	low	cellularity	and/or	high	ploidy	tumour	samples.		There	is	therefore	a	need	to	increase	the	sensitivity	of	the	SV	discovery	process.			The	simplest	approach	to	increasing	sensitivity	is	to	increase	the	sequencing	depth	and	therefore	the	physical	coverage	of	the	tumour	library.	However,	the	cost	of	whole	genome	sequencing	still	remains	an	issue	and	increasing	coverage	by	increasing	sequencing	depth	is	unlikely	to	be	feasible	in	large	studies.	In	addition,	increasing	sequencing	will	lead	to	a	further	accumulation	of	aberrant	ligation	events	and	sequencing	errors	leading	to	an	increased	false	positive	rate.		An	alternative	approach	to	increasing	physical	coverage	is	to	trim	back	read	lengths	in	the	raw	data	and	only	align	a	short	initial	portion	of	the	read.	Reads	spanning	a	rearrangement	junction	will	contain	sequence	from	non-contiguous	regions	of	the	genome.	Such	reads	will	be	referred	to	as	split	reads	from	here	on.	Typically,	fast	short-read	aligners	will	not	align	split	reads	and	will	instead	flag	the	read	as	unaligned	or	will	perform	a	local	alignment	of	a	portion	of	the	read	
	 107	
with	reference	to	it	aligned	partner.	The	latter	approach	is	known	as	soft-clipping	in	BWA	and	leads	to	the	masking	of	bases	that	do	not	align	to	the	local	genome	area.		These	read	pairs	are	therefore	prevented	from	providing	evidence	for	the	existence	of	the	rearrangement	junction.	Aligning	only	the	most	distal	portions	of	the	read	increases	the	physical	coverage	and	allows	split	reads	to	be	informative	for	discordant	read	pair	analysis.		A	library	with	an	average	fragment	size	of	300bp	sequenced	with	100bp	paired	end	reads	will	have	sequence	coverage	of	200bp	but	only	a	physical	coverage	window	of	100bp	(figure	3.10).	If	reads	are	trimmed	back	to	50bp	this	will	decrease	sequence	coverage	by	half	but	will	double	physical	coverage.	One	potential	issue	with	this	approach	is	that	as	read	size	decreases	the	mappability	decreases,	thereby	making	the	read	more	likely	to	be	unmappable	[397].	An	alternative	approach	would	therefore	be	to	perform	the	analysis	with	both	short	reads	and	long	reads	to	increase	the	physical	coverage	whilst	also	maintaining	accurate	mapping	to	less	unique	regions	of	the	genome.		For	many	regions	of	the	genome	even	very	short	fragments	of	DNA	will	be	unique,	a	dynamic	approach	to	trimming	reads	for	alignment	based	on	local	mappability	would	therefore	allow	for	reads	to	be	only	as	long	as	necessary	to	generate	a	unique	alignment[397].	Such	an	approach	is	possible	with	BWA-MEM	[289]	which	provides	a	split-alignment	of	single	reads.		Use	of	longer	reads	to	increase	mappability	and	to	span	long	repeat	sections	may	increase	sensitivity	for	SVs	falling	in	poorly	mappable	sequence.		This	can	be	achieved	either	by	increasing	the	effective	fragment	size	used	for	paired	end	sequencing	e.g.	Mate-pair	sequencing	or	by	using	novel	sequencing	approaches	capable	of	generating	long	reads	e.g.	Nanopore,	PACbio	[304,398].	The	use	of	mate-pair	sequencing	to	increase	effective	fragment	size	is	limited	by	the	large	quantities	of	high	quality	DNA	required	to	construct	such	libraries.	In	addition	studies	comparing	mate-pair	sequencing	to	standard	paired	end-sequencing	have	failed	to	identify	specific	rearrangements	that	are	only	detectable	by	mate-pair	sequencing	[304].	The	number	of	SVs	identified	in	this	study	was	small	and	it	remains	possible	that	variants	only	identifiable	with	longer	fragment	lengths	do	exist.		
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The	use	of	CN	changes	to	identify	sites	of	SVs	is	another	potential	approach	to	improve	sensitivity.	In	this	case	a	lower	level	of	split	read	/	paired	end	read	evidence	might	be	accepted	if	a	CN	change	was	also	present.	This	would	have	to	be	balanced	against	the	risk	of	false	positives	but	warrants	further	exploration.	In	particular	the	more	accurately	the	read	coverage	change	could	be	localized	the	less	likely	a	false	positive	discordant	read	pair	would	fall	in	the	potential	SV	site.	In	addition,	many	rearrangements	fall	wholly	within	repeat	sequences	that	will	not	be	accurately	mappable	even	with	currently	available	long	read	length	technologies.		Examples	may	include	telomere	capping	of	exposed	DSBs,	or	rearrangements	involving	centromere	sequences.	It	is	important	to	identify	such	junctions	as	they	may	still	have	functional	consequences.	For	example	fusion	of	an	expressed	gene	with	centromeric	heterochromatin	may	lead	to	suppression	of	this	gene.	The	use	of	the	above	CN	step	targeted	identification	of	SVs	is	one	approach.	An	alternative	would	be	to	identify	pairs	of	reads	where	unique	sequence	is	joined	to	unexpected	repeat	sequence.	Such	an	approach	has	been	used	to	identify	mobile	element	insertions	and	could	be	generalized	to	any	repeat	[95].	A	similar	approach	allowing	multiple	mappings	of	read	pairs	to	be	incorporated	into	discordant	read	pair	clustering	has	been	implemented	in	2	recently	published	SV	callers	[308,399].	
3.6.3 Increasing	specificity	
We	have	demonstrated	that	our	pipeline	has	a	high	specificity	with	95.1%	of	assessed	predicted	SVs	confirmed	as	true	somatic	variants.	The	drive	for	improvements	in	this	specificity	should	be	balanced	against	the	potential	for	losses	in	sensitivity.		The	incorporation	of	multiple	lines	of	evidence	for	an	SV	could	increase	the	specificity	of	SV	calling.	For	example,	some	published	SV	pipelines	require	the	SV	to	be	confirmed	by	split	reads	and	discordant	read	pairs	[309].	However	this	will	have	a	detrimental	effect	on	sensitivity	as	has	been	shown	in	previous	studies	of	somatic	SVs	[42].	As	discussed	previously	the	requirement	for	a	CN	change	would	bias	against	balanced	SVs	and	small	SVs.	An	alternative	approach	would	
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thus	be	to	accept	this	low	level	of	error	and	instead	perform	verification	using	orthogonal	approaches	e.g.	FISH	or	PCR	of	variants	of	interest.	Orthogonal	verification	would	be	particularly	beneficial	if	the	focus	was	on	a	cluster	of	variants	in	a	target	gene	where	mismapping	may	be	an	issue	and	to	confirm	the	true	structure	of	the	rearrangement.	Recent	studies	have	for	example	demonstrated	that	recurrent	rearrangements	identified	in	TTC28	in	colorectal	cancer	are	in	fact	mobile	element	movements	[42,95,96,400].	Our	approach	of	utilizing	discordant	read-pairs	identified	in	multiple	normal	samples	as	a	filter	leads	to	a	significant	reduction	in	false	positive	SVs.	A	caveat	to	this	approach	is	that	it	does	not	differentiate	between	germline	SVs	and	false	positive	SVs.	It	is	therefore	not	appropriate	for	identifying	germline	changes.	We	have	shown	here	that	there	were	diminishing	returns	in	improvements	of	specificity	with	the	incorporation	of	discordant	read	pairs	from	normals.	The	number	of	putative	false	SVs	removed	began	to	plateau	at	10	samples	(Figure	3.1).	Increasing	the	number	of	normals	beyond	this	point	should	be	carefully	evaluated.	An	important	next	step	in	development	of	this	pipeline	would	be	a	detailed	assessment	of	excluded	SVs	when	various	numbers	of	control	samples	are	used	aiming	to	identify	false	negative	calls	and	the	reasons	for	these.	This	approach	remains	agnostic	to	the	exact	mechanism	of	false	positive	rearrangement	generation	and	is	therefore	likely	to	be	more	efficient	than	pipelines	based	around	known	error	types	[401].	Other	variant	calling	pipelines	use	heuristic	filters	developed	from	prior	identification	of	false	positive	calls	[294,295,310,377].	With	increasing	numbers	of	normal	datasets	a	more	accurate	picture	of	potential	errors	could	be	identified	and	more	specific	filters	developed.	Using	our	data	set	of	normal	samples	we	were	able	to	identify	several	factors	as	causes	of	false	positive	rearrangements.	We	developed	filters	targeting	specific	areas	of	the	genome	that	were	characterized	by	high	read	depth	and	frequent	false	positive	SVs.	Notably	the	number	of	potential	mismappings	found	at	the	Chr10	repeat	regions	was	so	high	that	even	incorporation	of	discordant	read	pairs	from	10	normal	samples	failed	to	remove	all	false	SVs	identified	at	this	locus,	necessitating	the	use	of	a	targeted	filter	for	this	region.	We	also	identified	several	mismappings	missed	by	using	the	less	accurate	but	much	faster	short	
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read	aligners.	In	these	cases,	errors	in	the	sequencing	process	caused	the	read	to	be	mapped	to	an	alternative	location	with	significant	homology	to	the	germline	position	downstream	from	its	partner	read.	However	performing	an	in-depth	local	alignment	identified	the	highly	similar	local	match.	Though	it	is	possible	that	a	rearrangement	has	occurred	between	near-homologus	regions	of	the	genome	it	remains	significantly	more	likely	that	these	are	false	positives.	In	keeping	with	this	explanation	our	filter	removed	a	greater	proportion	of	SVs	from	the	normal	unique	set	(i.e.	the	putative	false	positives)	than	from	the	tumour	set.	An	ideal	extension	to	this	filtering	approach	would	be	to	use	the	normal	data	to	develop	a	more	probabilistic	model	utilizing	number	of	supporting	read	pairs	in	tumour	and	normal	and	mappabilty	of	the	area	amongst	other	variables	to	generate	a	probability	that	a	variant	is	real.	This	would	aim	to	limit	the	elimination	of	true	positive	SVS	when	incorporating	more	discordant	read	pairs	from	normal.	A	similar	approach	has	been	used	in	the	identification	of	low	variant	allele	frequency	SNVs	[402].		
3.6.4 Observed	patterns	of	structural	variation	in	oesophageal	adenocarcinoma	
Compared	to	SNV	signature	analysis,	for	the	SV	signature	analysis	an	additional	complication	is	the	choice	of	factors	that	define	the	SV.	In	this	study	we	have	selected	size	and	rearrangement	type	as	the	main	differentiators	of	SVs.	Size	cut-offs	were	taken	from	a	previous	study	[211]	as	this	had	demonstrated	extraction	of	relevant	signatures	that	correlated	with	previously	known	mechanisms	of	genetic	instability.	Several	recent	studies	focusing	on	tandem	duplications	have	further	refined	the	size	distributions	seen	for	this	SV	type	and	it	would	be	of	interest	to	reanalyze	our	data	with	the	cut-offs	identified	in	these	studies	[366,385,386].	In	addition	other	criteria	that	could	be	incorporated	into	this	analysis	include;	extent	of	homology	at	the	breakpoint,	presence	of	repeat	sequence,	association	with	copy	number	steps,	clustering	of	SVs,	association	with	transcription	and	association	with	replication	timing.	
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We	have	demonstrated	here	that	a	single	tumour,	7442,	harboured	a	rearrangement	pattern	indicative	of	BRCA1-deficiency	[40,389].	This	tumour	was	also	enriched	for	the	SNV	signature	associated	with	HR	deficiency,	signature	6.	No	somatic	BRCA1	mutation	was	identified	in	this	sample,	however	we	did	not	investigate	for	germline	variants	or	for	methylation	of	the	BRCA1	promoter.		Recent	studies	have	suggested	tumours	harbouring	a	SNV	mutational	signature	of	BRCA	deficiency	may	respond	well	to	platinum	based	chemotherapy	[39,403].	This	patient	had	not	received	chemotherapy	and	so	we	are	not	able	to	assess	their	response.	We	have	identified	several	tumours	enriched	for	the	previously	identified	point	mutation	signature	linked	to	HR	deficiency.	However	we	observed	no	correlation	between	presence	of	the	SV	signature	and	the	SNV	signature.	This	is	in	keeping	with	the	SNV	signatures	association	with	mechanisms	of	HR	deficiency	other	than	BRCA1	loss.		The	identification	of	this	SV	signature	confirms	the	functional	role	of	BRCA	gene	loss	in	a	small	subset	of	oesophageal	cancers	[381,387],	a	potential	target	of	novel	therapies.	Given	that	our	cohort	is	a	mixture	of	chemotherapy	treated	and	untreated	patients	it	is	possible	that	we	have	underestimated	the	rate	at	which	this	mechanism	occurs.	Re-analysis	of	these	signatures	within	chemotherapy	treated	and	chemotherapy	naïve	cases	would	help	to	clarify	this.	Of	particular	interest	would	be	a	comparison	between	the	prevalence	in	chemo-naïve	versus	chemo-treated	tumours	of	mutation	in	HR-related	genes,	the	SNV	signature	of	HR	deficit	and	the	SV	signature	of	HR	deficit.	We	have	additionally	identified	the	presence	of	a	signature	of	genome-wide	large	tandem	duplications	in	our	data.	This	signature	has	recently	been	identified	and	found	to	be	associated	with	disruption	of	the	CCNE1	pathway,	either	by	amplification	of	CCNE1	or	mutation	of	its	regulator	FBXW7.	In	our	series,	6	of	7	tumours	affected	by	this	signature	harboured	CCNE1	CN	changes.	One	tumour	had	both	an	FBXW7	mutation	and	amplification	of	CCNE1;	no	tumour	had	an	
FBXW7	mutation	alone.	This	finding	confirms	this	as	a	significant	additional	mechanism	of	genomic	instability	with	a	relatively	high	prevalence	in	OAC	(6/43	cases,	16%).	When	this	signature	was	active	it	generated	the	vast	majority	of	SVs	within	samples	as	could	be	seen	in	our	simple	plots	of	numbers	of	INS	type	SVs.		
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The	most	prolific	signatures	in	our	data	set	were	signature	C	and	signature	E.	Signature	E	is	attributable	to	a	combination	of	chromothripsis	occurring	between	two	separate	chromosomes	and	novel	MEs	not	identified	in	our	earlier	analysis	and	therefore	not	removed	prior	to	the	signature	extraction	step	[96].	Several	studies	have	shown	focal	high	level	CN	changes	to	be	frequent	in	OAC[334,381,404].	Our	analysis	of	signatures	confirms	and	quantifies	this	finding	with	the	combination	of	chromothripsis	(signature	C),	BFB	signatures	(signature	B)	and	DIF	(signature	E)	signatures	contributing	66%	of	all	SVs	(37%	if	signature	E	is	removed).	Even	within	the	tumours	dominated	by	tandem	duplication	signatures,	focal	large-scale	rearrangements	were	common,	suggesting	that	no	one	mutational	mechanism	is	sufficient	to	drive	oesophageal	carcinogenesis.	The	high	prevalence	of	chromothripsis	may	be	explained	by	the	high	rates	of	TP53	mutations	and	hyperploidy	observed	in	OACs,	both	of	which	have	been	associated	with	chromothripsis	[405,406].	We	were	unable	to	demonstrate	any	significant	correlation	between	SV	signatures	and	SNV	signatures.	Previously	it	has	been	shown	that	tumours	with	BRCA1	mutations	have	a	specific	SNV	signature	(signature	6	in	our	data).	This	lack	of	correlation	may	be	due	to	the	fact	that	in	our	analysis,	the	signature	of	small	TDs	seen	with	combined	BRCA1	and	TP53	mutation	was	indistinguishable	from	a	signature	of	fragile	site	disruption.	In	a	larger	cohort	of	tumours	with	a	greater	number	of	BRCA1	mutant	samples	these	signatures	may	be	distinguishable	and	a	clearer	correlation	may	occur.		Furthermore	the	SNV	signature	of	HR	deficiency	is	also	seen	in	tumours	with	mutations	of	other	HR	genes	e.g.	BRCA2	and	PALB2.	Mutation	in	BRCA2	does	not	appear	to	correlate	with	a	clear	SV	phenotype	and	thus	may	also	confound	correlation	between	SV	and	SNV	signatures	[386].		The	lack	of	correlation	with	the	SNV	signatures	suggests	that	different	processes	are	responsible	for	SNV	patterns	and	SV	patterns.	We	have	identified	2	new	SNV	signatures,	which	are	highly	prevalent	in	OAC.		Acid	and	bile-acids	are	a	unique	exposure	to	the	oesophagus	and	stomach	and	may	be	the	cause	of	these	mutational	signatures.	There	is	evidence	to	suggest	that	bile-acid	and	low	pH	may	cause	genetic	instability	and	thus	may	generate	SVs	[110,407-409].	
	 113	
However	these	mutagens	may	generate	generic	SV	signatures	that	may	also	be	caused	by	multiple	other	insults.	A	more	focused	analysis	of	sequence	specificity	of	rearrangements	in	our	data	may	identify	signatures	more	closely	associated	with	SNV	patterns	and	mutagen	exposure.		We	also	describe	here	an	SV	signature	that	appears	to	represent	the	disruption	of	fragile	sites,	by	both	deletion	and	tandem	duplication.	Tumours	with	high	levels	of	exposure	to	this	signature	also	had	high	rates	of	fragile	site	rearrangement.		Fragile	site	rearrangement	is	ubiquitous	in	OAC;	100%	of	the	tumours	analysed	in	our	study	had	rearrangements	in	2	common	fragile	site	genes	FHIT	or	WWOX.		However	the	tumours	most	enriched	for	this	signature	showed	a	striking	pattern	of	hypermutation	of	fragile	sites	with,	for	example,	tumour	7407	contains	14	rearrangements	within	the	FHIT	locus.	Several	mechanisms	have	been	proposed	for	the	high	rates	of	SVs	within	these	loci,	including	collisions	of	RNA	and	DNA,	paucity	of	replication	origins	and	presence	of	factors	leading	to	increased	rate	of	replication	fork	stalling	and	late-replication	[410].	Recently	it	has	been	proposed	that	depletion	of	the	nucleotide	pool	may	mediate	the	instability	and	increased	error	rates	seen	in	the	late	stages	of	replication.	Notably,	acid	reflux	has	been	identified	as	a	cause	of	oxidation	of	unincorporated	nucleotides	and	may	deplete	the	nucleotide	pool	predisposing	these	late	replicating	regions	to	damage	[411].		In	summary	,we	have	developed	and	validated	a	novel	SV	identification	pipeline	that	has	an	excellent	specificity	and	sensitivity	when	compared	to	currently	available	tools.	In	addition	we	have	set	up	an	easy	to	use	large	scale	pipeline	analysis	tool	kit.	Using	these	tools	in	a	preliminary	analysis	of	OAC	rearrangement	patterns	we	have	confirmed	the	presence	of	5	patterns	of	SV	mutagenesis	in	OAC.	We	quantify	the	burden	of	rearrangements	driven	by	focal	amplicons	showing	that,	when	MEs	are	excluded,	over	66%	of	all	SVs	in	OAC	are	located	in	focal	rearrangements	that	are	often	connected	across	chromosomes.	Finally,	we	have	identified	a	signature	of	fragile	site	rearrangement	consisting	of	both	deletions	of	varying	sizes	and	tandem	duplications	and	have	shown	that		this	signature	is	present	in	almost	all	OAC	cases.	Furthermore,	we	show	that	
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some	tumours	can	be	classified	as	fragile	site	hypermutators	with	extensive	rearrangement	of	individual	fragile	site	genes.	Further	exploration	of	these	samples	may	help	to	clarify	the	underlying	mechanism	of	fragile	site	disruption.	
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Figure	3.1	and	Table	3.1:	(red	=	normal	sample),	numbers	of	SVs	found	to	be	unique	to	a	
sample	for	matched	tumour	and	normal	cases.	The	matched	normal	should	contain	no	or	very	few	unique	SVs	as	the	tumour	DNA	is	for	the	main	part	the	same	as	the	normal	DNA.	The	high	level	of	normal	unique	SVs	suggests	a	high	false	positive	rate.	This	is	improved	by	filtering	using	discordant	read	pairs	from	further	unmatched	normal	samples.	
Table	3.2:	Table	of	coverage	characteristics	and	unique	SV	numbers	of	the	22	pilot	
tumours	and	their	matched	normal.	Discordant	read	pairs	from	22	normal	samples	are	used	as	a	filter,	the	putative	validation	rates	and	95%	CI	are	given	calculated	using	the	median	number	of	unique	SVs	in	matched	normals	as	a	predicted	false	positive	rate	
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Figure	3.2.	Circos	plots	showing	the	inter	SV	distances	for	SVs	predicted	in	43	normal	
samples.	Includes	22	normals	from	the	pilot	batch	plus	an	additional	21	normals	from	batch	1	run	with	a	PCR	free	library	preparation.	Outer	most	track	SV	distance	(track	1),	plotted	against	the	positions	of	areas	of	exceptionally	high	sequencing	read	depth	(track	2	top	0.1	percent,	track	3	top	0.5	percent	and	track	4	top	1	percent).	The	overlap	of	clusters	of	SVs	(shown	as	areas	of	decreased	inter	SV	distance)	with	areas	of	high	read	depth	is	striking	and	is	quantified	in	Table	3.3,	interestingly	there	are	clearly	areas	of	clustered	SVs	that	are	not	accounted	for	by	areas	of	high	read	depth		
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Figure	3.3:	Detailed	view	of	an	area	of	tightly	clustered	SVs	seen	on	Chr4.	This	area	overlaps	significantly	with	the	areas	of	high	sequencing	read	depth	seen	on	the	UCSC	genome	browser	tracks		
Table	3.3:	The	overlap	of	clusters	of	SVs	with	areas	of	high	read	depth.	
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Figure	3.4	Schematic	of	verification	strategies	employed	in	SV	analysis.	(a)	In	this	diagram		a	translocation	occurs	between	the	red	and	the	green	chromosome	with	subsequent	loss	of	the	derivative	containing	the	centromere	from	the	green	chromosome.	(b)	This	results	in	a	CN	change	on	both	chromosomes	that	can	be	detected	using	read	depth	analysis	i.e.	counting	the	number	of	read	pairs	occurring	in	fixed	length	genome	intervals	also	known	as	‘bins’.	(c)	In	addition	primers	(represented	as	single	headed	arrows	running	5’	to	3’)	can	be	designed	across	the	novel	junction	such	that	a	PCR	product	will	only	be	observed	in	tumour	DNA	in	which	the	novel	junction	occurs		(‘T’	on	the	schematic	of	the	PCR	product	run	on	an	agarose	gel)		 	
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Figure	3.5	High	throughput	verification	pipelines.	(a)	output	of	the	verification	by	CN	analysis	pipeline,	the	red	dots	represent	the	number	of	reads	found	in	each	10Kb	segment	of	genome	(non	overlapping	windows)	whilst	the	green	line	represents	the	probability	of	a	change	point	in	the	data	calculated	using	Bayesian	change	point	analysis.	Node	1	refers	to	the	downstream	portion	of	the	breakpoint	i.e.	closest	to	the	start	of	the	p–arm	of	the	chromosome.	The	black	dotted	line	is	the	position	of	the	breakpoint	predicted	by	the	SV	prediction	pipeline.	In	this	example	there	is	a	clear	copy	number	step	at	both	nodes	with	out	any	change	in	the	same	genomic	position	in	the	matched	normal	genome.	(b)	outline	of	the	high	throughput	verification	by	PCR	pipeline,	green	bars	denote	processes	that	previously	required	substantial	manual	intervention		 	
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Figure	3.6:	Final	summarised	verification	results.	(a)	Verification	results	are	summarised	as	a	compound	bar	chart,	each	of	the	6	categories	of	verified	SV	is	flagged	in	a	different	colour.		
Table	3.4:	Summary	of	the	criteria	that	must	be	met	for	an	SV	to	be	included	in	each	
category.	Categories	1	–	6	are	considered	to	be	true	somatic	SVs.	A	total	of	255	SVs	were	screened	with	12	identified	as	false	positives	(TF	=	True	False	positive	category)	
Table	3.5:	Numbers	of	each	type	of	SV	verified.	Each	tumour	is	included	along	with	the	patterns	and	types	of	SVs	verified	in	each.	Figure	3.7	shows	a	comparison	of	the	relative	proportions	of	SVs	types	verified		
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Figure	3.7	Comparison	of	the	proportions	of	each	SV	type	in	verification	and	in	sequencing	
batches.	There	is	an	excess	of	INS	type	SVs	in	the	Batch	1	tumours	this	phenomenon	is		restricted	to	6	tumours	which	contain	large	numbers	of	this	SV	type.	The	verification	contains	a	lower	proportion	of	INS	type	SVs.	If	these	SVs	were	to	represent	an	artifact	in	the	pipeline	it	could	be	argued	that	there	lack	of	representation	within	the	verification	may	falsely	inflate	the	specificity	of	the	pipeline.	However	it	is	clear	from	the	copy	number	plots	of	each	of	these	tumours	that	the	INS	type	SVs	represent	true	positive	SVs.	With	3	of	the	tumours	showing	extensive	areas	of	chromothripsis	and	3	showing	a	tandem	duplicator	phenotype	(Ng	et	al	2013).	Both	phenotypes	are	consistent	with	large	numbers	of	INS	type	SVs.	This	is	discussed	in	more	detail	later	however	crucially	the	fact	that	the	excess	SVS	in	this	cohort	are	true	SVs	supports	the	applicability	of	the	verification	exercise.		 	
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Figure	3.8	Comparison	of	alternative	alignment	strategies.	As	an	end	point	for	aligner	comparison	we	chose	number	of	SVs	passing	all	pipeline	filters.	(a)	The	venn	diagram	shows	fully	filtered	SVs	predicted	using	identical	clustering	and	filtering	strategies	but	with	different	alignment	protocols	to	generate	the	discordant	SVs.	As	expected	using	discordant	read	pairs	with	a	lower	mapping	quality	from	BWA	(BWA-10)	leads	to	the	detection	of	the	greatest	number	of	SVs,	whilst	Novoalign	and	BWA-30	identify	identical	numbers	of	SVs	(Both	identify	an	additional	19	SVs,	Novoalign	shares	7	with	BWA-10	that	are	not	found	by	BWA-30	and	12	unique	SVs	whilst	BWA-30	shares	8	with	BWA-10	and	identifies	11	unique	SVs).	As	shown	in	(b)	the	majority	of	SVs	identified	uniquely	using	BWA-10	alone	are	false	positives.	Those	identified	by	Novoalign	alone	(n	=	12)	or	in	conjunction	with	either	BWA-10	(n	=	7)	had	a	higher	verification	rate	than	those	identified	by	BWA-30	with	or	without	BWA-10	(12/19	versus	6/19	respectively),	supporting	the	choice	of	Novoalign	as	the	aligner	of	choice.	 	
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Figure	3.9:	Predicted	sensitivity	analysis	of	the	SV	calling	pipeline.	Graphs	show	the	expected	proportion	of	SVs	covered	by	3	or	more	reads	at	each	level	of	physical	coverage	determined	using	the	Poisson	distribution	formula.	(a)	In	a	triploid	tumour	with	varying	levels	of	normal	contamination,	(b)	In	a	diploid	tumour	with	varying	levels	of	normal	contamination.	
Table	3.6:	Physical	coverage	required	to	detect	a	fixed	proportion	of	SVs.	Diploid	and	triploid	cell	lines	with	varying	proportions	normal	cell	contamination.	DET50	=	detection	of	50%	of	SVs,	DET	95	=	detection	of	95%	of	SVs		 	
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Figure	3.10:	Physical	coverage	of	the	cancer	genome.	(a)	Schematic	demonstrating	the	area	of	a	sequenced	fragment	that	contributes	towards	physical	coverage.	The	fragment	marked	with	a	*	cannot	be	used	in	discordant	read	pair	analysis	to	detect	the	SV	(in	this	case	a	translocation	between	chr1	and	chr2).	(b)	Bar	chart	of	physical	and	sequence	coverage	of	all	tumours	used	in	the	analysis	of	this	SV	pipeline,	all	tumours	were	sequenced	with	100	bp	paired	end	reads.		
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Table	3.7:	Verification	results	from	alternative	SV	calling	pipelines.	Data	from	the	current	
study	is	highlighted	in	bold	text	
	 	
	 126	
	
Figure	3.11:	Numbers	of	each	type	of	structural	variant	within	the	43	tumours.	Tumours	are	ordered	by	their	total	number	of	SVs	running	from	highest	to	lowest	left	to	right.		
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Figure	3.12:	Plots	of	structural	variant	size	by	structural	variant	type.	Smoothed	line	is	plotted	using	the	density	function	in	R	with	default	settings.	All	SV	types	show	a	peak	of	SVs	within	the	1-10Mb	range.	INS	and	DEL	type	SVs	show	a	further	peak	between	100k	and	1Mb.	INV	type	SVs	show	a	unique	peak		at	1Kb	in	size	whilst	DEL	type	SVs	also	show	a	unique	peak	between	1k	and	10kb	in	size.	Note	as	previously	discussed	DEL	type	SVs	less	than	1000bp	in	size	have	been	excluded.	
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Figure	3.13:	Plots	of	INS-type	SV	size	in	tumour.	Each	graph	represents	a	different	subset	of	tumours	defined	by	the	dominant	SV	type	within	each	tumour.		
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Figure	3.14:	Plots	of	INV-type	SV	size	in	tumours.	Each	graph	represents	a	different	subset	of	tumours	defined	by	the	dominant	SV	type	within	each	tumour.		
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Figure	3.15:	Plots	of	DEL-type	SV	size	in	tumours.	Each	graph	represents	a	different	subset	of	tumours	defined	by	the	dominant	SV	type	within	each	tumour.		
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Figure	3.16:	Structural	variant	signatures	A,	B	and	C.		
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Figure	3.17:	Structural	variant	signatures	D	and	E.		
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Figure	3.18.	INS	size	variation	in	tumours	enriched	for	SV	signature	D	
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Figure	3.19.	INS	size	variation	in	tumours	enriched	for	SV	signature	D	
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Figure	3.20:	Examples	of	the	genome	wide	large	TD	mutator	pattern	seen	in	tumours	
enriched	for	SV	signature	A.	The	bottom	half	of	each	graph	represents	the	copy	number	at	each	position	in	the	genome	generated	using	FREEC.	The	upper	half	shows	the	areas	connected	by	structural	variants.	Green	=	INS,	Red	=	DEL,	Blue	=	DIF,	purple	=	INV,	orange	=	ITR.	
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Figure	3.21:	Examples	of	the	DIF	type	signature	generated	by	catastrophic	rearrangement	
happening	to	multiple	areas	of	the	genome	simultaneously.	In	this	tumour	7416,	DIF	type	rearrangements	link	amplifications	on	chr	16,	chr	7	and	chr	3.	The	bottom	half	of	each	graph	represents	the	copy	number	at	each	position	in	the	genome	generated	using	FREEC.	The	upper	half	shows	the	areas	connected	by	structural	variants.	Green	=	INS,	Red	=	DEL,	Blue	=	DIF,	purple	=	INV,	orange	=	ITR.	The	black	arrows	identify	clusters	of	DIF	type	SVs	connecting	each	of	the	
amplicons.	
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Figure	3.22:	BFB	example	in	tumour	7416.	Pyramid	amplicon	structure	with	numerous	inversions	including	several	small	inversions	(fold-back	inversions)	bordering	CN	step.	
	 	
	 138	
	
Figure	3.23:	BFB	example	in	tumour	3137.	Pyramid	amplicon	structure	with	numerous	inversions	including	several	small	inversions	(fold-back	inversions)	bordering	CN	step.	
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Figure	3.24.	BFB	example	in	tumour	3111.	Pyramid	amplicon	structure	with	numerous	inversions	including	several	small	inversions	(fold-back	inversions)	bordering	CN	step.	
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Figure	3.25:	Enlargement	of	a	single	panel	of	figure	3.2	
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Chapter	4 	
Single	nucleotide	variation	in	OAC		 	
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4.1 Introduction	
4.1.1 Single	nucleotide	variants	and	cancer	
As	discussed	in	the	Introduction,	SNVs	contribute	the	majority	of	the	known,	well-	studied,	cancer	driving	events.	In	addition,	the	patterns	and	numbers	of	variants	provides	valuable	insight	into	the	causative	agents	involved	in	disease	development	and	may	identify	therapeutic	targets	[39,140,412].	No	definitive	NGS	SNV	calling	pipeline	has	been	identified	and	therefore	verification	of	results	is	essential.	In	this	chapter	I	aim	to	verify	the	results	of	a	mutation-calling	pipeline	in	our	oesophageal	cancer	data	set.	I	will	use	this	data	to	identify	the	number	and	patterns	of	mutations	in	the	average	OAC	with	the	aim	of	better	understanding	the	mutational	processes	that	drive	its	development.		It	has	long	been	known	that	certain	mutation	types	tend	to	co-occur,	and	that	this	likely	represents	the	action	of	a	single	mutagenic	process	[40,64,361,413].		A	recent	publication	adopted	a	machine	learning	technique	known	as	non-negative	matrix	factorization	(NMF)	to	extract	co-occurring	mutation	patterns	[77].	NMF	has	previously	been	shown	to	extract	interpretable	metagenes	from	large	gene-expression	datasets	that	have	clear	representations	in	the	biology	of	cancer	[362].		NMF	allows	the	extraction	of	the	constituent	‘parts’	of	a	dataset	that	can	be	represented	as	an	N	x	M	matrix	where	N	represents	samples	and	M	represents	variables.	The	output	of	this	algorithm	is	two	matrices;	N	x	k	and	k	x	N,	where	k	represents	the	number	of	‘parts’.	The	N	x	k	matrix	therefore	provides	the	contribution	of	each	‘part’	to	each	sample	and	the	k	x	M	matrix	represents	the	contribution	of	each	variable	to	each	‘part’.	In	the	case	of	mutations,	in	a	cancer	the	total	burden	in	an	individual	sample	can	be	seen	as	being	derived	from	exposure	to	a	set	of	mutagens.	It	is	therefore	dependent	on	the	type	of	mutagen	and	the	extent	of	the	exposure.	In	the	case	of	a	matrix	for	application	of	NMF,	N	would	represent	a	list	of	samples	for	which	information	on	mutation	number	and	types	were	available.	M	would	represent	
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the	mutations,	where	each	type	of	mutation	is	considered	in	its	trinucleotide	context	(as	discussed	in	the	Introduction)	giving	a	total	of	96	variables.	Therefore	the	two	output	matrices	would	represent;	1.)	the	types	of	mutation	that	contribute	to	an	individual	mutagen	(N	x	k)	aka	signatures	and	2.)	contribution	of	each	mutagen	to	the	overall	mutagenic	burden	in	a	given	tumour	(k	x	M)	aka	exposures.	Unlike	principal	component	analysis	the	possibilities	of	what	can	constitute	a	‘part’	are	constrained	in	that	within	each	‘part’	the	contribution	of	each	variable	must	be	non-negative.	The	original	authors	demonstrated	that	-	in	the	field	of	facial	recognition	–	NMF	generates	more	intuitively	understandable	parts	than	PCA	i.e.	it	was	able	to	recognize	what	we	would	consider	standard	components	of	a	face;	ears,	eyes,	mouths	etc.[414].	For	mutational	processes	this	is	also	intuitive,	as	you	cannot	have	a	mutational	process	that	removes	mutations	from	a	tumour.	Utilizing	these	recently	published	methods	for	identifying	mutational	signatures,in	this	chapter	I	will	develop	a	pipeline	with	the	open	source	statistics	package,	R,	to	identify	and	characterize	mutational	signatures	present	in	OAC.		
4.2 Identification	of	single	nucleotide	variants	and	verification	of	the	results	
Following	BWA	alignment,	SomaticSniper	was	used	to	identify	somatic	single	nucleotide	variants	(SNVs)	in	all	tumours	[295].	The	results	from	SomaticSniper	were	filtered	following	the	guidelines	in	the	original	paper	and	with	additional	filters	employed	in	Varscan2	[294]	(Methods),	to	give	a	final	list	of	high	confidence	variants.	A	total	of	184	variants	were	randomly	selected	from	a	single	tumour	for	verification	by	PCR	and	Sanger	sequencing.	(Figure	4.1a)	Sequence	traces	were	obtained	from	both	tumour	and	normal	DNA	samples	for	166	/	191	(86.9%).		In	total	15	SNVs	were	identified	as	false	positives	giving	a	specificity	of	91.0%	(151/166)	for	this	pipeline.	Two	of	the	15	false	positive	SNVs	were	identified	as	
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germline	variants	whilst	the	remaining	13	were	not	found	in	the	tumour	or	normal	samples.	To	expand	these	findings,	a	further	round	of	verification	was	performed	on	a	larger	set	of	tumours	from	Batch	0.		The	tumour	and	normal	samples	in	this	batch	were	all	prepared	using	the	same	Illumina	library	preparation	protocol.		To	increase	sensitivity	for	the	detection	of	low	allele	frequency	variants,	the	PCR	products	for	each	mutation	were	pooled	and	sequenced	on	individual	lanes	of	a	HiSeq	flowcell.	Normal	andtumour	PCR	products	were	pooled	separately	to	allow	the	identification	of	germline	and	somatic	variants.		Dr	Nicholas	Shannon	(the	CRUK	Cambridge	Institute)	and	I	performed	variant	selection,	and	sample	preparation	was	performed	by	myself	and	Dr	Mariganese	Barbera	(Hutchison-MRC	Cancer	Unit).	The	PCR	and	sequencing	were	performed	by	Dr	Arusha	Oloumi	(Ontario	Institue	of	Cancer	Research,	British	Columbia,	Cananda).		Reads	were	aligned	using	BWA	and	Samtools	v1.17	was	used	to	count	the	reference	and	alternative	allele	counts	at	each	variant	position.	Average	read	depth/coverage	was>	10	000	fold.	A	minimum	of	50-fold	coverage	in	both	tumour	and	normal	samples	was	required	for	a	variant	to	be	considered	successfully	analysed.		By	these	criteria	1086	of	1130	(96.1%)	selected	SNVs	could	be	analysed.		Variants	were	considered	somatic	if	the	allele	frequency	was	≤	1%	in	the	matched	normal	and	≥	2%	in	the	tumour.		Where	coverage	of	the	normal	was	less	than	100X,	in	order	to	prevent	variants	erroneously	being	identified	as	germline	due	to	rare	stochastic	sequencing	errors	in	normal	reads	they	were	also	accepted	as	somatic	where	the	allele	fraction	in	the	tumour	was	>=10%	with	the	number	in	the	normal	only	1.	This	reclassified	three	SNVs	as	true	somatic	variants	(tumour	variant	allele	frequencies	were	72%,	73%	and	25%).		In	total	1079/	1085	adequately-covered	variants		(99%)	variants	were	classified	as	somatic	SNVs.	Of	the	6	variants	that	were	identified	as	false	positive	calls,	2	were	found	in	both	the	germline	and	tumour	samples,	whilst	4	were	not	seen	in	either	sample.				
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4.3 Number	of	SNVs	in	OAC	and	comparison	to	other	tumour	types	
In	total	we	identified	932	894	mutations	across	the	43	samples	in	Batch1	and	Batch	0	(Appendix	1).	The	mean	number	of	mutations	across	the	43	tumours	was	therefore	21,424	(range	4,104	–	101,573).	The	total	size	of	the	mappable	genome	(with	100bp	reads)	is	2.79Gb,	giving	a	mutational	density	of	7.8	mutations/	Mb	(range	1.5	–	36.2)	[374,415].	Mutation	rates	have	been	demonstrated	to	vary	widely	across	the	genome	[396].	Due	to	the	combined	action	of	purifying	selection,	transcription	coupled	repair	and	altered	accessibility	to	mismatch	repair	proteins,	the	lowest	rates	of	mutation	are	typically	seen	within	the	coding	regions	of	cancer	genomes.	We	annotated	our	variants	using	the	Refseq	gene	list	and	a	custom	Perl	script	(SNV_annotator.pl).	The	mutation	rate	was	highest	in	intergenic	regions,	9.7/Mb	(range:	46.4	–	1.8	/Mb),	decreased	within	gene	bodies	to	5.2/Mb	and	was	lowest	within	the	coding	regions	of	the	genome	at	4.2/Mb.	We	next	compared	the	number	of	SNVs	in	OAC	to	the	number	of	SNVs	in	a	variety	of	tumour	types	for	which	whole	genome	sequencing	was	available.			Only	melanoma	on	sun	exposed	skin	(30/Mb),	lung	cancer	in	smokers	(10.2/Mb,	8.49/Mb),	transitional	cell	bladder	cancer		(10.8/Mb)	and	tumours	with	microsatellite	instability	(23.7/Mb)	had	higher	mutation	rates	than	OAC	(Figure	4.1)	[42,118,120,133,165,416,417]..		
4.4 Patterns	of	transitions	and	transversions	in	the	OAC	genome	
The	high	rates	of	mutation	in	OAC	suggest	the	action	of	a	strong	mutagen,	exogenous	or	endogenous.	To	identify	the	effect	of	possible	mutagens	on	the	OAC	genome	we	looked	at	the	pattern	of	mutations	present	in	the	genome.		Each	of	the	four	nucleotides,	A,	T,	C	and	G	can	be	mutated	to	any	of	the	other	3	giving	a	total	of	12	possible	mutation	types.	As	each	base	undergoes	Watson-Crick	pairing	(A:T,	G:C)	across	strands	we	can	collapse	the	12	possible	mutation	types	into	6	where	the	mutated	base	is	always	considered	to	be	the	pyrimidine	(C	or	T).		The	most	predominant	mutation	type	in	OAC	was	T:A	>	G:C	mutations,	making	up	35%	of	all	mutations.		Additionally	the	Transition:Transversion	
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(Ti/Tv)	ratio	was	0.65,	markedly	different	from	1.9:1		seen	in	germline	single	nucleotide	polymorphisms	(SNPs)[413]	and	in	fact	closer	to	that	expected	by	chance	(Figure	4.2).	
4.5 Sequence	context	of	mutations	in	oesophageal	adenocarcinoma	
As	noted	previously,	sequence	context	plays	a	major	role	in	the	rate	at	which	a	particular	position	becomes	mutated.	In	particular	there	is	an	exceptionally	strong	effect	on	mutation	of	the	base	5’	and	3’	to	the	target	site	[40,77,413,418,419].			We	first	made	a	preliminary	analysis	of	the	proportion	of	mutations	for	each	of	the	16	possible	trinucleotides	across	the	43	cancer	genomes	by	manual	review.		We	displayed	the	trinucleotides	using	the	heatmap	plots	first	presented	in	Nik-Zainal	et	al,	[40]	plotting	the	fold	enrichment	of	mutation	at	a	given	trinucleotide	relative	to	the	abundance	of	that	trinucleotide	in	the	normal	genome	(Figures	4.3	and	4.4),	using	a	pair	of	custom	Perl	scripts	(Sequence_extractor_SNV.pl	and	Context_Summariser.pl).	It	was	clear	from	this	that	several	previously	described	signatures	were	present.	For	example,	C:G	>	T:A	at	XpCpG	trinucleotides	(where	X	is	any	of	the	4	possible	nucleotides),	represented	as	the	thick	red	line	running	down	the	centre	of	the	plots.	This	is	the	dominant	nucleotide	change	seen	in	germline	SNPs,	contributes	to	the	observed	imbalance	in	Tv:Ti	ratio	and	is	thought	to	be	caused	by	spontaneous	deamination	of	methylated	cytosine	to	thymine.	The	signature	associated	with	the	action	of	APOBEC3B	on	single	stranded	DNA	[40,83,84]		enrichment	of	C:G	>	T:A	and	C:G	>	G:C	mutations	at	TpCpXp	sites,	is	also	seen	in	several	samples	e.g.	3117,	3113	and	3109		(Figures	4.3	and	4.4).		More	strikingly,	a	strong	enrichment	for	T:A	>	G:C/C:G/A:T	transversions	and	transitions	can	be	seen	at	XpTpT	trinucleotides,	in	particular	where	the	5’	base	is	a	Cytosine	(Box	b,	figure	4.5).	This	signature	is	present	in	all	tumours	but	to	varying	degrees,	suggesting	differential	exposures	to	the	putative	mutagen.	To	
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assess	this	more	accurately,		we	chose	to	use	the	principles	outlined	in	Alexandrov	et	al	to	extract	so	called	mutational	signatures.	
4.6 Identifying	mutational	signatures	in	OAC	
Alexandrov	et	al	demonstrated	the	use	of	non-negative	factorization	to	extract	mutational	signatures	from	cancer	genome	sequencing	data	[40,77,361].	We	developed	alternative	software,	following	the	same	process	but	utilizing	the	open	source	language	R	(NMF_for_sig_extraction.R).	We	benchmarked	our	pipeline	using	the	dataset	from	Nik-Zainal	et	al,	2012,	and	identified	the	same	optimal	solution	of	5	mutational	signatures	(Figures	4.5,	4.6	and	4.7).	For	selection	of	the	correct	number	of	signatures	we	used	the	same	approach	as	in	Alexandrov	et	al,	comparing	average	silhouette	width,	as	a	marker	of	reproducibility	of	the	derived	signatures	over	multiple	iterations,	and	Frobenius	reconstruction	error	as	a	marker	of	accuracy,	for	each	signature	number.	We	then	applied	the	pipeline	to	the	43	oesophageal	adenocarcinoma	samples.	To	identify	signatures,	the	optimal	number	of	signatures	has	to	be	chosen,	by	striking	a	balance	between	breaking	down	the	data	into	too	many	signatures	and	not	fitting	the	original	data	sufficiently	robustly,	reflected	respectively	in	the	average	silhouette	width	and	Frobenius	reconstruction	error	[420](Fig.	4.6).	As	the	number	of	signatures	increases,	improvements	in	reconstruction	error	begin	to	plateau	above	6	signatures,	i.e.	increasing	the	number	of	signatures	from	this	point	does	not	markedly	improve	the	ability	to	reconstruct	the	original	data	accurately.	The	silhouette	width	decreases	substantially	from	0.77	to	0.69	between	6	and	7	signatures—compared	to	decreasing	from	only	0.82	to	0.77	from	5	to	6	signatures.	Using	these	method	6	signatures	appears	optimal	(Figure	4.8).		Several	alternative	approaches	to	calculating	the	appropriate	number	of	signatures	have	been	suggested	in	addition	to	that	detailed	in	Alexandrov	et	al	[362,382,421].	We	used	the	“nmfEstimateRank”	function	of	the	R	package	‘nmf’	
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to	compare	the	number	of	signatures	suggested	by	each	method	[363].		The	following	code	was	used:	>	estimate.rank	<-	nmfEstimateRank(as.matrix(mydata),	range=2:15,	nrun=100,	seed=123456)	Following	the	approach	in	Brunet	et	al	[362],	of	selecting	the	number	of	signatures	at	which	the	cophenetic	correlation	begins	to	decrease,	gives	a	signature	number	of	5	(figure	4.9a).		Utilising	the	approach	used	in	Hutchins	et	
al,	looking	for	the	inflection	point	in	the	residual	sum	of	squares	(RSS),	6	signatures	appears	as	the	optimal	solution	(Figure	4.9b)[382].	To	resolve	this	discrepancy	we	next	visually	inspected	the	signatures	and	compared	them	to	a	list	of	previously	described	signatures	from	30	tumour	types	[77].	Increasing	the	expected	number	of	signatures	from	5	to	6	leads	to	the	splitting	of	one	signature	into	two	separate	signatures,	signature	1and	signature	2		(Figures	4.10	and	4.11).	Intriguingly,	both	signatures	have	been	shown	to	accumulate	in	non-cancerous	tissue.	Signature	1	(figure	4.11)	is	seen	in	neuroblastoma	[77]	and	normal	small	intestine	cells	in	mice	[422],	but	not	in	other	tissues,	whilst	signature	2	represents	the	well-described	germline/ageing	signature	of	C:G	>	T:A	mutations	occurring	at	CpG	dinucleotides	thought	to	be	driven	by		spontaneous	deamination	of	methylated	cytosines.		As	both	signatures	have	been	previously	identified,	it	seems	appropriate	to	conclude	that	they	are	in	fact	separate	entities.	The	incomplete	separation	of	signatures	is	a	known	issue	with	the	non-negative	matrix	factorisation	method	and	may	resolve	with	larger	datasets	[361,381].	
4.7 Description	of	identified	mutational	signatures	
Signature	1	shows	an	enrichment	for	C:G>A:T	mutations	at	XpCpA/T	sites	and	contributed	a	median	of	2,332	mutations	(range:	102	–	13,907)	to	each	tumour.	Mutation	of	C:G>A:T	has	been	associated	with	oxidative	damage	and	in	particular	with	oxidative	damage	due	to	high	energy	acoustic	shearing	of	DNA	during	the	Illumina	library	preparation	process	[287].		The	signature	we	observe	in	OAC	
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lacks	enrichment	at	the	trinucleotide	most	strongly	associated	with	the	shearing	artefact,	CCG	>	CAG,	suggesting	that	it	is	not	related	to	this	artefact.	In	addition	the	verification	rates	showed	no	bias	towards	lower	verification	for	C:G>A:T	mutations.		Of	note	C:G>A:T	mutations		are	enriched	in	smoking-related	carcinomas	[132],	in	particular	XpCpG	trinucleotides	are	the	main	target	for	these	mutations.	It	has	been	suggested	that	smoking	leads	to	an	~	2	fold	increased	risk	of	developing	OAC	though	more	recent	studies	have	refuted	this	claim	[423,424].	In	lung	cancer	and	head	and	neck	squamous	carcinoma,	the	smoking	related	signature	follows	a	dose	response	relationship	with	the	number	of	cigarettes	smoked[87,88,132,425],	and	TP53	mutations	in	smoking	related	cancers	are	frequently	C:G>A:T	transversions	providing	a	direct	mechanistic	link	between	smoking	and	cancer	causation.	In	contrast,	our	C:G>A:T	signature	does	not	demonstrate	the	same	trinucleotide	enrichment		and	is	therefore	unlikely	to	mediated	by	the	same	process.	To	confirm	this	we	re-extracted	the	signature	of	smoking	damage	found	in	lung	adenocarcinoma,	using	our	software,	[425]	and	directly	compared	it	to	our	signature	1.	The	cosine	similarity	was	0.73,	suggesting	limited	similarity	between	these	signatures	and	likely	reflecting	the	fact	that	both	signatures	are	dominated	by	C:G>A:T	transversions	but	with	differing	trinucleotide	enrichments	(Figure	4.13).	A	closely	related	C:G>A:T	dominated	signature	has	been	identified	in	neuroblastoma	samples	and	we	therefore	re-extracted	the	signatures	from	the	neuroblastoma	data	sets	available	from	Alexandrov	et	al		to	compare	with	our	signature	1.	The	cosine	similarity	was	much	greater	at	0.91.	Both	signatures	have	a	strong	enrichment	for	mutations	at	XpCpA/T	sites	and	there	is	no	observed	transcriptional	strand	bias.	Thus	the	signature	seen	in	neuroblastoma	likely	represents	the	same	or	similar	mutational	process.		A	recent	study	also	identified	this	signature	in	somatically	acquired	point	mutations	in	small	intestinal	cells	in	mice	[422].	The	mutation	spectrum	of	two	of	the	43	tumours	was	dominated	by	signature	1:	Tumours	3133	and	3311	contained	66%	and	87%	Signature	1	mutations	respectively.		
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Signature	2	is	a	well-described	signature	seen	in	normal	SNPs	as	well	as	in	all	tumour	types	studied	so	far.	It	is	characterized	by	C:G>T:A	mutations	at	XpCpG	sites	and	is	thought	to	represent	the	spontaneous	deamination	of	methylated	cytosines	occurring	as	a	natural	phenomenon	of	cell	aging.	In	OAC	it	contributes	an	average	of	2,991	mutations	(range	4	–	7,597)	per	tumour	(Figure	4.12).	In	the	majority	of	tumour	types	this	signature	correlates	well	with	the	age	of	the	patient	at	diagnosis,	and	has	been	designated	the	‘ageing	signature’	[64].	In	our	dataset	no	significant	correlation	was	observed	between	age	and	number	of	mutations	generated	by	any	of	the	6	signatures	(for	signature	1,	Pearson’s	correlation	coefficient	r	=	0.135,	n	=	43,	p	=	0.387).	Signatures	3	and4	show	enrichment	for	T>G/C/A	at	XpTpTp	trinucleotides,	where	X	represents	A/C/G/T.	The	strongest	enrichment	is	present	at	sites	where	X	is	C	or	G.	Signature	3	is	dominated	by	T:A>G:C	mutation	at	CpTpTp,	with	36.0%	of	all	mutations	occurring	at	this	site,	whilst	only	5.84%	of	mutations	provided	by	this	signature	are	T:A>C:G.	In	contrast,	signature	4	shows	a	more	balanced	accumulation	of	T:A>G/C	mutations	with	28.6%	of	mutations	being	T:A>G:C	and	14.8%	of	mutations		being	T:A>C:G	(Figures	4.10	and	4.12).	Signature	3	contributes	a	median	of	2,186	mutations	(range	0	–	73,406)	per	tumour	whilst	signature	4	contributes	a	median	of	5,371	mutations	(range	0	–	44,713)	per	tumour	(Figure	4.12).	Previous	studies	have	suggested	T:A>G:C	mutations	may	be	enriched	in	more	proximal	tumours;	this	was	not	observed	in	our	data	(median	number	of	mutations	from	signature	3	and	4,	7540	versus	5157,	Siewert	1	versus	Siewert	2	and	3,	p	=	0.66,	Mann-Whitney	U	test	)	Signature	5	is	present	in	some	cases	of	most	tumour	types	and	is	thought	to	represent	the	effect	of	the	enzyme	APOBEC3B	on	DNA.	It	is	dominated	by	C:G>T:A	and	C:G>G:C	mutations	at	TpCpXp	trinucelotides	(Figure	4.10).	In	our	cases	it	contributes	a	median	of	740	mutations	per	tumour	(range	3	–	9,329).	It	is	the	predominant	signature	in	only	one	sample,	3117	(60.7%	of	all	mutations)	(Figure	4.12).		Signature	6	shows	no	specific	enrichment	for	any	mutation	(Figure	4.10).	It	provides	a	median	of	1,987	mutations	per	tumour	(range	33	–	11,056)	(Figure	
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4.12).	It	most	closely	resembles	a	signature	identified	in	all	tumour	types	(signature	5)	currently	studied	by	Alexandrov	et	al.	This	signature	shows	a	slight	enrichment	for	T:A>C:G	mutations	at	ApTpXp	sites,	with	a	strong	transcriptional	strand	bias.		Of	note,	this	signature	also	resembles	signature	3,	seen	in	HR	deficient	cancers.	Comparison	to	signatures	from	Alexandrov	et	al	showed	a	cosine	similarity	of	0.922	for	the	comparison	with	the	BRCA	signature	(signature	3)	and	0.923	for	the	comparison	with	signature	5.	The	cosine	similarity	of	these	two	signatures	is	only	0.821.	It	may	therefore	be	that	our	signature	6	in	fact	represents	the	incomplete	extraction	of	these	two	signatures	and	that	both	may	be	present	in	OAC,	extending	the	total	number	of	signatures	to	7.		
4.8 Effects	of	transcription	on	each	mutational	signature	
Several	mutational	patterns	have	been	shown	to	exhibit	a	bias	for	enrichment	on	the	non-transcribed	strand	of	actively	expressed	genes.	One	potential	explanation	for	this	is	that	DNA	damage	that	leads	to	the	presence	of	the	signature	may	be	repaired	by	transcription-coupled	nucleotide	excision	repair	leading	to	a	deficit	of	mutations	within	the	strand.	Alternatively,	it	is	possible	that	the	lesions	may	disrupt	transcription	in	such	a	manner	that	they	are	toxic	to	the	cell	leading	to	a	deficit	in	mutations	on	transcribed	strands.		Either	way	the	presence	of	a	transcriptional	strand	bias	may	provide	insight	into	the	underlying	mechanism	of	each	signature.	To	determine	if	any	of	our	6	identified	signatures	were	affected	by	transcription,	we	first	identified	a	list	of	genes	highly	expressed	in	oesophageal	adenocarcinoma.	RNA-seq	datasets	for	89	OACs	were	downloaded	from	the	Cancer	Genome	Atlas.	Information	on	expression	was	assessed	as	reads	per	kilobase	per	million	reads,	as	provided	by	the	TCGA	pipeline.	This	format	corrects	for	the	length	of	the	gene	and	the	total	number	of	reads	generated	from	the	RNA-seq	library	[426].	Genes	without	UCSC	gene	identifiers	were	removed	from	the	list	along	with	genes	mapping	to	the	Y	chromosome.	Within	each	sample	we	ranked	each	gene	based	on	its	expression	level.	We	then	calculated	the	average	rank	across	all	samples	for	each	gene.	The	top	2000	and	bottom	2000	ranked	genes	were	selected	and	used	to	annotate	mutations	occurring	in	
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these	genes.		Mutations	were	further	separated	as	to	whether	the	affected	pyrimidine	base	(cytosine	or	thymidine)	occurred	on	the	transcribed	or	untranscribed	strand.	For	a	negative	stranded	gene	the	transcribed	strand	is	the	positive	strand	and	for	a	positive	strand	gene	the	transcribed	strand	is	the	negative	strand.	There	was	a	nearly	6-fold	difference	in	mutation	rates	between	genes	with	low	and	high	levels	of	expression	(12.6	/	Mb	versus		1.92	/Mb).	This	affected	all	mutation	types	though	to	varying	degrees.	T:A>G:C	mutations	demonstrated	the	greatest	reduction	in	prevalence	(4.19	mutations	/	Mb	versus	0.19	mutations	/	Mb,	low	versus	high	expression)	whilst	C:G>G:C	mutations	were	the	least	altered	by	transcription	(0.49	mutations	/	Mb	versus	0.24	mutations	/	Mb).		Comparing	mutation	rates	for	each	of	the	6	collapsed	mutation	types	across	all	43	tumours	identified	no	significant	difference	between	rates	on	the	transcribed	and	untranscribed	strands	for	non-expressed	genes	(Figure	4.14).	For	mutations	occurring	in	highly	expressed	genes	there	was	a	significant	enrichment	for	T:A>G:C	and	C:G>T:A	mutation	types	on	the	untranscribed	strand	(199	versus	280	T:A>G:C	mutations,	and	961	versus		1122,	transcribed	versus	untranscribed,	paired	Wilcoxon	signed	rank	test,	p	<	0.05).	Additionally	there	was	a	significant	enrichment	for	T:A>C:G	and	C:G>A:T	mutation	types	on	the	transcribed	strand	(405	versus	311	T:A>C:G	mutations,	and	341	versus		250	C:G>A:T	mutations,	transcribed	versus	untranscribed,	Wilcoxon	signed	rank	test,	p	<	0.05)	(Figure	4.14).	To	determine	which	signatures	were	affected	by	transcription	we	next	focused	on	the	specific	trinucleotides	that	demonstrated	differences	between	strands.	To	correct	for	multiple	testing	a	signature	was	considered	to	demonstrate	transcriptional	bias	only	if	at	least	two	trinucleotides	enriched	in	that	signature	demonstrated	transcriptional	strand	bias.	By	these	criteria	only	signatures	3	and	4	showed	a	significant	effect	of	transcription	with	T:A	>	G:C	mutations	at	CpTpTp	and	TpTpTp		enriched	on	the	untranscribed	strand	(53	versus	81	and	24	versus	46	mutations,	transcribed	versus	untranscribed,	respectively)	(Figures	4.14	and	4.10).		This	is	in	keeping	
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with	the	relative	deficit	of	T:A	>	G:C	mutations	seen	in	high	expression	gene	footprints.	Intriguingly	T:A	>	C:G	mutations	occurring	at	either	of	these	trinucleotides	did	not	show	any	significant	strand	bias	(	27	versus	27	and	27	versus	27	mutations,	respectively).	To	determine	if	the	strand	bias	was	limited	to	one	or	both	of	signatures	3	and	4	we	compared	strand	mutational	rates	in	samples	enriched	for	each	signature.	In	both	samples	where	signature	3	was	predominant	(3121	and	7442)	T:A>G:C	T:A	>	G:C	mutations	demonstrated	a	transcriptional	strand	bias	(transcribed	vs	untranscribed,	3121,	6	vs	10	mutations,	7442,		26	vs	35).	In	contrast	in	the	two	samples,	3323	and	7424	where	signature	4	was	prevalent	no	transcriptional	strand	bias	was	observed	(transcribed	vs	untranscribed,	3323,	2	vs	3,	7424	12	vs	12)	though	of	course	the	numbers	are	too	small	to	draw	any	significant	conclusions.	Additionally,	T:A>C:G	mutations	demonstrated	a	significant	enrichment	on	the	transcribed	strand	at	all		sites	where	adenine	was	the	5’	base	regardless	of	which	base	was	located	at	the	3’	site	(Figure	4.14).	Mutations	at	these	sites	were	not	enriched	in	any	of	the	6	signatures	we	identified	in	OAC.	However	2	additional	signatures	identified	by	Alexandrov	et	al,	signatures	5	and	16,	contain	T:A>C:G	at	ApTpXp	mutations,	with	a	strong	bias	towards	occurrence	on	the	transcribed	strand	[77].	Signature	5	is	present	in	almost	all	tumour	types	whilst	signature	16	provides	16.5%	of	mutations	in	the	set	of	hepatocellular	carcinomas	they	analysed.	As	discussed	earlier,	our	signature	6	shows	strong	similarity	to	both	signatures	5	and	3	(cosine	similarity	0.921	and	0.923	respectively).	This	coupled	with	the	presence	of	a	transcriptional	strand	bias	strongly	supports	the	idea	that	it	in	fact	represents	the	incomplete	extraction	of	both	signatures.	The	transcriptional	strand	bias	seen	for	C:G>A:T	mutations	was	significant	only	for	ApCpAp	and	GpCpCp	trinucleotides.	No	individual	signature	is	enriched	for	either	trinucelotide.	In	addition,	the	transcriptional	strand	bias	seen	for	C:G	>	T:A	mutations	was	significant	for	ApCpAp,	GpCpAp	and	GpCpGp.	No	additional	signature	identified	in	tumour	type	to	date	is	enriched	for	this	pattern	of	trinucleotides	and	so	the	significance	of	this	result	remains	unclear.	
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4.9 Presence	of	each	signature	in	additional	tumour	types	
The	predominant	signature	of	oesophageal	adenocarcinoma,	identified	here	as	T:A>G:C	enriched	at	XpTpTp	trinucleotides,	has	no	known	aetiology.	It	has	been	identified	in	several	other	tumour	types	including	gastric	cancer	(GC),	hepatocellular	carcinoma		(HCC)	and	diffuse	large	B-cell	lymphoma		(DLBCL)	To	confirm	the	presence	and	extent	of	this	signature	in	these	samples,	and	to	account	for	any	variability	between	techniques	used,	we	re-extracted	signatures	for	DLBCL	and	hepatocellular	carcinoma	samples	used	in	the	Alexandrov	study	[77]	Though	81%	of	OACs	contain	greater	than	15%	of	mutations	from	either	signature	3	or	4,	only	a	single	DLBCL	harboured	this	proportion,	so	these	oesophageal	signatures	are	not	such	a	prominent	feature	in	this	disease.		DLBCL	may	arise	from	a	mucosa	associated	lymphoid	tissue	(MALT)	lymphoma	and	this	may	explain	a	similar	mutagen	exposure.	MALT	lymphomas	are	characterized	by	a	series	of	unique	translocations,	so	to	see	whether	these	DLBCLs	were	likely	MALT-derived,	we	identified	SV	data	for	them,	from	the	TCGA	database.	However,	no	translocations	that	would	suggest	a	MALT	precursor	had	been	detected,	in	the	case	containing	enrichment	for	the	OAC	signatures.	In	the	hepatocellular	carcinomas	(HCCs)	analysed	by	Alexandrov	et	al,	there	is	enrichment	for	T:A>G:C	mutations	at	XpTpTp	nucleotide	[77].	The	levels	were	lower	than	seen	in	OAC,	with	a	median	of	410	mutations	across	87	analysed	HCCs	(range,	11	–	10,182).	In	addition,	the	enrichment	pattern	was	different	to	that	seen	on	OAC	with	enrichment	for	T:A>G:C	mutations	at	CpTpTp	sites	not	strongly	coupled	to	enrichment	of	T:A	>	C/A	at	these	sites	as	seen	in	OAC.	Re-extraction	of	mutational	signatures	for	these	samples	identified	only	a	single	signature	associated	with	XpTpTp	mutations.	This	signature	most	closely	resembled	OAC	signature	4,	with	an	excess	of	T:A>G:C	mutations	over	T:A>C:G.	Only	4	samples	showed	a	greater	than	15%	contribution	from	the	single	signature	dominated	by	XpTpTp	(Figure	4.15).	In	a	more	recent	analysis	of	300	whole	genome	sequences	from	HCC,	7	signatures	were	identified	of	which	none	
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closely	resemble	the	oesophageal	signatures	[427].	Overall	this	suggests	possible	but	limited	activity	of	the	putative	oesophageal	mutagen	in	HCC	and	DLBCL.	
4.10 Discussion	
4.10.1 Pipeline	verification	
There	are	several	strengths	to	the	verification	strategy	utilized	in	this	study.	Firstly	the	use	of	orthogonal	technologies;	Sanger	sequencing	and	high-depth	NGS	both	confirmed	a	high	specificity	of		>	90%	for	this	pipeline.		Hopefully	accounting	for	errors	to	which	each	may	be	susceptible.		With	Sanger	sequencing	alone	the	verification	rate	was	91.0%	whilst	with	high	depth	NGS	the	verification	rate	was	99.3%.	This	difference	in	verification	rates	may	have	been	secondary	to	chance	or	may	be	due	to	differences	in	the	samples	used	in	each	arm	of	the	verification.	Though	samples	were	sequenced	using	the	same	technology,	the	quality	of	the	library	preparation	is	known	to	create	samples	specific	artefacts	giving	varying	verification	rates	between	samples	[287].	Alternatively,	the	lower	sensitivity	of	Sanger	sequencing	may	explain	these	results.	Only	2	variants	were	found	to	be	false	positive	germline	variants	whilst	the	remaining	13	were	not	identified	in	the	tumour	or	the	normal.	Studies	of	Sanger	sequencing	have	identified	a	lower	threshold	of	15-20%	variant	allele	frequency	(VAF)	for	the	identification	of	known	mutations	and	25%	VAF	for	novel	variants	[428].		The	sensitivity	of	our	pipeline	is	high	compared	to	other	published	SNV	pipelines	[293].		One	possible	explanation	for	this	is	the	stringency	of	our	filters.	We	utilize	an	adapted	set	of	filters	combined	from	two	pipelines	[294,295]	.	We	may	therefore	have	traded	specificity	for	sensitivity	and	this	may	explain	why	our	mutational	frequency	falls	below	that	seen	in	the	other	two	recent	studies	of	OAC	[333,381].	For	the	detection	of	mutational	signatures,	high	specificity	is	essential	and	several	artefactual	signatures	have	been	identified	in	data	not	subject	to	rigorous	verification	[77].	For	the	detection	of	driver	genes	it	is	possible	that	a	
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more	sensitive	pipeline	with	a	higher	error	rate	would	be	optimal	if	coupled	with	verification	of	the	prevalence	of	mutations	in	the	driver	in	a	larger	panel	of	tumours	using	alternative	methods.	The	selection	bias	inherent	in	using	a	PCR	based	strategy	for	verification	may	artificially	inflate	our	specificity.	Repetitive	regions	of	the	genome	are	more	likely	to	generate	errors	due	to	errors	inserted	during	PCR	and	mapping	artefacts	where	sequences	with	minimal	differences	are	mapped	to	each	other’s	location.	These	repetitive	areas	of	the	genome	are	largely	excluded	from	our	SNV	calling	pipeline	by	using	decoy	sequences	for	alignment	(representing	common	polymorphisms	in	the	human	genome)	and	black-listing	regions	with	exceptionally	high	rates	of	read	mapping	strongly	suggestive	of	residual	repeat	sequence	in	the	reference	genome.		However,	error	prone	regions	still	remain.	Due	to	the	repetitive	nature	of	these	sequences	it	is	more	difficult	to	develop	primers	that	target	these	regions,	this	being	a	particular	issue	for	NGS	based	verification	as	smaller	fragment	sizes	are	required	limiting	the	available	sequence	for	primer	design.		It	is	therefore	possible	that	the	areas	most	prone	to	errors	in	SNV	calling	may	also	be	the	areas	most	difficult	to	target	for	verification.	This	would	lead	to	artificial	inflation	of	a	pipeline’s	specificity.	Probes	for	capture	sequencing	based	on	verification	approaches	suffer	from	the	same	constraints	and	thus	are	not	a	solution.		One	solution	is	to	utilize	sequencing	data	from	additional	normal	samples	to	filter	for	errors.	Both	the	tumour	and	the	normal	samples	would	be	expected	to	harbour	similar	errors	caused	by	mapping.		These	errors	may	be	rare	and	may	not	be	seen	in	a	single	50x	coverage	normal	genome.	A	large	panel	of	normal	samples	may	be	more	appropriate	to	screen	for	errors.	This	strategy	is	discussed	in	more	detail	in	chapter	5,	when	looking	at	SV	verification.	The	recent	ICGC	benchmarking	exercise	represents	the	current	verification	gold	standard.	The	key	conclusions	of	this	study	are	that	no	single	pipeline	is	sufficiently	sensitive	and	that	a	combination	of	pipelines	may	provide	the	most	accurate	data,	and	that	a	minimum	coverage	of	100x	is	required	for	normal	genomes	to	prevent	misclassification	of	germline	variants	[293].	
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4.10.2 Discussion	of	signatures	number	selection	
Selection	of	the	optimal	number	of	factorisation	ranks	for	NMF	is	an	unresolved	problem.	In	this	thesis	I	have	implemented	3	previously	suggested	methods	[361,362].		Each	method	provided	support	for	between	5	and	6	signatures.	Close	assessment	of	the	signatures	strongly	favours	the	6-signature	solution,	as	it	is	clear	from	analysis	of	previously	derived	signatures	that	in	the	5-signature	solution	signatures	1	and	2	have	been	merged.	Incomplete	extraction	of	signatures	is	a	known	problem	of	NMF	approaches	particularly	when	signatures	show	similarities	and	co-vary	across	samples	[361,362].	Alternative	methods	for	signature	extraction	have	been	devised,	including	an	approach	based	around	expectation	maximization	[429].	A	combinatorial	approach	to	signature	assessment	is	likely	to	be	most	appropriate,	to	maximize	sensitivity	and	specificity	for	signature	numbers.	Supporting	this	approach,	a	close	analysis	of	the	transcriptional	strand	bias	observed	in	our	OAC	cohort	identified	the	hallmarks	of	a	7th	signature,	with	a	prevalence	of	T:A>C:G	mutations	at	ApTpX	sites.	This	signature	has	now	been	shown	to	be	present	across	all	cancers	supporting	its	presence	in	our	dataset	[430].	It	was	not	identified	by	NMF	in	our	analysis	nor	in	a	recent	analysis,	again	using	NMF,	of	an	extended	cohort	of	OAC	cases	[387].	
4.10.3 Transcriptional	strand	bias	
Our	transcriptional	strand	bias	analysis	utilized	data	generated	from	the	TCGA	tumour	specimens.	This	identified	transcriptional	strand	bias	for	several	specific	mutations	types	including	T:A>G:C	mutations	at	XpTpTp	dinucleotides	and	T:A>C:G	mutations	at	ApTp	Xp	sites.	However	it	is	not	clear	if	whole	tumour	gene	expression	profiles	are	the	most	suitable	choice	for	this	analysis.	Firstly,	as	discussed	in	Chapter	5,	many	mutations	occur	early	in	the	development	of	OAC	even	at	the	stage	of	pre-malignancy	when	no	phenotypic	alterations	have	occurred	in	the	tissue	[364,431].	Expression	profiles	are	known	to	be	significantly	different	between	BE,	dysplasia	and	cancer[432-434].	Secondly	there	is	on-going	debate	regarding	which	cell	type	within	a	tissue	gives	rise	to	
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cancer.	Typically	it	has	been	felt	that	long-lived	stem	cells	would	be	the	only	ones	capable	of	accumulating	sufficient	mutations	to	progress	to	malignancy.	However	recent	evidence	has	shown	that	in	certain	cases	de-differentiation	of	committed	progenitor	cells	is	possible	[435-438].	One	intriguing	possibility	is	that	deviations	from	the	expected	transcriptional	strand	bias	and	pattern	of	decreased	mutations	in	transcribed	regions	could	be	used	to	predict	expression	levels	at	the	time	a	particular	mutational	signature	was	active.	This	may	allow	us	to	predict	the	expression	profiles	of	the	precursor	tissue	and/or	precursor	cell	stage,	a	contentious	issue	in	OAC	biology	and	cancer	biology	in	general	[435,438-444].	Some	work	has	already	demonstrated	preliminary	evidence	that	this	may	be	possible,	however	more	detailed	studies	utilizing	single	cell	RNA-seq	and	chromatin	profiles	would	provide	more	accurate	information	[178,445].	Transcription	factor	binding	has	been	shown	to	block	the	action	of	NER	leading	to	increased	density	of	mutations	within	active	promoters.	This	too	has	the	potential	to	be	exploited	to	determine	the	originating	cell-type	in	malignancy	[63,188].	T:A>G:C	mutations	at	TpTp	dinucleotides	are	the	hallmark	of	two	signatures	in	our	dataset,	signatures	3	and	4.	Transcriptional	strand	bias	is	thought	to	be	due	mainly	to	the	action	of	transcription	coupled	nucleotide	excision	repair	[183,446].	Supporting	this,	in	cases	of	melanoma	with	mutations	in	genes	of	this	pathway	there	is	an	absence	in	the	transcriptional	bias	seen	with	UV-light	mediated	damage	[180].	
Given	the	propensity	for	transcription	coupled	nucleotide	excision	repair	to	remove	bulky	base	adducts,	it	is	possible	that	these	signatures	are	driven	by	a	mutagen	that	affects	DNA	in	this	way.	Both	bile	acids	and	low	pH	have	been	shown	to	induce	DNA	damage	[407-409,447,448].	Human	bile	acid	mixtures	have	been	shown	to	form	DNA	adducts	and	this	is	enhanced	at	low	pH	making	them	a	likely	candidate	for	these	signatures	with	transcriptional	strand	bias	[449,450].	This	of	course	does	not	rule	out	other	causative	agents	[451,452].		
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4.10.4 Causes	of	the	oesophageal	specific	signatures,	clues	from	tumour	location	
The	cause	of	the	oesophageal	specific	signatures	is	unknown.	Signatures	3	and	4	dominated	by	T	>	G/C/A	mutations	at	XpTpT	sites	are	highly	enriched	in	our	oesophageal	adenocarcinoma	samples.	In	larger	data	sets	they	are	associated	with	position	in	the	oesophagus	with	the	more	proximal	tumours	demonstrating	a	greater	level	of	mutation	due	to	these	signatures.	This	was	not	seen	in	our	dataset	with	no	significant	difference	between	the	number	of	signature	3	and	4	mutations	in	oesophageal	and	Siewert	type	1	tumours	versus	Siewert	type	2	and	3	tumours.	This	maybe	due	to	the	small	numbers	used.	An	alternative	explanation	is	that	our	cohort	was	specifically	enriched	for	true	oesophageal	tumours	with	no	inclusion	of	gastric	cardia	cancers.	A	recent	study	has	shown	significant	differences	between	OAC	and	the	majority	of	gastric	tumours	with	OAC	clustering	only	with	the	chromosomal	instability	(CIN)	–	type	gastric	cancers	[160].	These	tumours	display	an	enrichment	for	the	T:A>G:C	signature	at	TpTp	dinucleotides	when	compared	to	other	gastric	cancers.	It	is	therefore	possible	that	OAC	tumour	enrichment	for	the	CIN	type	of	cancer	and	the	increase	in	non-CIN	type	cancers	at	the	gastro-oesophageal	junction	is	the	cause	of	the	previously	identified	enrichment	of	signatures	3	and	4	in	more	proximal	tumours.	The	tissue	sites	in	which	a	mutational	signature	can	be	seen	may	allow	us	to	predict	which	mutagens	are	responsible.	A	similar	signature	is	seen	to	a	lesser	extent	in	DLBCL,	HCC	and	recently	also	in	acral/	mucosal	melanoma	and	breast	cancer.	Our	review	of	HCC	and	DLBCL	demonstrated	that	the	signature	is	uncommon	in	these	tumour	types,	contributing	significant	proportions	of	mutations	to	only	1-2	samples	and	then	low	levels	to	other	cases.		This	is	similar	for	both	breast	and	melanoma	where	this	signature	was	only	identified	in	few	cases	of	exceptionally	large	cohorts	of	patients	[211,453].		Tumour	cells	tend	to	harbour	an	acidic	microenvironment	[454].	The	absence	of	our	signatures	3	and	4	in	the	majority	of	tumours	argues	against	acid	alone	being	sufficient	to	generate	this	damage.	However	it	should	be	noted	that	the	presence	of	an	acidic	environment	is	likely	to	be	a	late	development	following	expansion	
	 160	
of	the	tumour	and	onset	of	hypoxia	[455].	Recent	evidence	would	suggest	that	the	majority	of	mutational	heterogeneity	is	already	present	at	this	stage	and	therefore	the	action	of	additional	signatures	may	not	be	visible	in	the	tumour	genome	[456].	Further	studies	of	metastatic	tissue	and	relapsed	malignancy	may	provide	insight	into	the	effect	of	an	acidic	microenvironment	on	the	tumour	genome.	Additionally,	tumour	cells	are	known	to	adapt	to	the	gradual	onset	of	an	acidic	environment	[457].	It	may	be	that	the	intermittent	exposure	present	in	GORD	prevents	this	adaption	and	associated	genomic	protection.	If	bile	acids	are	the	culprit	for	our	signatures,	what	then	is	the	explanation	for	the	presence	of	this	mutation	pattern	in	rare	examples	of	tumours	from	diverse	tissues?	One	possibility	is	that	the	presence	of	the	signature	may	be	an	artefact	of	the	NMF	method.	Our	re-analysis	of	the	HCC	genomes	suggests	that	this	is	at	least	in	part	the	explanation	in	this	case	as	the	enrichment	in	HCC	does	not	follow	the	pattern	seen	in	OAC.	In	DLBCL	the	signature	is	more	apparent,	though	constrained	to	only	a	very	small	number	of	cases.	DLBCL	may	arise	from	mucosal	associated	lymphoid	tissue	in	the	gastric	epithelium	and	therefore	may	be	exposed	to	acid	and	bile	acids.	[458].	In	addition,	HCC	may	be	directly	exposed	to	bile	acids	and	bile	acids	are	known	to	circulate	in	the	blood	and	to	be	increased	in	liver	disease,	thus	potentially	allowing	them	to	access	any	tissue	in	the	body.	[459].	Finally,	these	tumours	may	represent	rare	metastases	from	an	undiagnosed	oesophageal	primary	or	samples	may	have	been	mislabelled[460].	A	detailed	analysis	of	the	clinical	backgrounds	of	cases	of	melanoma	and	breast	cancer	demonstrating	this	signature	would	be	informative.	Whether	or	not	these	signatures	exist	at	other	sites,	they	are	the	predominant	signature	in	OAC	and,	as	shown	in	larger	recently	published	studies,	they	are	more	strongly	associated	with	oesophageal	tumours	than	diffuse	type	gastric	tumours	[160].	Gastric	tumours	have	many	putative	causative	factors,	including	MSI,	EBV	and	Helicobacter	Pylori	induced	chronic	inflammation.		OAC	on	the	other	hand,	is	linked	strongly	only	to	gastro-oesophageal	reflux	disease	and	obesity.		
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The	gastric	epithelium	remains	largely	protected	from	the	effects	of	acid	whilst	the	oesophageal	epithelium	is	poorly	adapted	to	this.	The	link	of	these	signatures	to	cancers	associated	with	GORD	strongly	supports	the	role	of	this	in	their	pathogenesis.	As	discussed	previously,	both	low	pH	and	bile	acid	have	been	shown	to	cause	DNA	damage.		Mutagenesis	in	E.Coli	represents	a	long-standing	and	detailed	data	set	on	the	causes	of	certain	mutation	patterns.	Intriguingly,	the	only	study	to	show	an	enhancement	of	T:A>G:C	mutations	attributed	this	to	the	presence	of	8-hydroxyguanine,	an	oxidized	form	of	guanine	[110].	The	low	pH	present	in	gastro-oespohageal	refluxate	may	generate	ROS	[447]	and	may	damage	guanine	nuleotides	incorporated	in	DNA,	or	may	damage	unincorporated	nucleotides,	which	subsequently	may	be	incorporated	during	replication	[108,447,461].		In	summary,	OAC	has	a	highly	mutated	genome.	We	have	identified	the	action	of	7	mutational	processes.		Larger	cohorts	with	long	follow	up	are	clearly	required	to	determine	the	clinical	relevance	of	these	signatures.	In	addition,	further	in	vitro	studies	are	required	to	identify	the	causative	agents.	This	will	be	discussed	further	in	Chapter	6.		 	
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Figure	4.1	Comparison	of	mutation	densities	across	various	tumour	types	
and	normal	tissues.	Oesophageal	adenocarcinoma	has	now	been	assessed	by	3	different	groups	including	Dulak	et	al,	2013	(mutation	density	9.9/Mb),	None	et	
al,	2015	(8.0/Mb)	and	our	own	data	(7.8/Mb).	With	the	exception	of	Bladder	cancer	all	cancer	types	with	higher	rates	of	mutation	than	OAC	have	a	strong	relationship	with	known	mutagens,	endogenous	(e.g.	defective	mismatch	repair)	or	exogeneous	e.g.	UV	light	or	cigarette	smoke.	
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Figure	4.2	Numbers	of	transition	and	transversion	type	mutations	in	OAC	demonstrates	a	
preponderance	of	T:A>G:C	transversions.	(a),	figure	demonstrating	the	difference	between	transition	mutations,	labeled	as	a	green	arrow	(pyrimidine-	pyrimidine	or	purine	to	purine)	and	transversion	mutations	labeled	as	an	orange	arrow	(pyrimidine	to	purine	or	purine	to	pyrimidine).	(b)	Pie	charts	showing	the	types	of	mutations	observed	in	OAC.	Mutations	at	thymidine	bases	predominate	with	an	excess	of	T:A>G:C	mutations.	The	two	additional	satellite	pie	charts	show	the	proportion	of	transition	and	transversion	mutation	types	seen	in	our	dataset	(Tumour)	and	in	the	germline	single	nucleotide	polymorphism	from	the	1000	genomes	project	
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Figure	4.3.	Heatmap	demonstrating	mutational	patterns	in	OAC	Batch	0.	Several	mutational	patterns	are	obvious	on	visual	inspection	including	a	strong	enrichment	for	C:G>T:A	mutations	at	XpCpG	sites	and	T:A>A/C/G	at	CpTpT	trinucleotides.		
	 165	
Figure	4.4.	Heatmap	demonstrating	mutational	patterns	in	OAC	Batch	1.	
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Figure	4.5	Extraction	of	mutational	signatures	from	21	breast	cancer	data	
set,	(a)	Frobenius	reconstruction	error	for	solutions	with	increasing	numbers	of	signatures,	(b),	average	silhouette	widths	for	solutions	with	increasing	numbers	of	signature.	Following	the	Alexandrov	et	al	approach	we	selected	the	number	of	signatures	that	provided	the	optimal	balance	between	accuracy	for	rebuilding	the	original	source	data	(assessed	using	Frobenius	reconstruction	error)	and	reproducibility	of	the	derived	signatures	(assessed	by	clustering	all	signatures	generated	over	100	iterations	with	randomly	seeded	initial	matrices	and	calculating	the	average	silhouette	width).	
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Figure	4.6	Five	extracted	breast	signatures.	Comparison	with	Nik-Zainal	et	al	shows	that		signature	1	from	our	pipeline	matches	signature	B	(APOBEC	signature),	signature	2	matches	signature	C,	signature	3	matches	signature	A,	signature	4	matches	signature	E	and	signature	5	matches	signature	D.	
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Figure	4.7	Five	extracted	breast	signatures	from	Nik-Zainal	et	al.	Provided	for	comparison	with	the	signatures	generated	using	our	R	implementation	of	the	MATLAB	pipeline	provided	in	this	paper.		
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Figure	4.8	Extraction	of	mutational	signatures	from	oesophageal	
adenocarcinoma	data.	The	reconstruction	error	significantly	improves	up	till	a	total	of	6	signatures.	Increasing	the	number	of	signatures	from	this	point	does	not	markedly	improve	the	ability	to	reconstruct	the	original	data,	however	the	silhouette	width	decreases	from	0.77	to	0.69	between	6	and	7	signatures	whilst	only	decreasing	from	0.82	to	0.77	from	5	to	6	signatures	
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Figure	4.9	Number	of	signatures	as	assessed	by	alternative	published	
measures	
	 171	Figure	4.10	Extracted	signatures	when	expected	number	of	signatures	is	set	to	6.	
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Figure	4.11	Additional	signature	seen	when	signature	number	for	NMF	is	
set	to	5.	Increasing	the	number	of	signatures	to	6	splits	apart	this	signature	into	2	identifying	the	ageing	signature	and	an	additional	signature	seen	to	accumulate	in	non	cancerous	small	bowel	cells.	
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Figure	4.12	Contribution	of	each	signature	to	the	total	mutation	burden	of	
all	samples.	Samples	are	sorted	by	total	number	of	mutations	running	from	left	to	right	
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Figure	4.13	Comparison	of	Signature	1	(C:G>A:T	at	XpCpT/A)	to	the	most	
closely	related	signatures	seen	in	other	tumour	types.	
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Figure	4.14	Number	and	context	of	mutations	found	in	transcribed	(blue)	
and	untranscribed	(red)	strands	of	high	expression(top	chart)		and	low	
expression	gene	sets	(bottom	chart).	Trinucleotides	demonstrating	a	significant	difference	in	expression	on	the	transcribed	and	untranscribed	strands	are	labelled	with	an	asterix	
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Figure	4.15:	Relative	contribution	of	signature	3	and	4	to	other	tumour	types.	Tumours	
ranked	by	percentage	of	mutations	contributed	by	signatures	3	and	4	(left	to	right).	Note	for	hepatocellular	carcinomas	only	a	single	signature	was	extracted,	signature	4.	The	black	dotted	line	on	each	plot	represents	a	threshold	of	15%	of	mutations	generate	by	XpTpTp	dominated	signatures	
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Chapter	5 	
Analysis	of	potential	driver	mutations	and	their	
timing	in	the	development	of	oesophageal	
adenocarcinoma		 	
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5.1 Introduction	
At	the	time	of	the	initiation	of	this	project	little	was	known	about	genes	involved	in	the	development	of	OAC.	Whole	genome	sequencing	provides	an	unbiased	screen	of	all	mappable	genes	and	allows	the	detection	of	unknown	candidate	driver	genes.	Methods	for	elucidating	driver	genes	have	evolved	significantly	during	the	progression	of	this	project	but	even	basic	techniques	may	be	suitable	for	the	detection	of	highly	recurrent	mutations.	Though	next	generation	sequencing	studies	have	the	power	to	detect	novel	driver	genes	they	cannot	predict	the	functionality	and	importance	of	these	mutations	at	differing	disease	stages.	Clonality	analysis	of	mutations	found	in	heterogeneous	tumour	samples	can	be	used	to	infer	the	relative	timing	of	mutations;	however	it	is	an	indirect	measure	and	is	subject	to	significant	difficulties	in	interpretation.	In	these	analyses,	mutations	are	assigned	as	either	occurring	before	or	after	the	original	clonal	expansion	(subclonal	Vs	fully	clonal	mutations)	or	before	or	after	loss	or	gain	of	copy	number.	Thus	mutations	that	occur	in	the	original	clonal	expansion	and	before	significant	structural	rearrangement	of	the	genome	cannot	be	separated	temporally	from	each	other.	The	progression	of	Barrett’s	oesophagus	to	oesophageal	adenocarcinoma	via	a	dysplastic	intermediate	is	well	documented	and	is	the	basis	for	current	screening	programmes.	These	screening	programmes	provide	an	abundant	source	of	material	at	each	stage	of	the	developing	disease,	normal	epithelium,	dysplastic	epithelium	and	malignant	epithelium.	By	analysing	the	genomes	of	tissue	representing	each	of	these	stages	it	should	be	possible	to	determine	accurately	the	stage	at	which	a	specific	mutation	occurs,	therefore	providing	information	on	the	function	of	that	mutation.	The	purpose	of	this	chapter	is	firstly	identifying	potential	novel	driver	genes	in	OAC	and	secondly	to	determine	accurately	the	disease	stage	at	which	mutations	in	these	genes	occurs.	
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5.2 Next	generation	sequencing	of	22	OACs	and	case	demographics	
A	total	of	22	cases	were	selected	for	whole	genome	sequencing.	The	cohort	reflected	the	known	clinico-demographic	features	of	the	disease:	male	predominance	(M:F,	4.5:1),	a	mean	age	of	68	years	(range	53	to	82),	and	a	majority	with	advanced	disease	(81.8%	(18/22)	>	stage	I).	Of	the	22	cases,	17	(77.3%)	had	evidence	of	Barrett’s	oesophagus	in	the	resection	specimen	(Table	1).	Patient	samples	were	sequenced	to	a	mean	coverage	of	63-	and	67-fold	in	tumour	and	normal	samples	respectively	(Table	2).		Normal	samples	were	either	blood	(55%	12/22)	or	normal	squamous	oesophagus		(45%,	10/22)	taken	from	the	proximal	resection	margin.	DNA	for	sequencing	was	extracted	from	frozen	tissue.	All	frozen	samples	had	a	single	haemotoxylin	and	eosin	stained	section	assessed	by	a	trained	histopathologist	(Dr	Maria	O’Donovan)	to	confirm	the	nature	of	the	specimen	and	to	quantify	tumour	cell	content.	The	proximal	resection	margin	may	be	infiltrated	by	tumours	which	may	not	be	identified	in	the	section	taken	for	histology.	Due	to	the	filtering	criteria	applied	to	our	SNVs	-	we	removed	any	SNV	seen	in	>1	read	in	the	matched	normal	sample	–	tumour	contamination	of	the	normal	sample	may	lead	to	reduced	SNV	calling	rates.	We	compared	the	number	of	SNVs	identified	in	those	tumours	with	matched	normal	DNA	from	whole	blood	versus	those	tumours	with	normal	DNA	extracted	from	nearby	normal	squamous	epithelium.	There	was	no	significant	difference	between	the	numbers	of	SNVs	identified	in	each	sample	(mean	SNV	number	20	989	Vs	15	461,	blood	Vs	normal	squamous	epithelium,	p	=	0.28,	2	tailed	Student’s	T-test).	
5.3 Coverage	of	the	mappable	genome	in	each	of	the	22	cases	
Coverage	must	be	similar	to	ensure	that	assessment	of	base	line	and	driver	gene	mutation	rates	are	comparable	between	samples.	Our	mutation	calling	pipeline	required	a	minimum	depth	of	10x	in	the	tumour	and	10x	in	the	matched	normal.	We	therefore	assessed	what	proportion	of	the	mappable	genome	was	covered	at	10x	in	both	the	tumour	and	normal	of	each	matched	pair.	Here	the	mappable	genome	is	defined	as	the	proportion	of	the	genome	that	is	sufficiently	unique	to	
	 180	
allow	the	accurate	mapping	of	100bp	read	pairs.	The	mappable	genome	for	Hg19	is	2	684	578	480bp	in	size.	Greater	than	99%	of	the	mappable	genome	was	covered	in	all	samples,	both	tumour	and	normal	(range	99.85%	-	99.03%).	The	minimum	percentage	covered	at	10x	in	both	tumour	and	normal	sample	pairs	was	99.0%	(range	99.79%	-		99.0%).	There	was	no	correlation	between	mutation	number	and	the	10x	coverage	percentage	for	each	pair.	
5.4 Validation	of	INDELs	by	Sanger	sequencing	
As	detailed	in	Chapter	4	we	have	verified	the	single	nucleotide	predictions	of	our	pipeline.	Insertion	or	deletion	of	small	(<	100bp)	sections	of	sequence	within	the	coding	region	of	a	gene	has	the	potential	to	profoundly	disrupt	its	structure	by	causing	frame	shifts	most	often	leading	to	truncation	of	the	protein.	In	addition.	frame	shifts	may	lead	to	decreased	expression	of	the	protein	by	stimulating	nonsense-mediated	decay.	We	developed	an	in-house	INDEL	calling	and	filtering	pipeline	(Methods).	To	confirm	the	accuracy	of	this	pipeline	we	randomly	selected	25	coding	INDELs	that	had	been	manually	reviewed	using	the	Integrative	Genomics	Viewer	(IGV).	Sanger	sequencing	of	the	tumour	and	normal	for	each	INDEL	confirmed	23/25	(92%)	as	somatic	variants.	
5.5 Identifying	driver	genes	
The	small	size	of	the	discovery	cohort	meant	that	we	had	little	power	to	detect	all	but	the	most	commonly	mutated	genes.	We	therefore	used	a	combination	of	methods	to	identify	potential	candidate	genes	for	further	screening	in	a	larger	cohort.	Using	SNV	calls	generated	by	STRELKA	(Illumina),	genes	were	ordered	by	an	estimated	probability	of	frequency	of	mutation	above	a	baseline,	non-silent	calling	rate	generated	using	the	non-silent	mutation	rate	across	all	22	tumours.	Frequently	mutated	genes	with	a	p-value	<	4x10-5	(n=26	genes)	were	selected.	We	applied	filtering	criteria	to	this	cohort,	removing	those	genes	for	which	a	mutation	fell	in	a	poorly	mapping	region	(n=7)	and	those	classified	as	
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uncharacterized	(n=1),	to	enrich	for	functionally	relevant	mutation	targets.	We	also	removed	a	further	two	genes	as	members	of	large	families	we	suspected	were	more	likely	to	be	passengers	(OR10R2,	C10orf71).	A	further	two	genes	were	removed	as	no	mutations	were	identified	in	either	in	the	discovery	cohort	under	the	adapted	SNV	filtering	criteria	(PCDHGA11,	HMX2)	as	discussed	in	Chapter	4.		Additional	genes	were	selected	for	validation	based	on	a	known	association	with	carcinogenesis	(ABCB1,	SMARCA4,	UNC13C,	CNTNAP5,	MYO18B,	MMP16)	and	for	their	relevance	to	the	NFκB	pathway,	known	to	be	associated	with	the	development	of	OAC	(TLR1,	TLR4,	TLR7,	TLR9,	MYD88,	TRAF3,	TRAF6).	In	total	27	potential	driver	genes	were	taken	forward	to	the	primer	design	stage.		
5.6 Targeted	amplicon	re-seqeuncing	in	an	expanded	cohort	of	OAC	cases	
To	highlight	genes	most	likely	to	be	relevant	in	the	development	of	OAC	we	sought	to	determine	the	degree	to	which	mutated	genes	identified	in	our	discovery	cohort	(n=22	cases)	were	representative	of	the	spectrum	of	mutations	in	an	expanded	cohort.	We	therefore	identified	a	further	90	OAC	samples.	These	samples	again	had	demographics	in	keeping	with	those	seen	in	the	disease	as	a	whole.		In	total	15%	(14/90)	were	female,	and	85%	(76/90)	were	advanced	disease	(>	stage	1).		Amplicon	re-sequencing	was	performed	using	the	fluidigm	microfluidics	PCR	platform.	This	aims	to	achieve	equal	coverage	of	each	amplicon	by	performing	PCR	in	microfluidic	systems	with	limited	reagents	in	each	volume	such	that	each	reaction	runs	to	completion	giving	similar	levels	of	product.	Complex	areas	of	the	genome	may	be	difficult	to	PCR	and	so	these	reactions	may	not	run	to	completion,	leading	to	variations	in	coverage	achieved.	Variable	coverage	in	genes	may	lead	to	underestimation	of	the	number	of	driver	genes.		As	amplification	in	the	fluidigm	system	takes	place	in	nanolitre	volumes,	the	absolute	quantity	of	starting	DNA	in	each	reaction	is	low.	Errors	in	amplification	may	therefore	occur	in	a	substantial	proportion	of	the	reads	generated	in	a	given	
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reaction.	Similarly	Illumina	sequencing	chemistry	is	known	to	make	errors	at	specific	sequences.	Random	insertion	of	errors	would	be	expected	to	occur	only	at	relatively	low	frequency	in	the	same	position,	however	systematic	errors	might	accumulate	at	specific	base	pairs	and	give	the	appearance	of	genuine	variants.	To	correct	for	this	we	re-sequenced	all	mutations	identified	in	the	first	round	of	fluidigm	sequencing	in	both	the	tumour	and	normal	samples	where	available	(either	blood	or	normal	epithelium	from	the	D2	segment	of	the	duodenum).	In	total	we	re-sequenced	594	mutations	(note	this	includes	mutations	from	Barrett’s	and	high	grade	dysplasia	as	discussed	later	in	the	chapter)	of	which	219	(36.9%)	were	true	positives,	40	(6.7%)	were	germline	and	335	(56.4%)	were	false	positives.	Comparing	the	patterns	of	mutations	between	these	3	groups	revealed	substantial	differences	with	a	marked	enrichment	for	T:A>C:G	mutations	in	the	false	positive	group.	This	is	in	keeping	with	the	error	profile	generated	by	Taq	Polymerase	and	supports	amplification	as	the	major	source	of	errors	in	this	pipeline.	We	combined	the	data	from	both	the	discovery	and	validation	cohorts	giving	a	total	of	112	tumours	and	identified	15	genes	that	were	mutated	in	four	or	more	samples	(Figure	2).	These	included	those	previously	identified	as	OAC	candidate	genes	(ARID1A,	SMARCA4,	TP53,	SMAD4),	and	several	novel	candidates:	MYO18B,	
SEMA5A	and	ABCB1.	Whilst	our	paper	was	under	review,	Dulak	et	al	published	an	exome-sequencing	study	of	145	OACS.	We	compared	the	rate	of	mutation	of	our	15	candidate	genes	across	both	studies.		There	was	no	significant	difference	in	the	mutation	rates	for	any	of	the	15	genes	between	the	cohorts	(Fisher’s	exact	test,	p	>0.05),	therefore	confirming	the	relevance	of	our	candidate	genes	in	an	external	cohort.		
TP53	was	the	most	commonly	altered	gene	mutated	in	the	vast	majority	of	cases;	however	31%	of	cases	are	wild	type	for	TP53.	Investigation	of	our	SV	data	detected	no	SVs	affecting	the	TP53	gene.	Although	we	do	not	have	enough	power	to	detect	mutually	exclusive	mutations	in	our	cohort,	we	can	detect	significantly	co-occurring	mutations.	SEMA5A	and	ABCB1	mutations	occurred	more	commonly	in	the	same	tumour	than	would	be	expected	by	chance	(Benjamini–
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Hochberg-adjusted	p-value	=	0.0021)	although	the	reason	for	this	association	remains	unclear.	
5.7 Mutations	of	the	SWI/SNF	complex	in	OAC	
After	TP53	the	SWI/SNF	complex	was	the	next	most	commonly	mutated	gene	set	in	our	cohort.	A	total	of	20/112	tumours	harboured	a	SWI/SNF	complex	mutation	with	7	mutations	in	SMARCA4	and	13	in	ARID1A.	These	mutations	were	mutually	exclusive	and	frequently	inactivating	(9/20,	splice	donor,	nonsense	or	frameshit	INDEL).	This	supports	the	role	of	this	complex	as	an	inhibitor	of	tumour	progression	in	OAC.	To	extend	this	finding	to	a	larger	cohort	of	samples,	and	to	assess	the	clinical	relevance	of	mutations	of	the	ARID1A,	we	performed	immunohistochemistry	on	a	large	cohort	of	OACs	in	tissue	microarrays	(TMAs).		Two	independent	observers	scored	all	TMAs	and	any	discrepant	results	were	discussed	to	identify	a	consensus	opinion.	In	total	298	OACs	were	screened	by	immunohistochemistry	identifying	absent	or	decreased	expression	in	41%	(122/298).	This	suggests	alternative	mechanisms	of	down	regulation	may	be	present	though	we	did	not	identify	any	large-scale	structural	variants	within	the	WGS	data	from	our	discovery	cohort.		
5.8 Analysis	of	mutation	in	Barrett’s	oesophagus	and	high	grade	dysplasia	
The	stage	specificity	of	mutations	can	be	derived	from	patients	at	discrete	stages	of	Barrett’s	oesophagus	carcinogenesis.	Mutations	occurring	at	disease-stage	boundaries	would	be	candidate	biomarkers	of	malignant	progression.	In	addition,	mutations	occurring	early	in	the	development	of	disease	should	represent	ideal	targets	for	novel	therapeutic	interventions	due	to	their	presence	in	the	majority	of	cells	in	more	advanced	lesions.	We	therefore	sought	to	identify	the	mutation	status	of	the	26	genes	in	our	panel	in	Barrett’s	oesophagus	samples	obtained	from	a	prospective	cohort	of	patients	undergoing	endoscopic	surveillance.	This	included	109	Barrett’s	oesophagus	biopsies	from	79	patients	.	We	selected	66	never-dysplastic	Barrett’s	oesophagus	samples	from	40	Barrett’s	
	 184	
oesophagus	patients	for	whom	there	was	no	evidence	for	progression	to	dysplasia	or	malignancy	(median	follow-up	time	58	months,	range	4-132),	and	43	Barrett’s	oesophagus	biopsy	samples	(from	39	patients)	of	histopathologically	confirmed	high	grade	dysplasia	(HGD),	the	stage	just	prior	to	the	development	of	invasive	EAC	(Table	1).	All	slides	were	re-reviewed	by	a	specialist	gastrointestinal	histopathologist	(Dr	Maria	O’Donovan).	We	did	not	include	low-grade	dysplasia	due	to	the	poor	agreement	on	the	histopathological	grading	of	this	lesion.	The	findings	were	striking	and	unexpected.	For	the	never-dysplastic	Barrett’s	oesophagus	cohort,	21/40	(53%)	patients	were	found	to	have	mutations	within	their	Barrett’s	oesophagus	segment	with	several	biopsies	containing	multiple	mutations.	In	total,	we	identified	29	SNVs	and	7	INDELS	within	this	cohort.	Importantly,	the	mutations	identified	in	never-dysplastic	Barrett’s	oesophagus	occurred	in	several	genes	previously	identified	as	drivers	in	OAC	and	other	cancers,	including	SMARCA4,	ARID1A,	and	CNTNAP5.	Of	interest,	seven	of	these	29	SNVs	were	mutations	at	T:A	base	pairs.	Of	these,	5/7	(71%)	occurred	at	TT	dinucleotide	sequences,	the	mutational	context	identified	as	highly	enriched	in	the	OAC	WGS	data.	Thus,	this	mutational	process	may	well	be	active	at	the	earliest	stages	of	disease.	Of	the	43	HGD	biopsy	samples,	39	(91%)	were	found	to	have	mutations	in	at	least	one	of	the	genes	in	our	panel	with	a	total	of	67	SNVs	and	7	INDELS.	Hence,	rather	than	the	frequency	of	mutation	in	a	given	gene	increasing	across	disease	stages,	we	observed	that	for	the	vast	majority	of	genes	the	mutational	frequency	was	not	significantly	different	between	never-dysplastic	Barrett’s	oesophagus,	HGD	and	OAC	(Fisher’s	exact	test	with	Benjamini-Hochberg	correction	for	multiple	testing,).	To	confirm	this	finding	we	performed	additional	amplicon	sequencing	for	two	of	our	most	commonly	mutated	genes,	MYO18B	and	ARID1A.	In	this	expanded	cohort	we	included	an	additional	25	NDBE	samples	and	11	HGD	increasing	the	cohort	to	a	total	of	91	NDBE	and	54	HGD,	but	did	not	identify	any	significant	difference	in	frequency	of	mutation	between	disease	stages.		Only	TP53	(p<0.0001)	and	SMAD4	(p=0.0061)	exhibited	mutational	frequencies	that	would	distinguish	between	disease	stages	and	thus	identify	progression	
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towards	malignancy.	TP53	was	found	to	be	recurrently	mutated	in	both	HGD	(72%)	and	EAC	(69%)	samples,	but	only	in	a	single	case	(2.5%)	of	never-dysplastic	Barrett’s	oesophagus.	SMAD4	was	mutated	at	a	lower	frequency	(13%)	and	intriguingly	was	only	found	in	OAC,	the	invasive	stage	of	disease.	
5.9 Clonal	analysis	of	recurrent	mutations	
Having	identified	the	occurrence	of	mutations	in	the	earliest	stages	of	disease	development	we	next	sought	to	identify	whether	these	mutations	were	fully-clonal	or	sub-clonal	in	our	original	discovery	cohort	of	22	EACs.	Dr	Andy	Lynch	at	the	Cambridge	Research	Institute	performed	this	analysis.	For	each	of	the	15	genes	mutated	in	≥4	samples	from	our	expanded	cohort	we	combined	our	high-depth	re-sequencing	of	SNVs,	copy	number	variant	data	and	LOH	analysis	to	determine	the	fraction	of	tumour	cells	containing	the	mutation.	If	mutation	occurs	at	the	earliest	stage	of	disease	development,	prior	to	the	clonal	expansion	of	the	malignancy,	we	would	expect	that	the	mutation	would	be	present	in	all	cells	of	the	tumour.	For	7/15	genes;	SMAD4,	TP53,	ARID1A,	SMARCA4,	TLR4,	
CDKN2A	and	PNLIPRP3	this	was	the	case.	Mutation	in	the	other	8	genes	(MYO18B,	TRIM58,	CNTNAP5,	ABCB1,	PCDH9,	UNC13C	and	CCDC102B)	was	not	always	present	in	the	major	clone	suggesting	that	mutation	of	these	genes	may	be	selected	for	at	multiple	stages	of	tumourigenesis.	
5.10 Discussion	
5.10.1 Driver	gene	identification	
In	the	time	since	this	analysis	was	completed,	several	advances	have	been	made	in	the	identification	of	driver	genes.	All	driver	gene	calculations	seek	to	identify	genes	in	which	the	observed	rate	of	mutation	is	greater	than	expected	by	chance	given	the	background	mutation	rate	in	the	cancer	genome.	This	represents	a	signature	of	positive	selection.	However,	a	key	development	has	been	the	process	of	eliminating	factors	that	bias	toward	higher	rates	of	mutations	in	genes	independently	of	positive	selection.		
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As	discussed	in	Chapter	3,	mutation	rate	is	not	fixed	across	the	genome	and	instead	rates	appear	to	be	affected	by	the	local	sequence	context	and	the	mutational	processes	to	which	a	tumour	is	exposed	[77].	The	two	signatures	dominant	in	OAC	show	a	propensity	for	mutation	at	the	5’	thymidine	of	TpTp	dinucleotides,	therefore	a	gene	with	an	above	average	level	of	TT	dinucleotides	would	show	a	higher	rate	of	mutation	than	that	of	the	baseline	genome	rate.	It	is	therefore	essential	to	account	for	the	sequence	context	of	a	gene	coding	region	when	calculating	its	expected	mutation	rate.		Recent	work	has	also	demonstrated	the	importance	of	chromatin	state	and	replication	timing	in	altering	the	local	background	mutation	rate.	Heterochromatin	has	a	higher	mutation	rate	than	euchromatin	[177,181,462].	This	difference	appears	to	be	driven	by	differential	access	of	DNA	repair	factors	[179].	A	recent	study	has	extended	this	work,	demonstrating	that	transcription	in	heterochromatin	regions	leads	to	decreased	mutation	rate	on	both	transcribed	and	untranscribed	strands,	by	targeting	global	genome	nucleotide	excision	repair	factors	to	these	areas	[463].	Active	transcription	of	genes	also	decreases	mutational	rates	on	the	transcribed	strand	due	to	the	action	of	transcription	coupled	NER	[464-466].	Some	areas	of	open	chromatin	have	also	been	identified	as	sites	of	hypermutation	[63].	In	this	case	protein	binding	to	open	and	active	promoters	prevented	access	for	NER	machinery	causing	higher	error	rates.		Correction	of	all	these	factors	has	been	integrated	into	a	single	pipeline	[177]	and	this	has	become	the	gold	standard	across	NGS	studies.	This	pipeline	starts	from	the	assumption	that	within	a	single	sample,	or	even	a	large	cancer	genome	sequencing	study,	the	data	on	any	gene	background	mutation	rate	will	be	too	sparse	to	be	accurately	calculated.	Instead,	MutsigCV	identifies	genes	with	similar	replication	timing,	expression	and	chromatin	state	and	pools	them	to	allow	a	more	accurate	calculation	of	the	background	mutation	rate.	It	then	compares	the	observed	rate	to	the	expected	rate	for	each	gene	and	applies	a	p-value	cut-off	threshold	to	control	the	false	discovery	rate.		A	potential	limitation	of	this	software	tool	is	its	use	of	replication	timings,	chromatin	states	and	expression	values	that	are	not	derived	from	the	specific	
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primary	tumour	type	under	analysis.	For	example,	replication	timings	are	derived	from	analysis	of	HeLa	cells,	a	cervical	cancer	cell	line.	Customisation	of	the	covariate	calculations	to	be	cell	type	specific	may	be	helpful	in	improving	the	sensitivity	and	specificity	of	this	approach	to	driver	gene	identification.		In	tumour	types	with	higher	mutation	rates,	or	where	large	numbers	of	samples	are	available,	the	individual	gene	background	mutation	rate	may	be	observed	more	accurately.	An	alternative	tool	-termed	InVEx	-takes	all	mutations	falling	within	the	local	area	of	a	gene,	and	simulates	their	placement,	correcting	for	mutation	trinucleotide	context	and	assuming	a	random	distribution.	The	number	of	mutations	that	fall	within	exons	is	calculated	after	each	simulation	and	compared	to	that	observed	in	the	primary	tumour	data	set	[120].		Counting	the	number	of	simulations	that	generate	an	exon	mutation	rate	greater	than	or	equal	to	that	observed	in	the	primary	data	generates	a	p-value.	However,	this	tool	assumes	that	a	gene	will	have	the	same	background	mutation	rate	across	all	tumours	in	the	cohort	analysed.	This	assumption	is	likely	to	be	false	given	the	ability	of	gene-expression	profiling	to	identify	subgroups	in	most	tumour	types.	However	the	effect	of	this	is	unclear	and	warrants	further	study.		How	close	are	we	to	detecting	all	significant	mutations	in	OAC?	The	baseline	mutation	rate	in	cancers	can	be	thought	of	as	noise	complicating	the	identification	of	driver	genes,	which	represents	the	signal.	It	has	been	demonstrated	that	as	background	mutation	rates	increase,	the	number	of	cases	required	to	identify	true	drivers	increases	dramatically.	This	is	particularly	true	for	drivers	that	occur	at	very	low	frequency.	A	recent	analysis	has	suggested	that,	to	identify	drivers	that	occur	in	2%	of	cases,	approximately	650	tumours	would	be	required	for	a	tumour	type	with	a	background	mutation	rate	of	0.5	mutations	/	Mb	(e.g.	neuroblastoma)	and	approximately	5300	tumours	would	be	needed	for	a	tumour	type	with	a	background	mutation	rate	of	12.9	mutations	/	Mb	(e.g.	melanoma)	[396].	Our	calculated	background	mutation	rate	for	OAC	was	7.8	mutations	/	Mb	genome	wide	and	4.2	mutations	per	Mb	in	the	coding	region.	We	are	likely	therefore	to	be	some	way	from	detecting	all	relevant	drivers	in	OAC	and	additional	sequencing	is	required.	This	is	demonstrated	by	the	work	following	on	from	this	project	which	has	identified	additional	driver	genes	in	
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OAC	using	a	larger	cohort	[387].	An	important	caveat	to	this	work	is	that	the	calculations	were	based	on	a	false	negative	mutation	identification	rate	of	10%.	Whilst	this	may	be	a	reasonable	figure	for	high	cellularity	tumours	with	normal	ploidy,	it	may	be	significantly	higher	in	samples	with	lower	cellularity	and	higher	ploidy,	where	mutant	allele	frequencies	will	be	lower.	In	addition,	sub-clonal	drivers	will	also	have	a	higher	false	negative	rate	due	to	lower	mutant	allele	frequencies	and	accurate	detection	of	these	will	require	an	even	greater	number	of	tumour-normal	pairs.		An	alternative	approach	to	take,	rather	than	simple	frequency	analysis,	is	to	look	at	the	functional	effects	of	mutations.	Several	pipelines	have	been	developed	to	identify	an	increased	rate	of	functional	mutation	in	a	genome.	Firstly	it	is	possible	to	predict	the	functional	consequences	of	a	mutation	based	on	amino	acid	changes,	location	in	a	protein	relevant	to	important	functional	domains	and	prior	knowledge	of	how	other	mutations	have	affected	similar	functional	domains	[467,468].	These	pipelines,	however,	have	been	validated	only	with	known	deleterious	germline	mutations	and	that	may	bias	against	the	successful	detection	of	cancer	causing	mutations,	particularly	the	gain	of	function	mutations.		Alternatively,	it	is	possible	to	look	for	the	clustering	of	mutations.	Most	common	oncogenes	(i.e.	genes	where	an	increase	in	function	promotes	malignancy)	contain	a	specific	site	which	is	recurrently	mutated,	leading	to	their	activation.	Prevalent	examples	of	this	include	activating	mutations	of	KRAS	(G12D)	and	
BRAF	(V600E).		An	example	of	a	software	package	that	performs	such	an	analysis	is	OncodriveCLUST	[375,469].	Finally,	a	recent	study	has	been	published	using	dN/dS	ratios	to	identify	positive	selection	in	genes	of	interest	(dN	is	the	number	of	non	synonymous	mutations	per	possible	non	synonymous	site	in	a	gene	and	dS	is	the	corresponding	figure	for	synonymous	mutations).	In	this	process	a	gene	is	predicted	to	be	a	driver	if	its	dN/dS	ratio	is	greater	than	1	i.e.	there	is	an	excess	of	non	synonymous	mutations	within	that	gene.	This	approach	requires	large	datasets	in	order	to	identify	a	sufficiently	large	number	of	mutations	within	each	gene	and	is	not	applicable	to	our	cohort.	Overall,	a	combined	use	of	all	these	modalities	will	be	essential	to	identify	a	full	set	of	driver	genes	in	OAC.	
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	Finally,	an	important	difficulty	to	be	considered	in	cancer	driver	detection	lies	in	the	fact	that	cancer	may	pass	through	several	bottlenecks	in	which	different	challenges	necessitate	the	dysregulation	of	different	genes	[10,11,18,470].	We	and	others	have	demonstrated	that	mutations	occur	readily	in	normal	tissue	and	are	under	selective	pressure	[364,471-473].	These	mutations	may	play	no	significant	role	in	the	cancer	once	it	has	progressed	to	an	invasive	stage.	Such	genes	would	show	as	drivers	by	any	bioinformatics	analysis	but	would	play	no	current	functional	role	and	may	therefore	represent	poor	targets	for	novel	therapeutics.	Thus	studies	of	pre-cursor	lesions	are	vital	to	understand	the	timings	and	importance	of	drivers	identified	in	cancer	sequencing	studies.	
5.10.2 The	role	of	Chromatin	remodeling	in	OAC	and	gastric	cancer	and	cancer	in	
general	
Our	analysis	here	has	identified	several	novel	driver	genes	in	OAC.	The	most	striking	finding	was	the	identification	of	recurrent	mutations	in	the	SWI/SNF	complex.	In	particular	we	have	found	recurrent	mutations	in	ARID1A	and	
SMARCA4.	These	were	mutually	exclusive	in	our	dataset	but	the	low	numbers	of	cases	prevented	any	definitive	statistical	analysis.	Further	analysis	on	a	larger	set	of	cases	has	confirmed	this	finding	[387],	supporting	the	role	of	this	pathway	in	the	development	of	OAC.	There	was	no	hotspot	for	mutations	in	ARID1A	and	mutations	were	frequently	inactivating	e.g.	INDEL	or	nonsense.	These	are	characteristics	of	a	tumour	suppressor	gene	[474].	To	establish	if	loss	of	expression	was	the	result	of	these	mutations	and	if	it	occurred	by	other	mechanisms	we	performed	immunohistochemistry	on	tissue	microarrays	containing	material	from	298	cases	of	OAC.	Nearly	half	of	the	cases	(41%)	showed	a	loss	of	ARID1A	expression	suggesting	alternative	methods	of	dysregulation.	Alternative	mechanisms	of	inactivation	may	include	promoter	methylation	and	SVs	however	in	our	cohort	we	did	not	identify	any	truncating	structural	variants	[475].	
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The	role	of	ARID1A	mutation	in	OAC	is	unclear.	Mutations	were	found	in	BE	and	HGD	suggesting	they	are	likely	an	early	change.	Knockdown	of	ARID1A	in	OAC	cells	by	Strepell	et	al	lead	to	increased	proliferation	and	invasion	[335].	ARID1A	loss	has	been	suggested	to	contribute	to	genomic	instability	through	its	interaction	with	MSH2	leading	to	disruption	of	MMR	and	increased	mutation	rate.	We	did	not	observe	the	signature	of	MMR	deficiency	in	our	dataset	suggesting	that	in	OAC	at	least	ARID1A	is	not	mediating	MSI.	Consistent	with	this,	Shen	et	al	did	not	demonstrate	a	significant	difference	in	mutation	rates	between	ARID1A	wild	type	and	mutant	OAC	[476].	ARID1A	has	also	been	shown	to	be	recruited	to	DSBs	via	its	interaction	with	ATR.	Loss	of	ARID1A	leads	to	impairment	of	homologous	recombination	and	single	strand	annealing	[477].	
ARID1A	has	been	identified	as	a	TOP2A	interactor	directing	it	to	bind	to	DNA	and	deconcatenate	it	during	mitosis[478].	Its	loss	has	therefore	been	shown	to	lead	to	increased	anaphase	bridging	and	polyploidy,	a	frequent	finding	in	OAC	[217].	It	will	be	interesting	to	compare	ARID1A	status	and	the	mutational	signatures	seen	in	a	larger	cohort	of	OACs.		As	well	as	it’s	role	in	genomic	instability,	ARID1A	also	appears	to	regulate	cell-cycle	progression.	As	mentioned	above,	knockdown	of	ARDI1A	leads	to	increased	proliferation.	Additionally,	in	gastric	cancer	cell	lines	with	ARID1A	deficiency,	re-expression	decreased	proliferation.	This	may	be	mediated	by	its	ability	to	arrest	the	cell	cycle	following	differentiation	via	interaction	with	the	cyclin	dependent	kinase	inhibitor	p21.		
5.10.3 Function	of	other	potential	driver	genes	
Several	other	potential	driver	genes	were	identified	in	our	analysis	of	OAC.	Of	particular	note	we	identified	recurrent	mutations	of	the	Toll-like	receptor	genes	and	members	of	the	downstream	signalling	pathways.	These	receptors	are	present	on	epithelial	cells	within	the	digestive	track.	They	are	a	key	component	of	the	innate	immune	system,	sensing	the	presence	of	pathogenic	organisms	by	recognizing	conserved	epitopes,	e.g.	Lipopolysaccharide	present	in	bacterial	cell	
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walls.	Further	work	from	our	lab	has	shown	that	the	TLR4	mutations	are	functional,	leading	to	decreased	signalling	in	response	to	ligand	[479].	
5.10.4 Mutations	in	pre	malignant	tissue	
In	this	study	we	have	shown	that	the	majority	of	putative	driver	genes	are	also	mutated	in	precursor	lesions	of	OAC.	Importantly,	we	selected	precursor	samples	from	patients	with	long	follow-up	and	without	any	subsequent	history	of	malignancy	or	dysplasia.		Though	Barrett’s	oesophagus	does	increase	the	risk	of	developing	oesophageal	adenocarcinoma,	the	absolute	risk	remains	low	and	the	majority	of	people	with	BE	will	not	develop	OAC	[480].	Previous	studies	have	identified	mutations	in	CKDN2A	in	BE	from	patients	without	malignancy	and	who	do	not	go	on	to	develop	malignancy	[481,482].	These	have	been	shown	to	arise	in	multiple	clones	within	the	same	segment	of	Barrett’s	and	to	show	clonal	selection	[337,483].	Furthermore	it	is	clear	that	in	patients	who	go	on	to	progress	to	malignancy,	TP53	mutations	and	CN	changes	can	be	detected	24	–	48	months	prior	to	the	malignant	biopsy	[484].		Prior	to	initiating	this	study,	based	on	previous	literature,	we	predicted	that	additional	drivers	may	be	mutated	in	a	stepwise	fashion,	with	TP53	and	copy	number	changes	representing	the	final	changes	prior	to	malignant	conversion.	The	additional	driver	mutations	would	therefore	have	served	as	early	markers	for	risk	of	progression	to	malignancy.	Since	even	early	BE	in	never-dysplastic	patients	has	clonally	expanded	to	replace	the	resident	squamous	epithelium,	it	may	be	expected	to	harbour	a	few	detectable	passenger	mutations.	Our	results	are	therefore	surprising.	We	show	that	all	identified	novel	driver	genes	are	mutated	in	large,	easily	detectable,	clones	in	never-dysplastic	BE	and	at	similar	frequencies	to	those	seen	in	cancer	and	HGD.	In	our	expanded	cohort	of	BE	cases	looking	at	MYO18B	and	ARID1A	alone,	there	were	a	total	of	98	cases	of	NDBE.		Thus,	it	is	highly	unlikely	that	there	is	a	significant	difference	in	mutation	rates	between	BE	and	OAC.		A	previous	report	identified	ARID1A	mutation	in	only	5%	of	BE	cases	by	IHC	[335].	This	discrepancy	may	be	due	to	smaller	clone	sizes	and	increased	heterogeneity	within	the	Barrett’s,	potentially	
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making	identification	by	IHC	challenging,	though	there	is	no	complete	documentation	of	the	scoring	system	used	to	assess	IHC	in	this	paper.	Unlike	previous	studies	we	have	analysed	a	carefully	curated	sample	set	selecting	BE	samples	from	patients	without	a	subsequent	development	of	OAC	or	HGD.	This	is	key,	as	it	confirms	that	these	mutations	play	a	role	in	pre-malignancy/	normal	tissue	and	do	not	simply	represent	a	finding	of	incident	OAC/	HGD.		What	is	the	role,	then,	of	these	mutations	in	‘normal’	Barrett’s	Epithelium?	Normal	epithelial	layers	in	the	body,	both	squamous	and	glandular,	have	been	shown	to	consist	of	competing	clones	that	interact	stochastically	and	expand	via	neutral	drift	[28,485,486].	It	may	be	that	these	mutations	provide	a	competitive	advantage	to	the	normal	cell	clone	by,	for	example	causing	fate	imbalance	favouring	progenitors	capable	of	dividing	rather	than	differentiating	[29].	This	has	been	shown	to	drive	clonal	sweeps	in	normal	epithelial	compartments	leading	to	fixation	of	the	mutation	[29].	ARID1A	and	the	SWI/SNF	complex	has	been	shown	to	have	a	role	in	regulating	differentiation	of	cells	and	this	may	explain	the	advantage	of	mutating	this	gene	in	normal	epithelium.	Several	studies	have	now	identified	a	similar	pattern	of	mutation	in	other	normal	tissues.	Sequencing	of	the	blood	of	a	115-year	old	with	no	evidence	of	malignancy	revealed	several	mutant	clones[487].	These	clones	contained	as	many	mutations	as	an	acute	myeloid	leukaemia	but	demonstrated	no	malignant	behaviour.	In	addition,	PTEN	mutations	have	been	found	to	occur	in	the	endometrium	of	women	without	malignancy	and	do	not	predict	risk	of	progression	[488].	As	mentioned	earlier,	in	sun-	exposed	skin	numerous	highly	mutated	clones	have	been	seen	containing	many	of	the	mutations	associated	with	malignancy,	including	NOTCH	and	TP53	[472,489].	These	patients	did	not	have	any	overt	evidence	of	malignancy	at	the	time	biopsies	were	collected.	It	is	possible	that	should	we	use	a	deeper	sequencing	approach	we	may	be	able	to	detect	very	low	levels	of	TP53	mutation	within	never	dysplastic	BE,	suggesting	the	presence	of	very	small	mutant	clones.			The	finding	that	TP53	mutant	clones	are	uncommon	in	non-progressing	BE	is	in	contrast	to	the	high	levels	of	TP53	mutation	seen	in	sun-exposed	skin	[472].	Both	
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are	sites	of	cancers	with	high	rates	of	Tp53	mutation.	Whilst	this	may	be	due	to	methodological	constraints	it	may	also	suggest	that	the	biology	of	TP53	mutation	is	fundamentally	different	between	these	two	tissue	types.	It	appears	at	least	that	
TP53	mutation	may	therefore	accelerate	progression	more	rapidly	to	malignancy	in	BE	than	in	squamous	epithelium.		In	summary,	we	present	here	a	first	pass	collection	of	potential	driver	genes	in	OAC	and	an	assessment	of	their	timing	in	the	development	of	this	disease.	Though	it	is	possible	that	this	list	contains	some	false	positive	predictions,	we	have	identified	several	genes	that	have	subsequently	been	validated	as	drivers	of	OAC,	including	members	of	the	SWI/SNF	complex	and	Toll-like	receptors.	Intriguingly,	we	also	show	that	the	vast	majority	of	these	genes	are	mutated	very	early	in	the	development	of	oesophageal	adenocarcinoma	and	that	they	occur	in	Barrett’s	from	patients	who	do	not	go	on	to	progress	to	OAC.		This	is	in	contrast	to	the	findings	for	TP53	mutation	(which	we	have	confirmed	to	be	rare	in	never	dysplastic	Barrett’s)	and	significant	copy	number	changes,	which	have	both	been	shown	to	herald	the	onset	of	malignancy.	Given	that	the	majority	of	non-dysplastic	BE	never	progresses	to	invasive	malignancy,	the	role	of	these	mutations	in	the	development	of	cancer	is	unclear.	It	is	possible	that	the	relative	frequencies	of	many	driver	genes	in	cancer	may	simply	reflect	the	relative	frequency	of	mutation	of	that	gene	within	the	normal	tissue	from	which	the	cancer	arises	rather	than	any	selective	advantage	to	the	cancer	itself.		 	
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Figure	5.1:	Patterns	of	mutation	seen	in	true	positive	mutations,	false	positive	mutations	
and	germline	mutations	in	the	amplicon-resequencing	experiment.	False	positive	mutations	have	a	unique	spectrum	with	enrichment	for	T:A>C:G	mutations	that	resembles	the	error	profile	of	Taq	polymerase	suggesting	that	this	is	the	source	of	these	errors.		
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Figure	5.2:	Mutation	in	oesophageal	adenocarcinoma.	The	bar	graph	on	the	top	indicates	the	percentage	of	samples	with	aberrations	for	a	given	gene.	The	number	in	bold	denotes	the	total	number	of	mutations	for	each	gene.	Genes	with	four	or	more	mutations	in	our	OAC	discovery	and	validation	cohort	(combined	total	of	112	patients)	were	included.	The	proportion	of	missense,	nonsense/splice	and	indel	mutations	are	shown.	The	matrix	below	shows	the	number	of	samples	with	mutations	in	both	genes	for	each	possible	pairing	of	genes.	The	red	highlighted	box	indicates	significantly	co-occurring	mutations	(Significance	was	assessed	empirically	from	100,000	permutations.	False	discovery	rate	was	controlled	using	the	Benjamini–Hochberg	procedure.).				
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Figure	5.3:	TP53	and	SMAD4	mutations	accurately	define	the	boundaries	in	the	
progression	towards	cancer	whilst	other	mutations	appear	to	occur	independent	of	
disease	stage.	A.	Bar	graph	showing	the	number	of	never-dysplastic	Barrett’s	oesophagus	patients	(NDBE)	(n=40),	Barrett’s	oesophagus	patients	with	high	grade	dysplasia	(HGD)	(n=39)	and	OAC	patients	(n=112)	with	at	least	one	mutation	in	our	panel	consisting	of	26	genes.	B.	Percentage	of	never-dysplastic	Barrett’s	oesophagus,	Barrett’s	oesophagus	with	HGD	and	OAC	samples	with	mutations	in	recurrently-mutated	genes	(mutated	in	≥4	samples)	identified	in	the	OAC	discovery	cohort	and	EAC	Validation	cohort.	TP53	and	SMAD4	are	the	only	genes	for	which	mutations	separate	the	boundaries	between	never-dysplastic	and	dysplastic	Barrett’s	oesophagus	(TP53)	or	cancer	(SMAD4)	(two-tailed	Fisher’s	exact	test	with	Benjamini-Hochberg	correction	for	multiple	testing,	*	p<0.05).	C.	Proposed	model	for	the	boundary-defining	mutations	in	Barrett’s	oesophagus	carcinogenesis.	The	hashed	box	depicts	multiple	other	mutations	which	may	occur	and	provide	selective	advantage	at	any	stage	of	disease.		
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Figure	5.4:	Dysregulation	of	ARID1A	in	OAC.	(a)	Mutations	seen	in	ARID1A	in	a	cohort	of	112	OACs.	In	our	cohort	ARID1A	contained	many	truncating	mutations	suggesting	a	loss	of	function	(b)	immunohistochemistry	on	a	large	panel	of	OACs	showed	frequent	loss	of	or	decreased	expression	throughout	the	cohort.	However	there	was	no	correlation	with	survival.	Note	normal	cells	within	the	tumour	stroma	act	as	a	positive	control	for	the	success	of	immunohistochemistry	on	each	tissue	core.			
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Figure	5.5:	Summary	of	the	clonality	of	potential	driver	mutations	in	the	original	22	OACs	
that	underwent	whole	genome	sequencing.	Notably	TP53	and	SMAD4	are	fully	clonal	in	all	samples	supporting	their	role	as	early	drivers	in	the	initial	clonal	outgrowth	of	OACs.	Thoug	we	have	demonstrated	that	all	other	genes	may	be	mutated	at	much	earlier	stages	in	disease	progression	i.e.	before	phenotypic	changes	are	seen	many	of	these	genes	also	appear	to	have	subclonal	outgrowths	in	the	tumour	suggesting	that	they	are	selected	at	muliplt	stages	in	the	progression	of	OAC.							
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Chapter	6 	
Discussion		 	
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6.1 Driver	genes	in	OAC	and	steps	to	finding	them	all	
In	the	work	presented	in	this	thesis	I	have	identified	an	initial	cohort	of	potential	driver	genes	in	OAC.	These	include	recurrent	and	mutually	exclusive	disruption	of	SWI/SNF	complex	genes	and	TLR	pathway	mutations.	Since	the	publication	of	this	work,	several	other	larger	studies	have	enlarged	the	cohort	of	potential	drivers	[333,381,387,490,491].	Perhaps	the	most	striking	finding	from	this	work	is	the	lack	of	highly	recurrent	driver	genes.	Oesophageal	adenocarcinoma	appears	to	be	an	extreme	example	of	the	mountains	and	hills	of	model	of	cancer	somatic	variants.	Only	the	TP53	pathway	and	SWI/SNF	complex	mutations	recur	frequently.		Though	I	have	not	investigated	it	in	detail	in	this	thesis,,	recurrent	CN	changes	in	OAC	appear	to	be	a	major	source	of	somatic	variation	and	potential	driver	alterations[334,348,404,492].	Recurrent	deletions	are	seen	in	several	genes	of	interest,	including	CDKN2A,	PDE4D	and	RUNX1.	Focal	amplifications	are	also	common	with	frequent	amplification	of	receptor	tyrosine	kinases	(ERBB2,	EGFR,	
VEGFA),	members	of	the	TP53	pathway	(MDM2)	and	transcription	factors	(MYC,	
GATA4,	GATA6).	No	recurrent	fusion	genes	have	been	identified.	Nonetheless,	is	is	likely	that	there	are	more	drivers	to	find.	As	discussed	previously,	a	recent	analysis	has	predicted	that	several	thousand	OACs	will	be	needed	to	generate	a	comprehensive	catalogue	of	all	low	frequency	drivers	[396].	With	on-going	projects	this	is	likely	to	be	reached	in	the	near	future.	Despite	this,	our	understanding	of	the	pathways	disrupted	in	OAC	is	will	remain	incomplete	due	to	the	relative	insensitivity	of	the	approach	to	SNV	detection.	My	own	analysis	of	our	SV	pipeline,	and	a	recent	large	scale	analysis	of	SNV	callers,	suggests	sensitivity	is	poor	for	both	SV	and	SNV	calling,	particularly	in	low	cellularity	high	ploidy	samples	where	variant	allele	frequency	is	reduced	[293].	This	poor	sensitivity	contributes	to	missed	mutations	within	individual	samples	increasing	the	number	needed	to	identify	recurrent	drivers	and	providing	a	
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skewed	view	of	the	interactions	between	mutations	within	individual	samples.	To	improve	sensitivity	for	identification	of	drivers,	several	possible	avenues	present	themselves.	Firstly	it	will	be	important	to	increase	the	depth	of	sequencing	for	samples	with	low	MAF	as	recommended	by	the	ICGC	working	groups	[293].	This	however	may	remain	prohibitively	expensive,	as	lower	MAFs	require	an	exponentially	greater	amount	of	sequencing.	An	alternative	possibility	would	be	to	use	error	corrected	approaches	to	sequencing	for	example	with	Illumina	library	preparations	that	barcode	individual	molecules	of	DNA	allowing	the	removal	of	errors	generated	in	the	sequencing	process	[227,493].		I	have	also	not	considered	the	role	of	epigenetic	drivers	in	this	thesis.	Epigenetic	suppression	of	TSGs	is	known	to	occur	in	OAC	and	integration	of	somatic	changes	with	this	would	be	of	interest.		
6.2 Understanding	the	role	of	driver	genes	and	moving	towards	clinical	
applications	
The	mechanism	by	which	most	of	the	above	genes	drive	malignancy	is	unclear.	Clearly	the	next	step	in	developing	our	understanding	of	OAC	is	to	explore	the	phenotypic	effect	of	these	predicted	drivers.	Standard	approaches	include	expressing	mutant	constructs	in	cell	lines	without	the	mutation	or	knocking	down	the	mutation	using	siRNA	or	CRISPR	technology	in	cell	lines	expressing	the	mutant	protein	(if	available).	Various	downstream	assays	can	then	be	performed	to	assess	‘hallmarks’	of	malignant	behaviour	including	cell	viability,	proliferative	response	and	invasiveness.		A	particular	issue	of	studying	OAC	has	been	a	lack	of	suitable	verified	models.	[494]	confirmed	that	10	of	13	commonly	used	OAC	cell	lines	matched	the	original	tumour.	Sequencing	of	these	10	confirmed	cell	lines	has	been	performed	and	will	allow	them	to	be	used	as	models,	however	this	remains	a	limited	resource.	For	example	all	cell	lines	are	known	to	harbour	TP53	mutations	and	therefore	are	not	representative	of	the,	admittedly	rare,	population	of	wild	type	TP53	OACs.		
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Generation	of	additional	cell	lines	has	proved	difficult	with	a	large	number	of	samples	required	for	every	success	[495].	Alternative	approaches	are	required.	Recently	Li	et	al	successfully	generated	organoids	from	8	OACs	with	a	significantly	greater	success	rate	than	that	seen	previously	for	cell	line	culture	[496].	These	organoids	replicated	genomic	sub	types	seen	in	OAC	and,	importantly,	closely	resemble	the	original	tumours	with	little	evidence	of	selection.	However	all	of	these	models	lack	features	characteristic	of	OAC,	including	complex	heterogeneity	and	stromal	cell	interactions	[497].	This	is	likely	to	limit	their	applicability	as	has	been	seen	with	the	variable	reproducibility	and	culture	specific	evolution	evidenced	in	dose-response	studies	of	cell	lines	in	tissue	culture	and	patient	derived	xenografts		[498,499].	The	speed	at	which	NGS	data	can	be	generated	and	the	relatively	small	amount	of	material	required	opens	up	the	possibility	that	mutation	function	may	be	assessed	in	vivo.	Working	with	primary	tumours	and	targeted	therapies,	it	is	possible	to	track	the	evolution	of	tumours,	identify	sub	clonal	drivers	and	drivers	of	resistance	to	therapies	[500].	Several	groups	have	demonstrated	this	possibility	and	have	demonstrated	significant	insights	into	the	role	of	genetic	instability	in	metastasis,	mechanisms	of	resistance	to	therapies	and	sub-clonal	evolution	[149,501-507].		Collecting	additional	material	from	patients	on	treatment	is	difficult	due	to	cost	and	the	invasive	nature	of	procedures	required.	Fortunately,	it	has	been	shown	that	tumour	cell-free	DNA	can	provide	an	accurate	model	of	tumour	evolution	[506,507].	During	this	PhD	I	initiated	a	study	collecting	serial	blood	samples	from	patients	recruited	to	the	ICGC	project.	This	represents	an	excellent	resource	for	tracking	clonal	evolution	in	these	patients	in	response	to	chemotherapy	and	thereby	analysing	the	role	of	different	mutations.	Perhaps	more	importantly	for	understanding	these	drivers,	we	have	recently	demonstrated	in	our	lab	that	it	is	possible	to	track	evolving	clones	in	patients	with	Barrett’s	using	the	cytosponge	[431].	Repeated	sampling	of	the	entire	oesophageal	epithelium	using	the	cytosponge	in	patients	who	do	not	go	on	to	progress	to	cancer	would	potentially	allow	the	tracking	of	the	emergence	of	driver	gene	mutations	in	NDBE,	allowing	us	to	begin	to	understand	how	they	
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alter	the	clonal	dynamics.	This	in	vivo	sampling	is	likely	to	provide	a	more	realistic	view	of	these	mutations’	role.	
6.3 Exploring	mutational	signatures	in	OAC?	
In	this	thesis	I	have	demonstrated	the	presence	of	7	SNV	and	5	SV	signatures	in	OAC.	As	discussed	in	the	relevant	chapters,	the	origins	of	several	of	these	signatures	remain	unclear.	Identifying	the	causative	insult	is	relevant	to	identifying	future	preventative	strategies	[139-141]and	potentially	for	identifying	the	signatures	as	predictive	biomarkers	of	therapy	response.	It	is	possible	to	identify	the	cause	of	signatures	by	linking	them	to	an	exposure	unique	to	tumours	in	which	the	signature	is	active	[19,87,120,129,453].	Lung	cancers	from	patients	with	an	extensive	smoking	history	demonstrate	a	greater	enrichment	for	smoking	related	mutational	patterns	than	those	with	less	exposure	to	smoke	[88].	Similarly,	acral	melanomas	show	little	to	no	UV	light	signature		[453]	in	keeping	with	their	limited	association	with	this	exposure.	A	limiting	factor	in	my	analysis	of	mutational	signatures	was	the	small	number	of	cases	used.	This	prevented	any	clear	correlations	being	identified	between	patient	exposures	and	signatures.		In	the	past,	mutation	signatures	have	been	assessed	using	reporter	assays	in	bacteria.	In	these	only	mutant	bacteria	survive	and	sequencing	of	the	target	area	in	the	surviving	clones	reveals	the	pattern	of	mutations	that	are	caused	by	the	mutagen.		An	alternative	approach	is	to	treat	cells	with	a	potential	mutagen	and	assess	for	the	appearance	of	the	mutational	signature	in	their	genome	using	whole	genome	or	exome	sequencing.	This	has	recently	been	used	with	a	simple	cell	culture	based	assay	to	demonstrate	the	unique	signature	associated	with	exposure	to	aristolochic	acid,	a	mutagen	associated	with	renal	malignancy	[140,141].	A	recent	study	used	a	similar	approach	with	c.elegans	to	screen	multiple	chemotherapy	compounds	and	assess	the	mutational	signatures	they	generated	[146].	Any	of	these	would	be	suitable	for	analysing	the	mutational	signature	of	bile	acids	and	acids	to	determine	if	they	are	responsible	for	the	patterns	we	have	observed.	However,	given	the	large	number	of	human	bile	
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acids	and	the	necessity	to	assess	their	mutagenicity	at	differing	levels	of	acidity,	a	high	throughput	approach	such	as	in	the	latter	paper	may	be	most	appropriate.	
6.4 Timing	of	mutations	and	potential	for	screening	
I	have	shown	in	this	thesis	that	most	of	the	currently	known	functional	driver	mutations	occur	in	benign	never-dysplastic	BE.	Furthermore,	our	evidence	suggests	that	they	do	not	contribute	to	an	increased	risk	of	malignancy;	being	as	prevalent	in	cancer	as	in	never-dysplastic	BE	(patients	with	a	median	follow	up	of	43	months	and	no	sign	of	malignancy	or	dysplasia).	Their	role	in	early	BE	is	unclear,	but	given	that	they	are	clonally	expanded	sufficiently	to	be	detected	and	are	present	at	the	same	frequency	as	seen	in	OAC,	potentially	they	may	provide	a	selective	advantage.		Recent	studies	in	transgenic	mice	that	allow	the	tracking	of	cell	fates	by	fluorescently	labelling	them	have	demonstrated	that	mutations	common	to	malignancy	(NOTCH1	and	KRAS),	when	activated	in	normal	cells	to	colonise	an	epithelium,	displace	non-mutant	clones	[29,30]	without	enhancing	the	rate	of	malignancy.	It	would	be	interesting	to	see	if	mutation	of	our	identified	genes	provided	a	similar	imbalance	in	cell	fates	and	clonal	expansion.		Which	variants	may	predict	a	risk	of	progression?	Others	have	previously	shown	that	aneuploidy	and	TP53	mutation	represent	late	changes	in	the	development	of	OAC.	However,	their	appearance	does	not	seem	to	correlate	directly	with	the	onset	of	a	malignant	phenotype.	The	evidence	from	these	studies	is	that	a	cell	can	exist	with	highly	rearranged	genome	and	TP53	mutation	whilst	resembling	BE	histologically	(i.e.	normal	epithelium)	i.e.	there	is	an	additional	requirement	for	progression	to	malignancy	beyond	somatic	variation	[431,508].	This	ability	of	cells	with	a	highly	mutated	genome	to	maintain	normal	tissue	development	has	been	seen	in	models	where	cancer	cells	are	reprogrammed	to	a	pluripotent	state.	Using	melanoma	cells	and	somatic	cell	nuclear	transfer,	Hoecdinger	et	al	were	able	to	show	that	melanoma	cells	converted	to	a	pluripotent	state	and	injected	into	chimeric	embryos	(i.e.	with	normal	embryonic	stem	cells)	were	able	to	contribute	fully	differentiated	cells	to	multiple	lineages	[509].	
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Nonetheless	the	presence	of	a	TP53	mutation	or	aneuploidy	strongly	predicts	the	development	of	malignancy	and	is	only	rarely	seen	in	non-progressors	(patients	who	do	not	go	on	to	develop	malignancy	or	high	grade	dysplasia).	By	performing	CN	analysis	on	multiple	biopsies	over	multiple	time	points	Li	et	al	were	able	to	show	highly	rearranged	genomes	emerging	in	normal	BE	24	months	before	the	diagnosis	of	HGD	or	OAC	[484].	Such	high	levels	of	genome	rearrangement	were	not	seen	in	cases	that	did	not	go	on	to	progress	to	HGD	or	malignancy,	making	this	a	potential	target	for	identifying	disease	at	high	risk	of	malignant	transformation.	Clearly	there	is	a	lag	period	in	which	early	intervention	(e.g.	radio	frequency	ablation	of	the	epithelium)	could	prevent	the	development	of	invasive	disease.		An	obvious	next	requirement	is	to	gain	a	better	understanding	of	the	genome	of	non-dysplastic	BE	in	patients	without	cancer.	Two	recent	studies	have	performed	exome	and	whole	genome	sequencing	on	BE	from	patients	who	have	synchronous	tumours.		In	both	these	cases	BE	next	to	cancer	was	shown	to	have	a	highly	mutated	genome.	SNV	mutation	rates	in	non-dysplastic	BE	(2.8/Mb)	were	comparable	to	those	seen	in	many	other	cancer	types	whilst	the	SV	rate	was	dramatically	lower	compared	to	OAC(0.42	vs	8.44	amplicons	per	genome).	The	SNV	mutational	signatures	observed	were	the	same	as	those	seen	in	OAC	genomes	suggesting	they	are	active	at	all	stages	of	disease	development.	These	signatures	would	therefore	not	represent	good	biomarkers	for	the	development	of	malignancy.	Whole	genome	sequencing	of	cases	of	NDBE	would	allow	the	identification	of	differences	between	BE	in	people	who	develop	malignancy	and	those	who	do	not.		It	will	be	particularly	important	to	screen	multiple	areas	from	the	same	patients	to	clarify	the	interactions	between	mutant	clones	over	the	years	preceding	malignancy.	Clonal	dynamics	and	heterogeneity	have	been	suggested	as	markers	of	risk	for	progression.	Of	particular	note	would	be	an	assessment	of	clonal	heterogeneity	within	large	sections	of	BE	with	mutant	TP53	since	this	appears	to	be	the	earliest	high	risk	marker	for	malignant	progression.		
6.5 Furthering	our	understanding	of	the	burden	of	mutations	in	normal	tissue	I	have	shown	the	majority	of	putative	driver	point	mutations	identified	in	OAC	occur	early	in	normal	tissue.	In	our	study	the	rate	at	which	most	mutations	
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occurred	in	normal	tissue	was	identical	to	that	seen	in	tumour	samples.	This	would	appear	to	be	incompatible	with	these	mutations	contributing	towards	a	step-wise	progression	to	cancer.	If	they	increased	the	risk	of	becoming	a	malignant	tissue	they	would	expect	to	occur	at	a	higher	rate	in	malignancy	than	in	normal	tissue.		Rather	this	equality	in	mutation	rates	is	more	compatible	with	cancer	arising	simply	from	the	available	pool	of	oesophageal	cells	without	preference	for	the	presence	or	absence	of	these	mutations.	There	is	now	additional	evidence	showing	that	this	finding	is	generalizable	to	multiple	other	tissue	types.	Recent	studies	of	squamous	oesophageal	epithelium,	which	have	shown	increased	rates	of	NOTCH1	mutations	(a	previously	flagged	driver	of	oesophageal	squamous	neoplasia)	in	normal	tissue	when	compared	to	tumours	[510,511].	This	suggests	there	is	in	fact	a	slight	selective	disadvantage	to	these	mutations	in	the	progression	to	malignancy.		In	total	25-42%	of	oesophageal	epithelial	cells	were	found	to	contain	NOTCH1	mutations	as	opposed	to	10%	of	cancers.	Additionally	studies	of	normal	endometrial	tissue	have	identified	frequent	occurrence	of	mutations	in	ARDI1A,	PIK3CA	and	PTEN	all	genes	considered	to	be	drivers	of	endometrial	malignancy	[512].	An	exception	to	this	rule	appears	to	be	colorectal	epithelium	[513].In	a	recent	study	2043	glands	were	isolated	using	laser	capture	microdissection	and	underwent	whole	genome	sequencing.	Mutations	were	seen	frequently	in	colorectal	epithelium	however	the	common	colorectal	cancer	genes,	APC,	TP53	and	KRAS	were	not	found	to	be	mutated	at	similar	frequencies	to	those	seen	in	colorectal	cancers	[513].		Given	the	relatively	low	prevalence	of	clonally	expanded	single	nucleotide	driver	mutations	in	OAC	our	cohort	is	limited	in	power	to	detect	smaller	differences	in	the	rates	of	driver	gene	mutation	between	tissue	stages.	However	our	findings	have	been	recently	been	validated	in	an	independent	cohort	[514]	.	Note	this	study	was	limited	by	the	absence	of	normal	germline	controls	potentially	leading	to	false	positive	somatic	calls	that	in	fact	represent	germline	changes	limiting	its	validity	somewhat.		
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Clearly	screening	of	a	larger	panel	of	cases	would	be	invaluable	to	confirm	the	rate	and	heterogeneity	of	drivers	within	NDBE	segment.	Given	the	clonality	of	mutations	seen	in	our	preliminary	sequencing,	whole	genome	sequencing	of	NDBE	biopsies	from	progressors	and	non-progressors	would	be	feasible	however	cost	remains	an	issue.		Whole	genome	sequencing	has	a	significant	advantage	over	other	methods	in	that	it	can	provide	information	on	total	mutational	burden	and	mutational	processes	both	of	which	allow	more	accuracy	in	identifying	heterogeneity	and	ongoing	evolution	in	a	section	of	tissue	[513].	Ideally	this	should	be	done	at	the	single	gland	or	single	cell	level	to	provide	insight	into	the	true	tissue	heterogeneity.	Previous	work	has	identified	significant	single	gland	heterogeneity	in	BE	and	suggested	this	correlates	with	risk	of	progression	[481,515].	However	this	was	done	using	restricted	genome	screening	and	a	whole	genome	sequencing	approach	would	provide	significantly	greater	insight	into	the	evolution	to	cancer.		
6.6 What	drives	the	malignant	phenotype?	Opportunities	for	early	detection.	Building	on	from	this	work	clarifying	mutational	burden	in	normal	epithelium	the	crucial	next	question	is	what	then	drives	the	transformation	to	a	cell	with	the	ability	to	invade	and	metastasize	i.e.	malignancy.	Primarily	this	is	of	interest	as	it	most	likely	represents	the	true	onset	of	a	cancer	that	requires	early	intervention,	without	which	it	would	progress	to	life-limiting	metastatic	disease.	There	is	no	invasive	lesion	that	would	not	warrant	removal	either	by	surgery	or	other	ablative	techniques	(e.g.	radio	frequency	ablation,	photo	dynamic	therapy	or	systemic	chemotherapy	and	radiotherapy)	as	all	inevitably	progress	to	metastasis.	When	considering	opportunities	for	early	detection	it	is	important	to	consider	which	if	any	drivers	of	malignancy	occur	at	a	timepoint	sufficiently	far	removed	form	the	commitment	to	this	phenotype	to	act	as	early	detection	markers	in	a	screening	programme.		For	example	if	a	putative	molecular	biomarker	occurs	only	3	months	prior	to	the	onset	of	metastatic	malignancy	then	it	is	unlikely	to	be	suitable	for	use	in	a	screening	programme	with	yearly	interventions.	It	is	possible	that	the	molecular	events	leading	to	malignancy	progress	at	such	a	rapid	pace	that	it	will	not	be	feasible	to	identify	disease	prior	to	the	onset	of	
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invasion	in	the	majority	of	cases.	This	rapid	progression	has	been	suggested	to	explain	the	failure	of	several	screening	programmes	to	reliably	detect	and	prevent	the	bulk	of	target	organ	cancers	[516].	Crucially	any	new	markers	must	also	meaningfully	improve	on	well-established	markers	of	risk	such	as	the	macroscopic	changes	in	tissue	architecture	or	microscopic	cellular	and	glandular	structural	changes	typical	of	cancer	and	dysplasia.	That	is	to	say	they	should	occur	before	these	phenotypic	changes	and	predict	their	onset	with	100%	sensitivity	and	specificity.		Despite	the	presence	of	most	driver	mutation	in	non-progressing	normal	tissues	there	are	clearly	genetic	changes	that	associate	with	the	risk	of	progression	to	malignancy.	Current	literature	supports	two	factors	that	appear	to	be	stage	specific	and	predict	the	development	of	malignant	phenotype;	the	presence	of	TP53	mutations	and	the	development	of	genome	wide	structural	variation.			In	two	recent	studies,	in	oesophageal	squamous	epithelium	TP53	mutations	were	seen	to	be	common	in	normal	epithelium	(10%-30%	of	cells,	increasing	with	age)	but	present	at	a	lower	rate	than	is	seen	in	malignancy	(90%	of	squamous	oesophageal	cancer)	suggesting	that	this	alone	is	not	sufficient	for	the	progression	to	an	invasive	phenotype	[511]Marticorena	et	al.,	2019).	A	recent	study	using	high	specificity	sequencing	techniques	to	allow	the	detection	of	exceptionally	low	allele	frequency	mutations	found	the	majority	of	healthy	women	had	detectable	TP53	mutations	in	uterine	lavage	specimens	[517]	.	Data	from	our	lab	and	others	suggests	that	in	Barrett’s	the	presence	of	a	reasonably	expanded	TP53	clone	is	highly	predictive	of	the	development	of	malignancy.	[508,514].	Additionally	the	expansion	of	a	TP53	mutated	clone	has	been	shown	to	pre-date	the	expansion	of	aneuploidy	and	to	predate	the	presence	of	any	phenotypic	change	[431,508,518]	.	These	findings	support	its	role	as	an	excellent	potential	biomarker	of	malignant	progression.	Larger	studies	are	needed	to	determine	the	exact	prevalence	of	expanded	TP53	mutant	clones	in	normal	BE	from	patients	who	have	not	gone	on	to	develop	HGD	or	OAC	(non-	progressors).	The	low	rates	seen	so	far	in	our	analysis	and	others	suggests	that	at	the	point	at	which	a	TP53	mutated	clone	is	expanding	there	is	a	
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relatively	rapid	progression	to	malignant	phenotypic	change.	An	important	point	to	recognize	is	that	it	may	be	this	is	also	the	case	in	our	cohort	and	in	fact	TP53	mutations	may	be	present	in	clones	below	the	limit	of	detection	for	our	assay.	This	could	be	solved	either	with	single	cell/	gland	sequencing,	restricted	biopsy	sizes	(thereby	enriching	for	clones)	or	more	sensitive	mutational	analysis	on	whole	biopsies	as	discussed	above	[472,493].	A	simple	experiment	would	be	to	extend	this	to	the	single	cell	level	by	taking	biopsies	of	NDBE,	stripping	the	epithelium	and	dissociating	this	to	single	cells.	Limiting	dilutions	and	PCR	panels	(as	used	in	our	panel	screen)	could	then	be	used	to	identify	mutations	in	TP53.		This	would	allow	us	to	confirm	firstly	the	rate	at	which	these	mutations	occur	in	individual	cells	and	secondly	the	rate	at	which	they	are	capable	of	clonal	expansion	(by	comparison	with	the	data	from	IHC	fro	TP53	in	NDBE	as	a	surrogate	for	TP53	mutation	in	glands).		This	would	also	be	interesting	to	apply	to	other	commonly	mutated	genes	in	Barrett’s	oesophagus	and	OAC	as	well	as	other	tumour	sites	to	provide	insight	into	the	ability	of	mutations	to	clonally	expand.	For	example	though	we	know	that	80%	of	melanocytic	naevi	contain	BRAFV600E	mutations	and	it	is	assumed	there	presence	leads	to	the	expansion	of	these	lesions	[125,519].	However	it	is	unclear	what	the	rate	of	mutation	is	in	individual	melanocytes	that	do	not	go	on	to	clonally	expand	and	form	naevi.	
6.7 What	is	the	role	of	TP53	in	malignant	progression	of	NDBE	Tp53	mutations	are	selected	for	in	stressed	environments	in	particular	those	subjected	to	DNA	damage	and	demonstrate	little	selective	benefit	in	normal	unstressed	epithelium	[520,521]	.	It	is	tempting	to	speculate	that	the	presence	of	additional	driver	mutations	in	normal	tissue	that	promote	clonal	dominance	may	facilitate	the	expansion	of	TP53	clones.	This	combined	with	an	intermittently	stressed	environment	e.g.	acid	reflux,	or	intermittent	UV	exposure	may	allow	the	outgrowth	of	these	clones.	Alternatively	the	fact	that	mutations	occur	as	commonly	in	non-TP53	mutated	clones	as	mutated	ones	suggests	that	the	presence	of	TP53	mutations	may	be	simply	stochastic	and	likely	does	not	require	the	presence	of	additional	mutations	to	occur.	In	this	scenario	we	can	see	that	TP53	mutations	may	be	selected	simply	by	their	ability	to	survive	in	a	toxic	
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environment.	It	has	also	been	suggested	they	may	be	selected	for	in	a	senescent	microenvironment	[522].	The	increase	in	senescent	cells	occurs	with	ageing	of	tissue	thought	the	exact	reasons	are	unclear.	They	can	also	be	promoted	in	the	environment	of	constant	tissue	damage	e.g.	liver	cirrhosis	were	damage	leads	to	fibrosis	and	an	increased	density	of	senescent	cells	[523].	If	TP53	mutated	clones	are	present	at	high	rates	in	normal	epithelium	the	simple	presence	or	absence	of	the	mutation	may	not	be	an	appropriate	predictor	of	risk	of	malignancy.	Instead	there	is	evidence	that	the	expansion	of	a	TP53	mutant	clone	is	closely	correlated	with	incidence	of	malignancy	[508].	However	it	is	not	clear	if	expanded	clones	may	always	precede	the	expansion	of	the	phenotypically	malignant	clone.	In	Ulcerative	colitis	expanded	TP53	mutant	clones	are	seen	spreading	throughout	the	colon	and	precede	phenotypic	changes	and	invasive	changes	[521].		Recent	large	scale	sequencing	of	multiple	cancer	types	confirmed	that	TP53	mutation	precedes	the	onset	of	significant	chromosomal	aneuploidy	[217].TP53	contributes	to	genome	instability	via	a	number	of	possible	mechanisms	including	loss	of	checkpoint	control,	increased	survival	following	DNA	damage	and	entotic	engulfment	[196,524].	Therefore	a	TP53	clone	able	to	expand	due	to	its	survival	in	a	‘toxic’	environment	provides	a	fertile	soil	for	the	development	of	aneuploidy.	What	remains	unclear	is	whether	significant	aneuploidy	and	genome	rearrangement	occurs	in	phenotypically	normal	tissue	and	if	so	do	these	cells	immediately	undergo	clonal	expansion	and	develop	the	malignant	phenotype.	The	studies	of	normal	tissues,	detailed	above	have	shown	an	absence	of	clonally	expanded	genome	rearranged	clones	in	all	normal	tissues.	
6.8 Aneuploidy	and	progression	to	malignancy	Evidence	from	genomic	studies	using	allele	frequencies	to	time	mutations	has	suggested	that	aneuploidy	occurs	very	early	in	the	malignant	process	prior	to	significant	clonal	expansion	[456,525].	The	time	taken	to	progress	from	aneuploidy	to	phenotypically	invasive	malignancy	is	not	known.		
	 211	
To	clarify	this	timing	two	recent	studies	compared	genomes	of	OAC,	HGD	and	adjacent	NDBE[431,518].	In	the	vast	majority	of	cases	little	structural	rearrangement	was	seen	within	adjacent	BE	whilst	nearby	HGD	often	shared	rearrangements.	In	Ross-Innes	et	al	a	single	biopsy	of	NDBE	were	shown	to	contain	significant	aneuploidy	however	this	was	from	bulk	biopsy	DNA	extraction	and	it	is	possible	that	this	represents	contamination	with	nearby	tumour	material.	Supporting	this	interpretation,	in	the	same	case	areas	of	HGD	with	aneuploidy	genomes	were	also	seen	suggesting	contamination	or	sample	error	as	a	likely	explanation	for	these	findings.	Supporting	this,	in	Stachler	et	al	several	areas	of	NDBE	were	isolated	with	laser	capture	microdissection	from	three	patients	none	of	which	were	shown	to	harbor	aneuploidy	[518].	The	absence	of	rearrangement	in	Barrett’s	adjacent	to	cancer	suggests	that	the	presence	of	rearrangements	leads	to	rapid	conversion	to	a	malignant	phenotype.	In	keeping	with	the	evidence	from	breast	and	colorectal	cancer.	In	contrast	to	this	view	a	large	study	collecting	serial	biopsies	from	oesophageal	epithelium	demonstrated	the	expansion	of	extensively	structurally	rearrange	clones	up	to	2	years	prior	to	the	diagnosis	of	malignancy	[484].	This	study	was	limited	by	a	lack	of	histopathological	assessment	of	specimens	used	for	copy	number	analysis.	This	may	explain	the	apparent	presence	of	rearrangements	in	segments	of	non-dysplastic	Barrett’s	if	for	example	these	areas	were	in	fact	focal	high	grade	dysplasia.	In	keeping	with	this	several	additional	studies	support	the	restriction	of	rearrangements	to	the	HGD	and	OAC	phenotypes	supporting	aneuploidy	as	the	key	driver	of	this	transition	[525,526].		Studies	using	FISH	to	screen	larger	areas	of	tissue	have	suggested	the	presence	of	isolated	cells/	glands	with	altered	copy	number	for	individual	probes	[527].	However	isolated	chromosomal	arm	level	loss	and	gain	is	known	to	occur	in	many	normal	tissues	and	whether	these	FISH	studies	truly	represent	a	more	extensive	aneuploidy	is	unclear	[513].	Thus	additional	studies	using	WGS	with	confirmatory	LCM	or	FISH	studies	would	be	useful	in	clarifying	the	timeline	of	aneuploidy	and	phenotypic	changes	in	Barrett’s	oesophagus.	Interestingly	if	highly	aneuploidy	cells	were	confirmed	be	able	to	colonise	large	areas	with	the	appearance	of	normal	epithelium	this	would	be	concerning	for	the	ability	of	histopathology	to	confirm	negativity	of	resection	
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margins.	Given	the	high	rates	of	relapse	in	R0	patients	following	oesophagectomy	it	would	be	interesting	to	perform	genomic	analysis	of	resection	margins	on	specimens	from	OAC	patients	with	and	without	relapse	to	determine	the	presence	of	mutation	and	see	if	this	correlated	with	locoregional	or	distal	relapse	rate.		In	support	of	these	findings	a	study	of	2568	cancers	that	underwent	WGS	has	confirmed	rearrangements	and	ploidy	changes	occur	in	bursts	in	multiple	cancer	types	(when	timed	against	the	single	nucleotide	mutational	background).	This	was	particularly	true	in	oesophageal	malignancy	with	the	vast	majority	of	rearrangements	occurring	late	in	mutational	time	[528].	From	the	above	data	we	can	conclude	significant	aneuploidy	occurs	late	in	the	evolution	the	OAC	genome	and	precedes	a	rapid	expansion	of	a	cells	with	a	malignant	phenotype.		The	rate	at	which	aneuploid	clones	arise	in	a	TP53	mutant	NDBE	background	remains	unclear.	As	previously	stated	the	heterogeneity	of	SVs	appears	to	be	limited	in	most	cases	of	OAC	cancer	and	develops	prior	to	expansion.	Multi-region	sequencing	on	several	OAC	cases	whilst	in	the	majority	structural	variation	patterns	are	broadly	similar	across	regions	occasional	samples	demonstrate	2	or	more	entirely	independent	rearrangement	profiles.	In	these	cases	a	significant	number	of	SNVs	are	shared	between	the	cancers	typically	of	the	order	of	that	seen	shared	between	a	cancer	and	its	associated	segments	of	NDBE	(3000	–	4000)	[431,529].In	addition	they	typically	share	the	same	TP53	mutation,	suggesting	they	arose	from	the	same	mutant	clone	and	that	
TP53	mutation	precedes	an	expansion	in	SVs	and	point	mutations.	If	this	were	to	be	confirmed	as	a	common	event	it	would	support	a	model	with	either	a	high	rate	of	aneuploidy	cell	generation	in	TP53	mutant	clones	or	a	high	survival	rate	of	cells	post	genome	catastrophe.		This	suggests	that	it	is	relatively	difficult	to	accrue	a	full	beneficial	set	of	SVs	i.e.	that	most	rearrangement	patterns	that	occur	provide	a	negative	selective	pressure	on	the	cell.	However	it	may	also	be	that	an	additional	change	is	required	to	allow	the	outgrowth	of	a	structurally	rearranged	clone.	Further	experiments	to	investigate	this	are	detailed	in	the	next	section.	
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To	summarise	the	above	data	on	molecular	aberrations	it	appears	that	a	TP53	mutant	clone	expands	through	a	permissive	environment	providing	the	fertile	ground	for	the	development	of	an	aneuploid	clone.		Focal	Amplifications	and	deletions	along	with	selected	loss	of	whole	chromosome	arms	alter	overall	gene	dosage	in	favour	of	proliferation	and	transformation	with	the	resulting	outgrowth	and	invasion	of	a	highly	rearranged	phenotypically	abnormal	clone	[241,530].	Interestingly	if	rearrangements	happen	in	one	significant	catastrophe	then	they	are	not	selected	for	individually	rather	it	is	their	summed	effect	on	proliferation	that	is	selected	for.	This	would	allow	negative	rearrangements	to	piggy	bank	on	the	success	of	others.	In	this	situation	it	is	possible	that	recurrently	rearranged	areas	targeted	due	to	some	form	of	instability	may	be	preserved	in	cancer	and	appear	as	drivers	even	if	they	contributed	negatively	to	the	tumors	growth.	Certainly	it	would	be	interesting	to	sequence	single	cells	or	glands	in	BE,	HGD	and	OAC	to	determine	if	intermediate	genomes	could	be	found.	In	this	way	genome	rearrangements	patterns	from	unsuccessful	lineages	could	be	compared	to	those	of	cells	that	successfully	became	tumours	to	identify	background	rearrangement	rates	and	novel	drivers.	Of	interest	it	has	recently	been	shown	that	the	presence	of	genome	istability	and	aneupliduploidy	can	promote	the	malignanct	phenotype	via	cytoplasmic	DNA	activating	the	cGAs/STING	pathway	(Bakhoum	et	al,	2019).	
6.9 The	microenvironment	in	progression	of	BE	Microenvironment,	this	represents	a	significantly	less	studied	area	of	oesophageal	biology.	Multiple	cell	types	are	known	to	support	the	malignant	epithelium	including	CAFs,	macrophages,	lymphocytes,	endothelial	cells	and	neurons.	Strong	evidence	supports	the	importance	of	fibroblasts	in	orchestrating	much	of	the	malignant	phenotype	in	OAC	[497]In	addition	several	studies	have	now	shown	a	gradual	progression	towards	an	immunosuppressive	TH2	response	as	BE	develops	from	reflux	oesophagitis	[531]..	The	order	in	which	these	changes	occur	is	less	clear,	likely	there	is	significant	cross	talk	between	tumour	and	epithelium	as	seen	in	other	cancers	with	both	modifying	each	other.	Understanding	the	timing	and	type	of	modifications	seen	
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in	the	microenvironment	may	allow	the	development	of	novel	biomarkers	for	the	identification	of	individuals	at	high	risk	of	progression	to	cancer.		
6.10 Details	on	further	experiments	to	explore	the	progression	to	malignancy	Whilst	we	have	identified	the	presence	of	clonally	expanded	driver	gene	mutations	in	NDBE	our	data	is	limited	in	that	we	only	looked	for	a	select	panel	of	genes	and	did	not	consider	whole	genome	mutation	rates	or	structural	variation.	Whole	genome	sequencing	of	glands	within	BE	would	provide	valuable	insight	into	the	types	and	timings	of	the	mutational	processes	governing	progression	of	BE.	The	ideal	experiment	would	identify	progressors	and	non-progressors	and	sequence	multiple	glands	from	multiple	time	points	to	identify	temporal	and	spatial	patterns	of	mutation	and	clonal	growth.	Current	studies	of	normal	epithelium	genomes	are	limited	in	that	biopsies	are	rarely	obtained	from	patients	prior	to	the	advent	of	malignancy	whilst	this	is	common	practice	in	a	cohort	undergoing	screening	for	Barrett’s	oesophagus.	Key	questions	from	this	study	would	be	to	determine	the	rate	at	which	small	TP53	mutant	clones	occur,	the	basal	rate	of	non-driver	point	mutations	across	the	genome	and	the	exact	percentage	of	BE	cells	containing	mutations	in	common	driver	genes.	Given	previous	findings	the	hypothesis	would	be	that	BE	in	progressors	contains	more	frequent	TP53	mutant	clones	and	higher	rates	of	driver	mutations	within	glands.	If	proven	a	clinically	applicable	test	may	include	the	standard	quadrantic	biopsies	at	first	diagnosis	of	BE	being	sent	for	high	sensitivity	detection	of	common	driver	mutations	allowing	a	calculation	of	mutational	burden	and	heterogeneity,	which	could	be	used	for	risk	stratification.	Longtitudinal	follow	up	to	assess	clonal	dynamics	between	driver	gene	mutation	carrying	clones	may	provide	an	additional	biomarker	of	malignant	development	[532,533]	Given	that	large	scale	structural	rearrangement	appears	to	be	the	rate-limiting	step	an	important	unknown	is	the	rate	at	which	these	structural	variants	accrue	in	BE	and	in	particular	in	TP53	mutant	BE.	Three	possible	mechanisms	may	occur;	1,	Slow	progressive	accumulation	of	SVs	with	proliferation	and	fixation	of	intermediates	at	a	size	below	the	detection	of	sequencing	of	whole	biopsies	2,	rare	rapid	accumulation	of	SVs	(true	punctuated	equilibrium)	with	occasional	evolutionary	dead	ends	limited	to	single	cells	but	with	the	majority	of	cells	
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showing	a	normal	genome	architecture	3,	common	rapid	accumulation	of	SVs	and	stabilization	of	rearranged	forms	within	individual	glands/	or	cells	areas	but	without	progression	to	frank	malignancy.	In	the	first	2	models	accumulation	of	the	correct	set	of	SVs	would	be	the	rate	limiting	step	whilst	the	third	model	suggests	an	additional	barrier	must	be	overcome	e.g.	evasion	of	the	immune	system	or	maturation	of	the	local	microenvironment	to	facilitate	tumour	outgrowth	[534].	An	ideal	experiment	to	answer	this	question	would	be	to	identify	a	TP53	mutant	clonal	section	of	BE		(using	IHC	or	sequencing)	and	to	perform	whole	genome	sequencing	of	glands	within	this	structure	to	see	if	multiple	different	highly	rearranged	clones	exist	or	if	instead	this	is	a	rare	occurrence	but	leading	to	rapid	outgrowth	and	displacement	of	non	aneuploid	tissues.	Ideally	single	cells	within	each	gland	would	be	studied	and	techniques	for	analyzing	copy	number	of	single	cells	whilst	retaining	geographic	information	have	been	developed	on	tumour	samples	[525].	Comparison	of	the	SV	mutation	rate	between	established	malignancy,	BE	with	TP53	mutations	and	BE	would	also	be	of	interest	in	order	to	clarify	the	role	of	TP53	in	increasing	SV	mutation	rate	in	BE	and	for	understanding	the	number,	pattern	and	gene	targets	of	SVS	most	in	keeping	with	risk	of	malignancy.		Whilst	the	above	experiments	would	allow	a	more	granular	look	at	the	timings	of	mutational	burdens	and	clonal	expansions	prior	to	the	malignant	transition	they	do	not	provide	any	insight	into	the	interaction	with	the	surrounding	microenvironment.		An	elegant	but	resource	intensive	experiment	would	again	involve	the	identification	of	high-risk	individuals	in	screening	cohorts	with	areas	of	TP53	expanded	BE.	A	comparison	of	the	microenvironment	surrounding	mutant	glands	versus	non-mutant	glands	would	provide	crucial	information	on	whether	the	transforming	microenvironment	precedes	the	onset	of	aneuploidy,	TP53	mutation	or	gradually	develops	between.	Studies	show	that	up	to	5-10%	of	patients	with	NDBE	without	a	history	of	progression	to	malignancy	have	TP53	IHC	positive	glands	(a	hallmark	of	mutation).	Therefore	identifying	cases	for	such	an	analysis	should	be	possible	with	a	reasonable	sized	cohort.	Bulk	tissue	analysis	is	unlikely	to	be	suitable	for	such	an	assessment	as,	mutant	and	non-mutant	glands	would	be	included	in	any	sample	leading	to	mixing	of	signals.	A	
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potential	solution	would	be	to	use	in-situ	RNA	sequencing	to	preserve	tissue	architecture	[535].	It	is	possible	to	sequence	both	DNA	and	RNA	allowing	the	colocalsiation	of	mutated	cells	and	microenvironments.	There	are	also	now	several	animal	models	of	Barrett’s	oesophagus	with	specific	expression	markers	identifying	the	putative	BE	stem	cell	[442,536].It	would	therefore	be	possible	to	introduce	genetic	changes	(in	our	case	TP53	mutation)	to	this	epithelium	in	such	a	fashion	that	only	a	small	percentage	of	cells	are	targeted	as	performed	in	[29].	Harvested	mouse	oesophagus	could	then	be	used	for	similar	analyses	of	aneuploidy	and	microenvironment	as	detailed	above.	This	has	the	added	advantage	that	mutant	glands	could	be	simply	identified	by	fluorescent	tagging	of	mutant	cells.	This	is	obviously	generalizable	to	other	tissues,	the	crucial	aspects	being	a	focus	on	individual	mutant	glands	/	cells	rather	than	bulk	tissue	analysis	given	the	expected	heterogeneity	in	tissue.	CONCLUSIONS	Multiple	mutational	processes	are	active	in	the	developmental	of	OAC.	The	unique	environmental	exposures	likely	contribute	the	majority	of	SNV	changes.	The	majority	of	driver	genes	appear	to	be	mutated	early	in	the	development	of	BE	and	do	not	predict	the	development	of	malignancy.	The	role	and	extent	of	mutations	in	early	non-malignant	BE	requires	further	investigation.		 	
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Figure	6.1:	Schematic	for	possible	models	of	progression	of	NDBE	to	OAC.		Green	phase,	Initially	mutated	clones	expand	throughout	the	Barrett’s	epithelium	competing	with	each	other	and	non-mutated	epithelium.	It	remains	unclear	if	any	of	these	mutations	provide	a	selective	advantage	to	the	epithelium	but	given	the	selective	enrichment	for	certain	sets	of	genes	it	appears	they	likely	do.	Further	evidence	is	required	to	understand	if	these	mutations	play	any	role	in	malignant	progression.			Amber	phase,	TP53	mutations	occur	in	individual	cells,	two	possibilities	fit	with	available	evidence,	Top,	they	occur	commonly	but	have	constrained	growth	in	normal	conditions	of	intragland	competition	cells	with	rare	clones	gaining	additional	mutations	or	occurring	on	the	correct	background	of	mutations	or	in	the	correct	conditioned	/	toxic	(to	TP53	WT	cells)	microenvironment	to	undergo	rapid	expansion.	Bottom,	TP53	mutations	are	rare	but	undergo	strong	positive	selection	in	the	highly	genotoxic	acid	exposed	Barrett’s	epithelium.	The	TP53	clones	provide	a	fertile	background	for	genetic	instability,	it	is	unclear	the	rate	at	which	this	occurs,	evidence	from	tumours	supports	a	consistent	rate	of	chromosomal	instability	but	with	significant	bursts	of	activity.	The	lag	time	between	onset	of	TP53	mutation	and	progression	to	a	successfully	rearranged	aneuploidy	clone	is	not	known	Red	phase,	aneuploidy	phase,	as	with	TP53	mutation	it	is	not	clear	if	aneuploid	cells	occur	commonly	and	are	constrained	in	growth	either	by	microenvironment	,	cell	competition	or	unsuccessful	genome	rearrangement,	or	if	they	occur	rarely	and	the	rate	limiting	step	is	rate	of	mutation.	Crucially	for	early	detection	we	do	not	know	if	cells	immediately	change	phgeootype	once	a	stable	aneuploid	rearrangement	has	occurred	or	if	they	grow	first	and	only	undergo	a	pheonotypic	change	in	the	correct	microenvironment	or	after	accruing	additional	genomic	changes.	
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Table	6.1:	Unanswered	questions	by	stage	from	figure	6.1	
	 	
Green	stage	 Amber	stage	 Red	stage	Could	heterogeneity	of	mutant	clones	at	a	single	timepoint	in	NDBE	predict	progression?	IS	this	a	surrogate	marker	for	tissue	age	or	mutational	exposure?	
Are	TP53	mutant	clones	highly	prevalent	e.g.	TOP	pathway	on	fig	6.1.	Will	this	limit	the	utility	of	TP53	alteration	as	a	biomarker	of	risk	of	malignant	progression	in	NDBE?	
What	rate	do	SVs	accrue	at?	Does	this	change	over	time?	What	is	the	rate	at	which	two	independent	aneuploidy	clones	emerge	in	a	single	patient?	Can	clonal	dynamic	overtime	in	NDBE	predict	progression	/	risk	of	TP53	mutant	clone	expansion?	
Does	number	and	size	of	TP53	mutant	clones	i.e.	diversity,	predict	the	risk	of	malignant	progression?	Can	this	be	assessed	on	cytology	specimens	or	quadrantic	biopsy	protocols?	
What	is	the	probability	a	cell	will	undergo	a	positively	selected	genome	catastrophe,	i.e.	more	positive	rearrangements	occur?	Does	gland/	single	cell	level	mutational	burden	show	signs	of	ongoing	mutational	damage	in	NDBE?	Could	this	represent	a	predictive	biomarker	i.e.	patients	with	high	gland	level	mutational	burden	at	high	risk	of	progression	
Does	the	microenvironment	differ	around	TP53	mutant	clones?	Does	this	precede	the	clone	and	facilitate	its	outgrowth	or	do	TP53	mutant	clones	modify	their	environment?If	so	how	quickly	do	they	convert	their	environment	and	is	this	the	rate-limiting	step	for	the	outgrowth	of	an	aneuploid	clone?	
Does	the	emergence	of	an	aneuploidy	clone	lead	immediately	to	phenotypic	changes	detectable	by	light	microscopy?	Do	aneuploid	cells	clones	need	to	reach	a	certain	size	before	phenotypic	change	occurs?	Does	aneuploidy	therefore	represent	an	appropriate	marker	for	early	detection	of	malignant	transformation?	Do	mutations	in	normal	tissue	represent	a	potential	target	for	chemoprevention	strategies?	E.g	chromatin	remodelling	complex	mutations	
Is	ongoing	genome	damage	common	in	TP53	mutant	clones	or	rare?	Is	the	rate	of	chromosomal	instability	the	rate	limiting	step	in	development	of	invasive	disease	in	a	TP53	mutant	clone?	
What	is	the	lag	between	onset	of	aneuploidy	and	development	of	incurable	disease	e.g.	distant	metastasis?	Do	mutations	in	normal	tissue	alter	its	function?	Do	they	they	play	a	role	in	site	specific	chemo	toxicities?		
What	is	the	lag	period	between	Tp53	mutation	and	emergence	of	an	aneuploidy	clone?	Is	it	dependant	on	TP53	mutant	clone	size?	
	
Does	the	microenvironment	differ	around	mutated	clones	and	does	this	promote	progression	to	or	clonal	expansion	malignancy?	
Is	TP53	all	that	is	needed	to	facilitate	the	emergence	of	an	invasive	aneuploid	cell?	Do	other	drive	mutations	seen	in	NDBE	modify	the	rate	of	this	progression?	
	
Do	microenvironmental	markers	represent	predictive	biomarkers	for	progression?	E.g.	proportion	of	senescent	cells,	immune	infiltrate	pattern,	biomarkers	of	tissue	age	(may	differ	from	chronological	age	in	toxic	environments)	
	 	
What	is	the	driver	mutation	burden	in	NDBE,	does	this	differ	between	progressors	and	non-progressors?	
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	Appendix	1:	Perl	and	R	scripts	Appendix	1.1:	R	script	for	running	the	NMF	based	extraction	of	mutational	signatures	#load	matrix	of	mutation	data	separated	into	mutation	types	mydata	<-	Data_for_NMF	#declare	the	storage	lists	that	will	hold	the	final	data	resultsclustmatrixsdallE	<-	list()	resultsclustmatrixmeanallE	<-	list()	resultsclustmatrixsdallSig	<-	list()	resultsclustmatrixmeanSig	<-	list()	partitioning_data	<-	list()	averagesilwidth	<-	list()	MatrixNMFSTORE	<-	list()	#Set	the	starting	number	of	factors	into	which	the	matrix	will	be	split	r	=	2	while	(r<10){	r	<-	r+1	#declare	the	strorage	lists	to	contain	the	average	signatures	and	average	#exposures	for	each	of	the	possible	factorization	ranks			resultsclustmatrixsd	<-	list()	resultsclustmatrixmean	<-	list()	resultsclustmatrixsdE	<-	list()	resultsclustmatrixmeanE	<-	list()	#create	the	first	round	of	nmf	solutions	before	entering	the	loop,	1000	#iterations	are	run	with	randomly	seeded	initial	matrices	and	the	most	optimal	#solution	is	selected	as	recommended	in	Alexandrov	et	al	and	Brunet	et	al	nmfData	<-	nmf(as.matrix(mydata),	r,nrun=1000)	temp	<-	coef(nmfData)	temp1	<-	basis(nmfData)	Matrixofallnmf	<-	temp	Matrixexposures	<-	temp1	#Set	the	number	of	iterations	to	run,	the	NMF	algorithm	is	initialized	with		#a	randomly	selected	pair	of	matrices	and	may	converge	on	different	solutions	a	=	0	while	(a<100)	{						 	 a<-(a+1)					 	 print(a)						 	 nmfData	<-	nmf(as.matrix(mydata),	r,nrun=10)					 	 temp	<-	coef(nmfData)						 	 temp1	<-basis(nmfData)						 	 Matrixofallnmf	<-	rbind(Matrixofallnmf,temp)						 	 Matrixexposures	<-	cbind(Matrixexposures,temp1)			 	 	}		#Store	the	data	generated	from	all	iterations#	MatrixNMFSTORE[[r]]		<-	Matrixofallnmf	
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#Partition	the	data	generated	from	each	new	iteration	assigning	a	single	#signature	from	each	iteration	(i.e.	random	starting	matrix)	to	one	cluster.	#Cluster	number	is	equal	to	the	factorization	rank	chosen.	This	is	done	in	order	#to	assess	the	reproducibility	in	solutions	that	the	NMF	process	is	converging	#towards.		partitionedset	<-	pam(Matrixofallnmf,	r)	partitioning_data[[r]]	<-	partitionedsetaveragesilwidth[r]	<-		partitionedset[7]$silinfo$avg.width	#extract	the	clustering	data	bind	it	to	the	original	data	matrix	to	label	each	#sample	with	the	cluster	it	has	been	assigned	to			clustdata	<-	partitionedset[3]	clustdatainteger	<-	clustdata[[1]]	clustdatainteger	<-	as.matrix(clustdatainteger)	Matrixofallnmf	<-	cbind(Matrixofallnmf,clustdatainteger)	Matrixexposures	<-	t(Matrixexposures)	Matrixexposures	<-	cbind(Matrixexposures,clustdatainteger)			#find	the	mean	values	for	the	contribution	of	each	mutation	type	to	each	#signature	for	(i	in	1:r)	{	temp2	<-	subset(Matrixofallnmf,Matrixofallnmf[,17]	==	i)	#remove	the	clustering	column	temp3	<-	temp2[,-17]	#calculate	the	standard	deviation	sdTemp	<-	colSds(temp3)	#calculate	the	mean	meanTemp	<-	colMeans(as.matrix(temp3))	#store	the	data	resultsclustmatrixsd[[i]]	<-	sdTemp	resultsclustmatrixmean[[i]]	<-	meanTemp		#identify	the	mean	and	median	of	the	contribution	of	each	signature	to	each	#sample	for	(i	in	1:r)	{						#same	process	as	above					temp4	<-	subset(Matrixexposures,Matrixexposures[,44]	==	i)					temp5	<-	temp4[,-44]					sdTempE	<-	colSds(temp5)					meanTempE	<-	colMeans(as.matrix(temp5))						resultsclustmatrixsdE[[i]]	<-	sdTempE					resultsclustmatrixmeanE[[i]]	<-	meanTempE			}	#Store	finalized	data	for	plotting	and	continue	to	next	factorization	rank			resultsclustmatrixsdallE[[r]]	<-	resultsclustmatrixsdE			resultsclustmatrixmeanallE[[r]]	<-	resultsclustmatrixmeanE			resultsclustmatrixsdallSig[[r]]	<-	resultsclustmatrixsd			resultsclustmatrixmeanSig[[r]]	<-	resultsclustmatrixmean	}			 	
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#Calculate	the	frobenius	reconstruction	error	for	each	of	the	factorization	ranks	#chosen	reconstructerrorlist	<-	list()	q	=	1	while	(q<10)	{				 print	(q)	q	=	q	+	1	#extract	the	matrix	of	mean	mutation	contributions	to	each	potential	signature	PP	<-	resultsclustmatrixmeanSig[[q]]	PPmat	<-	matrix(unlist(PP),	ncol	=	96,	byrow	=	TRUE)	#extract	the	matrix	of	the	mean	contribution	of	each	signature	to	each	sample			EE	<-	resultsclustmatrixmeanallE[[q]]	EEmat	<-	(matrix(unlist(EE),	ncol	=	43,	byrow	=	TRUE))	#calculate	the	frobenius	reconstruction	error	for	each	factorization	rank	by;		#1.)	multiplying	the	two	matrices	together	to	reconstruct	the	original		#2.)	subtracting	that	from	the	original	data	matrix			 reconstruct<-t(EEmat)%*%PPmat			 remenant	<-	mydata	-	reconstruct	reconstructerror	<-	norm(as.matrix(remenant),"F")	reconstructerrorlist[[q]]	<-	reconstructerror	}	The	remaining	appendix	items	are	available	on	the	attached	DVD	due	to	size	constraints	and	for	ease	of	viewing	Perl	and	R	code.	Appendix	1.2:	Perl	script	for	extracting	sequence	context	for	a	list	of	mutations	Appendix	1.3:	Perl	script	for	summarizing	context	data	from	a	list	of	mutations	Appendix	1.4:	Perl	script	for	extracting	sequence	for	SV	primer	design	
Appendix	2:	Additional	Data	tables	Appendix	Table	2.1:	Clinical	data	and	mutation	signature	exposures	for	structural	variants	and	single	nucleotide	variants	Appendix	Table	2.2:	All	structural	variants	from	43	tumours	Appendix	Table	2.3:	Mutation	context	summarized	all	43	tumours	Appendix	Table	2.4:	SV	verification	results	Appendix	Table	2.5:	False	positive	SVs	following	verification	
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